FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Coutinho, CM
   Negrini, SFBM
   Araujo, DCA
   Teixeira, SR
   Amaral, FR
   Moro, MCR
   Fernandes, JDCP
   da Motta, MSF
   Negrini, BVM
   Caldas, CACT
   Anastasio, ART
   Furtado, JM
   Barbaro, AAT
   Yamamoto, AY
   Duarte, G
   Mussi-Pinhata, MM
AF Coutinho, C. M.
   Negrini, S. F. B. M.
   Araujo, D. C. A.
   Teixeira, S. R.
   Amaral, F. R.
   Moro, M. C. R.
   Fernandes, J. D. C. P.
   da Motta, M. S. F.
   Negrini, B. V. M.
   Caldas, C. A. C. T.
   Anastasio, A. R. T.
   Furtado, J. M.
   Barbaro, A. A. T.
   Yamamoto, A. Y.
   Duarte, G.
   Mussi-Pinhata, M. M.
CA NATZIG Cohort Study Team
TI Early maternal Zika infection predicts severe neonatal neurological
   damage: results from the prospective Natural History of Zika Virus
   Infection in Gestation cohort study
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article; Early Access
DE Adverse outcomes; congenital Zika syndrome; infant; pregnancy; Zika
   virus
ID INTERNATIONAL STANDARDS; PREGNANCY OUTCOMES; BIRTH-DEFECTS; INFANTS;
   TERRITORIES; JANUARY
AB Objective To define the prevalence of adverse outcomes of maternal infection in a large cohort of ZIKV-infected Brazilian women and their infants. Design Prospective population-based cohort study. Setting Ribeirao Preto's region's private and public health facilities. Population Symptomatic ZIKV-infected mothers and their infants. Methods Prenatal/early neonatal data were obtained for all mother-child pairs. A subgroup of infants had cranial ultrasonography, eye fundoscopy, hearing and neurological examinations and Bayley III screening tests within 3 months of age. Main outcome measures Prevalence of pregnancy losses and anomalies detected at birth or within 3 months according to the gestational age of infection. Results Overall, 511 ZIKV-infected women were identified from a total of 1116 symptomatic women; as there were two twins, there were a total of 513 fetuses included. Of these, 13 (2.5%; 95% CI 1.5-4.3) presented with major signs of congenital Zika syndrome (CZS). Of the 511 women, there were 489 livebirths and 24 (4.7%) pregnancy losses (20 miscarriages and four stillbirths). ZIKV-related anomalies occurred in the offspring of 42/511 (8.2%) mothers. Microcephaly or other CNS malformations were diagnosed in 1/4 (25.0%) stillbirths and in 19/489 (3.9%; 95% CI 2.5-5.9) of the liveborn infants. Fetal abnormalities were 14.0 (95% CI 7.6-26.0) times more likely with gestational infection occurring in <= 11 weeks. On follow up of 280 asymptomatic infants, 2/155 (1.3%) had eye abnormalities, 1/207 (0.5%) had CNS imaging findings and 16/199 (8%) presented neurological alert signs. Conclusions This prospective population-based study represents the largest Brazilian cohort study of ZIKV in pregnancy. Congenital anomalies potentially associated with CZS are less frequent than previously thought. There is a strong association between the gestational age of infection (<= 11 weeks) and a poorer early infant prognosis. A notable proportion of apparently asymptomatic newborns can present with subclinical findings within 3 months of age.
C1 [Coutinho, C. M.; Moro, M. C. R.; Duarte, G.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynaecol & Obstet, Ribeirao Preto, Brazil.
   [Negrini, S. F. B. M.; Amaral, F. R.; Fernandes, J. D. C. P.; da Motta, M. S. F.; Negrini, B. V. M.; Barbaro, A. A. T.; Yamamoto, A. Y.; Mussi-Pinhata, M. M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Paediat, Ribeirao Preto, Brazil.
   [Araujo, D. C. A.] Secretary Hlth, Epidemiol & Dis Control Div, Dept Publ Hlth & Surveillance, Ribeirao Preto, Brazil.
   [Teixeira, S. R.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Imaging Haematol & Oncol, Ribeirao Preto, Brazil.
   [Caldas, C. A. C. T.] Ribeirao Preto Sch Med, Rehabil Ctr, Clin Hosp, Ribeirao Preto, Brazil.
   [Anastasio, A. R. T.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Ribeirao Preto, Brazil.
   [Furtado, J. M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Div Ophthalmol, Ribeirao Preto, Brazil.
RP Coutinho, CM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Hosp Clin, Campus Univ S-N, BR-14048900 Ribeirao Preto, Brazil.
EM cmcoutinho@hotmail.com
RI ; Reis Teixeira, Sara/N-7236-2016; Elias Junior, Jorge/A-6683-2008
OI Coutinho, Conrado/0000-0003-1966-0466; Reis Teixeira,
   Sara/0000-0001-5845-058X; Moro, Marilia Carolina/0000-0002-6592-6125;
   Elias Junior, Jorge/0000-0002-1158-1045; Cardoso de Almeida e Araujo,
   Daniel/0000-0002-1569-5541
FU Fundacao de Apoio ao Ensino Pesquisa e Assistencia (FAEPA) do Hospital
   das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade
   de Sao Paulo, Brazil
FX This study was supported by Fundacao de Apoio ao Ensino Pesquisa e
   Assistencia (FAEPA) do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto da Universidade de Sao Paulo, Brazil, and received
   partial support from the Centro de Vigilancia Epidemiologica 'Prof.
   Alexandre Vranjac' da SES-SP. The funding sources did not have any role
   in the writing of the manuscript, the decision to submit for
   publication, or any other aspect pertinent to study conduction. There
   was no funding from pharmaceutical companies or other agencies.
CR Adamski A, 2018, J INFECTION, V76, P529, DOI 10.1016/j.jinf.2018.02.010
   Aragao MFVV, 2017, AM J NEURORADIOL, V38, P1427, DOI 10.3174/ajnr.A5216
   Bayley N, 2006, BAYLEY SCALES INFANT, P146
   Brady OJ, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002755
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2019, B EPIDEMIOL, P1
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Coelho AVC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081714
   Cardoso TF, 2019, ARCH DIS CHILD, V104, P199, DOI 10.1136/archdischild-2018-314782
   Collins MH, 2019, ACS INFECT DIS, V5, P1055, DOI 10.1021/acsinfecdis.9b00003
   Conners EE, 2018, OBSTET GYNECOL, V132, P487, DOI [10.1097/aog.0000000000002737, 10.1097/AOG.0000000000002737]
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dubowitz L, 1998, J PEDIATR-US, V133, P406, DOI 10.1016/S0022-3476(98)70279-3
   Einspieler C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7235
   El-Sayed A, 2020, ENVIRON SCI POLLUT R, V27, P22336, DOI 10.1007/s11356-020-08896-w
   Moreira MEL, 2018, NEW ENGL J MED, V379, P2377, DOI 10.1056/NEJMc1800098
   Ellington SR, 2016, JAMA PEDIATR, V170, P940, DOI 10.1001/jamapediatrics.2016.2974
   EUROCAT Central Registry, 2013, EUR GUID 1 4 REF DOC
   FundacAo Sistema Estadual de Analise de Dados, 2020, SIST TAB MICR REG CI
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2019, EST POP RES MUN BRAS, P1
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lima GP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3908-4
   Mercuri E, 2005, EARLY HUM DEV, V81, P947, DOI 10.1016/j.earlhumdev.2005.10.007
   Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246
   Nogueira ML, 2018, CLIN MICROBIOL INFEC, V24, P646, DOI 10.1016/j.cmi.2017.11.004
   Pacheco O, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMoa1604037
   Paixao ES, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007721
   Papageorghiou AT, 2014, LANCET, V384, P869, DOI 10.1016/S0140-6736(14)61490-2
   Pomar L, 2019, PRENATAL DIAG, V39, P420, DOI 10.1002/pd.5446
   Pomar L, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4431
   Ramalho FS, 2017, CLIN INFECT DIS, V65, P687, DOI 10.1093/cid/cix374
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Rice ME, 2018, MMWR-MORBID MORTAL W, V67, P858, DOI 10.15585/mmwr.mm6731e1
   Rodriguez-Morales AJ, 2018, TRAVEL MED INFECT DI, V25, P20, DOI 10.1016/j.tmaid.2018.06.006
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Speybroeck N, 2012, INT J PUBLIC HEALTH, V57, P243, DOI 10.1007/s00038-011-0315-z
   Subissi L, 2018, EMERG INFECT DIS, V24, P1850, DOI 10.3201/eid2410.172079
   Sulleiro E, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015532
   Venturi G, 2019, J MED VIROL, V91, P1577, DOI 10.1002/jmv.25504
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   Wax JR, 2016, OBSTET GYNECOL, V128, pE231
   WHO, 2019, ZIK EP UPD
NR 43
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
DI 10.1111/1471-0528.16490
EA OCT 2020
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NX9NL
UT WOS:000576028300001
PM 32920998
DA 2020-12-17
ER

PT J
AU Anastasio, ART
   Yamamoto, AY
   Massuda, ET
   Manfredi, AKS
   Cavalcante, JMS
   Lopes, BCP
   Aragon, DC
   Boppana, S
   Fowler, KB
   Britt, WJ
   Mussi-Pinhata, MM
AF Anastasio, Adriana R. T.
   Yamamoto, Aparecida Y.
   Massuda, Eduardo T.
   Manfredi, Alessandra K. S.
   Cavalcante, Juliana M. S.
   Lopes, Bruno C. P.
   Aragon, Davi C.
   Boppana, Suresh
   Fowler, Karen B.
   Britt, William J.
   Mussi-Pinhata, Marisa M.
TI Comprehensive evaluation of risk factors for neonatal hearing loss in a
   large Brazilian cohort
SO JOURNAL OF PERINATOLOGY
LA English
DT Article; Early Access
ID BRAIN-STEM RESPONSE; NEWBORN; INFANTS; CHILDREN; PROGRAM
AB Objectives To determine the incidence and risk factors of hearing loss (HL) in Brazilian neonates. Study design 11,900 neonates were screened for hearing and congenital CMV (cCMV). Low and high-risk babies who did not pass their hearing screening and infants with cCMV were scheduled for a diagnostic audiologic evaluation. Results The incidence of HL was 2 per 1000 live-born infants (95% CI: 1-3). HL was higher in high-risk neonates than in low risk babies (18.6 vs. 0.3/1000 live births, respectively). Among infants exposed to isolated risk factors, association of HL with craniofacial abnormalities/syndromes (RR = 24.47; 95% CI: 5.9-100.9) and cCMV (RR = 9.54; 95% CI: 3.3-27.7) were observed. HL was 20 to 100-fold more likely in neonates exposed to ototoxic drugs in combination with cCMV or craniofacial/congenital anomalies. Conclusions Strategies for the prevention of cCMV and exposure to ototoxic drugs may decrease the incidence of HL in this population.
C1 [Anastasio, Adriana R. T.; Manfredi, Alessandra K. S.; Cavalcante, Juliana M. S.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Sao Paulo, SP, Brazil.
   [Yamamoto, Aparecida Y.; Aragon, Davi C.; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, SP, Brazil.
   [Massuda, Eduardo T.; Lopes, Bruno C. P.] Univ Sao Paulo, Dept Ophthalmol Otorhinolaryngol & Head & Neck Su, Ribeirao Preto Med Sch, Sao Paulo, SP, Brazil.
   [Boppana, Suresh; Fowler, Karen B.; Britt, William J.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA.
RP Anastasio, ART (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Sao Paulo, SP, Brazil.
EM anastasi@fmrp.usp.br
RI Massuda, Eduardo/K-5248-2014
OI Massuda, Eduardo/0000-0003-3441-5709; Reis,
   AlessanRSS/0000-0001-8486-7469
FU FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/06579-0]; Eunice Kennedy Shriver NICHD, USA
   [2R01HD061959-07A2]
FX All phases of this study were supported by FAPESP, Brazil, (Grant
   2013/06579-0 to MMMP); and Eunice Kennedy Shriver NICHD, USA (Grant
   2R01HD061959-07A2 to WJB).
CR [Anonymous], 2019, NAT ENERGY, V4, P1, DOI 10.1038/s41560-018-0323-9
   Barboza AC, 2013, ACR, V18, P285, DOI DOI 10.1590/S2317-64312013000400009
   BarskyFirkser L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e4
   Bevilacqua MC, 2010, INT J PEDIATR OTORHI, V74, P510, DOI 10.1016/j.ijporl.2010.02.009
   Bielecki I, 2011, INT J PEDIATR OTORHI, V75, P925, DOI 10.1016/j.ijporl.2011.04.007
   Boudewyns A, 2016, EUR J PEDIATR, V175, P993, DOI 10.1007/s00431-016-2735-5
   British Columbia Early Hearing Program (BCEHP), 2012, SERV BC CHILDR HOSP
   Busa J, 2007, PEDIATRICS, V120, P898, DOI 10.1542/peds.2007-2333
   Chapchap MJ, 2001, SCAND AUDIOL, V30, P33, DOI 10.1080/010503901750166600
   Cone-Wesson B, 2000, EAR HEARING, V21, P488, DOI 10.1097/00003446-200010000-00012
   Dumanch KA, 2017, AM J AUDIOL, V26, P129, DOI 10.1044/2017_AJA-16-0116
   Finitzo T, 1998, PEDIATRICS, V102, P1452, DOI 10.1542/peds.102.6.1452
   Fuchs A, 2016, PLOS ONE, V8, P1
   Johnson JL, 2005, PEDIATRICS, V116, P663, DOI 10.1542/peds.2004-1688
   Levit Y, 2015, PEDIATRICS, V136, pE641, DOI 10.1542/peds.2014-3784
   Meyer C, 1999, PEDIATRICS, V104, P900, DOI 10.1542/peds.104.4.900
   Ngo RYS, 2006, INT J PEDIATR OTORHI, V70, P1299, DOI 10.1016/j.ijporl.2005.12.004
   Nikolopoulos TP, 2015, INT J PEDIATR OTORHI, V79, P635, DOI 10.1016/j.ijporl.2015.02.010
   Ohl C, 2009, INT J PEDIATR OTORHI, V73, P1691, DOI 10.1016/j.ijporl.2009.08.027
   Onoda RM, 2011, BRAZ J OTORHINOLAR, V77, P775, DOI 10.1590/S1808-86942011000600015
   Pereira Tânia, 2014, Rev. CEFAC, V16, P422, DOI 10.1590/1982-0216201419712
   Puia-Dumitrescu M, 2018, J PEDIATR-US, V203, P131, DOI 10.1016/j.jpeds.2018.07.101
   Saki N, 2017, INT J PEDIATR OTORHI, V97, P89, DOI 10.1016/j.ijporl.2017.03.038
   Speybroeck N, 2012, INT J PUBLIC HEALTH, V57, P243, DOI 10.1007/s00038-011-0315-z
   STAPELLS DR, 1995, EAR HEARING, V16, P361, DOI 10.1097/00003446-199508000-00003
   Vashistha I, 2016, INDIAN J OTOLARYNGOL, V68, P214, DOI 10.1007/s12070-015-0869-9
   WHITE KR, 1994, INT J PEDIATR OTORHI, V29, P203, DOI 10.1016/0165-5876(94)90167-8
   WHO. World Health Organization, PREV BLINDN DEAFN GR
   Wrobel MJ, 2014, INT J PEDIATR OTORHI, V78, P209, DOI 10.1016/j.ijporl.2013.10.052
   Wroblewska-Seniuk K, 2018, INT J PEDIATR OTORHI, V105, P181, DOI 10.1016/j.ijporl.2017.12.007
   Wroblewska-Seniuk K, 2017, INT J PEDIATR OTORHI, V96, P4, DOI 10.1016/j.ijporl.2017.02.021
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2020, CLIN INFECT DIS, V70, P1379, DOI 10.1093/cid/ciz413
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
NR 34
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
EI 1476-5543
J9 J PERINATOL
JI J. Perinatol.
DI 10.1038/s41372-020-00807-8
EA SEP 2020
PG 9
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA NJ2BA
UT WOS:000565849200002
PM 32884104
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Anastasio, ART
   Massuda, ET
   Isaac, ML
   Manfredi, AKS
   Cavalcante, JMS
   Carnevale-Silva, A
   Fowler, KB
   Boppana, SB
   Britt, WJ
   Mussi-Pinhata, MM
AF Yamamoto, Aparecida Y.
   Anastasio, Adriana R. T.
   Massuda, Eduardo T.
   Isaac, Myriam L.
   Manfredi, Alessandra K. S.
   Cavalcante, Juliana M. S.
   Carnevale-Silva, Adriana
   Fowler, Karen B.
   Boppana, Suresh B.
   Britt, William J.
   Mussi-Pinhata, Marisa M.
TI Contribution of Congenital Cytomegalovirus Infection to Permanent
   Hearing Loss in a Highly Seropositive Population: The Brazilian
   Cytomegalovirus Hearing and Maternal Secondary Infection Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE cytomegalovirus; congenital infection; hearing screening; CMV screening;
   HL
ID CHILDREN
AB Background. The exact contribution of congenital cytomegalovirus infection (cCMVI) to permanent hearing loss (HL) in highly seropositive populations is unknown. We determined the contribution of cCMVI to HL and estimated the effectiveness of newborn hearing screening (HS) in identifying neonates with CMV-related HL.
   Methods. A total of 11 900 neonates born from a population with >= 97% maternal seroprevalence were screened for cCMVI and HL. cCMVI was confirmed by detection of CMV-DNA in saliva and urine at age <3 weeks.
   Results. Overall, 68 (0.6%; 95% confidence interval [CI], 0.4-0.7) neonates were identified with cCMVI. Of the 91 (0.8%) newborns who failed the HS, 24 (26.4%) were confirmed with HL, including 7 (29.2%; 95% CI, 17.2-59.3) with cCMVI. Another newborn with cCMVI passed the HS but was confirmed with HL at age 21 days. Of the 62 neonates with cCMVI who underwent a complete hearing evaluation, 8 (12.9%; 95% CI, 6.7-23.4) had HL and most (7/8; 87.5%; 95% CI, 46.6-99.7) were identified by HS. The rate of CMV-related HL was 8 per 11 887 neonates (0.7 per 1000 live births). The prevalence ratio of HL among neonates with cCMVI compared to CMV-uninfected neonates was 89.5 (95% CI, 39.7-202.0). No late-onset cCMVI-related HL was detected during a median follow-up of 36 months.
   Conclusions. cCMVI is an important cause of HL in childhood in all settings. Integrating targeted cCMVI screening among neonates who fail a HS could be a reasonable, cost-effective strategy to identify newborns with early-onset cCMVI-related HL.
C1 [Yamamoto, Aparecida Y.; Carnevale-Silva, Adriana; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Campus USP, Ribeirao Preto, SP, Brazil.
   [Anastasio, Adriana R. T.; Manfredi, Alessandra K. S.; Cavalcante, Juliana M. S.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Ribeirao Preto, Brazil.
   [Massuda, Eduardo T.; Isaac, Myriam L.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Ophthalmol Otorhinolaryngol & Head & Neck Su, Ribeirao Preto, Brazil.
   [Fowler, Karen B.; Boppana, Suresh B.; Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Campus USP, Ribeirao Preto, SP, Brazil.
EM yulie@fmrp.usp.br
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [2R01HD061959-07A2]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2013/06579-0]
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (grant number 2R01HD061959-07A2 to
   W. J. B.) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (grant number 2013/06579-0 to M. M. M. P.).
CR Barbi M, 2003, PEDIATR INFECT DIS J, V22, P39, DOI 10.1097/00006454-200301000-00012
   Busa J, 2007, PEDIATRICS, V120, P898, DOI 10.1542/peds.2007-2333
   Dahle A J, 2000, J Am Acad Audiol, V11, P283
   Dar L, 2017, PEDIATR INFECT DIS J, V36, P670, DOI [10.1097/INF.0000000000001527, 10.1097/inf.0000000000001527]
   de Vries JJC, 2013, REV MED VIROL, V23, P241, DOI 10.1002/rmv.1744
   Diener ML, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-0789
   Fletcher KT, 2018, OTOL NEUROTOL, V39, P854, DOI 10.1097/MAO.0000000000001861
   Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049
   Foulon I, 2015, INT J AUDIOL, V54, P714, DOI 10.3109/14992027.2015.1046506
   Fowler KB, 2018, SEMIN PERINATOL, V42, P149, DOI 10.1053/j.semperi.2018.02.002
   Fowler KB, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2128
   Fowler KB, 2013, CLIN INFECT DIS, V57, pS182, DOI 10.1093/cid/cit609
   Fowler KB, 1999, J PEDIATR-US, V135, P60, DOI 10.1016/S0022-3476(99)70328-8
   Fowler KB, 1997, J PEDIATR-US, V130, P624, DOI 10.1016/S0022-3476(97)70248-8
   Gantt S, 2016, JAMA PEDIATR, V170, P1173, DOI 10.1001/jamapediatrics.2016.2016
   Goderis J, 2016, J PEDIATR-US, V172, P110, DOI 10.1016/j.jpeds.2016.01.024
   Goderis J, 2014, PEDIATRICS, V134, P972, DOI 10.1542/peds.2014-1173
   HICKS T, 1993, J PEDIATR-US, V123, P779, DOI 10.1016/S0022-3476(05)80859-5
   Korver AMH, 2009, J CLIN VIROL, V46, pS27, DOI 10.1016/j.jcv.2009.09.007
   Meyer L, 2017, AM J OTOLARYNG, V38, P565, DOI 10.1016/j.amjoto.2017.06.002
   Rawlinson WD, 2017, LANCET INFECT DIS, V17, pE177, DOI 10.1016/S1473-3099(17)30143-3
   STAPELLS DR, 1995, EAR HEARING, V16, P361, DOI 10.1097/00003446-199508000-00003
   White KR, 2016, JEHDI, V1, P56
   World Health Organization, 2016, GRAD HEAR IMP
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
NR 26
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2020
VL 70
IS 7
BP 1379
EP 1384
DI 10.1093/cid/ciz413
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LN1DZ
UT WOS:000532686300020
PM 31102409
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
AF Mussi-Pinhata, Marisa Marcia
   Yamamoto, Aparecida Yulie
TI Natural History of Congenital Cytomegalovirus Infection in Highly
   Seropositive Populations
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE CMV seropositive mothers; congenital infection; cytomegalovirus; highly
   CMV seropositive populations; natural history
ID SENSORINEURAL HEARING-LOSS; POLYMERASE-CHAIN-REACTION; SAN-LUIS-POTOSI;
   RISK-FACTORS; INTRAUTERINE TRANSMISSION; INTELLECTUAL-DEVELOPMENT;
   RELATIVE IMPORTANCE; BIRTH PREVALENCE; NEWBORN-INFANTS; PREGNANT-WOMEN
AB Maternal preconceptional cytomegalovirus (CMV) immunity does not protect the fetus from acquiring congenital CMV infection (cCMV). Nonprimary infections due to recurrence of latent infections or reinfection with new virus strains during pregnancy can result in fetal infection. Because the prevalence of cCMV increases with increasing maternal CMV seroprevalence, the vast majority of the cases of cCMV throughout the world follow nonprimary maternal infections and is more common in individuals of lower socioeconomic background. Horizontal exposures to persons shedding virus in bodily secretions (young children, sexual activity, household crowding, low income) probably increase the risk of acquisition of an exogenous nonprimary CMV infection and fetal transmission. In addition, more frequent acquisition of new antibody reactivities in transmitter mothers suggest that maternal reinfection by new viral strains could be a major source of congenital infection in such populations. However, the exact frequency of CMV nonprimary infection in seroimmune women during pregnancy and the rate of intrauterine transmission in these women are yet to be defined. Usually, the birth prevalence of cCMV is high (>= 7:1000) in highly seropositive populations. There is increasing evidence that the frequency and severity of the clinical and laboratory abnormalities in infants with congenital CMV infection born to mothers with nonprimary CMV infection are similar to infants born after a primary maternal infection. This is particularly true for sensorineural hearing loss, which contributes to one third of all early-onset hearing loss in seropositive populations. This brief overview will discuss the need for more research to better clarify the natural history of cCMV in highly seropositive populations, which, in almost all populations, remains incompletely defined.
C1 [Mussi-Pinhata, Marisa Marcia; Yamamoto, Aparecida Yulie] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa M/G-6568-2012
OI Mussi-Pinhata, Marisa M/0000-0001-8985-1570
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); NICHDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD)
FX This supplement was sponsored by NIAID and NICHD.
CR AHLFORS K, 1984, SCAND J INFECT DIS, V16, P129, DOI 10.3109/00365548409087131
   Barbosa NG, 2018, CLIN INFECT DIS, V67, P743, DOI 10.1093/cid/ciy166
   Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   Britt W, 2015, MED MICROBIOL IMMUN, V204, P263, DOI 10.1007/s00430-015-0399-9
   Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655
   CONBOY TJ, 1986, PEDIATRICS, V77, P801
   Dahle A J, 2000, J Am Acad Audiol, V11, P283
   Dar L, 2008, PEDIATR INFECT DIS J, V27, P841, DOI 10.1097/INF.0b013e3181723d55
   de Vries JJC, 2013, REV MED VIROL, V23, P241, DOI 10.1002/rmv.1744
   Dollard SC, 2007, REV MED VIROL, V17, P355, DOI 10.1002/rmv.544
   Enders G, 2011, J CLIN VIROL, V52, P244, DOI 10.1016/j.jcv.2011.07.005
   Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049
   Fowler KB, 2006, PEDIATRICS, V118, pE286, DOI 10.1542/peds.2005-1142
   Fowler KB, 2018, J PEDIATR-US, V200, P196, DOI 10.1016/j.jpeds.2018.04.043
   Fowler KB, 2018, SEMIN PERINATOL, V42, P149, DOI 10.1053/j.semperi.2018.02.002
   Fowler KB, 2013, CLIN INFECT DIS, V57, pS182, DOI 10.1093/cid/cit609
   FOWLER KB, 1993, J INFECT DIS, V168, P552, DOI 10.1093/infdis/168.3.552
   FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003
   Goderis J, 2014, PEDIATRICS, V134, P972, DOI 10.1542/peds.2014-1173
   HUANG ES, 1980, NEW ENGL J MED, V303, P958, DOI 10.1056/NEJM198010233031702
   Hyde TB, 2010, REV MED VIROL, V20, P311, DOI 10.1002/rmv.659
   KAMADA M, 1983, SCAND J INFECT DIS, V15, P227, DOI 10.3109/inf.1983.15.issue-3.01
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Kimberlin DW, 2015, NEW ENGL J MED, V372, P933, DOI 10.1056/NEJMoa1404599
   Lanzieri TM, 2014, INT J INFECT DIS, V22, P44, DOI 10.1016/j.ijid.2013.12.010
   Leruez-Ville M, 2017, CLIN INFECT DIS, V65, P398, DOI 10.1093/cid/cix337
   Lopez AS, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1517
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Mussi-Pinhata MM, 2018, J INFECT DIS, V218, P1200, DOI 10.1093/infdis/jiy321
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   N'Diaye DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089857
   Nishida K, 2016, BRAIN DEV-JPN, V38, P209, DOI 10.1016/j.braindev.2015.08.003
   Noyola DE, 2011, SALUD PUBLICA MEXICO, V53, P513, DOI 10.1590/s0036-36342011000600007
   Noyola DE, 2003, PEDIATR INFECT DIS J, V22, P89, DOI 10.1097/00006454-200301000-00022
   Numazaki K, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-22
   Olusanya BO, 2015, PEDIATR INFECT DIS J, V34, P322, DOI 10.1097/INF.0000000000000555
   Pokalyuk C, 2017, MOL ECOL, V26, P1980, DOI 10.1111/mec.13953
   Prince HE, 2014, CLIN VACCINE IMMUNOL, V21, P1377, DOI 10.1128/CVI.00487-14
   Rawlinson WD, 2017, LANCET INFECT DIS, V17, pE177, DOI 10.1016/S1473-3099(17)30143-3
   Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.003
   Ross SA, 2011, J INFECT DIS, V204, P1003, DOI 10.1093/infdis/jir457
   Ross SA, 2010, J INFECT DIS, V201, P386, DOI 10.1086/649903
   Schlesinger Y, 2003, ARCH DIS CHILD-FETAL, V88, pF371, DOI 10.1136/fn.88.5.F371
   SCHOPFER K, 1978, ARCH DIS CHILD, V53, P536, DOI 10.1136/adc.53.7.536
   STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601
   STAGNO S, 1984, J MED VIROL, V13, P347, DOI 10.1002/jmv.1890130405
   Townsend CL, 2013, CLIN INFECT DIS, V56, P1232, DOI 10.1093/cid/cit018
   United Nations. DESA/Population Division, 2019, DESS POP DIV
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Wang CB, 2011, CLIN INFECT DIS, V52, pE11, DOI 10.1093/cid/ciq085
   Wang SW, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006007, 10.1097/md.0000000000006007]
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2011, PEDIATR INFECT DIS J, V30, P1043, DOI 10.1097/INF.0b013e31822d9640
   Yamamoto AY, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.018
   Yamamoto AY, 2019, CLIN INFECT DIS
   Zhang XW, 2007, J CLIN VIROL, V40, P180, DOI 10.1016/j.jcv.2007.08.018
   Zuhair M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2034
NR 58
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2020
VL 221
SU 1
BP 15
EP 22
DI 10.1093/infdis/jiz443
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LN1GN
UT WOS:000532693500003
PM 32134482
OA Bronze
DA 2020-12-17
ER

PT J
AU Lebov, JF
   Arias, JF
   Balmaseda, A
   Britt, W
   Cordero, JF
   Galvao, LA
   Garces, AL
   Hambidge, KM
   Harris, E
   Ko, A
   Krebs, N
   Marques, ETA
   Martinez, AM
   McClure, E
   Miranda, DB
   Moreira, MEL
   Mussi-Pinhata, MM
   Ochoa, TJ
   Osorio, JE
   Scalabrin, DMF
   Schultz-Cherry, S
   Seage, GR
   Stolka, K
   Ugarte-Gil, CA
   Vega, CMV
   Welton, M
   Ximenes, R
   Zorrilla, C
AF Lebov, Jill F.
   Arias, Juan F.
   Balmaseda, Angel
   Britt, William
   Cordero, Jose F.
   Galvao, Luiz Augusto
   Lucia Garces, Ana
   Hambidge, K. Michael
   Harris, Eva
   Ko, Albert
   Krebs, Nancy
   Marques, Ernesto T. A.
   Martinez, Alexander M.
   McClure, Elizabeth
   Miranda-Filho, Democrito B.
   Lopes Moreira, Maria Elisabeth
   Mussi-Pinhata, Marisa M.
   Ochoa, Theresa J.
   Osorio, Jorge E.
   Scalabrin, Deolinda M. F.
   Schultz-Cherry, Stacey
   Seage, George R., III
   Stolka, Kristen
   Augusto Ugarte-Gil, Cesar
   Vega, Carmen Milagros Velez
   Welton, Michael
   Ximenes, Ricardo
   Zorrilla, Carmen
TI International prospective observational cohort study of Zika in infants
   and pregnancy (ZIP study): study protocol (vol 19, 282, 2019)
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Correction
C1 [Lebov, Jill F.; McClure, Elizabeth; Stolka, Kristen] RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
   [Arias, Juan F.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Balmaseda, Angel] Complejo Nacl Salud, Ctr Nacl Diagnost & Referencia, Managua, Nicaragua.
   [Britt, William] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
   [Cordero, Jose F.; Welton, Michael] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Galvao, Luiz Augusto] Fiocruz MS, Ctr Global Hlth CRIS, Rio De Janeiro, Brazil.
   [Lucia Garces, Ana] Ctr Amer & Panama INCAP, Fdn Alimentac & Nutr, Guatemala City, Guatemala.
   [Hambidge, K. Michael; Krebs, Nancy] Univ Colorado, Sect Nutr, Pediat, Aurora, CO USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Fiocruz MS, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Martinez, Alexander M.] Imbanaco Med Ctr, Res Inst, Cali, Colombia.
   [Miranda-Filho, Democrito B.] Univ Pernambuco, Microcephaly Epidem Res Grp, PPGCS, Recife, PE, Brazil.
   [Lopes Moreira, Maria Elisabeth] Fiocruz MS, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru.
   [Osorio, Jorge E.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Seage, George R., III] Harvard Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Vega, Carmen Milagros Velez] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Ximenes, Ricardo] Univ Fed Pernambuco, Microcephaly Epidem Res Grp, Dept Med Trop, Recife, PE, Brazil.
   [Zorrilla, Carmen] Maternal Infant Studies Ctr CEMI, San Juan, PR USA.
RP Lebov, JF (corresponding author), RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
EM jlebov@rti.org
RI Ugarte-Gil, Cesar/E-6074-2013; Marques, Ernesto T. A/L-4967-2013
OI Ugarte-Gil, Cesar/0000-0002-2833-9087; Marques, Ernesto T.
   A/0000-0003-3826-9358; Galvao, Luiz Augusto/0000-0002-3918-0286;
   McClure, Elizabeth/0000-0001-8659-5444
FU NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25 MH083617] Funding Source: Medline; NATIONAL INSTITUTE OF
   MENTAL HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25MH083617, R25MH083617, R25MH083617] Funding Source: NIH
   RePORTER
CR Lebov JF, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2430-4
NR 1
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD NOV 19
PY 2019
VL 19
IS 1
AR 423
DI 10.1186/s12884-019-2589-8
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KE3OE
UT WOS:000508467800004
PM 31744466
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Lebov, JF
   Arias, JF
   Balmaseda, A
   Britt, W
   Cordero, JF
   Galvao, LA
   Garces, AL
   Hambidge, KM
   Harris, E
   Ko, A
   Krebs, N
   Marques, ETA
   Martinez, AM
   McClure, E
   Miranda, DB
   Moreira, MEL
   Mussi-Pinhata, MM
   Ochoa, TJ
   Osorio, JE
   Scalabrin, DMF
   Schultz-Cherry, S
   Seage, GR
   Stolka, K
   Ugarte-Gil, CA
   Vega, CMV
   Welton, M
   Ximenes, R
   Zorrilla, C
AF Lebov, Jill F.
   Arias, Juan F.
   Balmaseda, Angel
   Britt, William
   Cordero, Jose F.
   Galvao, Luiz Augusto
   Garces, Ana Lucia
   Hambidge, K. Michael
   Harris, Eva
   Ko, Albert
   Krebs, Nancy
   Marques, Ernesto T. A.
   Martinez, Alexander M.
   McClure, Elizabeth
   Miranda-Filho, Democrito B.
   Lopes Moreira, Maria Elisabeth
   Mussi-Pinhata, Marisa M.
   Ochoa, Theresa J.
   Osorio, Jorge E.
   Scalabrin, Deolinda M. F.
   Schultz-Cherry, Stacey
   Seage, George R., III
   Stolka, Kristen
   Augusto Ugarte-Gil, Cesar
   Vega, Carmen Milagros Velez
   Welton, Michael
   Ximenes, Ricardo
   Zorrilla, Carmen
TI International prospective observational cohort study of Zika in infants
   and pregnancy (ZIP study): study protocol
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Zika virus; Pregnancy; Latin America; Microcephaly
ID VIRUS-INFECTION; BIRTH-DEFECTS; CLINICAL-MANIFESTATIONS; EMERGENCE;
   EXPOSURE; FETUSES; HISTORY; UPDATE; STATES; BRAZIL
AB Background Until recently, Zika virus (ZIKV) infections were considered mild and self-limiting. Since 2015, they have been associated with an increase in microcephaly and other birth defects in newborns. While this association has been observed in case reports and epidemiological studies, the nature and extent of the relationship between ZIKV and adverse pregnancy and pediatric health outcomes is not well understood. With the unique opportunity to prospectively explore the full spectrum of issues related to ZIKV exposure during pregnancy, we undertook a multi-country, prospective cohort study to evaluate the association between ZIKV and pregnancy, neonatal, and infant outcomes. Methods At research sites in ZIKV endemic regions of Brazil (4 sites), Colombia, Guatemala, Nicaragua, Puerto Rico (2 sites), and Peru, up to 10,000 pregnant women will be recruited and consented in the first and early second trimesters of pregnancy and then followed through delivery up to 6 weeks post-partum; their infants will be followed until at least 1 year of age. Pregnant women with symptomatic ZIKV infection confirmed by presence of ZIKV RNA and/or IgM for ZIKV will also be enrolled, regardless of gestational age. Participants will be tested monthly for ZIKV infection; additional demographic, physical, laboratory and environmental data will be collected to assess the potential interaction of these variables with ZIKV infection. Delivery outcomes and detailed infant assessments, including physical and neurological outcomes, will be obtained. Discussion With the emergence of ZIKV in the Americas and its association with adverse pregnancy outcomes in this region, a much better understanding of the spectrum of clinical outcomes associated with exposure to ZIKV during pregnancy is needed. This cohort study will provide information about maternal, fetal, and infant outcomes related to ZIKV infection, including congenital ZIKV syndrome, and manifestations that are not detectable at birth but may appear during the first year of life. In addition, the flexibility of the study design has provided an opportunity to modify study parameters in real time to provide rigorous research data to answer the most critical questions about the impact of congenital ZIKV exposure.
C1 [Lebov, Jill F.; McClure, Elizabeth; Stolka, Kristen] RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
   [Arias, Juan F.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
   [Balmaseda, Angel] Complejo Nacl Salud, Ctr Nacl Diagnost & Referencia, Managua, Nicaragua.
   [Britt, William] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
   [Cordero, Jose F.; Welton, Michael] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Galvao, Luiz Augusto] Fiocruz MS, Ctr Global Hlth CRIS, Rio De Janeiro, Brazil.
   [Garces, Ana Lucia] Fdn Alimentac & Nutr Cent Amer & Panama INCAP, Guatemala City, Guatemala.
   [Hambidge, K. Michael; Krebs, Nancy] Univ Colorado, Sect Nutr, Pediat, Aurora, CO USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Ko, Albert; Scalabrin, Deolinda M. F.] Fundacao Oswaldo Cruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Fiocruz MS, Dept Virol & Expt Therapeut, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Martinez, Alexander M.] Imbanaco Med Ctr, Res Inst, Cali, Colombia.
   [Miranda-Filho, Democrito B.] Univ Pernambuco, Programa Posgrad Ciencias Saude PPGCS, Microcephaly Epidem Res Grp, Recife, PE, Brazil.
   [Lopes Moreira, Maria Elisabeth] Fiocruz MS, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Ochoa, Theresa J.; Augusto Ugarte-Gil, Cesar] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru.
   [Osorio, Jorge E.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Seage, George R., III] Harvard Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Vega, Carmen Milagros Velez] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Ximenes, Ricardo] Univ Fed Pernambuco, Microcephaly Epidem Res Grp, Dept Med Trop, Recife, PE, Brazil.
   [Zorrilla, Carmen] Maternal Infant Studies Ctr CEMI, San Juan, PR USA.
RP Lebov, JF (corresponding author), RTI Int, Social Stat & Environm Sci, Durham, NC 27709 USA.
EM jlebov@rti.org
RI Ugarte-Gil, Cesar/E-6074-2013; Marques, Ernesto T. A/L-4967-2013; Ko,
   Albert Icksang/P-2343-2015; Moreira, Maria Elisabeth Lopes/AAA-3775-2020
OI Ugarte-Gil, Cesar/0000-0002-2833-9087; Marques, Ernesto T.
   A/0000-0003-3826-9358; Ko, Albert Icksang/0000-0001-9023-2339; Moreira,
   Maria Elisabeth Lopes/0000-0002-2034-0294; McClure,
   Elizabeth/0000-0001-8659-5444; Martinez-Blanco, Alexander
   Maximiliano/0000-0001-5755-1776; Galvao, Luiz
   Augusto/0000-0002-3918-0286
FU U.S. National Institute of Child Health and Human Development
   (NICHD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute of Environmental Health Sciences (NIEHS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS);
   Fundacao Oswaldo Cruz-Fiocruz, Brazil; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD040636, U01HD040636, U01HD040636, U01HD040636]
   Funding Source: NIH RePORTER
FX This study is funded through grants from the U.S. National Institute of
   Child Health and Human Development (NICHD); National Institute of
   Allergy and Infectious Diseases (NIAID); National Institute of
   Environmental Health Sciences (NIEHS); and Fundacao Oswaldo
   Cruz-Fiocruz, Brazil. Representatives from each institution provided
   general support, scientific input, and peer review of the study design,
   protocol, consent forms, data collection forms, and analysis plan.
CR Albuquerque MDPM, 2016, EMERG INFECT DIS, V22, P1090, DOI [10.32032/eid2206.160062, 10.3201/eid2206.160062]
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Besnard M, 2016, EUROSURVEILLANCE, V21, P22, DOI 10.2807/1560-7917.ES.2016.21.13.30181
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Guillemette-Artur P, 2016, PEDIATR RADIOL, V46, P1032, DOI 10.1007/s00247-016-3619-6
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Hurtado-Villa P, 2017, PEDIATR INFECT DIS J, V36, P1017, DOI [10.1097/INF.0000000000001670, 10.1097/inf.0000000000001670]
   Kleber de Oliveira Wanderson, 2016, MMWR Morb Mortal Wkly Rep, V65, P242, DOI 10.15585/mmwr.mm6509e2
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Mallet H. P., 2016, Bulletin Epidemiologique Hebdomadaire, P367
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Prazeres J, 2016, BRAZIL JAMA OPHTHALM, V134, P529, DOI [10.1001/jamaophthalmol.2016.0267, DOI 10.1001/JAMA0PHTHALM0L.2016.0267]
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zin AA, 2017, JAMA PEDIATR, V171, P847, DOI 10.1001/jamapediatrics.2017.1474
NR 33
TC 5
Z9 5
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD AUG 7
PY 2019
VL 19
IS 1
AR 282
DI 10.1186/s12884-019-2430-4
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA IO2TY
UT WOS:000479235900001
PM 31391005
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Dirajlal-Fargo, S
   Mussi-Pinhata, MM
   Weinberg, A
   Yu, QL
   Cohen, R
   Harris, DR
   Bowman, E
   Gabriel, J
   Kulkarni, M
   Funderburg, N
   Chakhtoura, N
   McComsey, GA
   Losso, MH
   Foradori, I
   Hakim, A
   Stankievich, E
   Ivalo, S
   Pinto, JA
   Melo, VH
   Kakehasi, F
   Andrade, BM
   Sperhacke, RD
   Golin, N
   Costamilan, SM
   Pilotto, J
   Fernandes, LE
   Falco, G
   Santos, BR
   Lira, RDA
   Peixoto, MF
   Teles, E
   Kreitchmann, R
   Ribeiro, LC
   Motta, F
   Coelho, DF
   Duarte, G
   Barbaro, AAT
   Coutinho, CM
   Amaral, FR
   de Melo, AS
   Oliveira, RHS
   Machado, ES
   Sapia, MCC
   Joao, EC
   Sidi, LC
   Cruz, MLS
   Gouvea, MI
   Saavedra, MC
   Bressan, C
   Jundi, FCA
   Succi, RCD
   Chow, P
   Villaverde, JOA
   Vasquez, CV
   Villafuerte, CG
   Bertucci, Y
   Hance, LF
   Gonin, R
   Hennessey, R
   Korelitz, J
   Krauss, M
   Li, S
   Megazzini, K
   Ortega, O
   de Sanchez, SS
   Stoszek, SK
   Siberry, GK
   Hazra, R
   Mofenson, LM
AF Dirajlal-Fargo, Sahera
   Mussi-Pinhata, Marisa M.
   Weinberg, Adriana
   Yu, Qilu
   Cohen, Rachel
   Harris, D. Robert
   Bowman, Emily
   Gabriel, Janelle
   Kulkarni, Manjusha
   Funderburg, Nicholas
   Chakhtoura, Nahida
   McComsey, Grace A.
   Losso, Marcelo H.
   Foradori, Irene
   Hakim, Alejandro
   Stankievich, Erica
   Ivalo, Silvina
   Pinto, Jorge A.
   Melo, Victor H.
   Kakehasi, Fabiana
   Andrade, Beatriz M.
   Sperhacke, Rosa Dea
   Golin, Nicole
   Costamilan, Silvia Mariani
   Pilotto, Jose
   Fernandes, Luis Eduardo
   Falco, Gisely
   Santos, Breno Riegel
   Alves Lira, Rita de Cassia
   Peixoto, Mario Ferreira
   Teles, Elizabete
   Kreitchmann, Regis
   Ribeiro, Luis Carlos
   Motta, Fabrizio
   Coelho, Debora Fernandes
   Duarte, Geraldo
   Tiraboschi Barbaro, Adriana A.
   Coutinho, Conrado Milani
   Amaral, Fabiana Rezende
   de Melo, Anderson Sanches
   Oliveira, Ricardo Hugo S.
   Machado, Elizabeth S.
   Chermont Sapia, Maria C.
   Joao, Esau Custodio
   Sidi, Leon Claude
   Santos Cruz, Maria Leticia
   Gouvea, Maria Isabel
   Saavedra, Mariza Curto
   Bressan, Clarisse
   Jundi, Fernanda Cavalcanti A.
   de Menezes Succi, Regina Celia
   Chow, Prescilla
   Alarcon Villaverde, Jorge O.
   Velasquez Vasquez, Carlos
   Gutierrez Villafuerte, Cesar
   Bertucci, Yolanda
   Hance, Laura Freimanis
   Gonin, Rene
   Hennessey, Roslyn
   Korelitz, James
   Krauss, Margot
   Li, Sue
   Megazzini, Karen
   Ortega, Orlando
   de Sanchez, Sharon Sothern
   Stoszek, Sonia K.
   Siberry, George K.
   Hazra, Rohan
   Mofenson, Lynne M.
CA NISDI LILAC Protocol
TI HIV-exposed-uninfected infants have increased inflammation and monocyte
   activation
SO AIDS
LA English
DT Article
DE growth; HIV-exposed-uninfected infants; immune activation; inflammation;
   morbidity; oxidative stress
ID INTIMA-MEDIA THICKNESS; ANTIRETROVIRAL EXPOSURE; MICROBIAL
   TRANSLOCATION; ENDOTHELIAL ACTIVATION; MITOCHONDRIAL-DNA; IMMUNE
   ACTIVATION; INFECTED PATIENTS; CHILDREN BORN; T-LYMPHOCYTES; D-DIMER
AB Background: HIV-exposed-uninfected (HEU) infants have increased infectious morbidity and mortality; little is known about their levels of inflammation and monocyte activation.
   Methods: Plasma samples obtained at birth and 6 months from 86 HEU mother-infant pairs enrolled in the National Institute of Child Health and Human Development cohorts in Brazil were compared with 88 HIV-unexposed mother-infant pairs. HIV-infected mothers received antiretroviral therapy during pregnancy, their infants received zidovudine prophylaxis and were not breastfed. IL-6, soluble TNF alpha receptor I (sTNF-RI) and II, soluble CD14, soluble CD163, IFN-gamma-induced protein 10 (IP-10), vascular cell adhesion molecule, oxidized LDL, D-dimer and high-sensitivity C-reactive protein were assayed by ELISA at birth and at 6 months. sTNF-RI and IL-6 were considered coprimary endpoints.
   Results: Among HIV-infected mothers, 79% had HIV-RNA less than 400 copies/ml prior to delivery. Compared with HIV-unexposed, HEU infants had a lower mean gestational age (38.7 vs. 39.3 weeks) and weight (3.1 vs. 3.3 kg); and reached lower weight (5.9 vs. 8.5 kg) and height (53.6 vs. 68.8 cm) at 6 months. With the exception of vascular cell adhesion molecule, inflammatory markers were generally higher (P <= 0.005) in HEU at birth, but at 6 months only sTNF-RI and IL-6 remained higher. For HEU pairs, only IP-10 was associated with maternal levels at birth (P < 0.001). In HEU, elevated levels of high-sensitivity C-reactive protein and IP-10 at birth were associated with lower weight at birth (P = 0.04) and at 6 months (P = 0.04).
   Conclusion: HIV-exposed infants have heightened inflammation and monocyte activation at birth, which for some markers persisted to 6 months of life and was not related to maternal inflammatory status. Inflammation may contribute to the increased HEU infectious morbidity and poor growth. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Dirajlal-Fargo, Sahera; McComsey, Grace A.] Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.
   [Dirajlal-Fargo, Sahera; McComsey, Grace A.] Rainbow Babies & Childrens Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA.
   [Dirajlal-Fargo, Sahera; McComsey, Grace A.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
   [Weinberg, Adriana] Univ Colorado, Anschutz Med Ctr, Div Infect Dis, Denver, CO 80202 USA.
   [Yu, Qilu; Cohen, Rachel; Harris, D. Robert] Westat Corp, Rockville, MD USA.
   [Bowman, Emily; Gabriel, Janelle; Kulkarni, Manjusha; Funderburg, Nicholas] Ohio State Univ, Sch Hlth & Rehabil Sci, Div Med Lab Sci, Columbus, OH 43210 USA.
   [Chakhtoura, Nahida] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
   [Losso, Marcelo H.; Foradori, Irene; Hakim, Alejandro; Stankievich, Erica; Ivalo, Silvina] Hosp Gen Agudos Jose Maria Ramos Mejia, Buenos Aires, DF, Argentina.
   [Pinto, Jorge A.; Melo, Victor H.; Kakehasi, Fabiana; Andrade, Beatriz M.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Sperhacke, Rosa Dea; Golin, Nicole; Costamilan, Silvia Mariani] Univ Caxias do Sul, Serv Municipal Infectol, Caxias Do Sul, Brazil.
   [Pilotto, Jose; Fernandes, Luis Eduardo; Falco, Gisely] Hosp Geral Nova Iguacu, HIV Family Care Clin, Nova Iguacu, Brazil.
   [Sperhacke, Rosa Dea; Santos, Breno Riegel; Alves Lira, Rita de Cassia] Univ Caxias do Sul, Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Sperhacke, Rosa Dea; Peixoto, Mario Ferreira; Teles, Elizabete] Univ Caxias do Sul, Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis; Ribeiro, Luis Carlos; Motta, Fabrizio; Coelho, Debora Fernandes] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Mussi-Pinhata, Marisa M.; Duarte, Geraldo; Tiraboschi Barbaro, Adriana A.; Coutinho, Conrado Milani; Amaral, Fabiana Rezende; de Melo, Anderson Sanches] Univ Sao Paulo, Fac Med Ribeirao Preto, Hosp Clin, Ribeirao Preto, Brazil.
   [Oliveira, Ricardo Hugo S.; Machado, Elizabeth S.; Chermont Sapia, Maria C.] Inst Puericultura & Pediat Martagao Gesteira, Rio De Janeiro, Brazil.
   [Joao, Esau Custodio; Sidi, Leon Claude; Santos Cruz, Maria Leticia; Gouvea, Maria Isabel; Saavedra, Mariza Curto; Bressan, Clarisse; Jundi, Fernanda Cavalcanti A.] Hosp Servidores Estado, Rio De Janeiro, Brazil.
   [de Menezes Succi, Regina Celia; Chow, Prescilla] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Alarcon Villaverde, Jorge O.; Gutierrez Villafuerte, Cesar] UNMSM, Secc Epidemiol, Inst Med Tropicalal Daniel Alcides Carrion, Lima, Peru.
   [Velasquez Vasquez, Carlos] Inst Nacl Materno Perinatal, Lima, Peru.
   [Yu, Qilu; Cohen, Rachel; Harris, D. Robert; Bertucci, Yolanda; Hance, Laura Freimanis; Gonin, Rene; Hennessey, Roslyn; Korelitz, James; Krauss, Margot; Li, Sue; Megazzini, Karen; Ortega, Orlando; de Sanchez, Sharon Sothern; Stoszek, Sonia K.] Westat Corp, Data Management & Stat Ctr, Rockville, MD USA.
   [Siberry, George K.; Hazra, Rohan; Mofenson, Lynne M.] NICHD, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
RP McComsey, GA (corresponding author), Univ Hosp Cleveland Med Ctr, Pediat & Med, 2061 Cornell Rd,Mail Stop 5083, Cleveland, OH 44106 USA.; McComsey, GA (corresponding author), Case Sch Med, 2061 Cornell Rd,Mail Stop 5083, Cleveland, OH 44106 USA.
EM gam9@case.edu
RI Coutinho, Conrado Milani/I-2991-2019; Pinto, Jorge A/D-1743-2014;
   Pilotto, Jose Henrique/AAD-9773-2019
OI Coutinho, Conrado Milani/0000-0003-1966-0466; Pinto, Jorge
   A/0000-0003-2987-3238; Pilotto, Jose Henrique/0000-0003-0521-8597;
   Dirajlal-Fargo, Sahera/0000-0001-9945-9062; Funderburg,
   Nicholas/0000-0003-3113-1217; Bowman, Emily/0000-0003-1783-0361
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-HD-3-3345, HHSN267200800001C, HHSN275201300003C]; University
   Hospitals Cleveland Medical Center; NICHDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [N01-HD-3-3345, HHSN267200800001C, K23HD088295-01A1,
   N01-HD-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD088295, K23HD088295, K23HD088295, K23HD088295, K23HD088295]
   Funding Source: NIH RePORTER
FX The current work was supported by the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD) contracts
   N01-HD-3-3345 (2002-2007), HHSN267200800001C (2007-2012), and
   HHSN275201300003C (2012-2017); by internal funds from University
   Hospitals Cleveland Medical Center (to G.A.M.), and by NICHD to S.D.-F.
   (K23HD088295-01A1).; Principal investigators, coprincipal investigators,
   study coordinators, coordinating center representatives, and NICHD staff
   include: Argentina: Buenos Aires: Marcelo H. Losso, Irene Foradori,
   Alejandro Hakim, Erica Stankievich, Silvina Ivalo (Hospital General de
   Agudos Jose Maria Ramos Mejia); Brazil: Belo Horizonte: Jorge A. Pinto,
   Victor H. Melo, Fabiana Kakehasi, Beatriz M. Andrade (Universidade
   Federal de Minas Gerais); Caxias do Sul: Rosa Dea Sperhacke, Nicole
   Golin, Silvia Mariani Costamilan (Universidade de Caxias do Sul/Servico
   Municipal de Infectologia); Nova Iguacu: Jose Pilotto, Luis Eduardo
   Fernandes, Gisely Falco (Hospital Geral Nova de Iguacu -HIV Family Care
   Clinic); Porto Alegre: Rosa Dea Sperhacke, Breno Riegel Santos, Rita de
   Cassia Alves Lira (Universidade de Caxias do Sul/Hospital Conceicao);
   Rosa Dea Sperhacke, Mario Ferreira Peixoto, Elizabete Teles
   (Universidade de Caxias do Sul/Hospital Femina); Regis Kreitchmann, Luis
   Carlos Ribeiro, Fabrizio Motta, Debora Fernandes Coelho (Irmandade da
   Santa Casa de Misericordia de Porto Alegre); Ribeirao Preto: Marisa M.
   Mussi-Pinhata, Geraldo Duarte, Adriana A. Tiraboschi Barbaro, Conrado
   Milani Coutinho, Fabiana Rezende Amaral, Anderson Sanches de Melo
   (Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da
   Universidade de Sao Paulo); Rio de Janeiro: Ricardo Hugo S. Oliveira,
   Elizabeth S. Machado, Maria C. Chermont Sapia (Instituto de Puericultura
   e Pediatria Martagao Gesteira); Esau Custodio Joao, Leon Claude Sidi,
   Maria Leticia Santos Cruz, Maria Isabel Gouvea, Mariza Curto Saavedra,
   Clarisse Bressan, Fernanda Cavalcanti A. Jundi (Hospital dos Servidores
   do Estado); Sao Paulo: Regina Celia de Menezes Succi, Prescilla Chow
   (Escola Paulista de Medicina-Universidade Federal de Sao Paulo); Peru:
   Lima: Jorge O. Alarcon Villaverde (Instituto de Medicina Tropicalal
   'Daniel Alcides Carrion'-Seccion de Epidemiologia, UNMSM), Carlos
   Velasquez Vasquez (Instituto Nacional Materno Perinatal), Cesar
   Gutierrez Villafuerte (Instituto de Medicina Tropicalal 'Daniel Alcides
   Carrion' -Seccion de Epidemiologia, UNMSM); Data Management and
   Statistical Center: Yolanda Bertucci, Rachel Cohen, Laura Freimanis
   Hance, Rene Gonin, D. Robert Harris, Roslyn Hennessey, James Korelitz,
   Margot Krauss, Sue Li, Karen Megazzini, Orlando Ortega, Sharon Sothern
   de Sanchez, Sonia K. Stoszek, Qilu Yu (Westat, Rockville, MD, USA);
   NICHD: George K. Siberry, Rohan Hazra, Lynne M. Mofenson (Eunice Kennedy
   Shriver National Institute of Child Health and Human Development,
   Bethesda, Maryland, USA). Supported by NICHD Contract #N01-HD-3-3345
   (2002-2007) and by NICHD Contract #HHSN267200800001C (NICHD Control #:
   N01-HD-8-0001) (2007-2012).
CR Aaltonen R, 2005, OBSTET GYNECOL, V106, P802, DOI 10.1097/01.AOG.0000178750.84837.ed
   Abu-Raya B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00383
   Aldamiz-Echevarria T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148537
   Bailey RC, 1999, INT J EPIDEMIOL, V28, P532, DOI 10.1093/ije/28.3.532
   Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brennan AT, 2016, AIDS, V30, P2351, DOI 10.1097/QAD.0000000000001211
   Brites-Alves C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01469
   Brown TT, 2010, DIABETES CARE, V33, P2244, DOI 10.2337/dc10-0633
   Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Dirajlal-Fargo S, 2017, PEDIATR INFECT DIS J, V36, P761, DOI [10.1097/INF.0000000000001544, 10.1097/inf.0000000000001544]
   Economides A, 1998, CLIN DIAGN LAB IMMUN, V5, P230, DOI 10.1128/CDLI.5.2.230-234.1998
   Evans Ceri, 2016, Lancet Infect Dis, V16, pe92, DOI 10.1016/S1473-3099(16)00055-4
   Ford ES, 2010, AIDS, V24, P1509, DOI 10.1097/QAD.0b013e32833ad914
   Girard S, 2016, AM J REPROD IMMUNOL, V75, P8, DOI 10.1111/aji.12444
   Haga T, 2017, PAPILLOMAVIRUS RES, V3, P1, DOI 10.1016/j.pvr.2016.11.003
   Henderson RA, 1996, PEDIATR AIDS HIV INF, V7, P91
   Hileman CO, 2016, AIDS, V30, P65, DOI 10.1097/QAD.0000000000000885
   Hygino J, 2008, CLIN IMMUNOL, V127, P340, DOI 10.1016/j.clim.2008.01.020
   Jao J, 2017, AIDS, V31, P2475, DOI 10.1097/QAD.0000000000001647
   Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750
   Kelesidis T, 2016, AIDS, V30, P2625, DOI 10.1097/QAD.0000000000001238
   Kelesidis T, 2012, J INFECT DIS, V206, P1558, DOI 10.1093/infdis/jis545
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   McComsey GA, 2014, JAIDS-J ACQ IMM DEF, V65, P167, DOI 10.1097/01.qai.0000437171.00504.41
   McHenry MS, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2888
   Miller TL, 2012, HIV MED, V13, P264, DOI 10.1111/j.1468-1293.2011.00970.x
   Monnin ANN, 2018, C RETR OPP INF BOST
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Ono E, 2008, BRAZ J MED BIOL RES, V41, P700, DOI 10.1590/S0100-879X2008000800011
   Powis KM, 2016, AIDS, V30, P211, DOI 10.1097/QAD.0000000000000895
   Prendergast AJ, 2017, J INFECT DIS, V216, P651, DOI 10.1093/infdis/jix367
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
   Reikie BA, 2014, JAIDS-J ACQ IMM DEF, V66, P245, DOI 10.1097/QAI.0000000000000161
   Rosala-Hallas A, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0828-6
   Ross AC, 2012, HIV MED, V13, P98, DOI 10.1111/j.1468-1293.2011.00945.x
   Ross AC, 2010, ATHEROSCLEROSIS, V211, P492, DOI 10.1016/j.atherosclerosis.2010.04.008
   Ross AC, 2009, CLIN INFECT DIS, V49, P1119, DOI 10.1086/605578
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Slogrove AL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00164
   Slyker JA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-7
   So-Armah KA, 2016, JAIDS-J ACQ IMM DEF, V72, P206, DOI 10.1097/QAI.0000000000000954
   Stoszek SK, 2013, INT J GYNECOL OBSTET, V122, P37, DOI 10.1016/j.ijgo.2012.12.021
   Syed SS, 2013, AIDS RES HUM RETROV, V29, P493, DOI [10.1089/aid.2012.0086, 10.1089/AID.2012.0086]
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   Weinberg A, 2017, C RETR OPP INF SEATT
   Weinberg A, 2017, AIDS, V31, P669, DOI 10.1097/QAD.0000000000001393
   Zidar DA, 2015, JAIDS-J ACQ IMM DEF, V69, P154, DOI 10.1097/QAI.0000000000000566
NR 49
TC 12
Z9 12
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD APR 1
PY 2019
VL 33
IS 5
BP 845
EP 853
DI 10.1097/QAD.0000000000002128
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA IQ4AO
UT WOS:000480693500009
PM 30649056
OA Green Accepted, Bronze
DA 2020-12-17
ER

PT J
AU Vanarsdall, AL
   Chin, AL
   Liu, J
   Jardetzky, TS
   Mudd, JO
   Orloff, SL
   Streblow, D
   Mussi-Pinhata, MM
   Yamamoto, AY
   Duarte, G
   Britt, WJ
   Johnson, DC
AF Vanarsdall, Adam L.
   Chin, Andrea L.
   Liu, Jing
   Jardetzky, Theodore S.
   Mudd, James O.
   Orloff, Susan L.
   Streblow, Daniel
   Mussi-Pinhata, Marisa M.
   Yamamoto, Aparecida Y.
   Duarte, Geraldo
   Britt, William J.
   Johnson, David C.
TI HCMV trimer- and pentamer-specific antibodies synergize for virus
   neutralization but do not correlate with congenital transmission
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE congenital; neutralizing antibodies; transplant; cell-to-cell spread;
   vaccines
ID HUMAN CYTOMEGALOVIRUS ENTRY; GLYCOPROTEIN-H; COMPLEX; INFECTION;
   ENVELOPE; GH/GL; GH/GL/UL128-131; PREGNANCY; FETUS; CELLS
AB Human cytomegalovirus (HCMV) causes substantial disease in transplant patients and harms the development of the nervous system in babies infected in utero. Thus, there is a major focus on developing safe and effective HCMV vaccines. Evidence has been presented that a major target of neutralizing antibodies (NAbs) is the HCMV pentamer glycoprotein gH/gL/UL128-131. In some studies, most of the NAbs in animal or human sera were found to recognize the pentamer, which mediates HCMV entry into endothelial and epithelial cells. It was also reported that pentamer-specific antibodies correlate with protection against transmission from mothers to babies. One problem with the studies on pentamer-specific NAbs to date has been that the studies did not compare the pentamer to the other major form of gH/gL, the gH/gL/gO trimer, which is essential for entry into all cell types. Here, we demonstrate that both trimer and pentamer NAbs are frequently found in human transplant patients' and pregnant mothers' sera. Depletion of human sera with trimer caused reductions in NAbs similar to that observed following depletion with the pentamer. The trimer-and pentamer-specific antibodies acted in a synergistic fashion to neutralize HCMV and also to prevent virus cellto- cell spread. Importantly, there was no correlation between the titers of trimer-and pentamer-specific NAbs and transmission of HCMV from mothers to babies. Therefore, both the trimer and pentamer are important targets of NAbs. Nevertheless, these antibodies do not protect against transmission of HCMV from mothers to babies.
C1 [Vanarsdall, Adam L.; Chin, Andrea L.; Johnson, David C.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
   [Liu, Jing; Jardetzky, Theodore S.] Stanford Univ, Dept Struct Biol, Stanford, CA 94305 USA.
   [Mudd, James O.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA.
   [Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA.
   [Streblow, Daniel] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA.
   [Mussi-Pinhata, Marisa M.; Yamamoto, Aparecida Y.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, BR-14049 Sao Paulo, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, BR-14049 Sao Paulo, Brazil.
   [Britt, William J.] Univ Alabama Birmingham, Dept Pediat Microbiol & Neurobiol, Birmingham, AL 35233 USA.
RP Johnson, DC (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
EM johnsoda@ohsu.edu
RI Mussi-Pinhata, Marisa M/G-6568-2012
OI Mussi-Pinhata, Marisa M/0000-0001-8985-1570
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01HD061959, R01AI081517,
   R21AI133192]; Stanford Child Health Research Institute; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R01HD061959, R01HD061959,
   R01HD061959, R01HD061959] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI081517, R01AI081517, R21AI133192, R21AI133192, R01AI081517,
   R01AI081517] Funding Source: NIH RePORTER
FX The research reported in this publication was supported by NIH under
   Awards R01AI081517 (to D.C.J.) and R21AI133192 (to T.S.J.). The project
   was also supported by the Stanford Child Health Research Institute. Sera
   collected from pregnant women were supported by NIH Grant R01HD061959
   (to W.J.B.).
CR Arvin AM, 2004, CLIN INFECT DIS, V39, P233, DOI 10.1086/421999
   Backovic M, 2009, P NATL ACAD SCI USA, V106, P2880, DOI 10.1073/pnas.0810530106
   Britt WJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02392-16
   Burke HG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005227
   Chandramouli S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9176
   Chiuppesi F, 2015, J VIROL, V89, P11884, DOI 10.1128/JVI.01701-15
   Ciferri C, 2015, P NATL ACAD SCI USA, V112, P1767, DOI 10.1073/pnas.1424818112
   Fouts AE, 2012, J VIROL, V86, P7444, DOI 10.1128/JVI.00467-12
   Freed DC, 2013, P NATL ACAD SCI USA, V110, pE4997, DOI 10.1073/pnas.1316517110
   Gardner TJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13627
   Gerna G, 2017, J GEN VIROL, V98, P2215, DOI 10.1099/jgv.0.000882
   Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548
   Huber MT, 1998, J VIROL, V72, P8191, DOI 10.1128/JVI.72.10.8191-8197.1998
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Lilleri D, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1921
   Lilleri D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059863
   Liu J, 2018, J VIROL, V92, DOI 10.1128/JVI.01336-18
   Loughney JW, 2015, J BIOL CHEM, V290, P15985, DOI 10.1074/jbc.M115.652230
   Macagno A, 2010, J VIROL, V84, P1005, DOI 10.1128/JVI.01809-09
   Malito E, 2018, CURR OPIN VIROL, V31, P43, DOI 10.1016/j.coviro.2018.05.004
   Mussi-Pinhata MM, 2018, J INFECT DIS, V218, P1200, DOI 10.1093/infdis/jiy321
   Nigro G, 2005, NEW ENGL J MED, V353, P1350, DOI 10.1056/NEJMoa043337
   Nogalski MT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003463
   Permar SR, 2018, J VIROL, V92, DOI 10.1128/JVI.00030-18
   Revello MG, 2014, NEW ENGL J MED, V370, P1316, DOI 10.1056/NEJMoa1310214
   Revello MG, 2002, CLIN MICROBIOL REV, V15, P680, DOI 10.1128/CMR.15.4.680-715.2002
   Ryckman BJ, 2006, J VIROL, V80, P710, DOI 10.1128/JVI.80.2.710-722.2006
   Ryckman BJ, 2008, J VIROL, V82, P60, DOI 10.1128/JVI.01910-07
   SIMPSON JA, 1993, J VIROL, V67, P489, DOI 10.1128/JVI.67.1.489-496.1993
   Vanarsdall AL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005564
   Vanarsdall AL, 2012, CURR OPIN VIROL, V2, P37, DOI 10.1016/j.coviro.2012.01.001
   Visentin S, 2012, CLIN INFECT DIS, V55, P497, DOI 10.1093/cid/cis423
   Wang CB, 2011, CLIN INFECT DIS, V52, pE11, DOI 10.1093/cid/ciq085
   Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102
   Wang D, 2007, P NATL ACAD SCI USA, V104, P20037, DOI 10.1073/pnas.0709704104
   Wen YX, 2014, VACCINE, V32, P3796, DOI 10.1016/j.vaccine.2014.05.004
   Wille PT, 2010, J VIROL, V84, P2585, DOI 10.1128/JVI.02249-09
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.018
   Zeev-Ben-Mordehai T, 2014, STRUCTURE, V22, P1687, DOI 10.1016/j.str.2014.09.005
   Zhou MM, 2013, J VIROL, V87, P9680, DOI 10.1128/JVI.01167-13
NR 41
TC 14
Z9 14
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2019
VL 116
IS 9
BP 3728
EP 3733
DI 10.1073/pnas.1814835116
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HM7YA
UT WOS:000459694400060
PM 30733288
OA Green Published, Other Gold
DA 2020-12-17
ER

PT J
AU Yeganeh, N
   Watts, DH
   Xu, JH
   Kerin, T
   Joao, EC
   Pilotto, JH
   Theron, G
   Gray, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Veloso, V
   Camarca, M
   Mofenson, L
   Moye, J
   Nielsen-Saines, K
AF Yeganeh, Nava
   Watts, D. Heather
   Xu, Jiahong
   Kerin, Tara
   Joao, Esau C.
   Pilotto, Jose Henrique
   Theron, Gerhard
   Gray, Glenda
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Veloso, Valdilea
   Camarca, Margaret
   Mofenson, Lynne
   Moye, Jack
   Nielsen-Saines, Karin
TI Infectious Morbidity, Mortality and Nutrition in HIV-exposed,
   Uninfected, Formula-fed Infants: Results From the HPTN 040/PACTG 1043
   Trial
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HIV exposed; uninfected infants; formula feeding; undernutrition
ID CHILDREN BORN; BREAST-MILK; PREGNANT-WOMEN; YOUNG-CHILDREN;
   SOUTH-AFRICA; RISK-FACTORS; FOLLOW-UP; MOTHERS; TRANSMISSION; SURVIVAL
AB Background: HIV-exposed uninfected (HEU) infants are a growing population with potentially poor health outcomes. We evaluated morbidity and mortality in HEU formula-fed infants enrolled in the NICHD HPTN 040/PACTG 1043 trial.
   Methods: Infectious morbidity, mortality and undernutrition were evaluated within a cohort of 1000 HEU infants enrolled between April 2004 and April 2010 in Brazil (n = 766) and South Africa (n = 234) as part of the NICHD/HPTN 040 trial of 3 different antiretroviral regimens to decrease intrapartum HIV vertical transmission.
   Results: Twenty-three percent of infants had at least 1 infectious serious adverse effect. Infants born to mothers with <12 years of education [adjusted odds ratio (AOR), 2.6; 95% confidence interval [CI], 1.2-5.9), with maternal viral load of >1,000,000 copies/mL at delivery (AOR, 9.9; 95% CI, 1.6-63.1) were more likely to have infectious serious adverse effects. At 6 months, the infant mortality rate per 1000 live births overall was 222.6, 9.1 +/- 1.8 in Brazil and 64.1 +/- 3 in South Africa. Undernutrition and stunting peaked at 1 month of age with 18% having a weight-for-age Z score -2, and 22% with height for Z score -2. The likelihood of infant mortality was greater among infants born in South Africa compared with Brazil (AOR, 6.2; 95% CI, 2.5-15.8), high maternal viral load (AOR, 1.7; 95% CI, 1.01-2.9) and birth weight-for-age Z score -2 (AOR, 5.2; 95% CI, 1.8-14.8).
   Conclusions: There were high rates of undernutrition, stunting and infectious serious adverse effect in this study's formula-fed HEU population. Suppressing maternal HIV viral load during the peripartum period may be a modifiable risk factor to decrease infant mortality.
C1 [Yeganeh, Nava; Kerin, Tara; Nielsen-Saines, Karin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator & Hlth Diplomacy, Washington, DC 20520 USA.
   [Xu, Jiahong; Camarca, Margaret] Westat Corp, Rockville, MD USA.
   [Joao, Esau C.] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Theron, Gerhard] Stellenbosch Univ, Tygerberg Hosp, Perinatal HIV Res Unit, Cape Town, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa de Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Veloso, Valdilea] Fundacao Oswaldo Cruz Fiocruz, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa Clin DST & AIDS, Rio De Janeiro, Brazil.
   [Mofenson, Lynne] Elisabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
   [Moye, Jack] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Yeganeh, N (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
EM nyeganeh@mednet.ucla.edu
RI Pinto, Jorge A/D-1743-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Mofenson, Lynne/P-9631-2019
OI Pinto, Jorge A/0000-0003-2987-3238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mofenson, Lynne/0000-0002-2818-9808; Joao,
   Esau/0000-0002-2412-0627; Kreitchmann, Regis/0000-0002-1146-0497
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001, U01 AI047986]; National Institute of
   Allergy and Infectious Diseases (NIAID)/National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [K23 AI118584, U01
   AI068632]; National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [AI068632];
   Boehringer Ingelheim Pharmaceuticals, Inc (BIPI)Boehringer Ingelheim;
   GlaxoSmithKline on behalf of ViiV Healthcare; NIAID of the NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI068632, UM1AI068616, UM1AI106716]; Eunice Kennedy
   Shriver NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); NIMHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI068632,
   UM1AI068632, UM1AI069424, UM1AI068632, U01AI047986, UM1AI106716,
   UM1AI068616, UM1AI068616, UM1AI069424, UM1AI068616, UM1AI068616,
   UM1AI106716, U01AI047986, UM1AI106716, U01AI047986, UM1AI069424,
   UM1AI068632, K23AI118584, U01AI068632, U01AI047986, UM1AI106716,
   U01AI068632, K23AI118584, UM1AI068632, U01AI047986, UM1AI068616,
   UM1AI068632, UM1AI106716, UM1AI068632, U01AI068632, UM1AI106716,
   K23AI118584, UM1AI106716, UM1AI068616, UM1AI068616, U01AI068632,
   UM1AI069424, UM1AI068616, UM1AI069424, UM1AI068632, UM1AI068632,
   UM1AI068632, UM1AI068632, U01AI068632, K23AI118584, U01AI068632,
   U01AI047986, U01AI047986, U01AI068632, K23AI118584, U01AI068632,
   UM1AI068616, U01AI047986, U01AI068632, UM1AI069424, U01AI068632,
   UM1AI106716, UM1AI068616] Funding Source: NIH RePORTER
FX The Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) HPTN 040 study was supported by NICHD contract
   number HHSN267200800001C (NICHD control number N01-HD-8-0001) and U01
   AI047986 (Brazilian AIDS Prevention Trials International Network),
   National Institute of Allergy and Infectious Diseases (NIAID)/National
   Institutes of Health (NIH). N.Y. received funding from the NIAID (K23
   AI118584). Overall support for the International Maternal Pediatric
   Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the
   NIAID (U01 AI068632), the NICHD and the National Institute of Mental
   Health (NIMH) [AI068632]. In addition, the study was supported in part
   by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI), and GlaxoSmithKline
   on behalf of ViiV Healthcare. The authors meet criteria for authorship
   as recommended by the International Committee of Medical Journal Editors
   and were fully responsible for all aspects of manuscript development.
   BIPI and GlaxoSmithKline were given the opportunity to check the data
   used in the present manuscript for factual accuracy only. Overall
   support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Network (IMPAACT) was provided by the NIAID of the NIH
   under award numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT
   SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice
   Kennedy Shriver NICHD and the NIMH. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH nor the US Department of State. The authors
   have no other funding or conflicts of interest to disclose.
CR Abu-Raya B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00383
   Adachi K, 2017, CLIN INFECT DIS, V65, P405, DOI 10.1093/cid/cix222
   Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Afran L, 2014, CLIN EXP IMMUNOL, V176, P11, DOI 10.1111/cei.12251
   Asbjornsdottir KH, 2016, J HUM LACT, V32, pNP61, DOI 10.1177/0890334415607854
   Barlow-Mosha L, 2016, CLIN INFECT DIS, V63, P1113, DOI 10.1093/cid/ciw488
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Bork KA, 2014, AM J CLIN NUTR, V100, P1559, DOI 10.3945/ajcn.113.082149
   Caulfield LE, 2004, AM J CLIN NUTR, V80, P193
   Chopra M, 2010, ACTA PAEDIATR, V99, P694, DOI 10.1111/j.1651-2227.2009.01675.x
   CoordenacAo Nacional de DST/AIDS, 2010, REC PREV VERT TRANSM
   Coutsoudis A, 2005, EARLY HUM DEV, V81, P87, DOI 10.1016/j.earlhumdev.2004.10.010
   Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834
   Department of Health for the Republic of South Africa, 2015, NAT CONS GUID PMTCT
   Dewey K G, 1998, J Hum Lact, V14, P89, DOI 10.1177/089033449801400202
   Division of AIDS (DAIDS) Regulatory Support Center, 1994, TABL GRAD SEV PED AD
   Doherty T, 2011, B WORLD HEALTH ORGAN, V89, P62, DOI 10.2471/BLT.10.079798
   Epalza C, 2010, PEDIATRICS, V126, pE631, DOI 10.1542/peds.2010-0183
   Evans Ceri, 2016, Lancet Infect Dis, V16, pe92, DOI 10.1016/S1473-3099(16)00055-4
   Farquhar C, 2005, JAIDS-J ACQ IMM DEF, V40, P494, DOI 10.1097/01.qai.0000168179.68781.95
   Fawzy A, 2011, J INFECT DIS, V203, P1222, DOI 10.1093/infdis/jir019
   Fox MP, 2008, JAIDS-J ACQ IMM DEF, V48, P90, DOI 10.1097/QAI.0b013e31816e39a3
   Garcia-Knight MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143043
   Hanson LA, 2007, P NUTR SOC, V66, P384, DOI 10.1017/S0029665107005654
   Kafulafula G, 2010, JAIDS-J ACQ IMM DEF, V53, P6, DOI 10.1097/QAI.0b013e3181bd5a47
   Kelly MS, 2015, J PEDIAT INF DIS SOC, V4, pE117, DOI 10.1093/jpids/piu092
   Kidzeru EB, 2014, AIDS, V28, P1421, DOI 10.1097/QAD.0000000000000292
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Kuhn L, 2005, AIDS, V19, P1677, DOI 10.1097/01.aids.0000186817.38112.da
   Kuhn L, 2015, J NUTR, V145, P66, DOI 10.3945/jn.114.199794
   Kurewa EN, 2010, J PERINATOL, V30, P88, DOI 10.1038/jp.2009.121
   Marinda E, 2007, PEDIATR INFECT DIS J, V26, P519, DOI 10.1097/01.inf.0000264527.69954.4c
   Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601
   Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167
   Newburg DS, 2009, J ANIM SCI, V87, P26, DOI 10.2527/jas.2008-1347
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Noguera-Julian A, 2015, PEDIATR INFECT DIS J, V34, P1349, DOI 10.1097/INF.0000000000000894
   Omoni AO, 2017, PEDIATR INFECT DIS J, V36, P869, DOI 10.1097/INF.0000000000001574
   PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130
   PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443
   Shapiro RL, 2007, J INFECT DIS, V196, P562, DOI 10.1086/519847
   Slogrove AL, 2010, J TROP PEDIATRICS, V56, P75, DOI 10.1093/tropej/fmp057
   Slogrove A, 2012, J TROP PEDIATRICS, V58, P505, DOI 10.1093/tropej/fms019
   Slogrove AL, 2017, PEDIATR INFECT DIS J, V36, pE38, DOI 10.1097/INF.0000000000001391
   Smith Christiana, 2017, Front Immunol, V8, P470, DOI 10.3389/fimmu.2017.00470
   United Nations Children's Fund, 2015, CHILD SURV 5 MORT CH
   Venkatesh KK, 2011, J TROP PEDIATRICS, V57, P109, DOI 10.1093/tropej/fmq061
   von Mollendorf C, 2015, PEDIATR INFECT DIS J, V34, P27, DOI 10.1097/INF.0000000000000484
   Wahl A, 2015, J VIROL, V89, P10868, DOI 10.1128/JVI.01702-15
   Watts H, 2007, TROP MED INT HEALTH, V12, P584, DOI 10.1111/j.1365-3156.2007.01832.x
   WHO, 2012, IMM SURV ASS MON
   WHO (World Health Organization), 2006, WHO CHILD GROWTH STA
   World Health Organization, 2012, BRAZ CHILD MALN EST
   World Health Organization, 2014, HIV AIDS FACT SHEET
   World Health Organization, 2012, S AFR WHO GLOB DAT C
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
   Zaba B, 2005, EPIDEMIOLOGY, V16, P275, DOI 10.1097/01.ede.0000155507.47884.43
NR 60
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD DEC
PY 2018
VL 37
IS 12
BP 1271
EP 1278
DI 10.1097/INF.0000000000002082
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA HB0VF
UT WOS:000450735800033
PM 29750766
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
   Aragon, DC
   Duarte, G
   Fowler, KB
   Boppana, S
   Britt, WJ
AF Mussi-Pinhata, Marisa M.
   Yamamoto, Aparecida Y.
   Aragon, Davi C.
   Duarte, Geraldo
   Fowler, Karen B.
   Boppana, Suresh
   Britt, William J.
TI Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal
   Infection in a Highly Seropositive Population: "The BraCHS Study"
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE congenital infection; cytomegalovirus; pregnancy; seroconversion
ID CONGENITAL CYTOMEGALOVIRUS; CMV INFECTION; WOMEN; SEROPREVALENCE;
   TRANSMISSION
AB We determined the risk of seroconversion in seronegative pregnant women living in a high seroprevalence population. Cytomegalovirus (CMV)-immunoglobulin G reactivity was determined at the 1st trimester in all women and sequentially for seronegative women. A total of 1915 of 1952 (98.1%; 95% confidence interval [CI], 97.4%-98.7%) women were seropositive, and 36 (1.8%; 95% CI, 1.3%-2.6%) were seronegative. Five of the 36-seronegative women seroconverted for a cumulative rate of 13.9% (95% CI, 4.8%-30.6%). Congenital CMV infection was diagnosed in 1 of 36 infants (2.8%; 95% CI, 0.5%-63.9%) born to seronegative women compared with 8 of 1685 (0.5%; 95% CI, 0.2%-1.0%) infants born to seropositive mothers. Even with a high risk of primary infection in seronegative women, most CMV-infected infants were born to women with pre-existing seroimmunity.
C1 [Mussi-Pinhata, Marisa M.; Yamamoto, Aparecida Y.; Aragon, Davi C.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Sao Paulo, Brazil.
   [Fowler, Karen B.; Boppana, Suresh; Britt, William J.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
RP Mussi-Pinhata, MM (corresponding author), FMRP USP, Dept Puericultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Aragon, Davi C/R-6604-2016; Mussi-Pinhata, Marisa M/G-6568-2012
OI Aragon, Davi C/0000-0003-1019-3654; Mussi-Pinhata, Marisa
   M/0000-0001-8985-1570
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [2R01HD061959-07A2]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP), BrazilFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2013/06579-0]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [R01HD061959, R01HD061959, R01HD061959, R01HD061959] Funding
   Source: NIH RePORTER
FX This work was funded by Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (grant 2R01HD061959-07A2; to W. J.
   B.); and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   Brazil (grant 2013/06579-0; to M. M. M.-P.).
CR Adler SP, 2004, J PEDIATR-US, V145, P485, DOI 10.1016/j.jpeds.2004.05.041
   Barbosa NG, 2018, CLIN INFECT DIS, V67, P743, DOI 10.1093/cid/ciy166
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   Colugnati FAB, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-71
   do Canto C L, 2000, Rev Inst Med Trop Sao Paulo, V42, P179, DOI 10.1590/S0036-46652000000400001
   Griffiths PD, 2001, VACCINE, V19, P1356, DOI 10.1016/S0264-410X(00)00377-7
   Hyde TB, 2010, REV MED VIROL, V20, P311, DOI 10.1002/rmv.659
   KAMADA M, 1983, SCAND J INFECT DIS, V15, P227, DOI 10.3109/inf.1983.15.issue-3.01
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Lamarre V, 2016, EPIDEMIOL INFECT, V144, P1701, DOI 10.1017/S0950268815003167
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Numazaki K, 2000, J Infect Chemother, V6, P104, DOI 10.1007/PL00012146
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
NR 15
TC 14
Z9 14
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2018
VL 218
IS 8
BP 1200
EP 1204
DI 10.1093/infdis/jiy321
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA GT1UJ
UT WOS:000444261400004
PM 29868783
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Adachi, K
   Xu, JH
   Ank, B
   Watts, DH
   Camarca, M
   Mofenson, LM
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Machado, DM
   Ceriotto, M
   Morgado, MG
   Bryson, YJ
   Veloso, VG
   Grinsztejn, B
   Mirochnick, M
   Moye, J
   Nielsen-Saines, K
AF Adachi, Kristina
   Xu, Jiahong
   Ank, Bonnie
   Watts, D. Heather
   Camarca, Margaret
   Mofenson, Lynne M.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Machado, Daisy Maria
   Ceriotto, Mariana
   Morgado, Mariza G.
   Bryson, Yvonne J.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Mirochnick, Mark
   Moye, Jack
   Nielsen-Saines, Karin
CA MPH NICHD HPTN 040 Study Team
TI Congenital Cytomegalovirus and HIV Perinatal Transmission
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE congenital CMV; HIV MTCT; HIV perinatal transmission
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; BIRTH PREVALENCE;
   NEWBORN-INFANTS; REFERRAL CENTER; INFECTION; MOTHERS; EXPRESSION; BORN;
   ENHANCEMENT
AB Background: Congenital cytomegalovirus (CMV) infection (cCMV) is an important cause of hearing loss and cognitive impairment. Prior studies suggest that HIV-exposed children are at higher risk of acquiring cCMV. We assessed the presence, magnitude and risk factors associated with cCMV among infants born to HIV-infected women, who were not receiving antiretrovirals during pregnancy.
   Methods: cCMV and urinary CMV load were determined in a cohort of infants born to HIV-infected women not receiving antiretrovirals during pregnancy. Neonatal urines obtained at birth were tested for CMV DNA by qualitative and reflex quantitative real-time polymerase chain reaction.
   Results: Urine specimens were available for 992 (58.9%) of 1684 infants; 64 (6.5%) were CMV-positive. Mean CMV load (VL) was 470,276 copies/ml (range: < 200-2,000,000 copies/ml). Among 89 HIV-infected infants, 16 (18%) had cCMV versus 42 (4.9%) of 858 HIV-exposed, uninfected infants (P < 0.0001). cCMV was present in 23.2% of infants with in utero and 9.1% infants with intrapartum HIV infection (P < 0.0001). Rates of cCMV among HIV-infected infants were 4-fold greater (adjusted OR, 4.4; 95% CI: 2.3-8.2) and 6-fold greater among HIV in utero-infected infants (adjusted OR, 6; 95% CI: 3-12.1) compared with HIV-exposed, uninfected infants. cCMV was not associated with mode of delivery, gestational age, Apgar scores, 6-month infant mortality, maternal age, race/ethnicity, HIV viral load or CD4 count. Primary cCMV risk factors included infant HIV-infection, particularly in utero infection.
   Conclusion: High rates of cCMV with high urinary CMV VL were observed in HIV-exposed infants. In utero HIV infection appears to be a major risk factor for cCMV in infants whose mothers have not received combination antiretroviral therapy in pregnancy.
C1 [Adachi, Kristina; Ank, Bonnie; Bryson, Yvonne J.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Xu, Jiahong; Camarca, Margaret] Westat Corp, Rockville, MD USA.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Watts, D. Heather; Mofenson, Lynne M.; Moye, Jack] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, RJ, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC, Cape Town, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Cape Town, South Africa.
   [Theron, Gerhard] Stellenbosch Univ, Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Ceriotto, Mariana] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, SP, Brazil.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Mofenson, Lynne M.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
RP Adachi, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave,MDCC 22-442, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Pinto, Jorge A/D-1743-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Mofenson, Lynne/P-9631-2019
OI Pinto, Jorge A/0000-0003-2987-3238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mofenson, Lynne/0000-0002-2818-9808; Joao,
   Esau/0000-0002-2412-0627; Kreitchmann, Regis/0000-0002-1146-0497;
   Machado, Daisy/0000-0003-1993-6442
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001]; NIAID/ NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U01
   AI047986]; National Institute of Allergy and Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI068632, UM1AI068632, UM1AI068616,
   UM1AI106716]; Eunice Kennedy Shriver National Institute of Child Health
   and Human Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [AI068632]; Boehringer
   Ingelheim Pharmaceuticals Inc.Boehringer Ingelheim;
   GlaxoSmithKlineGlaxoSmithKline; UCLA Children's Discovery and Innovation
   Institute through the Harry Winston Fellowship Award; UCLA AIDS
   Institute; UCLA Center for AIDS Research (CFAR) NIH/ NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI02869, AI28697]; UCLA Pediatric AIDS Coalition; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, UM1AI069453,
   P30AI028697, P30AI028697, P30AI028697, U01AI068632, UM1AI069424,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI047986, P30AI028697, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, UM1AI069476, U01AI068632, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, UM1AI069424, P30AI028697,
   U01AI047986, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069424, P30AI028697, UM1AI106716, U01AI068632, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, U01AI068632, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, UM1AI069476, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, UM1AI069453, P30AI028697, P30AI028697,
   U01AI047986, P30AI028697, UM1AI068632, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI069424,
   UM1AI069453, P30AI028697, U01AI047986, UM1AI068616, P30AI028697,
   UM1AI069476, P30AI028697, UM1AI106716, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, UM1AI106716, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   U01AI047986, U01AI068632, UM1AI069453, P30AI028697, UM1AI069476,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, UM1AI069476, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, UM1AI068616, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, U01AI068632, P30AI028697, P30AI028697] Funding Source: NIH
   RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract #
   HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) U01 AI068632, UM1AI068632
   (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC),
   with co-funding from the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH) AI068632. The original parent study was supported
   in part by Boehringer Ingelheim Pharmaceuticals Inc. and
   GlaxoSmithKline, on behalf of ViiV Healthcare. Support was also provided
   by the UCLA Children's Discovery and Innovation Institute through the
   Harry Winston Fellowship Award, the UCLA AIDS Institute, the UCLA Center
   for AIDS Research (CFAR) NIH/ NIAID AI02869 and AI28697, and the UCLA
   Pediatric AIDS Coalition.
CR Barbi M, 2006, PEDIATR INFECT DIS J, V25, P156, DOI 10.1097/01.inf.0000199261.98769.29
   Barbi M, 2006, J CLIN VIROL, V35, P206, DOI 10.1016/j.jcv.2005.08.010
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Boppana SB, 2013, CLIN INFECT DIS, V57, pS178, DOI 10.1093/cid/cit629
   Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006
   DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642
   Delicio AM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-35
   DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315
   Dollard SC, 2007, REV MED VIROL, V17, P355, DOI 10.1002/rmv.544
   Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010
   DUDDING L, 1989, J IMMUNOL, V143, P3343
   Duryea EL, 2010, PEDIATR INFECT DIS J, V29, P915, DOI 10.1097/INF.0b013e3181e0ce05
   Ellington SR, 2016, J INFECT DIS, V213, P891, DOI 10.1093/infdis/jiv549
   Frederick T, 2012, CLIN INFECT DIS, V55, P877, DOI 10.1093/cid/cis535
   Gantt S, 2016, J MED VIROL, V88, P1051, DOI 10.1002/jmv.24420
   Guibert G, 2009, CLIN INFECT DIS, V48, P1516, DOI 10.1086/598934
   HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97
   Kaye S, 2008, J INFECT DIS, V197, P1307, DOI 10.1086/586715
   Khamduang W, 2011, JAIDS-J ACQ IMM DEF, V58, P188, DOI [10.1097/QAI.0B013E31822D0433, 10.1097/QAI.0b013e31822d0433]
   King CC, 2013, CURR HIV RES, V11, P10
   Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203
   LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101
   Manicklal S, 2014, CLIN INFECT DIS, V58, P1467, DOI 10.1093/cid/ciu096
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Marin Gabriel M A, 2005, An Pediatr (Barc), V62, P38
   MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0
   MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   Mwaanza N, 2014, CLIN INFECT DIS, V58, P728, DOI 10.1093/cid/cit766
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Olusanya BO, 2015, PEDIATR INFECT DIS J, V34, P322, DOI 10.1097/INF.0000000000000555
   Reitter A, 2016, MED MICROBIOL IMMUN, V205, P63, DOI 10.1007/s00430-015-0427-9
   RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134
   Robbins JR, 2012, CURR OPIN MICROBIOL, V15, P36, DOI 10.1016/j.mib.2011.11.006
   Ross Shannon A, 2005, Semin Pediatr Infect Dis, V16, P44, DOI 10.1053/j.spid.2004.09.011
   Roxby AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087855
   SCHOPFER K, 1978, ARCH DIS CHILD, V53, P536, DOI 10.1136/adc.53.7.536
   SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508
   Slyker JA, 2009, AIDS, V23, P2173, DOI 10.1097/QAD.0b013e32833016e8
   Spinillo A, 2014, EARLY HUM DEV, V90, pS7, DOI 10.1016/S0378-3782(14)70003-9
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 45
TC 3
Z9 3
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2018
VL 37
IS 10
BP 1016
EP 1021
DI 10.1097/INF.0000000000001975
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA HF0GQ
UT WOS:000453838400019
PM 30216294
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Barbosa, NG
   Yamamoto, AY
   Duarte, G
   Aragon, DC
   Fowler, KB
   Boppana, S
   Britt, WJ
   Mussi-Pinhata, MM
AF Barbosa, Nayara G.
   Yamamoto, Aparecida Y.
   Duarte, Geraldo
   Aragon, Davi C.
   Fowler, Karen B.
   Boppana, Suresh
   Britt, William J.
   Mussi-Pinhata, Marisa M.
TI Cytomegalovirus Shedding in Seropositive Pregnant Women From a
   High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing
   and Maternal Secondary Infection Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE cytomegalovirus; pregnancy; viral shedding; nonprimary maternal
   infections
ID CONGENITAL CYTOMEGALOVIRUS; GENITAL-TRACT; DAY-CARE; NONPREGNANT WOMEN;
   NATURAL-HISTORY; SEXUAL-ACTIVITY; RISK-FACTORS; YOUNG-WOMEN;
   TRANSMISSION; CHILDREN
AB Background. Most congenital cytomegalovirus (CMV) infections in highly seropositive populations occur in infants born to women with preexisting CMV seroimmunity. Although essential for developing prevention strategies, CMV shedding patterns in pregnant women with nonprimary infections have not been characterized. We investigated correlates of CMV shedding in a cohort of seropositive pregnant women.
   Methods. In a prospective study, saliva, urine, vaginal swabs, and blood were collected from 120 CMV-seropositive women in the first, second, and third trimesters and 1 month postpartum. Specimens were tested for CMV DNA by polymerase chain reaction. We analyzed the contribution of the specific maternal characteristics to viral shedding.
   Results. CMV shedding was detected at least once in 42 (35%) women. Mothers living with or providing daily care to young children (3-6 years) were twice as likely to shed CMV at least once compared to women with less exposure to young children (58% vs 26%; adjusted relative risk [aRR], 2.21; 95% confidence interval [CI], 1.37-3.56). Living in crowded households (>= 2 people per room) was associated with viral shedding (64% vs 31%; aRR, 1.99; 95% CI, 1.26-3.13). Sexual activity as indicated by the number of sexual partners per year or condom use was not found to be a correlate of viral shedding.
   Conclusions. CMV shedding is relatively frequent in seropositive pregnant women. The association between virus shedding and caring for young children as well as crowded living conditions may provide opportunities for increased exposures that could lead to CMV reinfections in seropositive women.
C1 [Barbosa, Nayara G.; Yamamoto, Aparecida Y.; Aragon, Davi C.; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ribeirao Preto, Brazil.
   [Fowler, Karen B.; Boppana, Suresh; Britt, William J.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Barbosa, Nayara G/B-9631-2017; Aragon, Davi C/R-6604-2016
OI Aragon, Davi C/0000-0003-1019-3654; Goncalves Barbosa,
   Nayara/0000-0003-3646-4133
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [2R01HD061959-07A2]; Sao Paulo Research Foundation, Brazil
   [2013/06579-0]; National Council for Scientific and Technological
   Development, BrazilNational Council for Scientific and Technological
   Development (CNPq); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959] Funding Source: NIH RePORTER
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (grant number 2R01HD061959-07A2 to
   W. J. B.); Sao Paulo Research Foundation, Brazil (grant number
   2013/06579-0 to M. M. M.-P.), and National Council for Scientific and
   Technological Development, Brazil (fellowship to N. G. B.).
CR ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903
   Arora N, 2010, J INFECT DIS, V202, P1800, DOI 10.1086/657412
   Berntsson M, 2013, ACTA OBSTET GYN SCAN, V92, P706, DOI 10.1111/aogs.12134
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   Britt W, 2015, MED MICROBIOL IMMUN, V204, P263, DOI 10.1007/s00430-015-0399-9
   Cannon MJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0569-1
   Cannon MJ, 2012, PREV MED, V54, P351, DOI 10.1016/j.ypmed.2012.03.009
   Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695
   CHANDLER SH, 1985, J INFECT DIS, V152, P249, DOI 10.1093/infdis/152.2.249
   COLLIER AC, 1995, J INFECT DIS, V171, P33, DOI 10.1093/infdis/171.1.33
   Fowler KB, 2006, PEDIATRICS, V118, pE286, DOI 10.1542/peds.2005-1142
   Gantt S, 2016, J INFECT DIS, V214, P36, DOI 10.1093/infdis/jiw076
   Hamprecht K, 2017, CLIN PERINATOL, V44, P121, DOI 10.1016/j.clp.2016.11.012
   Kaye S, 2008, J INFECT DIS, V197, P1307, DOI 10.1086/586715
   KNOWLES WA, 1982, ARCH VIROL, V73, P25, DOI 10.1007/BF01341724
   KNOX GE, 1979, J INFECT DIS, V140, P419, DOI 10.1093/infdis/140.3.419
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   MONTGOMERY R, 1972, PEDIATRICS, V49, P524
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Novak Z, 2008, J CLIN MICROBIOL, V46, P882, DOI 10.1128/JCM.01079-07
   PASS RF, 1984, PEDIATRICS, V74, P121
   PASS RF, 1986, NEW ENGL J MED, V314, P1414, DOI 10.1056/NEJM198605293142204
   Revello MG, 2014, J CLIN VIROL, V61, P590, DOI 10.1016/j.jcv.2014.10.002
   Ross SA, 2005, J INFECT DIS, V192, P1727, DOI 10.1086/497150
   Schoenfisch AL, 2011, J MED MICROBIOL, V60, P768, DOI 10.1099/jmm.0.027771-0
   SHEN CY, 1993, J CLIN MICROBIOL, V31, P1635, DOI 10.1128/JCM.31.6.1635-1636.1993
   Silver MI, 2011, J CLIN MICROBIOL, V49, P2435, DOI 10.1128/JCM.02206-10
   STAGNO S, 1975, J INFECT DIS, V131, P522, DOI 10.1093/infdis/131.5.522
   Stowell JD, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0568-2
   Tanaka K, 2006, J MED VIROL, V78, P757, DOI 10.1002/jmv.20619
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto A Y, 1998, Rev Soc Bras Med Trop, V31, P19, DOI 10.1590/S0037-86821998000100003
   Yamamoto AY, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.018
   Yan XC, 2015, J MED VIROL, V87, P1046, DOI 10.1002/jmv.24158
   YANG YS, 1995, J MED VIROL, V45, P179, DOI 10.1002/jmv.1890450212
   Zanghellini F, 1999, J INFECT DIS, V180, P702, DOI 10.1086/314939
NR 36
TC 16
Z9 16
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2018
VL 67
IS 5
BP 743
EP 750
DI 10.1093/cid/ciy166
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA GR1HT
UT WOS:000442284400013
PM 29490030
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU de Figueiredo, GG
   Marques, AA
   Mussi-Pinhata, MM
   Silva, WA
   Yamamoto, AY
AF de Figueiredo, Glauciane Garcia
   Marques, Adriana Aparecida
   Mussi-Pinhata, Marisa Marcia
   Silva, Wilson Araujo, Jr.
   Yamamoto, Aparecida Yulie
TI Is the mixture of human cytomegalovirus genotypes frequent in infants
   with congenital infection at birth in a high seroprevalence population?
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE congenital infection; human cytomegalovirus; reinfection; viral
   genotypes
ID MIXED INFECTION; PREGNANT-WOMEN; DIVERSITY; POLYMORPHISMS; GENES; UL144
AB It is still not well known, in a population with high human cytomegalovirus (HCMV) seroprevalence, whether a child with congenital infection harbors multiple viral strains at birth, and whether the prolonged viral excretion in these children is secondary to the persistence of the same viral strain. To verify the genomic diversity of HCMV detected in congenitally infected children, the nucleotide viral sequences from urine and/or saliva obtained at birth from 14 newborns with congenital infection and breast milk obtained from mothers of 5 of these children were analyzed. Among the 14 children, 10 had sequential samples until the median age of 10 months. The viral nucleotide sequences in the breast milk were compared with those identified in the respective children at birth. The differentiation of viral strains was based on the variability of 3 regions of viral genes (UL55/gB, UL144, and UL73/gN). In 13/14 children (92.8%), a single genotype was observed at birth. Different viral genotypes were found in 1 child (7.2%). Among the sequential samples from 10 children, the same genotype obtained at birth was detected in 9/10 (90%), and in 1 of them (10%), a genotype change in the urine was found. More than 1 HCMV strain in milk was observed in 2 mothers (2/5, 40%). In a population with high seroprevalence, a single genotype was found in the majority of infected children. Reinfection did not frequently occur in the first months of life. Maternal reinfection does not seem to be a rare event in transmitter mothers.
C1 [de Figueiredo, Glauciane Garcia; Mussi-Pinhata, Marisa Marcia; Yamamoto, Aparecida Yulie] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ave Bandeirantes 3900, Ribeirao Preto, SP, Brazil.
   [Marques, Adriana Aparecida; Silva, Wilson Araujo, Jr.; Yamamoto, Aparecida Yulie] Univ Sao Paulo, Ribeirao Preto Med Sch, Gen Hosp Ribeirao Preto, Ctr Med Genet, Ribeirao Preto, Brazil.
   [Silva, Wilson Araujo, Jr.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Ribeirao Preto, Brazil.
RP de Figueiredo, GG (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ave Bandeirantes 3900, Ribeirao Preto, SP, Brazil.
EM glaucianegf@yahoo.com.br
RI Silva, Wilson Araujo/E-9487-2011; de Figueiredo, Glauciane
   Garcia/Q-6674-2019; Mussi-Pinhata, Marisa M/G-6568-2012
OI Silva, Wilson Araujo/0000-0001-9364-2886; de Figueiredo, Glauciane
   Garcia/0000-0003-4136-9608; Mussi-Pinhata, Marisa M/0000-0001-8985-1570
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2013/26767-6]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant/Award
   Number: 2013/26767-6
CR Arav-Boger R, 2006, J INFECT DIS, V193, P788, DOI 10.1086/500508
   CHOU SW, 1991, J INFECT DIS, V163, P1229, DOI 10.1093/infdis/163.6.1229
   de Vries JJC, 2012, J CLIN MICROBIOL, V50, P232, DOI 10.1128/JCM.05253-11
   Gorzer I, 2015, J CLIN VIROL, V73, P101, DOI 10.1016/j.jcv.2015.11.003
   Hall TA., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Heo JH, 2008, VIROLOGY, V378, P86, DOI 10.1016/j.virol.2008.05.002
   Ji YH, 2006, J CLIN VIROL, V37, P252, DOI 10.1016/j.jcv.2006.09.007
   Lurain NS, 1999, J VIROL, V73, P10040, DOI 10.1128/JVI.73.12.10040-10050.1999
   Nijman J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108018
   Pati SK, 2013, PEDIATR INFECT DIS J, V32, P1050, DOI 10.1097/INF.0b013e31829bb0b9
   Pignatelli S, 2003, J GEN VIROL, V84, P647, DOI 10.1099/vir.0.18704-0
   Renzette N, 2015, P NATL ACAD SCI USA, V112, pE4120, DOI 10.1073/pnas.1501880112
   Ross SA, 2011, J INFECT DIS, V204, P1003, DOI 10.1093/infdis/jir457
   Rycel M, 2015, EUR J CLIN MICROBIOL, V34, P585, DOI 10.1007/s10096-014-2266-9
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.018
NR 17
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2018
VL 90
IS 8
BP 1389
EP 1397
DI 10.1002/jmv.25205
PG 9
WC Virology
SC Virology
GA GK0JY
UT WOS:000435797200018
PM 29704443
DA 2020-12-17
ER

PT J
AU Weinberg, A
   Mussi-Pinhata, MM
   Yu, QL
   Cohen, RA
   Almeida, VC
   Amaral, FR
   Freimanis, L
   Harris, DR
   Smith, C
   Siberry, G
AF Weinberg, Adriana
   Mussi-Pinhata, Marisa M.
   Yu, Qilu
   Cohen, Rachel A.
   Almeida, Volia C.
   Amaral, Fabiana R.
   Freimanis, Laura
   Harris, Donald Robert
   Smith, Christiana
   Siberry, George
CA NISDI Perinatal LILAC Protocols
TI Factors Associated with Lower Respiratory Tract Infections in
   HIV-Exposed Uninfected Infants
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE HIV-exposed infants; respiratory infection; respiratory syncytial virus;
   tetanus vaccine; HIV infection
ID REVERSE-TRANSCRIPTASE INHIBITORS; CORD BLOOD; NEGATIVE INFANTS;
   PREGNANT-WOMEN; INCREASED RISK; IN-UTERO; UNEXPOSED INFANTS;
   AMNIOTIC-FLUID; CYTOMEGALOVIRUS; ZIDOVUDINE
AB To identify factors that predispose human immunodeficiency virus (HIV)-exposed uninfected infants (HEUs) to higher incidence of severe infections, hospitalization, and death in the first 6-24 months of life compared with HEUs with and without lower respiratory tract infection (LRTI) in the first 6 months of life. Nested case-control study of 107 LRTI+ infants enrolled in the International Site Development Initiative (NISDI) Perinatal and Longitudinal Study in Latin American Countries (LILAC) studies with and 140 LRTI- in the first 6 months, matched by date and place of birth. Infants and mothers had plasma antibodies measured against respiratory syncytial virus (RSV), parainfluenza (PIV) 1, 2, 3, influenza, and pneumococcus 1, 5, 6B, and 14. Compared with LRTI-, mothers of LRTI+ HEUs had lower years of education, lower CD4(+) cells, and higher HIV plasma viral load at delivery, but similar use of antiretrovirals and cotrimoxazole and other sociodemographic characteristics. LRTI+ and LRTI- HEUs had similar demographic and hematological characteristics and antibody concentrations against respiratory pathogens at birth. At 6 months, the rates of seroconversions to respiratory pathogens and antibody responses to tetanus vaccine were also similar. However, antibody concentrations to RSV were significantly higher in LRTI+ compared with LRTI- HEUs and marginally higher to PIV1. Maternal factors associated with advanced HIV disease, but unrelated to the use of antiretrovirals, cotrimoxazole, or the level of maternal antibodies against respiratory pathogens, contribute to the increased risk of LRTI in HEUs. In HEUs, antiretroviral and cotrimoxazole use, exposure to respiratory pathogens and humoral immune responses were not associated with the incidence of LRTI.
C1 [Weinberg, Adriana; Smith, Christiana] Univ Colorado Denver, Dept Pediat, Anschutz Med Ctr, Aurora, CO USA.
   [Weinberg, Adriana; Smith, Christiana] Univ Colorado Denver, Dept Med, Anschutz Med Ctr, Aurora, CO USA.
   [Weinberg, Adriana; Smith, Christiana] Univ Colorado Denver, Dept Pathol, Anschutz Med Ctr, Aurora, CO USA.
   [Mussi-Pinhata, Marisa M.; Amaral, Fabiana R.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
   [Yu, Qilu; Cohen, Rachel A.; Freimanis, Laura; Harris, Donald Robert] Westat Corp, Rockville, MD USA.
   [Almeida, Volia C.] Univ Fed Sao Carlos, Dept Med, Sao Carlos, SP, Brazil.
   [Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Weinberg, A (corresponding author), Univ Colorado Denver, Anschutz Med Ctr, Mail Stop 8604,12700 East 19th Ave,Room 11126, Aurora, CO 80045 USA.
EM adriana.weinberg@ucdenver.edu
RI Smith, Christiana/AAK-7917-2020; Mussi-Pinhata, Marisa M/G-6568-2012
OI Mussi-Pinhata, Marisa M/0000-0001-8985-1570
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-HD-3-3345, HHSN267200800001C, HHSN275201300003C]
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (NICHD) contracts N01-HD-3-3345
   (2002-2007), HHSN267200800001C (2007-2012), and HHSN275201300003C
   (2012-2017). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the views of the National
   Institutes of Health or the Department of Health and Human Services.
CR Adachi K, 2017, CLIN INFECT DIS, V65, P405, DOI 10.1093/cid/cix222
   Adler C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135375
   Andre-Schmutz I, 2013, J INFECT DIS, V208, P235, DOI 10.1093/infdis/jit149
   Bennetto-Hood C, 2009, HIV CLIN TRIALS, V10, P41, DOI [10.1310/hct1001-41, 10.1310/hct1001-041]
   Borges-Almeida E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-38
   Bryson YJ, 2008, HIV CLIN TRIALS, V9, P115, DOI 10.1310/hct0902-115
   Cashat-Cruz Miguel, 2005, Semin Pediatr Infect Dis, V16, P84, DOI 10.1053/j.spid.2005.12.005
   Chappuy H, 2004, ANTIMICROB AGENTS CH, V48, P4332, DOI 10.1128/AAC.48.11.4332-4336.2004
   Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871
   Cohen C, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3272
   Coutsoudis A, 2011, AIDS, V25, P1797, DOI 10.1097/QAD.0b013e32834ad699
   Enomoto L, 2011, AIDS RES HUM RETROV, V27, P47, DOI 10.1089/aid.2010.0067
   Epalza C, 2010, PEDIATRICS, V126, pE631, DOI 10.1542/peds.2010-0183
   Frederick T, 2012, CLIN INFECT DIS, V55, P877, DOI 10.1093/cid/cis535
   GESNER M, 1994, PEDIATRICS, V93, P624
   Gompels UA, 2012, CLIN INFECT DIS, V54, P434, DOI 10.1093/cid/cir837
   Hygino J, 2008, CLIN IMMUNOL, V127, P340, DOI 10.1016/j.clim.2008.01.020
   Hygino J, 2011, J CLIN IMMUNOL, V31, P186, DOI 10.1007/s10875-010-9485-3
   Inostroza J, 2005, CLIN DIAGN LAB IMMUN, V12, P722, DOI 10.1128/CDLI.12.6.722-726.2005
   Jackson JB, 2006, AIDS, V20, P217
   Kelly MS, 2015, J PEDIAT INF DIS SOC, V4, pE117, DOI 10.1093/jpids/piu092
   Kidzeru EB, 2014, AIDS, V28, P1421, DOI 10.1097/QAD.0000000000000292
   Kourtis AP, 2013, AIDS, V27, P749, DOI 10.1097/QAD.0b013e32835ca29f
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Pinzon-Rondon AM, 2016, PAEDIATR INT CHILD H, V36, P84, DOI 10.1179/2046905515Y.0000000021
   Marinda E, 2007, PEDIATR INFECT DIS J, V26, P519, DOI 10.1097/01.inf.0000264527.69954.4c
   Mazzola TN, 2011, AIDS, V25, P2079, DOI 10.1097/QAD.0b013e32834bba0a
   McCormack SA, 2014, CLIN PHARMACOKINET, V53, P989, DOI 10.1007/s40262-014-0185-7
   Miyamoto M, 2010, J TROP PEDIATRICS, V56, P427, DOI 10.1093/tropej/fmq024
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Mussi-Pinhata MM, 2010, INT J INFECT DIS, V14, pE176, DOI 10.1016/j.ijid.2010.01.006
   Mwaanza N, 2014, CLIN INFECT DIS, V58, P728, DOI 10.1093/cid/cit766
   Nascimento-Carvalho CM, 2002, PEDIATR PULM, V33, P244, DOI 10.1002/ppul.10078
   Nielsen SD, 2001, BLOOD, V98, P398, DOI 10.1182/blood.V98.2.398
   Olivero OA, 1999, AIDS, V13, P919, DOI 10.1097/00002030-199905280-00007
   Ota MOC, 1999, AIDS, V13, P996, DOI 10.1097/00002030-199905280-00020
   Quataert S, 2001, IMMUNOL INVEST, V30, P191, DOI 10.1081/IMM-100105064
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
   Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997
   Shapiro RL, 2016, C RETR OPP INF BOST
   Simani OE, 2013, AIDS, V27, P1583, DOI 10.1097/QAD.0b013e32835fae26
   Slogrove A, 2012, J TROP PEDIATRICS, V58, P505, DOI 10.1093/tropej/fms019
   Slogrove AL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00164
   Smith Christiana, 2017, Front Immunol, V8, P470, DOI 10.3389/fimmu.2017.00470
   Sonego M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116380
   Taron-Brocard C, 2014, CLIN INFECT DIS, V59, P1332, DOI 10.1093/cid/ciu586
   Temmerman M, 2000, SEX TRANSM INFECT, V76, P117, DOI 10.1136/sti.76.2.117
   Van Rie A, 2006, CLIN VACCINE IMMUNOL, V13, P246, DOI 10.1128/CVI.13.2.246-252.2006
   von Mollendorf C, 2015, CLIN INFECT DIS, V60, P1346, DOI 10.1093/cid/civ059
   Weinberg A, 2017, AIDS, V31, P669, DOI 10.1097/QAD.0000000000001393
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 52
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2018
VL 34
IS 6
BP 527
EP 535
DI 10.1089/aid.2017.0245
EA APR 2018
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GI8LO
UT WOS:000430630600001
PM 29620934
OA Green Published
DA 2020-12-17
ER

PT J
AU Succi, RCM
   Krauss, MR
   Harris, DR
   Machado, DM
   de Moraes-Pinto, MI
   Mussi-Pinhata, MM
   Ruz, NP
   Pierre, RB
   Roca, LAK
   Joao, E
   Foradori, I
   Scotta, MC
   Hazra, R
   Siberry, GK
AF Succi, Regina C. M.
   Krauss, Margot R.
   Harris, D. Robert
   Machado, Daisy M.
   de Moraes-Pinto, Maria I.
   Mussi-Pinhata, Marisa M.
   Pavia Ruz, Noris
   Pierre, Russell B.
   Kolevic Roca, Lenka A.
   Joao, Esau
   Foradori, Irene
   Scotta, Marcelo C.
   Hazra, Rohan
   Siberry, George K.
CA NISDI Pediat Study Grp 2012
TI Immunity After Childhood Vaccinations in Perinatally HIV-exposed
   Children With and Without HIV Infection in Latin America
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pediatric HIV infection; vaccination; immunity; Latin America
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INFLUENZAE
   TYPE-B; PROTECTIVE ANTIBODY; MEASLES; IMMUNIZATION; VACCINES; TETANUS;
   PREVALENCE; IMMUNOGENICITY
AB Background: Perinatally HIV-infected (PHIV) children are at risk for under-vaccination and poor vaccine response at 4 years of age. Childhood vaccine coverage and immune response were compared between PHIV and HIV-exposed uninfected (HEU) children in Latin America and the Caribbean.
   Methods: PHIV and HEU children were enrolled prospectively at 15 sites from 2002 to 2009. Full vaccination by age 4 years was defined as: 3 hepatitis B virus vaccine doses; 4 tetanus toxoid-containing vaccine doses; 3 doses of Haemophilus influenzae type b vaccine by age 12 months or >= 1 dose given after age 12 months; one measles-containing vaccine dose; one rubella-containing vaccine dose. Immunity was defined by serum antibody titer. Fisher exact test (for categorical measures) and t test (for continuous measures) were used for comparisons.
   Results: Among 519 children seen at age 4 years, 191 had serum specimens available (137 PHIV, 54 HEU). Among those with specimens available, 29.3% initiated combination antiretroviral therapy (cART) <12 months of age, 30.9% initiated at >= 12 months of age, and 39.8% had not received cART by the time they were seen at 4 years of age. At 4 years of age, 59.9% were on PI-containing cART (cART/PI), and 20.4% were on no ART. PHIV children were less likely than HEU children to be fully vaccinated for tetanus (55.5% vs. 77.8%, P = 0.005) and measles and rubella (both 70.1% vs. 94.4%, P < 0.001). Among those fully vaccinated, immunity was significantly lower among PHIV than HEU for all vaccines examined: 20.9% versus 37.8% for hepatitis B virus (P = 0.04), 72.0% versus 90.5% for tetanus (P = 0.02), 51.4% versus 68.8% for H. influenzae type b (P = 0.05), 80.2% versus 100% for measles (P < 0.001) and 72.9% versus 98.0% for rubella (P < 0.001) vaccine, respectively.
   Conclusions: Compared with HEU, PHIV children were significantly less likely to be immune to vaccine-preventable diseases when fully vaccinated. Strategies to increase immunity against vaccine-preventable diseases among PHIV require further study.
C1 [Succi, Regina C. M.; Machado, Daisy M.; de Moraes-Pinto, Maria I.] Univ Fed Sao Paulo, Escola Paulista Med, UNIFESP, Sao Paulo, Brazil.
   [Krauss, Margot R.; Harris, D. Robert] Westat Corp, Rockville, MD USA.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Pavia Ruz, Noris] Hosp Infantil Mexico Dr Federico Gomez, Clin Inmunodeficiencias, Mexico City, DF, Mexico.
   [Pavia Ruz, Noris] Hosp Infantil Mexico Dr Federico Gomez, Dept Infectol, Mexico City, DF, Mexico.
   [Pierre, Russell B.] Univ West Indies, Dept Child & Adolescent Hlth, Kingston, Jamaica.
   [Kolevic Roca, Lenka A.] Natl Univ San Marcos, Natl Inst Child Hlth, Lima, Peru.
   [Kolevic Roca, Lenka A.] Natl Univ San Marcos, Fac Med, Lima, Peru.
   [Joao, Esau] Hosp Fed Serv Estado, Infect Dis Dept, Rio De Janeiro, Brazil.
   [Foradori, Irene] Univ Buenos Aires, Fac Med, Buenos Aires, DF, Argentina.
   [Scotta, Marcelo C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Dept Pediat, Porto Alegre, RS, Brazil.
   [Scotta, Marcelo C.] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Hazra, Rohan; Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, 6100 Execut Blvd,Room 4B11H, Bethesda, MD 20892 USA.
RP Siberry, GK (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, 6100 Execut Blvd,Room 4B11H, Bethesda, MD 20892 USA.
EM siberryg@mail.nih.gov
RI ; Mussi-Pinhata, Marisa M/G-6568-2012
OI Joao, Esau/0000-0002-2412-0627; Mussi-Pinhata, Marisa
   M/0000-0001-8985-1570; Machado, Daisy/0000-0003-1993-6442
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   HHSN267200800001C, HHSN275201300003C]
FX Supported by NICHD, Contract # N01-HD-3-3345 (2002-2007),
   HHSN267200800001C (2007-2012) and HHSN275201300003C (2012-2017). The
   findings and conclusions in this report are those of the authors and do
   not necessarily represent the views of the National Institutes of Health
   or the Department of Health and Human Services. The authors have no
   funding or conflicts of interest to disclose.
CR Aurpibul L, 2006, HIV MED, V7, P467, DOI 10.1111/j.1468-1293.2006.00409.x
   Bekker V, 2006, PEDIATRICS, V118, pE315, DOI 10.1542/peds.2005-2616
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036
   Choudhury SA, 2013, INT J INFECT DIS, V17, pE1249, DOI 10.1016/j.ijid.2013.07.008
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077, DOI 10.1093/infdis/173.5.1077
   Farquhar C, 2009, PEDIATR INFECT DIS J, V28, P295, DOI 10.1097/INF.0b013e3181903ed3
   Fernandes SJ, 2008, VACCINE, V26, P1032, DOI 10.1016/j.vaccine.2007.12.020
   Hazra R, 2009, INT J EPIDEMIOL, V38, P1207, DOI 10.1093/ije/dyn239
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Kristiansen M, 1997, APMIS, V105, P843, DOI 10.1111/j.1699-0463.1997.tb05093.x
   Lao-araya M, 2011, VACCINE, V29, P3977, DOI 10.1016/j.vaccine.2011.03.077
   Lima M, 2004, PEDIATR INFECT DIS J, V23, P604, DOI 10.1097/01.inf.0000128780.79145.5c
   Lindgren-Alves C R, 2001, J Pediatr (Rio J), V77, P496
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Mangtani P, 2010, VACCINE, V28, P1677, DOI 10.1016/j.vaccine.2009.12.011
   Melvin AJ, 2003, PEDIATRICS, V111, pE641, DOI 10.1542/peds.111.6.e641
   Menson EN, 2012, HIV MED, V13, P333, DOI 10.1111/j.1468-1293.2011.00982.x
   Ministry of Health Brazil, 2014, CLIN PROT ANT THER R
   Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61
   Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, 2013, GUID PREV TREATM OPP
   Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106
   Pichichero ME, 2009, PEDIATRICS, V124, P1633, DOI 10.1542/peds.2008-3645
   Pickering LK, 2012, RED BOOK 2012 REPORT, P369
   Siberry GK, 2015, CLIN INFECT DIS, V61, P988, DOI 10.1093/cid/civ440
   Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127
   Siriaksorn S, 2006, VACCINE, V24, P3095, DOI 10.1016/j.vaccine.2006.01.045
   Stark K, 1999, VACCINE, V17, P844, DOI 10.1016/S0264-410X(98)00269-2
   Succi RCM, 2013, PEDIATR INFECT DIS J, V32, P845, DOI 10.1097/INF.0b013e31828bbe68
   Watanaveeradej Veerachai, 2002, International Journal of Infectious Diseases, V6, P240, DOI 10.1016/S1201-9712(02)90120-7
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169, DOI 10.1080/00034989958654
NR 31
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 2018
VL 37
IS 4
BP 304
EP 309
DI 10.1097/INF.0000000000001831
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA GF1RP
UT WOS:000431713300013
PM 29140938
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Adachi, K
   Xu, JH
   Yeganeh, N
   Camarca, M
   Morgado, MG
   Watts, DH
   Mofenson, LM
   Veloso, VG
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, DM
   Bryson, YJ
   Grinsztejn, B
   Moye, J
   Klausner, JD
   Bristow, CC
   Dickover, R
   Mirochnick, M
   Nielsen-Saines, K
AF Adachi, Kristina
   Xu, Jiahong
   Yeganeh, Nava
   Camarca, Margaret
   Morgado, Mariza G.
   Watts, D. Heather
   Mofenson, Lynne M.
   Veloso, Valdilea G.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy Maria
   Bryson, Yvonne J.
   Grinsztejn, Beatriz
   Moye, Jack
   Klausner, Jeffrey D.
   Bristow, Claire C.
   Dickover, Ruth
   Mirochnick, Mark
   Nielsen-Saines, Karin
CA NICHD HPTN 040 Study Team
TI Combined evaluation of sexually transmitted infections in HIV-infected
   pregnant women and infant HIV transmission
SO PLOS ONE
LA English
DT Article
ID CONGENITAL CYTOMEGALOVIRUS-INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CHLAMYDIA-TRACHOMATIS INFECTION; GENITAL-TRACT INFECTIONS; TO-CHILD
   TRANSMISSION; PERINATAL TRANSMISSION; RISK; SYPHILIS; DISEASES;
   CHORIOAMNIONITIS
AB Background
   Sexually transmitted infections (STIs) including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Treponema pallidum (TP), and cytomegalovirus (CMV) may lead to adverse pregnancy and infant outcomes. The role of combined maternal STIs in HIV mother-to-child transmission (MTCT) was evaluated in mother-infant pairs from NICHD HPTN 040.
   Methodology
   Urine samples from HIV-infected pregnant women during labor were tested by polymerase chain reaction (PCR) for CT, NG, and CMV. Infant HIV infection was determined by serial HIV DNA PCR testing. Maternal syphilis was tested by VDRL and confirmatory treponemal antibodies.
   Results
   A total of 899 mother-infant pairs were evaluated. Over 30% had at least one of the following infections (TP, CT, NG, and/or CMV) detected at the time of delivery. High rates of TP (8.7%), CT (17.8%), NG (4%), and CMV (6.3%) were observed. HIV MTCT was 9.1% (n = 82 infants). HIV MTCT was 12.5%, 10.3%, 11.1%, and 26.3% among infants born to women with CT, TP, NG or CMV respectively. Forty-two percent of HIV-infected infants were born to women with at least one of these 4 infections. Women with these infections were nearly twice as likely to have an HIV-infected infant (aOR 1.9, 95% CI 1.1-3.0), particularly those with 2 STIs (aOR 3.4, 95% CI 1.5-7.7). Individually, maternal CMV (aOR 4.4 1.5-13.0) and infant congenital CMV (OR 4.1, 95% CI 2.2-7.8) but not other STIs (TP, CT, or NG) were associated with an increased risk of HIV MTCT.
   Conclusion
   HIV-infected pregnant women identified during labor are at high risk for STIs. Co-infection with STIs including CMV nearly doubles HIV MTCT risk. CMV infection appears to confer the largest risk of HIV MTCT.
C1 [Adachi, Kristina; Yeganeh, Nava; Bryson, Yvonne J.; Klausner, Jeffrey D.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA 90095 USA.
   [Xu, Jiahong; Camarca, Margaret] Westat Corp, Rockville, MD USA.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Mofenson, Lynne M.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, RJ, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC & Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Theron, Gerhard] Stellenbosch Univ, Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Moye, Jack] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Klausner, Jeffrey D.] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA.
   [Bristow, Claire C.] UCSD Sch Med, La Jolla, CA USA.
   [Dickover, Ruth] UC Davis Sch Med, Davis, CA USA.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Adachi, K (corresponding author), David Geffen UCLA Sch Med, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Pilotto, Jose Henrique/AAD-9773-2019; Mofenson, Lynne/P-9631-2019;
   Pinto, Jorge A/D-1743-2014; Mussi-Pinhata, Marisa M/G-6568-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Mofenson,
   Lynne/0000-0002-2818-9808; Pinto, Jorge A/0000-0003-2987-3238;
   Kreitchmann, Regis/0000-0002-1146-0497; Joao, Esau/0000-0002-2412-0627;
   Mussi-Pinhata, Marisa M/0000-0001-8985-1570; Machado,
   Daisy/0000-0003-1993-6442
FU NICHD (NICHD) [HHSN267200800001C, N01-HD-8-0001]; (Brazilian AIDS
   Prevention Trials International Network), NIAID/ NIH [U01 AI047986];
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI068632, UM1AI068632, UM1AI068616, UM1AI106716];
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [AI068632]; Boehringer
   Ingelheim Pharmaceuticals Inc. (BIPI)Boehringer Ingelheim;
   GlaxoSmithKline, on behalf of ViiV Healthcare; Cepheid for the testing
   of CT; NG in a prior HPTN [040]; UCLA Children's Discovery and
   Innovation Institute (CDI) through the Harry Winston Fellowship Award;
   UCLA AIDS Institute; UCLA Center for AIDS Research (CFAR) NIH/
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI02869, AI28697]; UCLA Pediatric AIDS
   Coalition, and Westat; NIH/NICHDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [HHSN275201300003C]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI068632, UM1AI069476,
   UM1AI068632, K23AI118584, K23AI118584, UM1AI069453, UM1AI069476,
   UM1AI068632, UM1AI069453, UM1AI068632, UM1AI069476, UM1AI069453,
   UM1AI069476, UM1AI068632, UM1AI069476, UM1AI068632, K23AI118584,
   UM1AI069476, UM1AI068632, K23AI118584, UM1AI068632, UM1AI068632,
   UM1AI068632, UM1AI069476, UM1AI069453, UM1AI069476, UM1AI069476,
   K23AI118584] Funding Source: NIH RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract
   #HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) U01 AI068632, UM1AI068632
   (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC),
   with co-funding from the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH) AI068632. The original parent study was supported
   in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and
   GlaxoSmithKline, on behalf of ViiV Healthcare and support was also
   received from Cepheid for the testing of CT and NG in a prior HPTN 040
   sub-study. Support was also provided by the UCLA Childrens Discovery and
   Innovation Institute (CDI) through the Harry Winston Fellowship Award,
   the UCLA AIDS Institute, the UCLA Center for AIDS Research (CFAR)
   NIH/NIAID AI02869 and AI28697, the UCLA Pediatric AIDS Coalition, and
   Westat contract with NIH/NICHD HHSN275201300003C. The content,
   conclusions and opinions expressed in this article are those of the
   authors and do not necessarily represent those of the National
   Institutes of Health, the U.S. Department of Health and Human Services,
   or the U.S. Department of State, affiliated universities, programs or
   companies. Co-authors Margaret Camarca and Jiahong Xu were employed by
   Westat. Westat provided support in the form of salary for the co-authors
   MC and JX but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The authors, themselves, did play a role in the study
   design, data collection, analysis, preparation of the manuscript. The
   specific roles of these authors to the study are articulated in the
   author contributions section.
CR Adachi K, 2017, CLIN INFECT DIS, V65, P405, DOI 10.1093/cid/cix222
   Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Adler SP, 2007, SEMIN PERINATOL, V31, P10, DOI 10.1053/j.semperi.2007.01.002
   Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695
   Chaisilwattana P, 1997, SEX TRANSM DIS, V24, P495, DOI 10.1097/00007435-199710000-00001
   Chen KT, 2005, OBSTET GYNECOL, V106, P1341, DOI 10.1097/01.AOG.0000185917.90004.7c
   Chi BH, 2006, AM J OBSTET GYNECOL, V194, P174, DOI 10.1016/j.ajog.2005.06.081
   CONBOY TJ, 1987, J PEDIATR-US, V111, P343, DOI 10.1016/S0022-3476(87)80451-1
   Drake AL, 2007, OBSTET GYNECOL, V109, P403, DOI 10.1097/01.AOG.0000251511.27725.5c
   Ellington SR, 2016, J INFECT DIS, V213, P891, DOI 10.1093/infdis/jiv549
   Fawzi W, 2001, AIDS, V15, P1157, DOI 10.1097/00002030-200106150-00011
   Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001
   Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6
   Goldenberg RL, 1998, LANCET, V352, P1927, DOI 10.1016/S0140-6736(98)04453-5
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1065, DOI 10.1016/j.ajog.2006.05.046
   Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158
   Hammerschlag MR, 2011, CLIN INFECT DIS, V53, pS99, DOI 10.1093/cid/cir699
   ISTAS AS, 1995, CLIN INFECT DIS, V20, P665, DOI 10.1093/clinids/20.3.665
   Ivarsson SA, 2003, J PEDIATR ENDOCR MET, V16, P1233
   Johnson EL, 2016, CURR OPIN INFECT DIS, V29, P248, DOI 10.1097/QCO.0000000000000267
   Johnson EL, 2015, J INFECT DIS, V211, P187, DOI 10.1093/infdis/jiu424
   Johnson LF, 2008, SEX TRANSM DIS, V35, P946, DOI 10.1097/OLQ.0b013e3181812d15
   Kaul R, 2008, J REPROD IMMUNOL, V77, P32, DOI 10.1016/j.jri.2007.02.002
   Khamduang W, 2011, JAIDS-J ACQ IMM DEF, V58, P188, DOI [10.1097/QAI.0B013E31822D0433, 10.1097/QAI.0b013e31822d0433]
   King CC, 2013, CURR HIV RES, V11, P10
   LeFevre ML, 2014, ANN INTERNAL MED
   Lurain NS, 2004, J INFECT DIS, V190, P619, DOI 10.1086/422533
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Maupin R Jr, 2004, J Matern Fetal Neonatal Med, V16, P45
   Mayaud P, 2004, SEX TRANSM INFECT, V80, P174, DOI 10.1136/sti.2002.004101
   McClelland RS, 2001, AIDS, V15, P105, DOI 10.1097/00002030-200101050-00015
   Mwaanza N, 2013, CLIN INFECT DIS OFFI
   Mwanyumba F, 2002, J ACQ IMMUN DEF SYND, V29, P262, DOI 10.1097/00126334-200203010-00006
   Nielsen-Saines K, 2013, INCREASED CMV COINFE
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Rotchford K, 2000, SEX TRANSM DIS, V27, P243, DOI 10.1097/00007435-200005000-00001
   Silveira MF, 2010, INT J STD AIDS, V21, P367, DOI 10.1258/ijsa.2010.009559
   Silveira MF, 2009, INT J STD AIDS, V20, P465, DOI 10.1258/ijsa.2008.008388
   Sullivan EA, 2004, INT J STD AIDS, V15, P116, DOI 10.1258/095646204322764316
   Taha TE, 2006, AIDS, V20, P1313, DOI 10.1097/01.aids.0000232240.05545.08
   Taha TE, 2000, ANN NY ACAD SCI, V918, P84
   Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379
   Walker DG, 2002, LANCET INFECT DIS, V2, P432, DOI 10.1016/S1473-3099(02)00319-5
   Walker GJA, 2007, SEMIN FETAL NEONAT M, V12, P198, DOI 10.1016/j.siny.2007.01.019
   Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P258, DOI 10.1053/j.spid.2005.06.006
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P245
   Woods CR, 2009, PEDIATR INFECT DIS J, V28, P536, DOI 10.1097/INF.0b013e3181ac8a69
   Workowski Kimberly A., 2010, Morbidity and Mortality Weekly Report, V59, P1
   World Health Organization, 2012, GLOB INC PREV SEL CU
   World Health Organization, 2006, GLOB STRAT PREV CONT
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 53
TC 11
Z9 13
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 5
PY 2018
VL 13
IS 1
AR e0189851
DI 10.1371/journal.pone.0189851
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FR9OU
UT WOS:000419403800025
PM 29304083
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Ramalho, FS
   Yamamoto, AY
   da Silva, LL
   Figueiredo, LTM
   Rocha, LB
   Neder, L
   Teixeira, SR
   Apolinario, LA
   Ramalho, LNZ
   Silva, DM
   Coutinho, CM
   Melli, PP
   Augusto, MJ
   Santoro, LB
   Duarte, G
   Mussi-Pinhata, MM
AF Ramalho, Fernando S.
   Yamamoto, Aparecida Y.
   da Silva, Luis L.
   Figueiredo, Luiz T. M.
   Rocha, Lenaldo B.
   Neder, Luciano
   Teixeira, Sara R.
   Apolinario, Leticia A.
   Ramalho, Leandra N. Z.
   Silva, Deisy M.
   Coutinho, Conrado M.
   Melli, Patricia P.
   Augusto, Marlei J.
   Santoro, Ligia B.
   Duarte, Geraldo
   Mussi-Pinhata, Marisa M.
TI Congenital Zika Virus Infection Induces Severe Spinal Cord Injury
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; flavivirus; spinal cord injury; cortical atrophy; cerebellar
   aplasia
ID BRAIN
AB We report 2 fatal cases of congenital Zika virus (ZIKV) infection. Brain anomalies, including atrophy of the cerebral cortex and brainstem, and cerebellar aplasia were observed. The spinal cord showed architectural distortion, severe neuronal loss, and microcalcifications. The ZIKV proteins and flavivirus-like particles were detected in cytoplasm of spinal neurons, and spinal cord samples were positive for ZIKV RNA.
C1 [Ramalho, Fernando S.; Neder, Luciano; Apolinario, Leticia A.; Ramalho, Leandra N. Z.; Silva, Deisy M.; Augusto, Marlei J.; Santoro, Ligia B.] Univ Fed Triangulo Mineiro, Dept Pathol, Uberaba, Brazil.
   [Yamamoto, Aparecida Y.; Mussi-Pinhata, Marisa M.] Univ Fed Triangulo Mineiro, Dept Pediat, Uberaba, Brazil.
   [da Silva, Luis L.] Univ Fed Triangulo Mineiro, Dept Cell & Mol Biol, Uberaba, Brazil.
   [Figueiredo, Luiz T. M.; Teixeira, Sara R.] Univ Fed Triangulo Mineiro, Dept Med, Uberaba, Brazil.
   [Rocha, Lenaldo B.] Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Uberaba, Brazil.
   [Coutinho, Conrado M.; Melli, Patricia P.; Duarte, Geraldo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ribeirao Preto, Brazil.
RP Ramalho, FS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pathol, BR-14049900 Ribeirao Preto, SP, Brazil.
EM framalho@fmrp.usp.br
RI daSilva, Luis LP/AAD-5657-2019; Mussi-Pinhata, Marisa/G-6568-2012;
   daSilva, Luis LP/A-9949-2010; Coutinho, Conrado Milani/I-2991-2019;
   Ramalho, Fernando Silva/G-3817-2012; Rocha, Lenaldo B/D-2382-2011;
   Duarte, Geraldo/J-7906-2012; Ramalho, Leandra/A-3983-2010; Reis
   Teixeira, Sara/N-7236-2016
OI daSilva, Luis LP/0000-0003-3558-0087; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; daSilva, Luis LP/0000-0003-3558-0087;
   Coutinho, Conrado Milani/0000-0003-1966-0466; Ramalho, Fernando
   Silva/0000-0002-7529-466X; Rocha, Lenaldo B/0000-0002-4345-6994;
   Ramalho, Leandra/0000-0002-3486-5294; Reis Teixeira,
   Sara/0000-0001-5845-058X
FU Fundacao de Apoio ao Ensino, Pesquisa e Assistencia of the University
   Hospital of the Ribeirao Preto Medical School
FX This work was supported by Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia of the University Hospital of the Ribeirao Preto Medical
   School.
CR da Silva LRC, 2016, REV SOC BRAS MED TRO, V49, P267, DOI 10.1590/0037-8682-0150-2016
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Fernandes NCCA, 2017, EXP TOXICOL PATHOL, V69, P63, DOI 10.1016/j.etp.2016.11.004
   HAGEMAN G, 1983, NEUROPEDIATRICS, V14, P6, DOI 10.1055/s-2008-1059546
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P68, DOI 10.5858/arpa.2016-0343-OA
   van der Linden V, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3899
NR 12
TC 9
Z9 9
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2017
VL 65
IS 4
BP 687
EP 690
DI 10.1093/cid/cix374
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FC2MB
UT WOS:000406670800024
PM 28444144
DA 2020-12-17
ER

PT J
AU Adachi, K
   Xu, JH
   Ank, B
   Watts, DH
   Mofenson, LM
   Pilotto, JH
   Joao, E
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Gray, G
   Theron, G
   Morgado, MG
   Bryson, YJ
   Veloso, VG
   Klausner, JD
   Moye, J
   Nielsen-Saines, K
AF Adachi, Kristina
   Xu, Jiahong
   Ank, Bonnie
   Watts, D. Heather
   Mofenson, Lynne M.
   Pilotto, Jose Henrique
   Joao, Esau
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Gray, Glenda
   Theron, Gerhard
   Morgado, Mariza G.
   Bryson, Yvonne J.
   Veloso, Valdilea G.
   Klausner, Jeffrey D.
   Moye, Jack
   Nielsen-Saines, Karin
CA NICHD HPTN 040 Study Team
TI Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and
   Congenital Cytomegalovirus Infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; pregnancy; congenital CMV; CMV viruria; HIV perinatal transmission
ID GENITAL-TRACT; RISK-FACTORS; INFANTS; VIRUS; MOTHERS; TRANSMISSION;
   ASSOCIATION; DISEASE; EXCRETION; DIAGNOSIS
AB Background. Cytomegalovirus (CMV) urinary shedding in pregnant women infected with human immunodeficiency virus (HIV) was evaluated to determine whether it poses an increased risk for congenital CMV infection (cCMV).
   Methods. A subset of mother-infant pairs enrolled in the perinatal NICHD HPTN 040 study (distinguished by no antiretroviral use before labor) was evaluated. Maternal and infant urines were tested by qualitative real-time polymerase chain reaction (RT-PCR) for CMV DNA with quantitative RT-PCR performed on positive specimens.
   Results. Urine specimens were available for 260 women with 85.4% from the Americas and 14.6% from South Africa. Twenty-four women (9.2%) had detectable CMV viruria by qualitative PCR. Maternal CMV viruria was not associated with mean CD4 cell counts or HIV viral load but was associated with younger maternal age (P = .02). Overall, 10 of 260 infants (3.8%) had cCMV. Women with detectable peripartum CMV viruria were more likely to have infants with cCMV than those without: 20.8% (5/24) versus 2.1% (5/236), (P = .0001). Women with CMV viruria had significantly higher rates of HIV perinatal transmission (29.2% vs. 8.1%, P = .002). They were 5 times (adjusted odds ratio [aOR] = 5.6, 95% confidence interval [CI] 1.9-16.8) and nearly 30 times (aOR, 29.7; 95% CI, 5.4-164.2) more likely to transmit HIV and CMV to their infants, respectively. Maternal gonorrhea (aOR, 19.5; 95% CI, 2.5-151.3) and higher maternal HIV log10 viral load (OR, 2.8; 95% CI, 1.3-6.3) were also significant risk factors for cCMV.
   Conclusion. In this cohort of HIV-infected pregnant women not on antiretrovirals, urinary CMV shedding was a significant risk factor for CMV and HIV transmission to infants.
C1 [Adachi, Kristina; Xu, Jiahong; Mofenson, Lynne M.; Pilotto, Jose Henrique; Fonseca, Rosana] David Geffen Univ Calif, Angeles Sch Med, Los Angeles, CA USA.
   [Joao, Esau; Gray, Glenda; Bryson, Yvonne J.] US Dept State, Off Global AIDS Coordinator, Washington, DC USA.
   [Joao, Esau; Kreitchmann, Regis; Theron, Gerhard] Eunice Kennedy Shriver Natl Inst Child Hlth & Hu, NIH, Bethesda, MD USA.
   [Watts, D. Heather; Mofenson, Lynne M.; Pilotto, Jose Henrique; Pinto, Jorge; Mussi-Pinhata, Marisa M.; Morgado, Mariza G.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Xu, Jiahong; Pilotto, Jose Henrique; Santos, Breno; Pinto, Jorge; Morgado, Mariza G.; Veloso, Valdilea G.] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Watts, D. Heather; Fonseca, Rosana; Pinto, Jorge] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Pilotto, Jose Henrique; Pinto, Jorge; Morgado, Mariza G.] Hosp Femina, Porto Alegre, RS, Brazil.
   [Joao, Esau; Pinto, Jorge; Gray, Glenda; Morgado, Mariza G.] Irmandade, Santa Casa Misericordia Porto Alegre, Rio Grande, Rio Grande, Brazil.
   [Pilotto, Jose Henrique; Joao, Esau; Pinto, Jorge; Morgado, Mariza G.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Watts, D. Heather; Joao, Esau; Kreitchmann, Regis; Theron, Gerhard] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Ank, Bonnie; Fonseca, Rosana; Gray, Glenda; Morgado, Mariza G.] Univ Witwatersrand, SAMRC & Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Joao, Esau; Gray, Glenda; Klausner, Jeffrey D.] Univ Stellenbosch, Tygerberg Hosp, Dept Obstet & Gynecol, Cape Town, South Africa.
   [Pilotto, Jose Henrique; Joao, Esau; Kreitchmann, Regis; Morgado, Mariza G.; Bryson, Yvonne J.] Fiocruz MS, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Adachi, K (corresponding author), David Geffen Univ Calif, Angeles Sch Med, Los Angeles, CA USA.
EM kadachi@mednet.ucla.edu
RI Pinto, Jorge A/D-1743-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Mofenson, Lynne/P-9631-2019; Mussi-Pinhata, Marisa/G-6568-2012; Vieira,
   Carolina Sales/N-6855-2015
OI Pinto, Jorge A/0000-0003-2987-3238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mofenson, Lynne/0000-0002-2818-9808;
   Mussi-Pinhata, Marisa/0000-0001-8985-1570; Vieira, Carolina
   Sales/0000-0003-2933-5755; Kreitchmann, Regis/0000-0002-1146-0497;
   Bastos, Francisco/0000-0001-5970-8896; Machado,
   Daisy/0000-0003-1993-6442; Joao, Esau/0000-0002-2412-0627
FU NICHD, NIAID/NIH [HHSN267200800001C, N01-HD-8-0001, U01 AI047986];
   National Institute of Allergy and Infectious Diseases (NIAID) of the
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI068632,
   UM1AI068616, UM1AI106716]; Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD); National Institute of Mental Health (NIMH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH);
   Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)Boehringer Ingelheim;
   GlaxoSmithKlineGlaxoSmithKline; ViiV Healthcare; UCLA Children's
   Discovery and Innovation Institute (CDI) through the Harry Winston
   Fellowship Award; UCLA AIDS Institute; UCLA Center for AIDS Research
   (CFAR) NIH/NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI02869, AI28697]; UCLA
   Pediatric AIDS Coalition; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI068632, UM1AI068632, UM1AI069453,
   UM1AI069453, UM1AI068632, UM1AI068632, UM1AI068632, UM1AI069453,
   UM1AI069453, UM1AI068632, UM1AI068632, UM1AI069453, UM1AI069453,
   UM1AI069453, UM1AI068632, UM1AI068632, UM1AI068632, UM1AI068632,
   UM1AI069453] Funding Source: NIH RePORTER
FX The NICHD HPTN 040 study was supported by NICHD contract no.
   HHSN267200800001C (NICHD Control no. N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Network (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) of the National Institutes of
   Health (NIH) under award numbers UM1AI068632 (IMPAACT LOC), UM1AI068616
   (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with cofunding from the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) and the National Institute of Mental Health (NIMH).
   The original parent study was supported in part by Boehringer Ingelheim
   Pharmaceuticals Inc. (BIPI), and GlaxoSmithKline, on behalf of ViiV
   Healthcare. Support was also provided by the UCLA Children's Discovery
   and Innovation Institute (CDI) through the Harry Winston Fellowship
   Award, the UCLA AIDS Institute, the UCLA Center for AIDS Research (CFAR)
   NIH/NIAID AI02869 and AI28697, and the UCLA Pediatric AIDS Coalition.
CR Adachi K, 2016, PEDIAT INFECT DIS J
   Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Barbi M, 2006, J CLIN VIROL, V35, P206, DOI 10.1016/j.jcv.2005.08.010
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695
   CHANDLER SH, 1985, J INFECT DIS, V152, P597, DOI 10.1093/infdis/152.3.597
   Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006
   Clarke LM, 1996, J INFECT DIS, V173, P77, DOI 10.1093/infdis/173.1.77
   de Vries JJC, 2012, J CLIN VIROL, V53, P167, DOI 10.1016/j.jcv.2011.11.006
   Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010
   EMBIL JA, 1985, SEX TRANSM DIS, V12, P224, DOI 10.1097/00007435-198510000-00011
   Fowler KB, 2006, PEDIATRICS, V118, pE286, DOI 10.1542/peds.2005-1142
   Guibert G, 2009, CLIN INFECT DIS, V48, P1516, DOI 10.1086/598934
   JORDAN MC, 1973, NEW ENGL J MED, V288, P932, DOI 10.1056/NEJM197305032881803
   Khamduang W, 2011, JAIDS-J ACQ IMM DEF, V58, P188, DOI [10.1097/QAI.0B013E31822D0433, 10.1097/QAI.0b013e31822d0433]
   Khare M, 2004, J VIROL METHODS, V119, P31, DOI 10.1016/j.jviromet.2004.02.013
   King CC, 2013, CURR HIV RES, V11, P10
   Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203
   Lazzarotto T, 2011, CLIN MICROBIOL INFEC, V17, P1285, DOI 10.1111/j.1469-0691.2011.03564.x
   Lazzarotto T, 2008, J CLIN VIROL, V41, P192, DOI 10.1016/j.jcv.2007.10.015
   Lurain NS, 2004, J INFECT DIS, V190, P619, DOI 10.1086/422533
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   MONTGOMERY R, 1972, PEDIATRICS, V49, P524
   Mostad SB, 1999, J MED VIROL, V59, P469, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;469::AID-JMV8&gt;3.0.CO;2-L
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Mwaanza N, 2014, CLIN INFECT DIS, V58, P728, DOI 10.1093/cid/cit766
   NANKERVIS GA, 1984, AM J OBSTET GYNECOL, V149, P435, DOI 10.1016/0002-9378(84)90159-5
   Nielsen-Saines K, 2013, PED AC SOC M WASH DC
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   NUMAZAKI Y, 1970, AM J EPIDEMIOL, V91, P410, DOI 10.1093/oxfordjournals.aje.a121151
   PASS RF, 1982, J INFECT DIS, V146, P1, DOI 10.1093/infdis/146.1.1
   PECKHAM CS, 1987, ARCH DIS CHILD, V62, P780, DOI 10.1136/adc.62.8.780
   PEREIRA LH, 1990, AM J EPIDEMIOL, V131, P683, DOI 10.1093/oxfordjournals.aje.a115552
   Pitt J, 1998, J ACQ IMMUN DEF SYND, V19, P462, DOI 10.1097/00042560-199812150-00004
   REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101
   ROLAPLESZCZYNSKI M, 1977, J INFECT DIS, V135, P386, DOI 10.1093/infdis/135.3.386
   Ross SA, 2005, J INFECT DIS, V192, P1727, DOI 10.1086/497150
   Ross SA, 2014, J INFECT DIS, V210, P1415, DOI 10.1093/infdis/jiu263
   Sahiner F, 2015, IRISH J MED SCI, V184, P475, DOI 10.1007/s11845-014-1149-5
   SHEN CY, 1993, J CLIN MICROBIOL, V31, P1635, DOI 10.1128/JCM.31.6.1635-1636.1993
   Slyker J, 2014, CLIN INFECT DIS, V58, P564, DOI 10.1093/cid/cit727
   STAGNO S, 1982, Clinical Obstetrics and Gynecology, V25, P563, DOI 10.1097/00003081-198209000-00014
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 45
TC 10
Z9 10
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2017
VL 65
IS 3
BP 405
EP 413
DI 10.1093/cid/cix222
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FA5RN
UT WOS:000405501300008
PM 28369278
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Pokalyuk, C
   Renzette, N
   Irwin, KK
   Pfeifer, SP
   Gibson, L
   Britt, WJ
   Yamamoto, AY
   Mussi-Pinhata, MM
   Kowalik, TF
   Jensen, JD
AF Pokalyuk, Cornelia
   Renzette, Nicholas
   Irwin, Kristen K.
   Pfeifer, Susanne P.
   Gibson, Laura
   Britt, William J.
   Yamamoto, Aparecida Y.
   Mussi-Pinhata, Marisa M.
   Kowalik, Timothy F.
   Jensen, Jeffrey D.
TI Characterizing human cytomegalovirus reinfection in congenitally
   infected infants: an evolutionary perspective
SO MOLECULAR ECOLOGY
LA English
DT Article
DE evolutionary medicine; molecular evolution; population genetics -
   empirical
ID DIVERSITY; DISSEMINATION; VARIANTS; VIRUS
AB Given the strong selective pressures often faced by populations when colonizing a novel habitat, the level of variation present on which selection may act is an important indicator of adaptive potential. While often discussed in an ecological context, this notion is also highly relevant in our clinical understanding of viral infection, in which the novel habitat is a new host. Thus, quantifying the factors determining levels of variation is of considerable importance for the design of improved treatment strategies. Here, we focus on such a quantification of human cytomegalovirus (HCMV) - a virus which can be transmitted across the placenta, resulting in foetal infection that can potentially cause severe disease in multiple organs. Recent studies using genomewide sequencing data have demonstrated that viral populations in some congenitally infected infants diverge rapidly over time and between tissue compartments within individuals, while in other infants, the populations remain highly stable. Here, we investigate the underlying causes of these extreme differences in observed intrahost levels of variation by estimating the underlying demographic histories of infection. Importantly, reinfection (i.e. population admixture) appears to be an important, and previously unappreciated, player. We highlight illustrative examples likely to represent a single-population transmission from a mother during pregnancy and multiple-population transmissions during pregnancy and after birth.
C1 [Pokalyuk, Cornelia] Goethe Univ Frankfurt, Inst Math, Frankfurt, Germany.
   [Pokalyuk, Cornelia] Otto von Guericke Univ, Fac Math, Magdeburg, Germany.
   [Pokalyuk, Cornelia; Irwin, Kristen K.; Pfeifer, Susanne P.; Jensen, Jeffrey D.] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland.
   [Pokalyuk, Cornelia; Renzette, Nicholas; Irwin, Kristen K.; Pfeifer, Susanne P.; Jensen, Jeffrey D.] SIB, Lausanne, Switzerland.
   [Renzette, Nicholas; Kowalik, Timothy F.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA USA.
   [Pfeifer, Susanne P.; Jensen, Jeffrey D.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA USA.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Med, Div Immunol, Worcester, MA USA.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Pediat, Div Infect Dis, Worcester, MA USA.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Pediat, Div Immunol, Worcester, MA USA.
   [Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA.
   [Yamamoto, Aparecida Y.; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Dept Pediat, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
RP Jensen, JD (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland.; Jensen, JD (corresponding author), SIB, Lausanne, Switzerland.; Kowalik, TF (corresponding author), Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA USA.
EM timothy.kowalik@umassmed.edu; jeffrey.d.jensen@asu.edu
RI Mussi-Pinhata, Marisa/G-6568-2012; Jensen, Jeffrey/S-1084-2016
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Jensen,
   Jeffrey/0000-0002-4786-8064
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF); European Research Council (ERC)European Research Council (ERC);
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HD061959, AI109001,
   F32AI084437]; National Center for Advancing Translational Sciences at
   the National Institutes of Health [UL1TR000161]; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [SPP 1590];
   EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959] Funding Source: NIH
   RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH
   &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R01HD061959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [F32AI084437,
   F32AI084437] Funding Source: NIH RePORTER
FX This work was supported by grants from the Swiss National Science
   Foundation and a European Research Council (ERC) Starting Grant to JDJ
   and by the National Institutes of Health (HD061959 (WJB, TFK), AI109001
   (TFK); F32AI084437 (NR)) and the National Center for Advancing
   Translational Sciences at the National Institutes of Health
   (UL1TR000161). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health. We thank the University of Massachusetts Deep
   Sequencing and Molecular Biology Core Laboratories for their
   contribution and services. CP received financial support in part from
   Deutsche Forschungsgemeinschaft (Priority Programme SPP 1590
   'Probabilistic Structures in Evolution'). We thank Matthieu Foll and
   Lisha Mathew for helpful discussion.
CR Arav-Boger R, 2002, J INFECT DIS, V186, P1057, DOI 10.1086/344238
   Bentz GL, 2006, J VIROL, V80, P11539, DOI 10.1128/JVI.01016-06
   Cicin-Sain L, 2005, J VIROL, V79, P9492, DOI 10.1128/JVI.79.15.9492-9502.2005
   Efron B, 1993, INTRO BOOTSTRAP
   Emery VC, 1999, J EXP MED, V190, P177, DOI 10.1084/jem.190.2.177
   Enders G, 2011, J CLIN VIROL, V52, P244, DOI 10.1016/j.jcv.2011.07.005
   Excoffier L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003905
   GRIFFITH BP, 1985, J VIROL, V55, P402, DOI 10.1128/JVI.55.2.402-409.1985
   Hassan J, 2007, CLIN EXP IMMUNOL, V149, P205, DOI 10.1111/j.1365-2249.2007.03454.x
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   MENG XL, 1993, BIOMETRIKA, V80, P267, DOI 10.1093/biomet/80.2.267
   Murthy S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015949
   Numazaki K, 1997, FEMS IMMUNOL MED MIC, V18, P91, DOI 10.1111/j.1574-695X.1997.tb01032.x
   Pereira L, 2014, J INFECT DIS, V209, P1573, DOI 10.1093/infdis/jiu019
   Pignatelli S, 2003, J GEN VIROL, V84, P647, DOI 10.1099/vir.0.18704-0
   Renzette N, 2017, J VIROL, V91, DOI 10.1128/JVI.01976-16
   Renzette N, 2016, MOL ECOL, V25, P403, DOI 10.1111/mec.13331
   Renzette N, 2015, P NATL ACAD SCI USA, V112, pE4120, DOI 10.1073/pnas.1501880112
   Renzette N, 2014, CURR OPIN VIROL, V8, P109, DOI 10.1016/j.coviro.2014.08.001
   Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735
   Ross SA, 2011, J INFECT DIS, V204, P1003, DOI 10.1093/infdis/jir457
   Sijmons S, 2015, J VIROL, V89, P7673, DOI 10.1128/JVI.00578-15
   Smith MS, 2004, J VIROL, V78, P4444, DOI 10.1128/JVI.78.9.4444-4453.2004
   WILLIAMSON WD, 1992, PEDIATRICS, V90, P862
   Zarate S, 2007, J VIROL, V81, P6643, DOI 10.1128/JVI.02268-06
NR 28
TC 16
Z9 16
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1083
EI 1365-294X
J9 MOL ECOL
JI Mol. Ecol.
PD APR
PY 2017
VL 26
IS 7
SI SI
BP 1980
EP 1990
DI 10.1111/mec.13953
PG 11
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA ES6EM
UT WOS:000399639200022
PM 27988973
DA 2020-12-17
ER

PT J
AU Jao, J
   Freimanis, L
   Mussi-Pinhata, MM
   Cohen, RA
   Monteiro, JP
   Cruz, ML
   Branch, A
   Sperling, RS
   Siberry, GK
AF Jao, Jennifer
   Freimanis, Laura
   Mussi-Pinhata, Marisa M.
   Cohen, Rachel A.
   Monteiro, Jacqueline Pontes
   Cruz, Maria Leticia
   Branch, Andrea
   Sperling, Rhoda S.
   Siberry, George K.
CA NISDI LILAC Protocol
TI Severe Vitamin D Deficiency in Human Immunodeficiency Virus-Infected
   Pregnant Women is Associated with Preterm Birth
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE vitamin D; preterm birth; HIV; pregnant women; pregnancy
ID GESTATIONAL-AGE; ANTIRETROVIRAL THERAPY; HIGH PREVALENCE; RISK; HIV;
   OUTCOMES; INFANTS; WEIGHT; GROWTH
AB Background Low maternal vitamin D has been associated with preterm birth (PTB). Human immunodeficiency virus (HIV)-infected pregnant women are at risk for PTB, but data on maternal vitamin D and PTB in this population are scarce. Methods In a cohort of Latin American HIV-infected pregnant women from the National Institute of Child Health and Human Development International Site Development Initiative protocol, we examined the association between maternal vitamin D status and PTB. Vitamin D status was defined as the following 25-hydroxyvitamin D levels: severe deficiency (< 10 ng/mL), deficiency (10-20 ng/mL), insufficiency (21-29 ng/mL), and sufficiency (>= 30 ng/mL). PTB was defined as delivery at < 37 weeks' gestational age (GA). Logistic regression was used to assess the association between maternal vitamin D status and PTB. Results Of 715 HIV-infected pregnant women, 13 (1.8%) were severely vitamin D deficient, 224 (31.3%) were deficient, and 233 were (32.6%) insufficient. Overall, 23.2% (166/715) of pregnancies resulted in PTB (median GA of PTBs = 36 weeks [interquartile range: 34-36]). In multivariate analysis, severe vitamin D deficiency was associated with PTB (odds ratio = 4.7, 95% confidence interval: 1.3-16.8]). Conclusion Severe maternal vitamin D deficiency is associated with PTB in HIV infected Latin American pregnant women. Further studies are warranted to determine if vitamin D supplementation in HIV-infected women may impact PTB.
C1 [Jao, Jennifer; Sperling, Rhoda S.] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA.
   [Jao, Jennifer; Branch, Andrea] Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.
   [Freimanis, Laura; Cohen, Rachel A.] Westat Corp, Rockville, MD USA.
   [Mussi-Pinhata, Marisa M.; Monteiro, Jacqueline Pontes] Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, SP, Brazil.
   [Cruz, Maria Leticia] Hosp Fed Servidores Estado, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, Brazil.
   [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, Bethesda, MD USA.
RP Jao, J (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.
EM jennifer.jao@mssm.edu
RI Cruz, Maria Leticia/Y-5632-2019; Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Eunice Kennedy
   Shriver National Institute of Child Health and Human Development
   [NICHD]United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [NO1-HD-3-3345];
   Abbott Laboratories (Abbott Park, IL)Abbott Laboratories; NICHDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [HHSN267200800001C, N01-HD-8-0001,
   K23HD070760]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH
   & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD070760, K23HD070760, K23HD070760, K23HD070760, K23HD070760]
   Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health (Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   [NICHD] contract NO1-HD-3-3345 [2002-2007] and NICHD contract
   HHSN267200800001C [NICHD control: N01-HD-8-0001] [2007-2012]) and by
   Abbott Laboratories (Abbott Park, IL). J. J. is supported by NICHD
   K23HD070760.
CR [Anonymous], 2011, ABB ARCH SYST 250HD
   Argentina Ministry of Health, NAT DAT MAT CHILDH H
   ATTICO NB, 1990, AM FAM PHYSICIAN, V41, P553
   Baker AM, 2011, AM J PERINAT, V28, P667, DOI 10.1055/s-0031-1276731
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   Baroncelli S, 2015, INFECT DIS LOND, P1
   Bodnar LM, 2015, OBSTET GYNECOL, V125, P439, DOI 10.1097/AOG.0000000000000621
   Catov JM, 2011, AM J CLIN NUTR, V94, P906, DOI 10.3945/ajcn.111.012393
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   Christiaens I, 2008, J REPROD IMMUNOL, V79, P50, DOI 10.1016/j.jri.2008.04.002
   Dawodu A, 2011, PEDIATR INT, V53, P207, DOI 10.1111/j.1442-200X.2010.03209.x
   Diaz L, 2009, J REPROD IMMUNOL, V81, P17, DOI 10.1016/j.jri.2009.02.005
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Harrison MS, 2016, SEMIN FETAL NEONAT M, V21, P74, DOI 10.1016/j.siny.2015.12.007
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Jao J, 2015, INT J GYNECOL OBSTET, V130, P54, DOI 10.1016/j.ijgo.2015.01.017
   Jao J, 2015, AIDS, V29, P111, DOI 10.1097/QAD.0000000000000501
   Manzon L, 2014, EUR J OBSTET GYN R B, V177, P84, DOI 10.1016/j.ejogrb.2014.03.008
   Mehta S, 2009, J INFECT DIS, V200, P1022, DOI 10.1086/605699
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Morley R, 2006, J CLIN ENDOCR METAB, V91, P906, DOI 10.1210/jc.2005-1479
   Nour Nawal M, 2012, Rev Obstet Gynecol, V5, P100
   Perez-Ferre N, 2012, ENDOCR PRACT, V18, P676, DOI 10.4158/EP12025.OR
   Powis KM, 2016, AIDS, V30, P211, DOI 10.1097/QAD.0000000000000895
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
   Shand AW, 2010, BJOG-INT J OBSTET GY, V117, P1593, DOI 10.1111/j.1471-0528.2010.02742.x
   Szyld EG, 2006, AIDS, V20, P2345, DOI 10.1097/01.aids.0000253362.01696.9d
   Tamblyn JA, 2015, J ENDOCRINOL, V224, pR107, DOI 10.1530/JOE-14-0642
   Townsend CL, 2010, BJOG-INT J OBSTET GY, V117, P1399, DOI 10.1111/j.1471-0528.2010.02689.x
   Triunfo S, 2016, J ENDOCRINOL INVEST, V39, P37, DOI 10.1007/s40618-015-0330-7
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   Wagner CL, 2016, J STEROID BIOCHEM, V155, P245, DOI 10.1016/j.jsbmb.2015.10.022
   Wagner CL, 2015, J STEROID BIOCHEM, V148, P256, DOI 10.1016/j.jsbmb.2014.11.013
   Wei SQ, 2013, J MATERN-FETAL NEO M, V26, P889, DOI 10.3109/14767058.2013.765849
   Zhu T, 2015, INT J CLIN EXP PATHO, V8, P1459
NR 35
TC 5
Z9 5
U1 0
U2 6
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
EI 1098-8785
J9 AM J PERINAT
JI Am. J. Perinatol.
PD APR
PY 2017
VL 34
IS 5
BP 486
EP 492
DI 10.1055/s-0036-1593536
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA EQ3YY
UT WOS:000398011100009
PM 27716863
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Weinberg, A
   Mussi-Pinhata, MM
   Yu, QL
   Cohen, RA
   Almeida, VC
   Amaral, F
   Pinto, J
   Teixeira, MLB
   Succi, RCM
   Freimanis, L
   Read, JS
   Siberry, G
AF Weinberg, Adriana
   Mussi-Pinhata, Marisa M.
   Yu, Qilu
   Cohen, Rachel A.
   Almeida, Volia C.
   Amaral, Fabiana
   Pinto, Jorge
   Teixeira, Maria L. B.
   Succi, Regina C. M.
   Freimanis, Laura
   Read, Jennifer S.
   Siberry, George
CA NISDI Perinatal LILAC
   CIRAI Protocols
TI Excess respiratory viral infections and low antibody responses among
   HIV-exposed, uninfected infants
SO AIDS
LA English
DT Article
DE antibody responses; childhood vaccines; HIV-exposed uninfected infants;
   immunogenicity; respiratory infections; respiratory viruses; tetanus
   vaccine
ID NEGATIVE INFANTS; INCREASED RISK; IN-UTERO; PNEUMOCOCCAL DISEASE;
   IMMUNE-RESPONSES; CHILDREN BORN; T-LYMPHOCYTES; CORD BLOOD; VIRUS;
   VACCINATION
AB Objective: HIV-exposed uninfected (HEUs) infants have frequent severe infection, hospitalization, and death. We performed a serologic investigation to determine the role of common childhood respiratory pathogens in the excess incidence of infections in HEUs.
   Design: Prospective cohort study of mother-infant pairs.
   Methods: Among 247 HEUs and 88 HIV-unexposed uninfected (HUU) infant-mother pairs, we measured maternal antibodies to respiratory syncytial virus (RSV) and pneumococcus (PNC 1, 5, 6B, 14); infant antibodies to RSV, influenza A (flu), parainfluenza viruses (1, 2, 3), and PNC 1, 5, 6B, and 14 were measured at 0 and 6 months, and antitetanus antibodies at 6 months.
   Results: HIV-infected mothers had higher RSV and lower PNC antibody concentrations at delivery than uninfected mothers. Transplacental transfer of maternal antibodies, particularly for RSV, was lower in HEUs compared with HUUs. At birth, HEUs had higher concentrations of anti-RSV antibodies than HUUs, but lower antibodies to the other respiratory agents. At 6 months, HEUs had significantly higher proportions of seroconversions and higher antibody concentrations against parainfluenza viruses 1, 2, and 3. There were no significant differences in seroconversions to flu and RSV, but antibody concentrations to RSV were six-fold lower in HEUs versus HUUs at 6 months. Antibody responses to at least two doses of tetanus vaccine were also six-fold lower in HEUs compared with HUUs.
   Conclusion: Six-month-old HEUs had a higher incidence of respiratory viral infections than HUUs. In addition to the low passive protection from maternal antibodies, low antibody responses of HEUs may contribute to increased morbidity and mortality. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Weinberg, Adriana] Univ Colorado Denver, Anschutz Med Ctr, Mail Stop 8604,12700 E 19th Ave,Room 11126, Aurora, CO 80045 USA.
   [Mussi-Pinhata, Marisa M.; Amaral, Fabiana] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Yu, Qilu; Cohen, Rachel A.; Freimanis, Laura] Westat Corp, Rockville, MD USA.
   [Almeida, Volia C.] Univ Fed Sao Carlos, Dept Med, Sao Paulo, Brazil.
   [Pinto, Jorge] Univ Minas Gerais, Escola Med, Belo Horizonte, MG, Brazil.
   [Teixeira, Maria L. B.] HFSE, Rio De Janeiro, Brazil.
   [Succi, Regina C. M.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Read, Jennifer S.; Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
   [Read, Jennifer S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Weinberg, A (corresponding author), Univ Colorado Denver, Anschutz Med Ctr, Mail Stop 8604,12700 E 19th Ave,Room 11126, Aurora, CO 80045 USA.
EM adriana.weinberg@ucdenver.edu
RI Mussi-Pinhata, Marisa/G-6568-2012; Pinto, Jorge A/D-1743-2014
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Pinto, Jorge
   A/0000-0003-2987-3238; /0000-0002-6896-0089
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-HD-3-3345, HHSN267200800001C, HHSN275201300003C]; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2010/19539-9]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [N01HD033345, N01HD033345,
   N01HD033345] Funding Source: NIH RePORTER
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (NICHD) Contracts N01-HD-3-3345
   (2002-2007), HHSN267200800001C (2007-2012) and HHSN275201300003C
   (2012-2017), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) 2010/19539-9 (to MMMP). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health or of the Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo.
CR Abramczuk BM, 2011, CLIN VACCINE IMMUNOL, V18, P1406, DOI 10.1128/CVI.05065-11
   Adler C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135375
   Andre-Schmutz I, 2013, J INFECT DIS, V208, P235, DOI 10.1093/infdis/jit149
   Chattha KS, 2013, VACCINE, V31, P1916, DOI 10.1016/j.vaccine.2013.02.020
   Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871
   Cohen C, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3272
   Coutsoudis A, 2011, AIDS, V25, P1797, DOI 10.1097/QAD.0b013e32834ad699
   Dangor Z, 2015, J INFECT DIS, V212, P453, DOI 10.1093/infdis/jiv064
   de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571
   Enomoto L, 2011, AIDS RES HUM RETROV, V27, P47, DOI 10.1089/aid.2010.0067
   Epalza C, 2010, PEDIATRICS, V126, pE631, DOI 10.1542/peds.2010-0183
   Garcia S, 2006, REV PANAM SALUD PUBL, V19, P340, DOI 10.1590/S1020-49892006000500007
   GESNER M, 1994, PEDIATRICS, V93, P624
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102
   Hygino J, 2008, CLIN IMMUNOL, V127, P340, DOI 10.1016/j.clim.2008.01.020
   Hygino J, 2011, J CLIN IMMUNOL, V31, P186, DOI 10.1007/s10875-010-9485-3
   Inostroza J, 2005, CLIN DIAGN LAB IMMUN, V12, P722, DOI 10.1128/CDLI.12.6.722-726.2005
   Izadnegahdar R, 2014, PEDIATR INFECT DIS J, V33, P70, DOI 10.1097/INF.0b013e31829f0ade
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   Kakkar F, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-236
   Kattan M, 2001, PEDIATR PULM, V31, P267, DOI 10.1002/ppul.1038
   Kelly MS, 2015, J PEDIAT INF DIS SOC, V4, pE117, DOI 10.1093/jpids/piu092
   Kidzeru EB, 2014, AIDS, V28, P1421, DOI 10.1097/QAD.0000000000000292
   Kourtis AP, 2013, AIDS, V27, P749, DOI 10.1097/QAD.0b013e32835ca29f
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Lalor MK, 2011, J INFECT DIS, V204, P1075, DOI 10.1093/infdis/jir515
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Marinda E, 2007, PEDIATR INFECT DIS J, V26, P519, DOI 10.1097/01.inf.0000264527.69954.4c
   Mazzola TN, 2011, AIDS, V25, P2079, DOI 10.1097/QAD.0b013e32834bba0a
   McNally LM, 2005, AIDS, V19, P1548, DOI 10.1097/01.aids.0000183941.67730.3a
   Miles DJC, 2010, IMMUNOLOGY, V129, P446, DOI 10.1111/j.1365-2567.2009.03186.x
   Miyamoto M, 2010, J TROP PEDIATRICS, V56, P427, DOI 10.1093/tropej/fmq024
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Mussi-Pinhata MM, 2010, INT J INFECT DIS, V14, pE176, DOI 10.1016/j.ijid.2010.01.006
   Nielsen SD, 2001, BLOOD, V98, P398, DOI 10.1182/blood.V98.2.398
   Ono E, 2008, BRAZ J MED BIOL RES, V41, P700, DOI 10.1590/S0100-879X2008000800011
   Ota MOC, 1999, AIDS, V13, P996, DOI 10.1097/00002030-199905280-00020
   Quataert S, 2001, IMMUNOL INVEST, V30, P191, DOI 10.1081/IMM-100105064
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
   Reikie BA, 2013, CLIN VACCINE IMMUNOL, V20, P33, DOI 10.1128/CVI.00557-12
   Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997
   Ruffini DD, 2002, AIDS, V16, P105, DOI 10.1097/00002030-200201040-00013
   Sanz-Ramos M, 2013, VACCINE, V31, P2042, DOI 10.1016/j.vaccine.2013.02.044
   Scott S, 2007, CLIN INFECT DIS, V45, P1417, DOI 10.1086/522989
   Shapiro RL, 2016, C RETR OPP INF
   Simani OE, 2013, AIDS, V27, P1583, DOI 10.1097/QAD.0b013e32835fae26
   Slogrove AL, 2017, PAEDIATR RESPIR REV, V21, P47, DOI 10.1016/j.prrv.2016.08.004
   Slogrove AL, 2010, J TROP PEDIATRICS, V56, P75, DOI 10.1093/tropej/fmp057
   Slogrove A, 2012, J TROP PEDIATRICS, V58, P505, DOI 10.1093/tropej/fms019
   Smolen KK, 2014, J IMMUNOL, V193, P3003, DOI 10.4049/jimmunol.1400895
   Taron-Brocard C, 2014, CLIN INFECT DIS, V59, P1332, DOI 10.1093/cid/ciu586
   Turfkruyer M, 2015, CURR OPIN INFECT DIS, V28, P199, DOI 10.1097/QCO.0000000000000165
   Van Rie A, 2006, CLIN VACCINE IMMUNOL, V13, P246, DOI 10.1128/CVI.13.2.246-252.2006
   von Mollendorf C, 2015, CLIN INFECT DIS, V60, P1346, DOI 10.1093/cid/civ059
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
   Zash R, 2016, C RETR OPP INF BOST
NR 57
TC 14
Z9 14
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 13
PY 2017
VL 31
IS 5
BP 669
EP 679
DI 10.1097/QAD.0000000000001393
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA EN4TT
UT WOS:000396000500008
PM 28060016
DA 2020-12-17
ER

PT J
AU Lourenco, AG
   Komesu, MC
   Duarte, G
   Del Ciampo, LA
   Mussi-Pinhata, MM
   Yamamoto, AY
AF Lourenco, Alan G.
   Komesu, Marilena C.
   Duarte, Geraldo
   Del Ciampo, Luiz A.
   Mussi-Pinhata, Marisa M.
   Yamamoto, Aparecida Y.
TI High Levels of Chemokine C-C Motif Ligand 20 in Human Milk and Its
   Production by Oral Keratinocytes
SO BREASTFEEDING MEDICINE
LA English
DT Article
DE CCL20; human milk composition; lactoferrin; oral keratinocytes
ID MACROPHAGE INFLAMMATORY PROTEIN; BREAST-MILK; EPITHELIAL-CELLS;
   TRANSCRIPTIONAL RESPONSE; SEXUAL TRANSMISSION; HIV TRANSMISSION; HUMAN
   COLOSTRUM; CCL20; SECRETION; IDENTIFICATION
AB Background: Chemokine C-C motif ligand 20 (CCL20) is implicated in the formation and function of mucosal lymphoid tissues. Although CCL20 is secreted by many normal human tissues, no studies have evaluated the presence of CCL20 in human milk or its production by oral keratinocytes stimulated by human milk.
   Objective: To evaluate the presence of CCL20 in breast milk and verify CCL20 secretion in vitro by oral keratinocytes stimulated with human and bovine milk, as well as its possible association with breast milk lactoferrin levels.
   Materials and Methods: The levels of CCL20 and lactoferrin were measured by enzyme-linked immunosorbent assay in human milk at three different stages of maturation from 74 healthy breastfeeding mothers. In vitro, oral keratinocytes were stimulated with human and bovine milk, and CCL20 was measured in their supernatant.
   Results: High concentrations of CCL20 were detected in the human breast milk samples obtained during the first week (1,777.07 pg/mL) and second week postpartum (1,523.44 pg/mL), with a significantly low concentration in samples at 3-6 weeks postpartum (238.42 pg/mL; p < 0.0001). Human breast milk at different weeks postpartum stimulated higher CCL20 secretion by oral keratinocytes compared with bovine milk (p < 0.05). Such stimulation had no association with breast milk lactoferrin concentration.
   Conclusion: CCl20 is present at high levels in human milk, predominantly in the first and second week postpartum, but at significantly lower levels at 3-6 weeks postpartum. Human milk is capable of stimulating CCL20 secretion by oral keratinocytes, and this induction had no association with breast milk lactoferrin concentration.
C1 [Lourenco, Alan G.; Del Ciampo, Luiz A.; Mussi-Pinhata, Marisa M.; Yamamoto, Aparecida Y.] Univ Sao Paulo, Dept Pediat, Ribeirao Preto Sch Med, BR-14049900 Sao Paulo, Brazil.
   [Komesu, Marilena C.] Univ Sao Paulo, Dept Morphol Physiol & Basic Pathol, Ribeirao Preto Sch Dent, Sao Paulo, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Dept Gynecol & Obstet, Ribeirao Preto Sch Med, Sao Paulo, Brazil.
RP Lourenco, AG (corresponding author), Univ Sao Paulo, Dept Pediat, Ribeirao Preto Sch Med, BR-14049900 Sao Paulo, Brazil.
EM alancravinhos@yahoo.com.br
RI Louren\\xc3\\xa7o, Alan Grupioni/T-8347-2019; Mussi-Pinhata,
   Marisa/G-6568-2012; Lourenco, Alan Grupioni/I-1190-2018
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Lourenco, Alan
   Grupioni/0000-0002-4005-157X
FU Coordination of Improvement of Higher Level Personnel (CAPES)CAPES
FX We are grateful to all mothers who participated in the study. We also
   acknowledge Professor Paulo Tambasco (University of Sao Paulo) for
   providing the SCC-9 cells. This study was supported by funds from
   Coordination of Improvement of Higher Level Personnel (CAPES).
CR Abiko Y, 2003, ARCH ORAL BIOL, V48, P171, DOI 10.1016/S0003-9969(02)00167-X
   Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893
   Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002
   Berlier W, 2006, HUM REPROD, V21, P1135, DOI 10.1093/humrep/dei496
   Bode L, 2014, ADV NUTR, V5, P571, DOI 10.3945/an.114.006643
   Broadhurst M, 2015, EARLY HUM DEV, V91, P7, DOI 10.1016/j.earlhumdev.2014.11.006
   Cremel M, 2005, J LEUKOCYTE BIOL, V78, P158, DOI 10.1189/jlb.0305147
   Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705
   Doncel GF, 2014, AM J REPROD IMMUNOL, V71, P564, DOI 10.1111/aji.12231
   Groer M, 2014, J HUM LACT, V30, P317, DOI 10.1177/0890334414527795
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Hosokawa Y, 2014, INFLAMMATION, V37, P381, DOI 10.1007/s10753-013-9750-8
   Hromas R, 1997, BLOOD, V89, P3315
   Jozwik M, 2013, AM J HUM BIOL, V25, P198, DOI 10.1002/ajhb.22352
   Khodayar-Pardo P, 2014, J PERINATOL, V34, P599, DOI 10.1038/jp.2014.47
   Komine K, 2005, J VET MED SCI, V67, P667, DOI 10.1292/jvms.67.667
   Komine K, 2007, MOL IMMUNOL, V44, P1498, DOI 10.1016/j.molimm.2006.09.003
   Lane JA, 2013, BRIT J NUTR, V110, P2127, DOI 10.1017/S0007114513001591
   Laurindo VM, 1992, PEDIATRIA SAO PAULO, V14, P14
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Lourenco Alan Grupioni, 2014, World J Virol, V3, P11, DOI 10.5501/wjv.v3.i2.11
   Lourenco AG, 2014, J MED VIROL, V86, P58, DOI 10.1002/jmv.23776
   Marcuzzi A, 2013, J HUM LACT, V29, P26, DOI 10.1177/0890334412466958
   O'Callaghan J, 2012, APPL ENVIRON MICROB, V78, P5196, DOI 10.1128/AEM.00507-12
   Piguet V, 2013, J INVEST DERMATOL, V133, P2662, DOI 10.1038/jid.2013.383
   Piskin IE, 2012, EUR CYTOKINE NETW, V23, P187, DOI 10.1684/ecn.2013.0324
   Radillo O, 2013, CYTOKINE, V61, P26, DOI 10.1016/j.cyto.2012.09.001
   Rossi DL, 1997, J IMMUNOL, V158, P1033
   Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2
   Trend S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117038
   Ustundag B, 2005, MEDIAT INFLAMM, P331, DOI 10.1155/MI.2005.331
NR 32
TC 1
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1556-8253
EI 1556-8342
J9 BREASTFEED MED
JI Breastfeed. Med.
PD MAR
PY 2017
VL 12
IS 2
BP 116
EP 121
DI 10.1089/bfm.2016.0067
PG 6
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA EN1PY
UT WOS:000395783500010
PM 27912038
DA 2020-12-17
ER

PT J
AU Barbosa, NG
   dos Reis, H
   Mantese, OC
   Mussi-Pinhata, MM
   Abdallah, VOS
   Gontijo, PP
AF Barbosa, Nayara Goncalves
   dos Reis, Heloisio
   Mantese, Orlando Cesar
   Mussi-Pinhata, Marisa Marcia
   Steffen Abdallah, Vania Olivetti
   Gontijo Filho, Paulo Pinto
TI Early-onset neonatal sepsis by Group B Streptococcus in a Brazilian
   public hospital
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID INFECTION
C1 [Barbosa, Nayara Goncalves; Gontijo Filho, Paulo Pinto] Univ Fed Uberlandia, Div Microbiol, Dept Ciancias Biomed, Uberlandia, MG, Brazil.
   [Barbosa, Nayara Goncalves; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Fac Med Ribeirao Preto, Div Pediat, Ribeirao Preto, SP, Brazil.
   [dos Reis, Heloisio; Steffen Abdallah, Vania Olivetti] Univ Fed Uberlandia, Dept Med, Div Neonatol, Uberlandia, MG, Brazil.
   [Mantese, Orlando Cesar] Univ Fed Uberlandia, Dept Med, Div Pediat, Uberlandia, MG, Brazil.
RP Barbosa, NG (corresponding author), Univ Fed Uberlandia, Div Microbiol, Dept Ciancias Biomed, Uberlandia, MG, Brazil.; Barbosa, NG (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Div Pediat, Ribeirao Preto, SP, Brazil.
EM nayara_akegawa@hotmail.com
RI Barbosa, Nayara G/B-9631-2017; Barbosa, Nayara/E-5114-2017;
   Mussi-Pinhata, Marisa M/G-6568-2012
OI Goncalves Barbosa, Nayara/0000-0003-3646-4133; Mussi-Pinhata, Marisa
   M/0000-0001-8985-1570
CR Evangelista MLB, 2015, BRAZ J INFECT DIS, V19, P98, DOI 10.1016/j.bjid.2014.06.007
   Mussi-Pinhata MM, 2004, J TROP PEDIATRICS, V50, P6, DOI 10.1093/tropej/50.1.6
   Pessoa-Silva CL, 2004, INFECT CONT HOSP EP, V25, P772, DOI 10.1086/502475
   Vaciloto Edinéia, 2002, Braz J Infect Dis, V6, P55, DOI 10.1590/S1413-86702002000200001
   Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1
NR 5
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2016
VL 20
IS 6
BP 647
EP 648
DI 10.1016/j.bjid.2016.07.013
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA EE9SF
UT WOS:000389965800022
PM 27565421
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Martins-Celini, FP
   Yamamoto, AY
   Passos, DM
   do Nascimento, SD
   Lima, EV
   Di Giovanni, CM
   Quadrado, ERS
   Barta, R
   Aragon, DC
   do Prado, SI
   de Almeida, MFB
   Mussi-Pinhata, MM
AF Martins-Celini, Fabia Pereira
   Yamamoto, Aparecida Yulie
   Passos, Debora Manzione
   do Nascimento, Suely Dornellas
   Lima, Edineia Vaciloto
   Di Giovanni, Celia Mara
   Sevilla Quadrado, Ellen Regina
   Barta, Roberta
   Aragon, Davi Casale
   do Prado, Seila Israel
   Branco de Almeida, Maria Fernanda
   Mussi-Pinhata, Marisa Marcia
TI Incidence, Risk Factors, and Morbidity of Acquired Postnatal
   Cytomegalovirus Infection Among Preterm Infants Fed Maternal Milk in a
   Highly Seropositive Population
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE cytomegalovirus; human milk; postnatal infection; prematurity
ID BIRTH-WEIGHT INFANTS; BREAST-MILK; PREMATURE-INFANTS; TRANSMISSION; DNA;
   SEROPREVALENCE; LACTATION; SYMPTOMS; MOTHER; ASSAY
AB Preterm infants born to mothers with high cytomegalovirus (CMV) seroprevalence are as frequently infected as those born to mothers with lower seroprevalence. CMV infection contributes to an uneven clinical course, severe stages of retinopathy of prematurity (ROP), and even death.Methods.aEuro integral A cohort of 188 a parts per thousand currency sign30-week-old infants was monitored from admission to discharge. CMV-DNA, hematology, liver enzymes, neutralizing antibodies, and CMV-DNA-lactia were tested periodically.
   Results.aEuro integral Mothers of 157 infants (83.5%) were CMV-seropositive. A total of 24/157 (15.3%) infants became infected (95% confidence interval [CI], 9.8-22.6), particularly those of lower gestational age (GA; relative risk [RR], 2.32; 95% CI, 1.01-5.34 for 23-26 weeks). Low (< 1:64) neutralizing antibody titers were similarly detected in CMV-infected and uninfected infants. Mean DNA-lactia in mothers was higher in CMV-infected than in uninfected infants (5.34 log vs 4.60 log). Clinical findings suggestive of CMV disease were similar in CMV-infected (50.0%) and CMV-uninfected (51.1%) infants. Although transitory, > 2 laboratory test abnormalities occurred more frequently among CMV-infected (39.1%) than CMV-uninfected (2.1%) infants. More severe stages of retinopathy of prematurity (ROP) were found among CMV-infected infants (adjusted RR, 2.51; 95% CI, 1.07-5.91). Although deaths were more frequent among infected infants, none of the deaths could be directly attributed to CMV.
   Conclusions.aEuro integral Postnatal CMV infection acquired by exposure to raw maternal milk is very frequent among extremely premature newborns, being facilitated by high DNA-lactia and lower GA, regardless of maternally acquired neutralizing antibody levels. The association with advanced stages of ROP is a concern and needs to be further explored in larger studies.
C1 [Martins-Celini, Fabia Pereira; Yamamoto, Aparecida Yulie; Aragon, Davi Casale; do Prado, Seila Israel; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pediat, BR-14048900 Sao Paulo, Brazil.
   [Passos, Debora Manzione; do Nascimento, Suely Dornellas; Lima, Edineia Vaciloto; Di Giovanni, Celia Mara; Sevilla Quadrado, Ellen Regina; Barta, Roberta] Univ Fed Sao Paulo, Pro Matre Paulista & Santa Joana Hosp Matern, Neonatol Grp, Sao Paulo, Brazil.
   [Branco de Almeida, Maria Fernanda] Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Dept Pediat, Ribeirao Preto Sch Med, Ave Bandeirantes 3900, BR-14048900 Sao Paulo, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Aragon, Davi C/R-6604-2016
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Aragon, Davi
   C/0000-0003-1019-3654
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/07315-6]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, Brazil (grant 2007/07315-6).
CR Beiner ME, 2003, AM J PERINAT, V20, P49, DOI 10.1055/s-2003-37948
   Bradshaw JH, 2003, J PAEDIATR CHILD H, V39, P563, DOI 10.1046/j.1440-1754.2003.00219.x
   BUCK C, 1994, PEDIATRICS, V93, P54
   Buxmann H, 2009, ACTA PAEDIATR, V98, P270, DOI 10.1111/j.1651-2227.2008.01105.x
   Capretti MG, 2009, J PEDIATR-US, V154, P842, DOI 10.1016/j.jpeds.2008.12.046
   Cheong JLY, 2004, ARCH DIS CHILD-FETAL, V89, pF367, DOI 10.1136/adc.2003.032821
   Chiavarini M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-6
   Coclite E, 2013, J MATERN-FETAL NEO M, V26, P1671, DOI 10.3109/14767058.2013.794207
   DIOSI P, 1967, LANCET, V2, P1063, DOI 10.1016/S0140-6736(67)90338-8
   Doctor S, 2005, ACTA PAEDIATR, V94, P53, DOI 10.1080/08035250410022332
   GONCZOL E, 1986, J VIROL METHODS, V14, P37, DOI 10.1016/0166-0934(86)90005-4
   Hamele M, 2010, PEDIATR INFECT DIS J, V29, P84, DOI 10.1097/INF.0b013e3181b6dbb5
   Hamprecht K, 2001, LANCET, V357, P513, DOI 10.1016/S0140-6736(00)04043-5
   Hamprecht K, 2008, J CLIN VIROL, V41, P198, DOI 10.1016/j.jcv.2007.12.005
   Jim WT, 2009, PEDIATR INFECT DIS J, V28, P891, DOI 10.1097/INF.0b013e3181a55c52
   Jim WT, 2004, PEDIATR INFECT DIS J, V23, P848, DOI 10.1097/01.inf.0000137571.35541.55
   Josephson CD, 2014, JAMA PEDIATR, V168, P1054, DOI 10.1001/jamapediatrics.2014.1360
   Lanzieri TM, 2013, PEDIATRICS, V131, pE1937, DOI 10.1542/peds.2013-0076
   Lombardi G, 2012, J MATERN-FETAL NEO M, V25, P57, DOI 10.3109/14767058.2012.712345
   Pilar RGM, 2015, J MED VIROL, V87, P845, DOI 10.1002/jmv.24101
   Maschmann J, 2006, ARCH DIS CHILD-FETAL, V91, pF288, DOI 10.1136/adc.2004.050625
   Meier J, 2005, J CLIN MICROBIOL, V43, P1318, DOI 10.1128/JCM.43.3.1318-1324.2005
   Melkie Mulugeta, 2012, BMC Res Notes, V5, P493, DOI 10.1186/1756-0500-5-493
   Mosca F, 2001, LANCET, V357, P1800, DOI 10.1016/S0140-6736(00)04914-X
   MOUZINHO A, 1994, PEDIATRICS, V94, P76
   Mussi-Pinhata MM, 2003, J MED VIROL, V69, P232, DOI 10.1002/jmv.10271
   Neuberger P, 2006, J PEDIATR-US, V148, P326, DOI 10.1016/j.jpeds.2005.09.030
   Nijman J, 2013, J MED VIROL, V85, P689, DOI 10.1002/jmv.23511
   Nijman J, 2012, ARCH DIS CHILD-FETAL, V97, pF259, DOI 10.1136/archdischild-2011-300405
   Staras SAS, 2006, CLIN INFECT DIS, V43, P1143, DOI 10.1086/508173
   Vochem M, 1998, PEDIATR INFECT DIS J, V17, P53, DOI 10.1097/00006454-199801000-00012
   Wakabayashi H, 2012, AM J PERINAT, V29, P377, DOI 10.1055/s-0031-1300971
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yamamoto AY, 2011, PEDIATR INFECT DIS J, V30, P1043, DOI 10.1097/INF.0b013e31822d9640
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
   Yasuda A, 2003, PEDIATRICS, V111, P1333, DOI 10.1542/peds.111.6.1333
NR 36
TC 10
Z9 12
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 1
PY 2016
VL 63
IS 7
BP 929
EP 936
DI 10.1093/cid/ciw394
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DZ7JL
UT WOS:000386041100019
PM 27313267
OA Bronze
DA 2020-12-17
ER

PT J
AU Slavov, SN
   Otaguiri, KK
   de Figueiredo, GG
   Yamamoto, AY
   Mussi-Pinhata, MM
   Kashima, S
   Covas, DT
AF Slavov, Svetoslav Nanev
   Otaguiri, Katia Kaori
   de Figueiredo, Glauciane Garcia
   Yamamoto, Aparecida Yulie
   Mussi-Pinhata, Marisa Marcia
   Kashima, Simone
   Covas, Dimas Tadeu
TI Development and Optimization of a Sensitive TaqMan (R) Real-Time PCR
   With Synthetic Homologous Extrinsic Control for Quantitation of Human
   cytomegalovirus Viral Load
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HCMV; molecular detection; optimization; internal controls
ID TRANSPLANT RECIPIENTS; CLINICAL UTILITY; RAPID DETECTION; WHOLE-BLOOD;
   CMV PCR; INFECTION; PLASMA; DNA; URINE; ASSAY
AB Human cytomegalovirus (Human herpesvirus 5, HCMV) causes frequent asymptomatic infections in the general population. However, in immunosuppressed patients or congenitally infected infants, HCMV is related to high morbidity and mortality. In such cases, a rapid viral detection is crucial for monitoring the clinical outcome and the antiviral treatment. In this study, we optimized a sensitive biplex TaqMan (R) real-time PCR for the simultaneous detection and differentiation of a partial HCMV UL97 sequence and homologous extrinsic control (HEC) in the same tube. HEC was represented by a plasmid containing a modified HCMV sequence retaining the original primer binding sites, while the probe sequence was substituted by a phylogenetically divergent one (chloroplast CF0 subunit plant gene). It was estimated that the optimal HEC concentration, which did not influence the HCMV amplification is 1,000 copies/reaction. The optimized TaqMan (R) PCR demonstrated high analytical sensitivity (6.97 copies/ reaction, CI = 95%) and specificity (100%). Moreover, the reaction showed adequate precision (repeatability, CV = 0.03; reproducibility, CV = 0.0027) and robustness (no carry-over or cross-contamination). The diagnostic sensitivity (100%) and specificity (97.8%) were adequate for the clinical application of the molecular platform. The optimized TaqMan (R) real-time PCR is suitable for HCMV detection and quantitation in predisposed patients and monitoring of the applied antiviral therapy. (C) 2016 Wiley Periodicals, Inc.
C1 [Slavov, Svetoslav Nanev; Otaguiri, Katia Kaori; Kashima, Simone; Covas, Dimas Tadeu] Univ Sao Paulo, Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Slavov, Svetoslav Nanev; Covas, Dimas Tadeu] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [Otaguiri, Katia Kaori; Kashima, Simone] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Analyses, Fac Pharmaceut Sci, Sao Paulo, Brazil.
   [de Figueiredo, Glauciane Garcia; Yamamoto, Aparecida Yulie; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Mol Biol Lab, Blood Ctr Ribeirao Preto, Fac Med Ribeirao Preto, Rua Tentente Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI de Figueiredo, Glauciane Garcia/Q-6674-2019; Glauciane Figueiredo, GG
   Garcia de Figueiredo/J-9557-2013; N, Svetoslav/M-5416-2017; Covas, Dimas
   T/C-5431-2013; Mussi-Pinhata, Marisa/G-6568-2012; Kashima,
   Simone/G-4876-2012; CTC USP, CEPID 13 18/J-8951-2014
OI de Figueiredo, Glauciane Garcia/0000-0003-4136-9608; Glauciane
   Figueiredo, GG Garcia de Figueiredo/0000-0003-4136-9608; Covas, Dimas
   T/0000-0002-7364-2595; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Kashima, Simone/0000-0002-1487-0141; CTC USP, CEPID 13
   18/0000-0002-7123-9524; Slavov, Svetoslav/0000-0003-0805-6140
CR Abu Al-Soud W, 2000, J CLIN MICROBIOL, V38, P345
   Babady NE, 2015, J CLIN MICROBIOL, V53, P1252, DOI 10.1128/JCM.03435-14
   Caliendo AM, 2000, J CLIN MICROBIOL, V38, P2122
   Garrigue I, 2008, J CLIN MICROBIOL, V46, P493, DOI 10.1128/JCM.01499-07
   Gullett JC, 2015, CLIN CHEM, V61, P72, DOI 10.1373/clinchem.2014.223289
   Halwachs-Baumann G, 2007, EXPERT REV ANTI-INFE, V5, P427, DOI 10.1586/14787210.5.3.427
   Hayden RT, 2015, J CLIN MICROBIOL, V53, P1500, DOI 10.1128/JCM.03375-14
   Hoorfar J, 2004, J CLIN MICROBIOL, V42, P1863, DOI 10.1128/JCM.42.5.1863-1868.2004
   Kearns AM, 2002, J CLIN VIROL, V24, P131, DOI 10.1016/S1386-6532(01)00240-2
   KHAN G, 1991, J CLIN PATHOL, V44, P360, DOI 10.1136/jcp.44.5.360
   Kohda C, 2014, J VIROL METHODS, V208, P160, DOI 10.1016/j.jviromet.2014.07.034
   Li W, 2015, JPN J INFECT DIS, V68, P135, DOI 10.7883/yoken.JJID.2014.017
   Lisboa LF, 2011, TRANSPLANTATION, V91, P231, DOI 10.1097/TP.0b013e3181ff8719
   Loens K, 2003, J CLIN MICROBIOL, V41, P4915, DOI 10.1128/JCM.41.11.4915-4923.2003
   Madi N, 2015, TRANSPL P, V47, P1802, DOI 10.1016/j.transproceed.2015.05.007
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Paixao P, 2012, EUR J PEDIATR, V171, P125, DOI 10.1007/s00431-011-1496-4
   Piiparinen H, 2002, J CLIN MICROBIOL, V40, P2945, DOI 10.1128/JCM.40.8.2945-2952.2002
   Pillet S, 2014, EXPERT REV ANTI-INFE, V12, P193, DOI 10.1586/14787210.2014.870887
   Revello MG, 2002, CLIN MICROBIOL REV, V15, P680, DOI 10.1128/CMR.15.4.680-715.2002
   Ross S A, 2011, Infect Disord Drug Targets, V11, P466
   Sanchez JL, 2002, J CLIN MICROBIOL, V40, P2381, DOI 10.1128/JCM.40.7.2381-2386.2002
   Schalasta G, 2000, J CLIN VIROL, V19, P175, DOI 10.1016/S1386-6532(00)00116-5
   Schrader C, 2012, J APPL MICROBIOL, V113, P1014, DOI 10.1111/j.1365-2672.2012.05384.x
   Slavov SN, 2015, BRAZ J MED BIOL RES, V48, P777, DOI 10.1590/1414-431X20154507
   Slavov SN, 2015, VIRAL IMMUNOL, V28, P123, DOI 10.1089/vim.2014.0057
   Tung YC, 2014, CLIN LAB, V60, P1895, DOI 10.7754/Clin.Lab.2014.140111
   von Muller L, 2002, J CLIN MICROBIOL, V40, P2285, DOI 10.1128/JCM.40.6.2285-2287.2002
   Waggoner J, 2012, J CLIN MICROBIOL, V50, P2378, DOI 10.1128/JCM.06800-11
   Wakabayashi H, 2012, AM J PERINAT, V29, P377, DOI 10.1055/s-0031-1300971
   Yamamoto AY, 2011, PEDIATR INFECT DIS J, V30, P1043, DOI 10.1097/INF.0b013e31822d9640
   Ziemann M, 2010, J VIROL METHODS, V170, P155, DOI 10.1016/j.jviromet.2010.09.020
NR 32
TC 2
Z9 2
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2016
VL 88
IS 9
BP 1604
EP 1612
DI 10.1002/jmv.24499
PG 9
WC Virology
SC Virology
GA DZ3BN
UT WOS:000385718800017
PM 26890091
DA 2020-12-17
ER

PT J
AU Adachi, K
   Klausner, JD
   Xu, JH
   Ank, B
   Bristow, CC
   Morgado, MG
   Watts, DH
   Weir, F
   Persing, D
   Mofenson, LM
   Veloso, VG
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, DM
   Bryson, YJ
   Grinsztejn, B
   Bastos, FI
   Siberry, G
   Nielsen-Saines, K
AF Adachi, Kristina
   Klausner, Jeffrey D.
   Xu, Jiahong
   Ank, Bonnie
   Bristow, Claire C.
   Morgado, Mariza G.
   Watts, D. Heather
   Weir, Fred
   Persing, David
   Mofenson, Lynne M.
   Veloso, Valdilea G.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy Maria
   Bryson, Yvonne J.
   Grinsztejn, Beatriz
   Bastos, Francisco I.
   Siberry, George
   Nielsen-Saines, Karin
CA NICHD HPTN 040 Study Team
TI Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant
   Women and Adverse Infant Outcomes
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HIV; pregnancy; chlamydia; gonorrhea; sexually transmitted infections;
   adverse infant outcomes
ID ACTIVE ANTIRETROVIRAL THERAPY; PRETERM BIRTH; PERINATAL-MORTALITY;
   ASSOCIATION; CHILDREN; SYPHILIS; TRANSMISSION; METAANALYSIS; MORBIDITY;
   DISEASE
AB Background: Sexually transmitted infections (STIs) in pregnancy such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) may lead to adverse infant outcomes.
   Methods: Individual urine specimens from HIV-infected pregnant women diagnosed with HIV during labor were collected at the time of infant birth and tested by polymerase chain reaction for CT and NG. Infant HIV infection was determined at 3 months with morbidity/mortality assessed through 6 months.
   Results: Of 1373 maternal urine samples, 277 (20.2%) were positive for CT and/or NG; 249 (18.1%) for CT, 63 (4.6%) for NG and 35 (2.5%) for both CT and NG. HIV infection was diagnosed in 117 (8.5%) infants. Highest rates of adverse outcomes (sepsis, pneumonia, congenital syphilis, septic arthritis, conjunctivitis, low birth weight, preterm delivery and death) were noted in infants of women with CT and NG (23/35, 65.7%) compared with NG (16/28, 57.1%), CT (84/214, 39.3%) and no STI (405/1096, 37%, P = 0.001). Death (11.4% vs. 3%, P = 0.02), low birth weight (42.9% vs. 16.9%, P = 0.001) and preterm delivery (28.6% vs. 10.2%, P = 0.008) were higher among infants of CT and NG-coinfected women. Infants who had any adverse outcome and were born to women with CT and/or NG were 3.5 times more likely to be HIV infected after controlling for maternal syphilis (odds ratio: 3.5, 95% confidence interval: 1.4-8.3). By adjusted multivariate logistic regression, infants born to mothers with any CT and/or NG were 1.35 times more likely to have an adverse outcome (odds ratio, 1.35; 95% confidence interval, 1.03-1.76).
   Conclusions: STIs in HIV-infected pregnant women are associated with adverse outcomes in HIV-exposed infected and uninfected infants.
C1 [Adachi, Kristina; Klausner, Jeffrey D.; Ank, Bonnie; Bryson, Yvonne J.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Klausner, Jeffrey D.; Bristow, Claire C.] UCLA Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
   [Xu, Jiahong] WESTAT Corp, Rockville, MD 20850 USA.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Bastos, Francisco I.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Weir, Fred; Persing, David] Cepheid, Sunnyvale, CA USA.
   [Mofenson, Lynne M.; Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, DST AIDS, Rio De Janeiro, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC, Cape Town, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Cape Town, South Africa.
   [Theron, Gerhard] Univ Stellenbosch, Tygerberg Hosp, Dept Obstet & Gynecol, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa de Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
RP Adachi, K (corresponding author), David Geffen Sch Med UCLA, Dept Pediat, Div Infect Dis, 10833 Conte Ave,MDCC 22-442, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Mofenson, Lynne/P-9631-2019; Mussi-Pinhata, Marisa/G-6568-2012; Pilotto,
   Jose Henrique/AAD-9773-2019; Pinto, Jorge A/D-1743-2014
OI Mofenson, Lynne/0000-0002-2818-9808; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pilotto, Jose Henrique/0000-0003-0521-8597;
   Pinto, Jorge A/0000-0003-2987-3238; Machado, Daisy/0000-0003-1993-6442;
   Joao, Esau/0000-0002-2412-0627; Kreitchmann, Regis/0000-0002-1146-0497;
   Bastos, Francisco/0000-0001-5970-8896
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001, U01 AI047986]; National Institute of
   Allergy and Infectious Diseases (NIAID)/NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIAIDU01 AI068632,
   UM1AI068632, UM1AI068616, UM1AI106716]; Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Institute of Mental HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [AI068632]; Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)Boehringer
   Ingelheim; GlaxoSmithKline on behalf of ViiV Healthcare; Cepheid,
   Sunnyvale, CA; UCLA Center for AIDS Research (CFAR) NIH/NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI028697]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI047986, UM1AI068616,
   P30AI028697, UM1AI106716, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069476, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI069476,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, UM1AI106716, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069476, UM1AI069453, P30AI028697, U01AI047986, P30AI028697,
   P30AI028697, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, UM1AI106716, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, UM1AI068632, U01AI047986, P30AI028697,
   U01AI047986, P30AI028697, UM1AI068616, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068632,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, UM1AI068616, P30AI028697, UM1AI069476, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, P30AI028697, P30AI028697, UM1AI069476, U01AI047986,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   U01AI047986, UM1AI068632, U01AI047986, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, UM1AI106716, UM1AI069476, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, UM1AI068632, P30AI028697,
   P30AI028697, P30AI028697, U01AI068632, UM1AI068632, P30AI028697,
   P30AI028697, UM1AI069453, U01AI068632, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   U01AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   U01AI068632, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   U01AI047986, UM1AI069453, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697] Funding
   Source: NIH RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract #
   HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), National
   Institute of Allergy and Infectious Diseases (NIAID)/NIH. Overall
   support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) of the National Institutes of
   Health (NIH) under Award Numbers NIAIDU01 AI068632, UM1AI068632 (IMPAACT
   LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with
   co-funding from the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH (AI068632). In addition, the parent study was
   supported in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI),
   and GlaxoSmithKline on behalf of ViiV Healthcare. The authors meet
   criteria for authorship as recommended by the International Committee of
   Medical Journal Editors (ICMJE) and were fully responsible for all
   aspects of manuscript development. This particular sub-study was
   supported by Cepheid, Sunnyvale, CA, where CT and NG testing of
   specimens was performed. Support was also provided by the UCLA Center
   for AIDS Research (CFAR) NIH/NIAID AI028697. Support for Kristina
   Adachi's work on this sub-study was also provided in part by the UCLA
   Children's Discovery and Innovation Institute (CDI). The content,
   conclusions and opinions expressed in this article are those of the
   authors and do not necessarily represent those of the National
   Institutes of Health, the U.S. Department of Health and Human Services,
   or the U.S. Department of State, affiliated universities, programs or
   companies of the authors.
CR Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Andrews WW, 2006, AM J OBSTET GYNECOL, V194, P493, DOI 10.1016/j.ajog.2005.08.054
   Andrews WW, 2000, AM J OBSTET GYNECOL, V183, P662, DOI 10.1067/mob.2000.106556
   Bias MM, 2007, SEX TRANSM INFECT, V83, DOI 10.1136/sti.2006.022665
   Bouwhuis SA, 2004, INT J DERMATOL, V43, P27, DOI 10.1111/j.1365-4632.2004.01841.x
   Brahmbhatt H, 2006, JAIDS-J ACQ IMM DEF, V41, P504, DOI 10.1097/01.qai.0000188122.15493.0a
   Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   COHEN I, 1990, JAMA-J AM MED ASSOC, V263, P3160, DOI 10.1001/jama.263.23.3160
   DONDERS GGG, 1993, GENITOURIN MED, V69, P98
   GENCAY M, 1995, CLIN INFECT DIS, V21, P424, DOI 10.1093/clinids/21.2.424
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V194, P650, DOI 10.1016/j.ajog.2006.01.004
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1065, DOI 10.1016/j.ajog.2006.05.046
   Gomez GB, 2013, B WORLD HEALTH ORGAN, V91, P217, DOI 10.2471/BLT.12.107623
   Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158
   Hammerschlag MR, 2011, CLIN INFECT DIS, V53, pS99, DOI 10.1093/cid/cir699
   Howson C. P., 2012, BORN TOO SOON GLOBAL
   Kapogiannis BG, 2011, CLIN INFECT DIS, V53, P1024, DOI 10.1093/cid/cir641
   Kim HY, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-138
   Kourtis AP, 2013, AIDS, V27, P749, DOI 10.1097/QAD.0b013e32835ca29f
   Kovacs L, 1998, INT J GYNECOL OBSTET, V62, P47, DOI 10.1016/S0020-7292(98)00075-7
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuznik A, 2015, SEX TRANSM DIS, V42, P369, DOI 10.1097/OLQ.0000000000000291
   Lawn JE, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S1
   Marazzi MC, 2011, AIDS, V25, P1611, DOI 10.1097/QAD.0b013e3283493ed0
   Martin D H, 1997, Infect Dis Obstet Gynecol, V5, P10, DOI 10.1002/(SICI)1098-0997(1997)5:1<10::AID-IDOG5>3.0.CO;2-I
   MARTIN DH, 1982, JAMA-J AM MED ASSOC, V247, P1585, DOI 10.1001/jama.247.11.1585
   MCGREGOR JA, 1990, AM J OBSTET GYNECOL, V163, P1580, DOI 10.1016/0002-9378(90)90632-H
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Newell ML, 2003, PEDIATRICS, V111
   Nielsen-Saines K, 2011, 3 PED HIV C ROM IT
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Nielsen-Saines K, 2012, PEDIATRICS, V129, pE1525, DOI 10.1542/peds.2011-2340
   Owor M, 2013, JAIDS-J ACQ IMM DEF, V64, P464, DOI 10.1097/QAI.0000000000000015
   Panaretto KS, 2006, AUST NZ J OBSTET GYN, V46, P217, DOI 10.1111/j.1479-828X.2006.00577.x
   Silva MJPMD, 2011, BRAZ J INFECT DIS, V15, P533, DOI 10.1590/S1413-86702011000600006
   Rollins NC, 2007, JAIDS-J ACQ IMM DEF, V44, P321, DOI 10.1097/QAI.0b013e31802ea4b0
   RYAN GM, 1990, AM J OBSTET GYNECOL, V162, P34, DOI 10.1016/0002-9378(90)90815-O
   Silveira MF, 2009, INT J STD AIDS, V20, P465, DOI 10.1258/ijsa.2008.008388
   Turner AN, 2013, JAIDS-J ACQ IMM DEF, V64, P392, DOI 10.1097/QAI.0b013e3182a2d13c
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P258, DOI 10.1053/j.spid.2005.06.006
   World Health Organization, 2012, GLOB INC PREV SEL CU
   World Health Organization, 2006, GLOB STRAT PREV CONT
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 44
TC 15
Z9 16
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2016
VL 35
IS 8
BP 894
EP 900
DI 10.1097/INF.0000000000001199
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DS4MK
UT WOS:000380755000018
PM 27164464
OA Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Smith, CE
   Jalbert, E
   de Almeida, V
   Mussi-Pinhata, M
   Cohen, RA
   Yu, QL
   Amaral, F
   Pinto, J
   Alarcon, J
   Siberry, G
   Weinberg, A
AF Smith, Christiana E.
   Jalbert, Emilie
   de Almeida, Volia
   Mussi-Pinhata, Marisa
   Cohen, Rachel A.
   Yu, Qilu
   Amaral, Fabiana
   Pinto, Jorge
   Alarcon, Jorge
   Siberry, George
   Weinberg, Adriana
TI Natural killer cell dysfunction in HIV-exposed uninfected infants
   correlates with acquisition of lower respiratory tract infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Immunologists (AAI)
CY MAY 13-17, 2016
CL Seattle, WA
SP Amer Assoc Immunologists
C1 [Smith, Christiana E.; Jalbert, Emilie; Weinberg, Adriana] Univ Colorado, Sch Med, Boulder, CO 80309 USA.
   [de Almeida, Volia] Univ Fed Sao Carlos, BR-13560 Sao Carlos, SP, Brazil.
   [Mussi-Pinhata, Marisa; Amaral, Fabiana] Univ Sao Paulo, Ribeirao Preto Fac Med, BR-05508 Sao Paulo, Brazil.
   [Cohen, Rachel A.; Yu, Qilu] WESTAT Corp, Rockville, MD 20850 USA.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Alarcon, Jorge] DA Carr Inst Trop Med, Lima, Peru.
   [Siberry, George] NICHD, NIH, Bethesda, MD USA.
RI Pinto, Jorge A/D-1743-2014; Smith, Christiana/AAK-7917-2020;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Pinto, Jorge A/0000-0003-2987-3238; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2016
VL 196
SU 1
PG 2
WC Immunology
SC Immunology
GA DS0LX
UT WOS:000380288301106
DA 2020-12-17
ER

PT J
AU Spaulding, AB
   Yu, QL
   Civitello, L
   Mussi-Pinhata, MM
   Pinto, J
   Gomes, IM
   Alarcon, JO
   Siberry, GK
   Harris, R
   Hazra, R
AF Spaulding, Alicen B.
   Yu, Qilu
   Civitello, Lucy
   Mussi-Pinhata, Marisa M.
   Pinto, Jorge
   Gomes, Ivete M.
   Alarcon, Jorge O.
   Siberry, George K.
   Harris, Robert
   Hazra, Rohan
CA NISDI LILAC Study Team
TI Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to
   Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID PERSISTENT MITOCHONDRIAL DYSFUNCTION; PERINATAL EXPOSURE; UNINFECTED
   INFANTS; CHILDREN; SCHIZOPHRENIA; TRANSMISSION; COMPROMISE; WOMEN;
   SIGNS; RISK
AB To evaluate antiretroviral (ARV) drug exposure and other factors during pregnancy that may increase the risk of neurologic conditions (NCs) in HIV-exposed/uninfected (HEU) infants. A prospective cohort study was conducted at 24 clinical sites in Latin America and the Caribbean. Data on maternal demographics, health, HIV disease status, and ARV use during pregnancy were collected. Infant data included measurement of head circumference after birth and reported medical diagnoses at birth, 6-12 weeks, and 6 months. Only infants with maternal exposure to combination ARV therapy (cART) (3 drugs from 2 drug classes) during pregnancy were included. Microcephaly, defined as head circumference for age z-score less than -2, and NC were evaluated for their association with covariates, including individual ARVs, using bivariable and logistic regression analyses. From 2002 to 2009, 1,400 HEU infants met study inclusion criteria. At least one NC was reported in 134 (9.6%; 95% confidence interval [CI]: 8.1-11.2), microcephaly in 105 (7.5%; 95% CI: 6.2-9.0), and specific neurologic diagnoses in 33 (2.4%; 95% CI: 1.6-3.3) HEU infants. Microcephaly and NC were not significantly associated with any specific ARV analyzed (p>0.05). Covariates associated with increased odds of NC included male sex (odds ratio [OR]=1.9; 95% CI: 1.3-2.8), birth weight <2.5kg (OR=3.1; 95% CI: 2.1-4.8), 1-min Apgar score <7 (OR=2.5; 95% CI: 1.4-4.4), and infant infections (OR=2.5; 95% CI: 1.5-4.1). No ARV investigated was associated with adverse neurologic outcomes. Continued investigation of such associations may be warranted as new ARVs are used during pregnancy and cART exposure during the first trimester becomes increasingly common.
C1 [Spaulding, Alicen B.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Yu, Qilu; Harris, Robert] Westat Corp, Rockville, MD USA.
   [Civitello, Lucy] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Sch Med, Div Immunol, Belo Horizonte, MG, Brazil.
   [Gomes, Ivete M.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Alarcon, Jorge O.] Univ San Marcos, Inst Med Trop Daniel Alcides Carrion, Lima, Peru.
   [Siberry, George K.; Hazra, Rohan] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
RP Hazra, R (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, 6100 Execut Blvd,Room 4B11, Bethesda, MD 20892 USA.
EM hazrar@mail.nih.gov
RI Pinto, Jorge A/D-1743-2014; Mussi-Pinhata, Marisa/G-6568-2012
OI Pinto, Jorge A/0000-0003-2987-3238; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-HD-3-3345, HHSN267200800001C, HHSN275201300003C]
FX The NICHD International Site Development Initiative Perinatal/LILAC
   Protocol principal investigators, coprincipal investigators, study
   coordinators, coordinating center representatives, and the NICHD staff
   include the following: Argentina: Buenos Aires: Marcelo H. Losso, Irene
   Foradori, Alejandro Hakim, Erica Stankievich, Silvina Ivalo (Hospital
   General de Agudos Jose 'Maria Ramos Mejia); Brazil: Belo Horizonte:
   Jorge A. Pinto, Victor H. Melo, Fabiana Kakehasi, Beatriz M. Andrade
   (Universidade Federal de Minas Gerais); Caxias do Sul: Rosa Dea
   Sperhacke, Nicole Golin, Silvia Mariani Costamilan (Universidade de
   Caxias do Sul/Servico Municipal de Infectologia); Nova Iguacu: Jose
   Pilotto, Luis Eduardo Fernandes, Gisely Falco (Hospital Geral Nova de
   Iguacu-HIV Family Care Clinic); Porto Alegre: Rosa Dea Sperhacke, Breno
   Riegel Santos, Rita de Cassia Alves Lira (Universidade de Caxias do
   Sul/Hospital Conceicao); Rosa Dea Sperhacke, Mario Ferreira Peixoto,
   Elizabete Teles (Universidade de Caxias do Sul/Hospital Femina); Regis
   Kreitchmann, Luis Carlos Ribeiro, Fabrizio Motta, Debora Fernandes
   Coelho (Irmandade da Santa Casa de Misericordia de Porto Alegre);
   Ribeirao Preto: Marisa M. Mussi-Pinhata, Geraldo Duarte, Adriana A.
   Tiraboschi Barbaro, Conrado Milani Coutinho, Fabiana Rezende Amaral,
   Anderson Sanches de Melo (Hospital das Clinicas da Faculdade de Medicina
   de Ribeirao Preto da Universidade de Sao Paulo); Rio de Janeiro: Ricardo
   Hugo S. Oliveira, Elizabeth S. Machado, Maria C. Chermont Sapia
   (Instituto de Puericultura e Pediatria Martagao Gesteira); Esau Custodio
   Joao, Leon Claude Sidi, Maria Leticia Santos Cruz, Maria Isabel Gouvea,
   Mariza Curto Saavedra, Clarisse Bressan, Fernanda Cavalcanti A. Jundi
   (Hospital dos Servidores do Estado); Sao Paulo: Regina Celia de Menezes
   Succi, Prescilla Chow (Escola Paulista de Medicina-Universidade Federal
   de Sao Paulo); Peru: Lima: Jorge O. Alarcon Villaverde (Instituto de
   Medicina Tropical "Daniel Alcides Carrion''- Seccion de Epidemiologia,
   UNMSM), Carlos Velasquez Vasquez (Instituto Nacional Materno Perinatal),
   Cesar Gutierrez Villafuerte (Instituto de Medicina Tropical "Daniel
   Alcides Carrion''- Seccion de Epidemiologia, UNMSM); Data Management and
   Statistical Center: Yolanda Bertucci, Rachel Cohen, Laura Freimanis
   Hance, Rene Gonin, D. Robert Harris, Roslyn Hennessey, James Korelitz,
   Margot Krauss, Sue Li, Karen Megazzini, Orlando Ortega, Sharon Sothern
   de Sanchez, Sonia K. Stoszek, Qilu Yu (Westat, Rockville, MD, USA); and
   NICHD: George K. Siberry, Rohan Hazra, Lynne M. Mofenson (Eunice Kennedy
   Shriver National Institute of Child Health and Human Development,
   Bethesda, MD, USA). This work was supported by the Eunice Kennedy
   Shriver National Institute of Child Health and Human Development (NICHD)
   contracts N01-HD-3-3345 (2002-2007), HHSN267200800001C (2007-2012), and
   HHSN275201300003C (2012-2017). The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health.
CR Barret B, 2003, AIDS, V17, P1769, DOI 10.1097/00002030-200308150-00006
   Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0
   Brogly SB, 2007, AIDS, V21, P929, DOI 10.1097/QAD.0b013e3280d5a786
   Brogly SB, 2010, JAIDS-J ACQ IMM DEF, V53, P154, DOI 10.1097/QAI.0b013e3181b3adc2
   Brown AS, 2010, AM J PSYCHIAT, V167, P261, DOI 10.1176/appi.ajp.2009.09030361
   Brown AS, 2005, AM J PSYCHIAT, V162, P767, DOI 10.1176/appi.ajp.162.4.767
   Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774
   Bulterys M, 2000, J ACQ IMMUN DEF SYND, V25, P261
   Bulterys M, 2000, ANN NY ACAD SCI, V918, P212
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Divi RL, 2007, TOXICOL SCI, V99, P203, DOI 10.1093/toxsci/kfm143
   Divi RL, 2005, CARDIOVASC TOXICOL, V5, P333, DOI 10.1385/CT:5:3:333
   Dominguez K, 2000, ANN NY ACAD SCI, V918, P236
   European Collaborative Study, 1999, J ACQ IMMUN DEF SYND, V32, P380
   Gibb DM, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001217
   Hazra R, 2009, INT J EPIDEMIOL, V38, P1207, DOI 10.1093/ije/dyn239
   Landreau-Mascaro A, 2002, LANCET, V359, P583, DOI 10.1016/S0140-6736(02)07717-6
   Lindegren ML, 2000, ANN NY ACAD SCI, V918, P222
   Noguera A, 2004, PEDIATRICS, V114, pE598, DOI 10.1542/peds.2004-0955
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   Saba J, 2002, LANCET, V359, P1178
   Sibiude J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001635
   Susser ES, 2000, SCHIZOPHRENIA BULL, V26, P257, DOI 10.1093/oxfordjournals.schbul.a033451
   Williams PL, 2010, PEDIATRICS, V125, pE250, DOI 10.1542/peds.2009-1112
   World Health Organization, 2009, WHO CHILD GROWTH STA
NR 25
TC 8
Z9 8
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR 1
PY 2016
VL 32
IS 4
BP 349
EP 356
DI 10.1089/aid.2015.0254
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DI5JE
UT WOS:000373533900007
PM 26879281
OA Green Published
DA 2020-12-17
ER

PT J
AU Renzette, N
   Pokalyuk, C
   Gibson, L
   Bhattacharjee, B
   Schleiss, MR
   Hamprecht, K
   Yamamoto, AY
   Mussi-Pinhata, MM
   Britt, WJ
   Jensen, JD
   Kowalik, TF
AF Renzette, Nicholas
   Pokalyuk, Cornelia
   Gibson, Laura
   Bhattacharjee, Bornali
   Schleiss, Mark R.
   Hamprecht, Klaus
   Yamamoto, Aparecida Y.
   Mussi-Pinhata, Marisa M.
   Britt, William J.
   Jensen, Jeffrey D.
   Kowalik, Timothy F.
TI Limits and patterns of cytomegalovirus genomic diversity in humans
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE human cytomegalovirus; HCMV; congenital CMV; virology; evolution
ID T-CELL RESPONSES; POLYMERASE SUBUNIT UL44; MUTATION-RATES; SIMULTANEOUS
   INFECTION; BACKGROUND SELECTION; GENETIC HITCHHIKING; HOMOSEXUAL-MEN;
   WIDE VIEW; STRAINS; GENOTYPES
AB Human cytomegalovirus (HCMV) exhibits surprisingly high genomic diversity during natural infection although little is known about the limits or patterns of HCMV diversity among humans. To address this deficiency, we analyzed genomic diversity among congenitally infected infants. We show that there is an upper limit to HCMV genomic diversity in these patient samples, with similar to 25% of the genome being devoid of polymorphisms. These low diversity regions were distributed across 26 loci that were preferentially located in DNA-processing genes. Furthermore, by developing, to our knowledge, the first genome-wide mutation and recombination rate maps for HCMV, we show that genomic diversity is positively correlated with these two rates. In contrast, median levels of viral genomic diversity did not vary between putatively single or mixed strain infections. We also provide evidence that HCMV populations isolated from vascular compartments of hosts from different continents are genetically similar and that polymorphisms in glycoproteins and regulatory proteins are enriched in these viral populations. This analysis provides the most highly detailed map of HCMV genomic diversity in human hosts to date and informs our understanding of the distribution of HCMV genomic diversity within human hosts.
C1 [Renzette, Nicholas; Bhattacharjee, Bornali; Kowalik, Timothy F.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA.
   [Pokalyuk, Cornelia] Goethe Univ Frankfurt, Inst Stochast, D-60325 Frankfurt, Germany.
   [Pokalyuk, Cornelia; Jensen, Jeffrey D.] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA.
   [Gibson, Laura] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01655 USA.
   [Schleiss, Mark R.] Univ Minnesota, Sch Med, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA.
   [Schleiss, Mark R.] Univ Minnesota, Sch Med, Dept Pediat, Div Pediat Infect Dis, Minneapolis, MN 55455 USA.
   [Hamprecht, Klaus] Univ Tubingen Hosp, Inst Med Virol, D-72076 Tubingen, Germany.
   [Yamamoto, Aparecida Y.; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, BR-14048900 Ribeirao Preto, SP, Brazil.
   [Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL 35294 USA.
   [Jensen, Jeffrey D.] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland.
   [Kowalik, Timothy F.] Univ Massachusetts, Sch Med, Immunol & Virol Program, Worcester, MA 01655 USA.
RP Kowalik, TF (corresponding author), Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA.
EM jeffrey.jensen@epfl.ch; Timothy.Kowalik@umassmed.edu
RI Mussi-Pinhata, Marisa/G-6568-2012; Jensen, Jeffrey/S-1084-2016
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Jensen,
   Jeffrey/0000-0002-4786-8064; Bhattacharjee, Bornali/0000-0002-0801-1543
FU Deutsche Forschungsgemeinschaft Priority Programme SPP 1590; Swiss
   National Science FoundationSwiss National Science Foundation (SNSF);
   European Research CouncilEuropean Research Council (ERC); National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HD061959, AI109001,
   F32AI084437]; National Center for Advancing Translational Sciences of
   the NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000161]; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD061959, R01HD061959, R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD061959] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000161, UL1TR000161, UL1TR000161, UL1TR000161] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI109001, F32AI084437, R01AI109001, R01AI109001,
   R01AI109001, F32AI084437] Funding Source: NIH RePORTER
FX We thank Stuart Adler for helpful advice and thoughtful input on the
   clinical interpretation of the data. We also thank all of the clinicians
   and patients who contributed samples. We thank the University of
   Massachusetts Deep Sequencing and Molecular Biology Core Laboratories
   for their contribution and services. This work was supported by grants
   from the Deutsche Forschungsgemeinschaft Priority Programme SPP 1590 (to
   C.P.), by the Swiss National Science Foundation and a European Research
   Council Starting Grant (to J.D.J.), by National Institutes of Health
   (NIH) Grants HD061959 (to W.J.B. and T.F.K.), AI109001 (to T.F.K.), and
   F32AI084437 (to N.R.), and by National Center for Advancing
   Translational Sciences of the NIH Grant UL1TR000161.
CR ALFORD CA, 1990, REV INFECT DIS, V12, pS745
   Ananda G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r27
   [Anonymous], 2011, PLOS PATHOG, V7
   Appleton BA, 2006, J BIOL CHEM, V281, P5224, DOI 10.1074/jbc.M506900200
   Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018
   BALFOUR HH, 1979, ARCH INTERN MED, V139, P279, DOI 10.1001/archinte.139.3.279
   BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0
   Bhattacharjee B, 2012, J VIROL, V86, P6815, DOI 10.1128/JVI.00015-12
   Bradley AJ, 2008, J MED VIROL, V80, P1615, DOI 10.1002/jmv.21241
   Bradley AJ, 2009, J GEN VIROL, V90, P2375, DOI 10.1099/vir.0.013250-0
   Britt W, 2015, MED MICROBIOL IMMUN, V204, P263, DOI 10.1007/s00430-015-0399-9
   Burkala E, 2007, MICROBIOL-SGM, V153, P2180, DOI 10.1099/mic.0.2007/005470-0
   Cannon MJ, 2009, J CLIN VIROL, V46, pS6, DOI 10.1016/j.jcv.2009.09.002
   Chan AH, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003090
   CHARLESWORTH B, 1993, GENETICS, V134, P1289
   CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151
   Cheng TP, 2010, J VIROL, V84, P2623, DOI 10.1128/JVI.02142-09
   Coaquette A, 2004, CLIN INFECT DIS, V39, P155, DOI 10.1086/421496
   Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862
   Corbett-Detig RB, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002112
   Cunningham C, 2010, J GEN VIROL, V91, P605, DOI 10.1099/vir.0.015891-0
   DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859
   Drake JW, 2005, GENETICS, V170, P969, DOI 10.1534/genetics.104.040410
   E XF, 2014, VIRUSES-BASEL, V6, P2155, DOI 10.3390/v6052155
   Emery VC, 1999, J EXP MED, V190, P177, DOI 10.1084/jem.190.2.177
   Fouts AE, 2014, P NATL ACAD SCI USA, V111, P8209, DOI 10.1073/pnas.1404653111
   Frange P, 2013, J CLIN MICROBIOL, V51, P4266, DOI 10.1128/JCM.02411-13
   Gao LZ, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-11
   Gawel D, 2008, J BACTERIOL, V190, P1730, DOI 10.1128/JB.01463-07
   Gibson L, 2004, J IMMUNOL, V172, P2256, DOI 10.4049/jimmunol.172.4.2256
   Gibson L, 2007, J INFECT DIS, V195, P1789, DOI 10.1086/518042
   Gibson L, 2015, J CLIN IMMUNOL, V35, P289, DOI 10.1007/s10875-015-0139-3
   Gorzer I, 2010, J VIROL, V84, P7195, DOI 10.1128/JVI.00475-10
   Goldner T, 2011, J VIROL, V85, P10884, DOI 10.1128/JVI.05265-11
   Griffiths P, 2013, VACCINE, V31, pB197, DOI 10.1016/j.vaccine.2012.10.074
   Hamprecht K, 2003, J INFECT DIS, V187, P139, DOI 10.1086/346240
   Hill JM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010643
   Hraber PT, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-103
   Huang E S, 1980, Ann N Y Acad Sci, V354, P332, DOI 10.1111/j.1749-6632.1980.tb27976.x
   Janeway CA, 2001, IMMUNOBIOLOGY IMMUNE
   Jia FZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095722
   Jombart T, 2008, BIOINFORMATICS, V24, P1403, DOI 10.1093/bioinformatics/btn129
   Jombart T, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-94
   Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997
   KAPLAN NL, 1989, GENETICS, V123, P887
   Kim Y, 2000, GENETICS, V155, P1415
   LEACH CT, 1994, J INFECT DIS, V170, P293, DOI 10.1093/infdis/170.2.293
   Liang Y, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005145
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lurain NS, 2010, CLIN MICROBIOL REV, V23, P689, DOI 10.1128/CMR.00009-10
   Lynch M, 2008, P NATL ACAD SCI USA, V105, P9272, DOI 10.1073/pnas.0803466105
   Lynch M, 2010, P NATL ACAD SCI USA, V107, P961, DOI 10.1073/pnas.0912629107
   Maechler M., 2015, CLUSTER CLUSTER ANAL
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI [10.1172/JCI200317470, 10.1172/JCI17470]
   Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]
   McGeoch DJ, 2006, VIRUS RES, V117, P90, DOI 10.1016/j.virusres.2006.01.002
   McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500
   Meyer-Konig U, 1998, J MED VIROL, V55, P75, DOI 10.1002/(SICI)1096-9071(199805)55:1<75::AID-JMV12>3.0.CO;2-Z
   Meyer-Konig U, 1998, LANCET, V352, P1280, DOI 10.1016/S0140-6736(05)70487-6
   Numazaki K, 1998, LANCET, V352, P1710, DOI 10.1016/S0140-6736(05)61490-0
   Pang XL, 2008, J CLIN MICROBIOL, V46, P4004, DOI 10.1128/JCM.01341-08
   Park C, 2012, EMBO REP, V13, P1123, DOI 10.1038/embor.2012.165
   Poole E, 2014, NEW J SCI, V2014, DOI DOI 10.1155/2014/313761
   Puchhammer-Stockl E, 2006, J CLIN VIROL, V36, P239, DOI 10.1016/j.jcv.2006.03.004
   Puchhammer-Stockl E, 2011, FUTURE VIROL, V6, P259, DOI 10.2217/FVL.10.87
   Rands CM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004525
   Renzette N, 2014, CURR OPIN VIROL, V8, P109, DOI 10.1016/j.coviro.2014.08.001
   Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735
   Renzette N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001344
   Ross SA, 2011, J INFECT DIS, V204, P1003, DOI 10.1093/infdis/jir457
   Ross SA, 2010, J INFECT DIS, V201, P386, DOI 10.1086/649903
   Ryckman BJ, 2008, P NATL ACAD SCI USA, V105, P14118, DOI 10.1073/pnas.0804365105
   Sanchez-Merino V, 2005, J IMMUNOL, V175, P6976, DOI 10.4049/jimmunol.175.10.6976
   Sanchez-Merino V, 2008, J INFECT DIS, V197, P300, DOI 10.1086/524845
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Sinzger C, 2008, CURR TOP MICROBIOL, V325, P63
   Sinzger C, 2008, J GEN VIROL, V89, P359, DOI 10.1099/vir.0.83286-0
   Snoeck J, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-87
   Sowmya P, 2009, J MED VIROL, V81, P861, DOI 10.1002/jmv.21459
   SPECTOR SA, 1984, J INFECT DIS, V150, P953, DOI 10.1093/infdis/150.6.953
   Stephan W, 2010, PHILOS T R SOC B, V365, P1245, DOI 10.1098/rstb.2009.0278
   Sun ZR, 2006, MICROBIOL IMMUNOL, V50, P773, DOI 10.1111/j.1348-0421.2006.tb03853.x
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Team R.C, 2014, R LANG ENV STAT COMP
   Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467-9868.00293
   Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290
   Wang CB, 2011, CLIN INFECT DIS, V52, pE11, DOI 10.1093/cid/ciq085
   Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   Zhang YJJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002946
   Zhou MM, 2013, J VIROL, V87, P9680, DOI 10.1128/JVI.01167-13
   Zhou YM, 2007, J GEN VIROL, V88, P932, DOI 10.1099/vir.0.82495-0
NR 92
TC 60
Z9 60
U1 1
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 28
PY 2015
VL 112
IS 30
BP E4120
EP E4128
DI 10.1073/pnas.1501880112
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN7ZW
UT WOS:000358656500020
PM 26150505
OA Bronze, Green Published
DA 2020-12-17
ER

PT J
AU Jao, J
   Freimanis, L
   Mussi-Pinhata, MM
   Cohen, RA
   Monteiro, JP
   Cruz, ML
   Sperling, RS
   Branch, A
   Siberry, GK
AF Jao, Jennifer
   Freimanis, Laura
   Mussi-Pinhata, Marisa M.
   Cohen, Rachel A.
   Monteiro, Jacqueline P.
   Cruz, Maria L.
   Sperling, Rhoda S.
   Branch, Andrea
   Siberry, George K.
CA NISDI LILAC Protocol
TI Low vitamin D status among pregnant Latin American and Caribbean women
   with HIV Infection
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Caribbean; HIV; Latin America; Pregnancy; Vitamin D
ID D DEFICIENCY; D SUPPLEMENTATION; D INSUFFICIENCY; MOTHERS; RISK;
   PREVALENCE; METABOLISM; COMMON
AB Objective: To evaluate the prevalence and predictors of low vitamin D status among pregnant women with HIV infection. Methods: The present cross-sectional study analyzed repository specimens collected at 12-34 weeks of pregnancy among women enrolled across 17 sites in Latin America and the Caribbean between 2002 and 2009. Logistic regression modeling was used to identify factors associated with low vitamin D status (25-hydroxyvitamin D <30 ng/mL). Results: Among 715 women, 218 (30.5%) were vitamin D deficient (<20 ng/mL) and 252 (35.2%) were insufficient (21-29 ng/mL). Factors associated with low vitamin D status included residence in subtropical latitudes (adjusted odds ratio [aOR] 1.97,95% confidence interval [CI] 1.35-2.88), assessment during non-summer seasons (autumn: aOR 1.85, 95% CI 1.20-2.86; spring: 43,2.65-6.95; winter: 10.82, 5.74-20.41), employment (aOR 1.56, 95% CI 1.06-238), and assessment before 20 weeks of pregnancy (aOR 1.89, 95% CI 1.18-3.06). Factors protective against low vitamin D status were CD4 count below 200 cells per mm(3) (aOR 0.45, 95% CI 0.26-0.77) and protease inhibitors (aOR 0.62, 95% CI 0.40-0.95). Conclusion: Low vitamin D status was prevalent among pregnant women with HIV infection. Further studies are warranted to identify the impact of low maternal vitamin D status. (C) 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Jao, Jennifer; Branch, Andrea] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Jao, Jennifer; Sperling, Rhoda S.] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA.
   [Freimanis, Laura; Cohen, Rachel A.] Westat Corp, Rockville, MD USA.
   [Mussi-Pinhata, Marisa M.; Monteiro, Jacqueline P.] Univ Sao Paulo, Fac Med, BR-14049 Ribeirao Preto, Brazil.
   [Cruz, Maria L.] Hosp Fed Servidores Estado, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, Brazil.
   [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, Bethesda, MD USA.
RP Jao, J (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Pl,Box 1087, New York, NY 10029 USA.
EM jenniferjao@mssm.edu
RI Cruz, Maria Leticia/Y-5632-2019; Monteiro, Jacqueline/F-6987-2012;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [N01-HD-3-3345,
   HHSN267200800001C, N01-HD-8-0001]; Abbott LaboratoriesAbbott
   Laboratories; NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD070760]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH
   & HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [K23HD070760, K23HD070760, K23HD070760, K23HD070760, K23HD070760]
   Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH
   RePORTER
FX The present study was supported by the National Institutes of Health
   (Eunice Kennedy Shriver NICHD contract N01-HD-3-3345 [2002-2007] and
   NICHD contract HHSN267200800001C [NICHD control N01-HD-8-0001]
   [2007-2012]) and by Abbott Laboratories. J.J. is supported by NICHD
   K23HD070760.
CR Abbott Architect System, 2011, 3L52 ABB LAB
   Adeyemi OM, 2011, JAIDS-J ACQ IMM DEF, V57, P197, DOI 10.1097/QAI.0b013e31821ae418
   Ardawi MSM, 1997, EUR J ENDOCRINOL, V137, P402, DOI 10.1530/eje.0.1370402
   Belderbos ME, 2011, PEDIATRICS, V127, pE1513, DOI 10.1542/peds.2010-3054
   Bodnar LM, 2010, J NUTR, V140, P999, DOI 10.3945/jn.109.119636
   Boggess KA, 2011, J PERIODONTOL, V82, P195, DOI 10.1902/JOP.2010.100384
   Cavalier E, 2012, CLIN BIOCHEM, V45, P505, DOI 10.1016/j.clinbiochem.2012.01.021
   Cozzolino M, 2003, AIDS, V17, P513, DOI 10.1097/00002030-200303070-00006
   CROSS NA, 1995, AM J CLIN NUTR, V61, P514
   Dao CN, 2011, CLIN INFECT DIS, V52, P396, DOI 10.1093/cid/ciq158
   Diogenes MEL, 2013, AM J CLIN NUTR, V98, P82, DOI 10.3945/ajcn.112.056275
   Farrant HJW, 2009, EUR J CLIN NUTR, V63, P646, DOI 10.1038/ejcn.2008.14
   Farrell CJL, 2012, CLIN CHEM, V58, P531, DOI 10.1373/clinchem.2011.172155
   Grant CC, 2014, PEDIATRICS, V133, pE143, DOI 10.1542/peds.2013-2602
   Haugen M, 2009, EPIDEMIOLOGY, V20, P720, DOI 10.1097/EDE.0b013e3181a70f08
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Kazemi A, 2009, J WOMENS HEALTH, V18, P835, DOI 10.1089/jwh.2008.0954
   Madeddu G, 2004, Q J NUCL MED MOL IM, V48, P39
   Maeda SS, 2007, BRAZ J MED BIOL RES, V40, P1653, DOI [10.1590/S0100-879X2006005000162, 10.1590/S0100-879X2007001200009]
   Maghbooli Z, 2008, DIABETES-METAB RES, V24, P27, DOI 10.1002/dmrr.737
   Mave V, 2012, HIV CLIN TRIALS, V13, P278, DOI 10.1310/hct1305-278
   Mehta S, 2010, EUR J CLIN NUTR, V64, P808, DOI 10.1038/ejcn.2010.76
   Mehta S, 2011, AIDS PATIENT CARE ST, V25, P579, DOI 10.1089/apc.2011.0182
   Mutlu GY, 2014, HORM RES PAEDIAT, V81, P402, DOI 10.1159/000358833
   OLIVERI MB, 1993, MEDICINA-BUENOS AIRE, V53, P315
   Prentice A, 2009, ACTA PAEDIATR, V98, P1360, DOI 10.1111/j.1651-2227.2009.01352.x
   Song SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085081
   Szep Z, 2011, AIDS, V25, P525, DOI 10.1097/QAD.0b013e328342fdfd
   Vandevijvere S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043868
   Viljakainen HT, 2011, OSTEOPOROSIS INT, V22, P883, DOI 10.1007/s00198-010-1499-4
   Wagner CL, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.888
   Weinert LS, 2014, AM J HYPERTENS, V27, P1316, DOI 10.1093/ajh/hpu043
   Welz T, 2010, AIDS, V24, P1923, DOI 10.1097/QAD.0b013e32833c3281
NR 33
TC 4
Z9 4
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUL
PY 2015
VL 130
IS 1
BP 54
EP 58
DI 10.1016/j.ijgo.2015.01.017
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CL5DH
UT WOS:000356979500013
PM 25912414
OA Green Published, Green Accepted
DA 2020-12-17
ER

PT J
AU Hyde, TB
   Sato, HK
   Hao, LJ
   Flannery, B
   Zheng, Q
   Wannemuehler, K
   Ciccone, FH
   Marques, HD
   YinWeckx, L
   Safadi, MA
   Moraes, ED
   Pinhata, MM
   Neto, JO
   Bevilacqua, MC
   Tabith, A
   Monteiro, TA
   Figueiredo, CA
   Andrus, JK
   Reef, SE
   Toscano, CM
   Castillo-Solorzano, C
   Icenogle, JP
AF Hyde, Terri B.
   Sato, Helena Keico
   Hao, LiJuan
   Flannery, Brendan
   Zheng, Qi
   Wannemuehler, Kathleen
   Ciccone, Flavia Helena
   Marques, Heloisa de Sousa
   YinWeckx, Lily
   Safadi, Marco Aurelio
   Moraes, Eliane de Oliveira
   Pinhata, Marisa Mussi
   Neto, Jaime Olbrich
   Bevilacqua, Maria Cecilia
   Tabith Junior, Alfredo
   Monteiro, Tatiana Alves
   Figueiredo, Cristina Adelaide
   Andrus, Jon K.
   Reef, Susan E.
   Toscano, Cristiana M.
   Castillo-Solorzano, Carlos
   Icenogle, Joseph P.
CA CRS Biomarker Study Grp
TI Identification of Serologic Markers for School-Aged Children With
   Congenital Rubella Syndrome
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE congenital rubella syndrome; CRS; biomarkers; rubella; serology; immune
   response
ID VIRUS; AVIDITY; BURDEN; BRAZIL; DIAGNOSIS; OUTBREAK; MEASLES; IGM
AB Background. Congenital rubella syndrome (CRS) case identification is challenging in older children since laboratory markers of congenital rubella virus (RUBV) infection do not persist beyond age 12 months.
   Methods. We enrolled children with CRS born between 1998 and 2003 and compared their immune responses to RUBV with those of their mothers and a group of similarly aged children without CRS. Demographic data and sera were collected. Sera were tested for anti-RUBV immunoglobulin G (IgG), IgG avidity, and IgG response to the 3 viral structural proteins (E1, E2, and C), reflected by immunoblot fluorescent signals.
   Results. We enrolled 32 children with CRS, 31 mothers, and 62 children without CRS. The immunoblot signal strength to C and the ratio of the C signal to the RUBV-specific IgG concentration were higher (P <.029 for both) and the ratio of the E1 signal to the RUBV-specific IgG concentration lower (P =.001) in children with CRS, compared with their mothers. Compared with children without CRS, children with CRS had more RUBV-specific IgG (P <.001), a stronger C signal (P <.001), and a stronger E2 signal (P <=.001). Two classification rules for children with versus children without CRS gave 100% specificity with >65% sensitivity.
   Conclusions. This study was the first to establish classification rules for identifying CRS in school-aged children, using laboratory biomarkers. These biomarkers should allow improved burden of disease estimates and monitoring of CRS control programs.
C1 [Hyde, Terri B.; Hao, LiJuan; Flannery, Brendan; Zheng, Qi; Wannemuehler, Kathleen; Reef, Susan E.; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Flannery, Brendan; Andrus, Jon K.; Toscano, Cristiana M.; Castillo-Solorzano, Carlos] Pan Amer Hlth Org, Washington, DC USA.
   [Sato, Helena Keico; Ciccone, Flavia Helena] Univ Sao Paulo, Univ Hosp, Sao Paulo State Hlth Dept, Sao Paulo, Brazil.
   [Marques, Heloisa de Sousa] Univ Sao Paulo, Univ Hosp, Childrens Inst, Sao Paulo, Brazil.
   [YinWeckx, Lily] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
   [Safadi, Marco Aurelio] Catholic Univ Sao Paulo, Sch Med Sci Santa Casa, Sao Paulo, Brazil.
   [Tabith Junior, Alfredo] Catholic Univ Sao Paulo, Div Educ & Rehabil Commun Disturbances, Sao Paulo, Brazil.
   [Monteiro, Tatiana Alves] USP Med Sch, Div Otorhinolaryngol, Sao Paulo, Brazil.
   [Figueiredo, Cristina Adelaide] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Moraes, Eliane de Oliveira] Univ Sao Paulo, Sch Med Sci, Campinas, SP, Brazil.
   [Pinhata, Marisa Mussi] Univ Sao Paulo, Univ Hosp, Ribeirao Preto, Brazil.
   [Neto, Jaime Olbrich] Univ Sao Paulo, Univ Hosp Botucatu, Bauru, Brazil.
   [Bevilacqua, Maria Cecilia] Univ Sao Paulo, Hosp Rehabil Cranofacial Abnormal, Audiol Res Ctr, Bauru, Brazil.
RP Icenogle, JP (corresponding author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,MS-C22, Atlanta, GA 30333 USA.
EM jicenogle@cdc.gov
RI Mussi-Pinhata, Marisa/G-6568-2012; safadi, marco aurelio
   palazzi/B-7157-2015
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; safadi, marco aurelio
   palazzi/0000-0002-4401-9446; Wannemuehler, Kathleen/0000-0001-9535-6277;
   WECKX, LILY/0000-0003-4949-3582
FU CDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA; Sao Paulo State Health Department;
   Pan American Health Organization
FX This work was supported by the CDC, the Sao Paulo State Health
   Department, and the Pan American Health Organization.
CR Andrade JQ, 2006, J CLIN VIROL, V35, P285, DOI 10.1016/j.jcv.2005.09.007
   Andrus JK, 2011, VACCINE, V29, pD91, DOI 10.1016/j.vaccine.2011.04.059
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P89
   [Anonymous], 1999, 13 TECHN ADV GROUP M, pXXI
   BELLINI WJ, 2003, MANUAL CLIN MICROBIO, P1389
   Bloom S, 2005, LANCET, V365, P135, DOI 10.1016/S0140-6736(05)17703-4
   Bottiger B, 1997, CLIN DIAGN VIROL, V8, P105, DOI 10.1016/S0928-0197(97)00018-4
   Castillo-Solorzano C, 2011, J INFECT DIS, V204, pS683, DOI 10.1093/infdis/jir471
   Center for Epidemiologic Surveillance. Sao Paulo State Health Department, 2001, RUB VACC CAMP WOM 20
   Cutts FT, 1999, INT J EPIDEMIOL, V28, P1176, DOI 10.1093/ije/28.6.1176
   Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55
   CUTTS FT, 1999, WHOVB9922
   Dabbagh AJ, 2013, MMWR-MORBID MORTAL W, V62, P983
   Departamento de Vigilancia Epidemiologica Secretaria de Vigilancia em Saude Ministerio da Saude, 2009, GUIA VIG EP
   Forrest JM, 2002, MED J AUSTRALIA, V177, P664, DOI 10.5694/j.1326-5377.2002.tb05003.x
   Irons B, 2000, AM J PUBLIC HEALTH, V90, P1545, DOI 10.2105/AJPH.90.10.1545
   Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568
   Kyaw-Zin-Thant, 2006, B WORLD HEALTH ORGAN, V84, P12
   Lanzieri TM, 2007, J PEDIAT INFECT DISE, V2, P15
   Lanzieri TM, 2004, PEDIATR INFECT DIS J, V23, P1116, DOI 10.1097/01.inf.0000145479.04559.97
   Lanzieri TM, 2003, PEDIATR INFECT DIS J, V22, P323
   Lawn JE, 2000, AM J PUBLIC HEALTH, V90, P1555, DOI 10.2105/AJPH.90.10.1555
   MAURACHER CA, 1993, J IMMUNOL, V151, P2041
   Nedeljkovic J, 1999, J CLIN VIROL, V14, P119, DOI 10.1016/S1386-6532(99)00048-7
   ORENSTEIN WA, 1985, REV INFECT DIS, V7, pS22
   Papania MJ, 2014, JAMA PEDIATR, V168, P148, DOI 10.1001/jamapediatrics.2013.4342
   Plotkin S, 2013, VACCINES
   Pustowoit B, 1998, INTERVIROLOGY, V41, P170, DOI 10.1159/000024932
   Reef SE, 2007, J PEDIAT INF DIS-GER, V2, P1
   Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623
   THOMAS HIJ, 1993, J MED VIROL, V41, P196, DOI 10.1002/jmv.1890410305
   Wandinger KP, 2011, J VIROL METHODS, V174, P85, DOI 10.1016/j.jviromet.2011.04.001
NR 33
TC 7
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2015
VL 212
IS 1
BP 57
EP 66
DI 10.1093/infdis/jiu604
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CM6SA
UT WOS:000357818900008
PM 25362195
OA Bronze, Green Accepted
DA 2020-12-17
ER

PT J
AU Yeganeh, N
   Watts, HD
   Camarca, M
   Soares, G
   Joao, E
   Pilotto, JH
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, M
   Ceriotto, M
   Machado, DM
   Veloso, VG
   Grinzstejn, B
   Morgado, MG
   Bryson, Y
   Mofenson, LM
   Nielsen-Saines, K
AF Yeganeh, Nava
   Watts, Heather D.
   Camarca, Margaret
   Soares, Gabriel
   Joao, Esau
   Pilotto, Jose Henrique
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa
   Ceriotto, Mariana
   Machado, Daisy Maria
   Veloso, Valdilea G.
   Grinzstejn, Beatriz
   Morgado, Mariza G.
   Bryson, Yvonne
   Mofenson, Lynne M.
   Nielsen-Saines, Karin
CA NICHD HPTP 040 P1043 Study Team
TI Syphilis in HIV-infected Mothers and Infants Results from the NICHD/HPTN
   040 Study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HIV mother to child transmission; congenital syphilis; prenatal care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SERONEGATIVE SECONDARY SYPHILIS; TO-CHILD
   TRANSMISSION; CD4 CELL COUNTS; CONGENITAL-SYPHILIS; MATERNAL SYPHILIS;
   RISK-FACTORS; VIRAL LOAD; PREGNANCY; IDENTIFICATION
AB Background: Untreated syphilis during pregnancy is associated with spontaneous abortion, stillbirth, prematurity and infant mortality. Syphilis may facilitate HIV transmission, which is especially concerning in low-and middle-income countries where both diseases are common.
   Methods: We performed an analysis of data available from NICHD/HPTN 040 (P1043), a study focused on the prevention of intrapartum HIV transmission to 1684 infants born to 1664 untreated HIV-infected women. This analysis evaluates risk factors and outcomes associated with a syphilis diagnosis in this cohort of HIV-infected women and their infants.
   Results: Approximately, 10% of women (n = 171) enrolled had serological evidence of syphilis without adequate treatment documented and 1.4% infants (n = 24) were dually HIV and syphilis infected. Multivariate logistic analysis showed that compared with HIV-infected women, co-infected women were significantly more likely to self-identify as non-white (adjusted odds ratio [AOR] 2.5, 95% CI: 1.5-4.2), to consume alcohol during pregnancy (AOR 1.5, 95% CI: 1.1-2.1) and to transmit HIV to their infants (AOR 2.1, 95% CI: 1.3-3.4), with 88% of HIV infections being acquired in utero. As compared with HIV-infected or HIV-exposed infants, co-infected infants were significantly more likely to be born to mothers with venereal disease research laboratory titers >= 1:16 (AOR 3, 95% CI: 1.1-8.2) and higher viral loads (AOR 1.5, 95% CI: 1.1-1.9). Of 6 newborns with symptomatic syphilis, 2 expired shortly after birth, and 2 were HIV-infected.
   Conclusion: Syphilis continues to be a common co-infection in HIV-infected women and can facilitate in utero transmission of HIV to infants. Most infants are asymptomatic at birth, but those with symptoms have high mortality rates.
C1 [Yeganeh, Nava; Soares, Gabriel; Bryson, Yvonne; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Watts, Heather D.; Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
   [Camarca, Margaret] WESTAT Corp, Rockville, MD 20850 USA.
   [Joao, Esau] Hosp Fed Serv Estado, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, Brazil.
   [Pilotto, Jose Henrique] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab AIDS & Immnol Mol, Rio De Janeiro, Brazil.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Theron, Gerhard] Univ Stellenbosch, Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Oporto, Portugal.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Veloso, Valdilea G.; Grinzstejn, Beatriz; Morgado, Mariza G.] Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisa Clin DST & AIDS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Yeganeh, N (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Infect Dis, MDCC 22-442 10833,Le Conte Ave, Los Angeles, CA 90095 USA.
EM nyeganeh@mednet.ucla.edu
RI Mussi-Pinhata, Marisa/G-6568-2012; Pinto, Jorge A/D-1743-2014; Mofenson,
   Lynne/P-9631-2019; Pilotto, Jose Henrique/AAD-9773-2019
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Pinto, Jorge
   A/0000-0003-2987-3238; Mofenson, Lynne/0000-0002-2818-9808; Pilotto,
   Jose Henrique/0000-0003-0521-8597; Joao, Esau/0000-0002-2412-0627;
   Kreitchmann, Regis/0000-0002-1146-0497; Soares de Sousa,
   Gabriel/0000-0002-5068-1647
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, U01 AI047986]; UCLA Center for AIDS Research; UCLA
   AIDS Institute [5P30 AI28697]; Boehringer Ingelheim Pharmaceuticals Inc.
   (BIPI)Boehringer Ingelheim; GlaxoSmithKline on behalf of ViiV
   Healthcare; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, U01AI047986,
   P30AI028697, P30AI028697, P30AI028697, U01AI047986, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, U01AI047986, UM1AI068632,
   U01AI047986, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, U01AI068632, P30AI028697,
   P30AI028697, P30AI028697, UM1AI068632, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, U01AI068632, U01AI068632, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   P30AI028697, P30AI028697, P30AI028697, U01AI068632, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, U01AI047986, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI047986, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, U01AI047986, P30AI028697] Funding Source: NIH
   RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract #
   HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) (U01 AI068634), the Eunice
   Kennedy Skiver National Institute of Child Health and Human Development
   (NICHD), and the National Institute of Mental Health (NIMH) (AI068632).
   This subanalysis was supported by the UCLA Center for AIDS Research and
   UCLA AIDS Institute (5P30 AI28697). In addition, the study was supported
   in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and
   GlaxoSmithKline on behalf of ViiV Healthcare. The authors meet criteria
   for authorship as recommended by the International Committee of Medical
   Journal Editors (ICMJE) and were fully responsible for all aspects of
   manuscript development. Boehringer-Ingelheim Pharmaceuticals, Inc and
   GlaxoSmithKline were given the opportunity to check the data used in the
   present manuscript for factual accuracy only. We thank the patients and
   their families who enrolled in this trial; and Marita McDonough and
   Lauren Petrella from Boehringer Ingelheim Pharmaceuticals and Helen
   Watson from GlaxoSmithKline (on behalf of ViiV Healthcare) for
   assistance with the donation of study drugs from their respective
   companies for the conduct of the study. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH. The conclusions and opinions expressed in
   this article are those of the authors and do not necessarily reflect
   those of the National Institutes of Health or US Department of Health
   and Human Services.
CR Buchacz K, 2004, AIDS, V18, P2075, DOI 10.1097/00002030-200410210-00012
   Burgard S, 2004, SOC SCI MED, V59, P1127, DOI 10.1016/j.socscimed.2004.01.006
   Chibwesha CJ, 2011, JAIDS-J ACQ IMM DEF, V58, P224, DOI 10.1097/QAI.0b013e318229147e
   Christian CW, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.1.e4
   Feigin R, 2009, FEIGIN CHERRYS TXB P
   FIUMARA NJ, 1952, NEW ENGL J MED, V247, P48, DOI 10.1056/NEJM195207102470203
   Kalichman SC, 2011, SEX TRANSM INFECT, V87, P183, DOI 10.1136/sti.2010.047514
   Kingston AA, 2005, ARCH DERMATOL, V141, P431, DOI 10.1001/archderm.141.4.431
   Lago EG, 2004, SEX TRANSM DIS, V31, P33, DOI 10.1097/01.OLQ.0000105003.72411.FB
   Lee MJ, 1998, INT J GYNECOL OBSTET, V63, P247, DOI 10.1016/S0020-7292(98)00165-9
   Liu JB, 2010, SEX TRANSM INFECT, V86, P292, DOI 10.1136/sti.2009.037549
   MCFARLIN BL, 1994, AM J OBSTET GYNECOL, V170, P535, DOI 10.1016/S0002-9378(94)70223-3
   Mwapasa V, 2006, AIDS, V20, P1869, DOI 10.1097/01.aids.0000244206.41500.27
   Newman L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001396
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Ortiz-Lopez N, 2012, PEDIATR INFECT DIS J, V31, P988, DOI 10.1097/INF.0b013e31825d3152
   Palacios R, 2007, JAIDS-J ACQ IMM DEF, V44, P356, DOI 10.1097/QAI.0b013e31802ea4c6
   Qin JB, 2014, SEX TRANSM DIS, V41, P13, DOI 10.1097/OLQ.0000000000000062
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   RICCI JM, 1989, OBSTET GYNECOL, V74, P687
   Sheffield JS, 2002, OBSTET GYNECOL, V100, P126, DOI 10.1016/S0029-7844(02)02010-0
   Southwick KL, 2001, B WORLD HEALTH ORGAN, V79, P33
   Su J. R., 2010, Morbidity and Mortality Weekly Report, V59, P413
   TIKJOB G, 1991, J AM ACAD DERMATOL, V24, P506, DOI 10.1016/S0190-9622(08)80082-5
   UNAIDS, 2011, GLOB PLAN EL NEW HIV
   van Toorn R, 2010, PEDIATR INT, V52, P332, DOI 10.1111/j.1442-200X.2010.03063.x
   Walker DG, 2004, B WORLD HEALTH ORGAN, V82, P401
   Watson-Jones D, 2002, J INFECT DIS, V186, P940, DOI 10.1086/342952
   WEBBER MP, 1993, AM J EPIDEMIOL, V137, P415, DOI 10.1093/oxfordjournals.aje.a116690
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P245
   Workowski Kimberly A., 2010, Morbidity and Mortality Weekly Report, V59, P1
   World Health Organization, 2012, INV CAS EL MOTH TO C
NR 32
TC 25
Z9 25
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2015
VL 34
IS 3
BP E52
EP E57
DI 10.1097/INF.0000000000000578
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA CB8VM
UT WOS:000349909700004
PM 25742089
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Ribeiro, HD
   Ribeiro, TCM
   de Mattos, AP
   Pontes, M
   Sarni, ROS
   Cruz, MLS
   Nogueira-de-Almeida, CA
   Mussi-Pinhata, MM
   Norton, RD
   Steenhout, P
AF Ribeiro Junior, Hugo da Costa
   Medrado Ribeiro, Tereza Cristina
   de Mattos, Angela Peixoto
   Pontes, Mariana
   Saccardo Sarni, Roseli Oselka
   Santos Cruz, Maria Leticia
   Nogueira-de-Almeida, Carlos Alberto
   Mussi-Pinhata, Marisa M.
   Norton, Rocksane de Carvalho
   Steenhout, Philippe
TI Normal Growth of Healthy Infants Born from HIV+ Mothers Fed a Reduced
   Protein Infant Formula Containing the Prebiotics
   Galacto-Oligosaccharides and Fructo-Oligosaccharides: A Randomized
   Controlled Trial
SO CLINICAL MEDICINE INSIGHTS-PEDIATRICS
LA English
DT Article
DE infant formula; galacto-oligosaccharides; fructo-oligosaccharides;
   safety; weight gain
AB OBJECTIVE: The aim of the current study was to evaluate the safety of a new reduced protein (2.1 g/100 kcal) infant formula containing 4 g/L of 90% galacto-oligosaccharides (GOS) and 10% fructo-oligosaccharides (FOS).
   METHODS: Healthy term infants from Brazil were enrolled. Those born to human immunodeficiency virus (HIV)-positive mothers were randomized to a test (n = 65) or control (n = 63) formula group. Infants born to HIV-negative mothers were either exclusively breast-fed (n = 79) or received a mixed diet (breast milk and test formula, n = 65). Between 2 weeks and 4 months of age, infants were exclusively fed according to their assigned group. Anthropometric measurements were taken at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 months. Digestive tolerance was evaluated during the first 4 months. The primary outcome was mean daily weight gain between 2 weeks and 4 months in the test formula and breast-fed groups.
   RESULTS: Data from all infants (N = 272) were used in the intention-to-treat (ITT) analysis and data from 230 infants were used in the per-protocol (PP) analysis. The difference in mean daily weight gain between 2 weeks and 4 months in the test formula and breast-fed groups was 1.257 g/day (onesided 95% confidence interval [CI]: -0.705 to inf, P < 0.001) in the PP analysis, showing that the lower bound of the 95% CI was above the -3.0 g/day non-inferiority margin. Results were similar in the ITT analysis. Symptoms of digestive tolerance and frequency of adverse events were similar in the two groups.
   CONCLUSIONS: The formula containing 2.1 g/100 kcal protein and GOS and FOS was safe and tolerated well.
C1 [Ribeiro Junior, Hugo da Costa; de Mattos, Angela Peixoto] Univ Fed Bahia, Sch Med, Pediat, Salvador, BA, Brazil.
   [Medrado Ribeiro, Tereza Cristina; Pontes, Mariana] Univ Fed Bahia, Fima Lifshitz Res Ctr, Salvador, BA, Brazil.
   [Saccardo Sarni, Roseli Oselka] Fac Med ABC, Santo Andre, SP, Brazil.
   [Santos Cruz, Maria Leticia] Hosp Fed Servidores Estado, Infect Dis Dept, Rio De Janeiro, Brazil.
   [Nogueira-de-Almeida, Carlos Alberto] Univ Ribeirao Preto, Nutrol Dept, Ribeirao Preto, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Pediat, Ribeirao Preto, SP, Brazil.
   [Norton, Rocksane de Carvalho] Univ Fed Minas Gerais, Sch Med, Pediat, Belo Horizonte, MG, Brazil.
   [Steenhout, Philippe] Nestle Clin Dev Unit, Vevey, Switzerland.
RP Steenhout, P (corresponding author), Nestle Clin Dev Unit, Vevey, Switzerland.
EM philippe.steenhout@nestle.com
RI Sarni, Roseli OS/O-7806-2015; CA, Nogueira-de-Almeida/C-4421-2013
OI CA, Nogueira-de-Almeida/0000-0003-1272-4404
FU Nestec Ltd.
FX This study was funded by Nestec Ltd. The authors confirm that the funder
   had no influence over the study design, content of the article, or
   selection of this journal.
CR Arslanoglu S, 2008, J NUTR, V138, P1091
   Arslanoglu S, 2007, J NUTR, V137, P2420
   Boehm G, 2007, J NUTR, V137, p847S, DOI 10.1093/jn/137.3.847S
   Cherbut C, 2002, BRIT J NUTR, V87, pS159, DOI 10.1079/BJN2002532
   Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI 10.1097/01.all.0000053262.39029.a1
   Knol J, 2005, J PEDIATR GASTR NUTR, V40, P36, DOI 10.1097/00005176-200501000-00007
   Lonnerdal B, 2003, AM J CLIN NUTR, V77, p1537S
   Mace K, 2006, NESTLE NUTR WORKS SE, V58, P189, DOI 10.1159/000095063
   Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251
   Moro G, 2002, J PEDIATR GASTR NUTR, V34, P291, DOI 10.1097/00005176-200203000-00014
   Mountzouris KC, 2002, BRIT J NUTR, V87, P405, DOI 10.1079/BJN2002563
   Newburg DS, 2009, J ANIM SCI, V87, P26, DOI 10.2527/jas.2008-1347
   Newburg DS, 2005, ANNU REV NUTR, V25, P37, DOI 10.1146/annurev.nutr.25.050304.092553
   Newburg DS, 2000, J PEDIATR GASTR NUTR, V30, pS8, DOI 10.1097/00005176-200000002-00003
   Puccio G, 2007, NUTRITION, V23, P1, DOI 10.1016/j.nut.2006.09.007
   Raiha NCR, 2002, J PEDIATR GASTR NUTR, V35, P275, DOI [10.1097/00005176-200209000-00008, 10.1097/01.MPG.0000024570.18154.C7]
   Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363
   Saavedra JM, 2007, NUTR CLIN PRACT, V22, P351, DOI 10.1177/0115426507022003351
   Turck D, 2006, J PEDIATR GASTR NUTR, V43, P364, DOI 10.1097/01.mpg.0000228113.29359.b1
   U.S. Food and Drug Administration/American Academy of Pediatrics Committee on Nutrition, 1988, CLIN TEST INF FORM R
   Walker WA, 2008, CLIN INFECT DIS, V46, pS87, DOI 10.1086/523335
   Ward RE, 2006, APPL ENVIRON MICROB, V72, P4497, DOI 10.1128/AEM.02515-05
   Ziegler EE, 2003, MONATSSCHR KINDERH, V151, pS65, DOI 10.1007/s00112-003-0804-0
   ZIEGLER EE, 2002, NESTLE NUTR WORKSHOP, V47, P97
NR 24
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1179-5565
J9 CLIN MED INSIGHTS-PE
JI Clin. MED. Insights-Pediatr.
PY 2015
VL 9
BP 37
EP 47
DI 10.4137/CMPed.s17841
PG 11
WC Pediatrics
SC Pediatrics
GA V33JL
UT WOS:000215761600006
PM 25788839
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Rugolo, LMSDS
   Bentlin, MR
   Mussi-Pinhata, M
   de Almeida, MFB
   Lopes, JMD
   Marba, STM
   Fiori, HH
   Procianoy, RS
   Leone, CR
AF Suppo de Souza Rugolo, Ligia Maria
   Bentlin, Maria Regina
   Mussi-Pinhata, Marisa
   Branco de Almeida, Maria Fernanda
   de Andrade Lopes, Jose Maria
   Martins Marba, Sergio Tadeu
   Fiori, Humberto Holmer
   Procianoy, Renato Soibelmann
   Leone, Clea Rodrigues
CA Brazilian Network Neonatal Res
TI Late-Onset Sepsis in very Low Birth Weight Infants: A Brazilian Neonatal
   Research Network Study
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
DE Sepsis; infection; newborn infant; very low birth weight; premature
ID INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTION; PROSPECTIVE COHORT; VLBW
   INFANTS; RISK-FACTORS; SURVEILLANCE
AB Background: Late-onset sepsis (LOS) is an important cause of morbidity and mortality in very low birth weight (VLBW) infants.
   Aim: To determine the incidence, risk factors and etiology of LOS.
   Methods: LOS was investigated in a multicenter prospective cohort of infants at eight public university neonatal intensive care units (NICUs). Inclusion criteria included inborn, 23-33 weeks of gestational age, 400-1499 g birth weight, who survived >3 days.
   Results: Of 1507 infants, 357 (24%) had proven LOS and 345 (23%) had clinical LOS. Infants with LOS were more likely to die. The majority of infections (76%) were caused by Gram-positive organisms. Independent risk factors for proven LOS were use of central venous catheter and mechanical ventilation, age at the first feeding and number of days on parenteral nutrition and on mechanical ventilation.
   Conclusion: LOS incidence and mortality are high in Brazilian VLBW infants. Most risk factors are associated with routine practices at NICU.
C1 [Suppo de Souza Rugolo, Ligia Maria; Bentlin, Maria Regina] Sao Paulo State Univ UNESP, Botucatu Sch Med, Dept Pediat, Botucatu, SP, Brazil.
   [Mussi-Pinhata, Marisa] Univ Sao Paulo, Dept Pediat, Ribeirao Preto, SP, Brazil.
   [Branco de Almeida, Maria Fernanda] Univ Fed Sao Paulo, Div Neonatal Med, Sao Paulo, SP, Brazil.
   [de Andrade Lopes, Jose Maria] Fundacao Oswaldo Cruz, Fernandes Figueira Inst, Neonatal Dept, Rio De Janeiro, RJ, Brazil.
   [Martins Marba, Sergio Tadeu] Univ Estadual Campinas, Dept Pediat, Campinas, SP, Brazil.
   [Fiori, Humberto Holmer] Pontificia Univ Catolica Rio Grande do Sul, Dept Pediat, Porto Alegre, RS, Brazil.
   [Procianoy, Renato Soibelmann] Univ Fed Rio Grande do Sul, Dept Pediat, Porto Alegre, RS, Brazil.
   [Leone, Clea Rodrigues] Univ Sao Paulo, Dept Pediat, BR-05508 Sao Paulo, Brazil.
RP Rugolo, LMSDS (corresponding author), Univ Estadual Paulista, Dept Pediat, Div Neonatol, BR-18618970 Sao Paulo, Brazil.
EM ligiasr@fmb.unesp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Leone, Clea/ABA-6374-2020; Procianoy,
   Renato/I-5133-2014; Lyra, Joao Cesar/B-9113-2012; Bentlin, Maria
   Regina/H-6282-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Procianoy,
   Renato/0000-0001-8297-4164; Lyra, Joao Cesar/0000-0002-1715-3893;
   Bentlin, Maria Regina/0000-0001-7310-0895
CR Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X
   Alfaleh Khalid M, 2010, Sultan Qaboos Univ Med J, V10, P227
   Aly H, 2005, PEDIATRICS, V115, P1513, DOI 10.1542/peds.2004-1785
   Auriti C, 2010, INFECT CONT HOSP EP, V31, P926, DOI 10.1086/655461
   Aziz Khalid, 2005, BMC Pediatr, V5, P22, DOI 10.1186/1471-2431-5-22
   Camacho-Gonzalez A, 2013, PEDIATR CLIN N AM, V60, P367, DOI 10.1016/j.pcl.2012.12.003
   Downey LC, 2010, EARLY HUM DEV, V86, pS7, DOI 10.1016/j.earlhumdev.2010.01.012
   Gordon A, 2006, PEDIATR INFECT DIS J, V25, P25, DOI 10.1097/01.inf.0000195628.35980.2e
   Graham PL, 2006, PEDIATR INFECT DIS J, V25, P113, DOI 10.1097/01.inf.0000199310.52875.10
   Gray JW, 2007, EARLY HUM DEV, V83, P157, DOI 10.1016/j.earlhumdev.2007.01.006
   Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723
   Kawagoe JY, 2001, AM J INFECT CONTROL, V29, P109, DOI 10.1067/mic.2001.114162
   Makhoul IR, 2002, PEDIATRICS, V109, P34, DOI 10.1542/peds.109.1.34
   McCallie KR, 2011, J PERINATOL, V31, pS61, DOI 10.1038/jp.2010.185
   PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0
   Profit J, 2011, J PERINATOL, V31, P702, DOI 10.1038/jp.2011.12
   Richardosn DK, 2001, J PEDIATR-US, V138, P92, DOI 10.1067/mpd.2001.109608
   Schulman J, 2011, PEDIATRICS, V127, P436, DOI 10.1542/peds.2010-2873
   Stoll BJ, 2003, SEMIN PERINATOL, V27, P293, DOI 10.1016/S0146-0005(03)00046-6
   Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285
   Tiskumara R, 2009, ARCH DIS CHILD-FETAL, V94, pF144, DOI 10.1136/adc.2008.139865
   Vain NE, 2012, EARLY HUM DEV, V88, pS53, DOI 10.1016/S0378-3782(12)70016-6
   van den Hoogen A, 2010, NEONATOLOGY, V97, P22, DOI 10.1159/000226604
   Vergnano S, 2011, ARCH DIS CHILD-FETAL, V96, pF9, DOI 10.1136/adc.2009.178798
   WALSH MC, 1986, PEDIATR CLIN N AM, V33, P179, DOI 10.1016/s0031-3955(16)34975-6
   Wirtschafter DD, 2011, PEDIATRICS, V127, P419, DOI 10.1542/peds.2010-1449
NR 26
TC 10
Z9 12
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
EI 1465-3664
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD DEC
PY 2014
VL 60
IS 6
BP 415
EP 421
DI 10.1093/tropej/fmu038
PG 7
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA AW1FN
UT WOS:000346035900003
PM 25063461
OA Bronze
DA 2020-12-17
ER

PT J
AU Monteiro, JP
   Cruz, MLS
   Mussi-Pinhata, MM
   Salomao, RG
   Jordao, A
   Hance, LF
   Read, JS
   Pilotto, JHD
   Cohen, RA
   Stoszek, SK
   Siberry, GK
AF Monteiro, Jacqueline Pontes
   Santos Cruz, Maria Leticia
   Mussi-Pinhata, Marisa Marcia
   Salomao, Roberta Garcia
   Jordao Junior, Alceu
   Hance, Laura Freimanis
   Read, Jennifer Suzanne
   da Silva Pilotto, Jose Henrique
   Cohen, Rachel Ann
   Stoszek, Sonia Karolina
   Siberry, George Kelly
TI Vitamin A, vitamin E, iron and zinc status in a cohort of HIV-infected
   mothers and their uninfected infants
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Micronutrients; HIV infection; Pregnancy; Infant; Nutrition; Cohort
ID BETA-CAROTENE; DEVELOPING-COUNTRIES; OXIDATIVE STRESS; PREGNANT-WOMEN;
   SERUM-LEVELS; CHILDREN; SUPPLEMENTATION; MICRONUTRIENTS; MORBIDITY;
   MORTALITY
AB Introduction: We hypothesized that nutritional deficiency would be common in a cohort of postpartum, human immunodeficiency virus (HIV)-infected women and their infants. Methods: Weight and height, as well as blood concentrations of retinol, alpha-tocopherol, ferritin, hemoglobin, and zinc, were measured in mothers after delivery and in their infants at birth and at 6-12 weeks and six months of age. Retinol and alpha-tocopherol levels were quantified by high performance liquid chromatography, and zinc levels were measured by atomic absorption spectrophotometry. The maternal body mass index during pregnancy was adjusted for gestational age (adjBMI). Results: Among the 97 women 19.6% were underweight. Laboratory abnormalities were most frequently observed for the hemoglobin (46.4%), zinc (41.1%), retinol (12.5%) and ferritin (6.5%) levels. Five percent of the women had mean corpuscular hemoglobin concentrations < 31g/dL. The most common deficiency in the infants was alpha-tocopherol (81%) at birth; however, only 18.5% of infants had deficient levels at six months of age. Large percentages of infants had zinc (36.8%) and retinol (29.5%) deficiencies at birth; however, these percentages decreased to 17.5% and 18.5%, respectively, by six months of age. No associations between infant micronutrient deficiencies and either the maternal adjBMI category or maternal micronutrient deficiencies were found. Conclusions: Micronutrient deficiencies were common in HIV-infected women and their infants. Micronutrient deficiencies were less prevalent in the infants at six months of age. Neither underweight women nor their infants at birth were at increased risk for micronutrient deficiencies.
C1 [Monteiro, Jacqueline Pontes; Mussi-Pinhata, Marisa Marcia; Salomao, Roberta Garcia] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Puericultura & Pediatria, Ribeirao Preto, SP, Brazil.
   [Santos Cruz, Maria Leticia] Hosp Fed Servidores Estado, Dept Doencas Infecciosas, Rio De Janeiro, RJ, Brazil.
   [Jordao Junior, Alceu] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sao Paulo, Brazil.
   [Hance, Laura Freimanis; Cohen, Rachel Ann; Stoszek, Sonia Karolina] Westat Corp, Rockville, MD USA.
   [Read, Jennifer Suzanne; Siberry, George Kelly] NICHHD, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD USA.
   [Read, Jennifer Suzanne] George Washington Univ, Sch Med, Dept Pediat, Div Infect Dis, Washington, DE USA.
   [da Silva Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept Doencas Infecciosas, Nova Iguacu, RJ, Brazil.
   [da Silva Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
RP Monteiro, JP (corresponding author), Univ Sao Paulo, Dept Puericultura Pediatria FMRP, Av Bandeirantes 3900,Campus USP, BR-14049900 Ribeirao Preto, SP, Brazil.
EM jacque@fmrp.usp.br
RI Monteiro, Jacqueline/F-6987-2012; Pilotto, Jose Henrique/AAD-9773-2019;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [N01-HD-3-3345, HHSN267200800001C,
   N01-HD-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH RePORTER
FX National Institute of Child Health and Human Development (NICHD) for
   financial support (Contract # N01-HD-3-3345, 2002-2007, and Contract #
   HHSN267200800001C, Control # N01-HD-8-0001, 2007-2012).
CR Ahmed F, 2003, PUBLIC HEALTH NUTR, V6, P447, DOI 10.1079/PHN2002454
   Allard JP, 1998, AM J CLIN NUTR, V67, P143
   Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013
   Allen LH, 2009, J NUTR, V139, P1022, DOI 10.3945/jn.107.086199
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   ARNAUD J, 1991, J CHROMATOGR-BIOMED, V572, P103, DOI 10.1016/0378-4347(91)80476-S
   Berti C, 2011, CLIN NUTR, V30, P689, DOI 10.1016/j.clnu.2011.08.004
   Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7
   Black RE, 2001, BRIT J NUTR, V85, pS193, DOI 10.1079/BJN2000314
   Caulfield LE, 1998, AM J CLIN NUTR, V68, p499S, DOI 10.1093/ajcn/68.2.499S
   Chatterjee A, 2010, J TROP PEDIATRICS, V56, P27, DOI 10.1093/tropej/fmp045
   Custer JW, 2009, HARRIET LANE HDB MAN
   Dairo M D, 2005, Afr J Med Med Sci, V34, P275
   El Beitune P, 2004, ARCH LATINOAM NUTR, V54, P419
   Falcone EL, 2010, AM J CLIN NUTR, V91, P1213, DOI 10.3945/ajcn.2009.28816
   FARRELL PM, 1978, AM J CLIN NUTR, V31, P1720
   Fawzi WW, 2007, AM J CLIN NUTR, V85, P1335
   Ferraz IS, 2007, J PEDIAT-BRAZIL, V83, P512, DOI [10.2223/JPED.1725, 10.1590/S0021-75572007000800006]
   Friis H, 2001, AM J CLIN NUTR, V73, P1058
   Graham SM, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-63
   Hatherill M, 1999, ARCH DIS CHILD, V81, P417, DOI 10.1136/adc.81.5.417
   Hotz C, 2003, AM J CLIN NUTR, V78, P756
   Irlam JH, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003650.pub3
   Jones CY, 2006, JAIDS-J ACQ IMM DEF, V43, P475, DOI 10.1097/01.qai.0000243096.27029.fe
   Keverenge-Ettyang GA, 2006, FOOD NUTR BULL, V27, P228, DOI 10.1177/156482650602700305
   Killip S, 2007, AM FAM PHYSICIAN, V75, P671
   Lai H, 2001, J ACQ IMMUN DEF SYND, V27, P56, DOI 10.1097/00126334-200105010-00010
   Lee BE, 2004, EUR J CLIN NUTR, V58, P1365, DOI 10.1038/sj.ejcn.1601976
   Levine AM, 2001, J ACQ IMMUN DEF SYND, V26, P28, DOI 10.1097/00126334-200101010-00004
   Meda N, 1998, INT J GYNECOL OBSTET, V61, P65, DOI 10.1016/S0020-7292(98)00016-2
   Mehta S, 2010, EUR J CLIN NUTR, V64, P808, DOI 10.1038/ejcn.2010.76
   Monteiro JP, 2009, NUTR RES, V29, P716, DOI 10.1016/j.nutres.2009.10.001
   Osendarp SJM, 2003, J NUTR, V133, p817S
   Passi S, 1990, G Ital Dermatol Venereol, V125, P487
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Ramalho Rejane Andréa, 2006, Rev. Assoc. Med. Bras., V52, P170, DOI 10.1590/S0104-42302006000300018
   Ramon R, 1999, T ROY SOC TROP MED H, V93, P419, DOI 10.1016/S0035-9203(99)90143-8
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
   Shin JY, 2013, CLIN CHIM ACTA, V421, P177, DOI 10.1016/j.cca.2013.02.025
   Tang JL, 2005, J AGR FOOD CHEM, V53, P6073, DOI 10.1021/jf0501037
   Tomkins A, 2000, P NUTR SOC, V59, P135, DOI 10.1017/S0029665100000161
   Volberding Paul A, 2003, Hematology Am Soc Hematol Educ Program, P294
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Wellinghausen N, 2001, BR J NUTR, V85, P81
   WHO, 1995, B WORLD HEALTH ORGAN, V73, pS1
   Wieringa FT, 2010, EUR J CLIN NUTR, V64, P1072, DOI 10.1038/ejcn.2010.115
   World Health Organization (WHO), 2009, WHO GLOB DATABASE VI, V2009
   Yamini S, 2001, EUR J CLIN NUTR, V55, P252, DOI 10.1038/sj.ejcn.1601152
   Zvandasara P, 2006, JAIDS-J ACQ IMM DEF, V43, P107, DOI 10.1097/01.qai.0000229015.77569.c7
NR 49
TC 0
Z9 0
U1 0
U2 10
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD NOV-DEC
PY 2014
VL 47
IS 6
BP 692
EP 700
DI 10.1590/0037-8682-0226-2014
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AZ4PE
UT WOS:000348204000004
PM 25626647
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Pileggi-Castro, C
   Camelo, JS
   Perdona, GC
   Mussi-Pinhata, MM
   Cecatti, JG
   Mori, R
   Morisaki, N
   Yunis, K
   Vogel, JP
   Tuncalp, O
   Souza, JP
AF Pileggi-Castro, C.
   Camelo, J. S., Jr.
   Perdona, G. C.
   Mussi-Pinhata, M. M.
   Cecatti, J. G.
   Mori, R.
   Morisaki, N.
   Yunis, K.
   Vogel, J. P.
   Tuncalp, O.
   Souza, J. P.
CA WHO Multicountry Survey Maternal N
TI Development of criteria for identifying neonatal near- miss cases:
   analysis of two WHO multicountry cross- sectional studies
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
DE Early neonatal death; neonatal morbidity assessment; neonatal near-miss
   criteria; perinatal care assessment; quality of care
ID CLINICAL RISK INDEX; GLOBAL SURVEY; NEWBORN HEALTH; CRIB-II; MORTALITY;
   WEIGHT; INFANTS
AB ObjectiveTo develop and test markers of neonatal severe morbidity for the identification of neonatal near-miss cases.
   DesignThis is a database analysis of two World Health Organization cross-sectional studies: the Global Survey on Maternal and Perinatal Health (WHOGS) and the Multicountry Survey on Maternal and Newborn Health (WHOMCS).
   SettingThe WHOGS was performed in 373 health facilities in 24 countries (2004-2008). The WHOMCS was conducted in 359 health facilities in 29 countries (2010-2011).
   PopulationData were collected from hospital records of all women admitted for delivery and their respective neonates.
   MethodsPragmatic markers (birthweight <1750g, Apgar score at 5minutes <7, and gestational age <33weeks) were developed with WHOGS data and validated with WHOMCS data. The diagnostic accuracy of neonatal characteristics and management markers of severity was determined in the WHOMCS.
   ResultsThis analysis included 290610 liveborn neonates from WHOGS and 310436 liveborn neonates from WHOMCS. The diagnostic accuracy of pragmatic and management markers of severity for identifying early neonatal deaths was very high: sensitivity, 92.8% (95% CI 91.8-93.7%); specificity, 92.7% (95% CI 92.6-92.8%); positive likelihood ratio, 12.7 (95% CI 12.5-12.9); negative likelihood ratio, 0.08 (95% CI 0.07-0.09); diagnostic odds ratio, 163.4 (95% CI 141.6-188.4). A positive association was found between the frequency of neonatal near-miss cases and Human Development Index.
   ConclusionNewborn infants presenting selected markers of severity and surviving the first neonatal week could be considered as neonatal near-miss cases. This definition and criteria may be seen as a basis for future applications of the near-miss concept in neonatal health. These tools can be used to inform policy makers on how best to apply scarce resources for improving the quality of care and reducing neonatal mortality.
C1 [Pileggi-Castro, C.; Camelo, J. S., Jr.; Mussi-Pinhata, M. M.] Univ Sao Paulo, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Perdona, G. C.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Social Med, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Cecatti, J. G.] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynaecol, Obstet Unit, Sao Paulo, Brazil.
   [Mori, R.; Morisaki, N.] Natl Ctr Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan.
   [Morisaki, N.] Univ Tokyo, Grad Sch Med, Dept Paediat, Tokyo, Japan.
   [Yunis, K.] Amer Univ Beirut, Dept Paediat, Beirut, Lebanon.
   [Vogel, J. P.; Tuncalp, O.; Souza, J. P.] WHO, Dept Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, CH-1211 Geneva, Switzerland.
   [Vogel, J. P.] Univ Western Australia, Sch Populat Hlth, Fac Med Dent & Hlth Sci, Perth, WA 6009, Australia.
RP Pileggi-Castro, C (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, 3900 Bandeirantes Av, BR-14049900 Ribeirao Preto, SP, Brazil.
EM cynthiapileggi@gmail.com
RI Camelo, Jose S/G-3169-2012; Cecatti, Jose Guilherme/M-5945-2013; Souza,
   Joao Paulo/G-1982-2010; Camelo, Jose/AAL-4716-2020; Mussi-Pinhata,
   Marisa/G-6568-2012; Vogel, Joshua/K-7649-2019; Tuncalp, Ozge/Y-2724-2018
OI Cecatti, Jose Guilherme/0000-0003-1285-8445; Souza, Joao
   Paulo/0000-0002-2288-4244; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Vogel, Joshua/0000-0002-3214-7096; Yunis, Khalid/0000-0002-6384-2745;
   Morisaki, Naho/0000-0001-6151-4513; Mori, Rintaro/0000-0001-7656-6156;
   Tuncalp, Ozge/0000-0002-5370-682X
CR Avenant T, 2009, BEST PRACT RES CL OB, V23, P369, DOI 10.1016/j.bpobgyn.2008.12.005
   Bhutani VK, 2009, PEDIAT HLTH, V3, P369
   Blair PS, 2006, LANCET, V367, P314, DOI 10.1016/S0140-6736(06)67968-3
   COCKBURN F, 1993, LANCET, V342, P193
   DECOURCYWHEELER RHB, 1995, ARCH DIS CHILD-FETAL, V73, pF32, DOI 10.1136/fn.73.1.F32
   Gagliardi L, 2004, ARCH DIS CHILD-FETAL, V89, pF419, DOI 10.1136/adc.2003.031286
   HADLOCK FP, 1991, RADIOLOGY, V181, P129, DOI 10.1148/radiology.181.1.1887021
   KEETON BR, 1977, BRIT MED J, V2, P600, DOI 10.1136/bmj.2.6087.600
   Knif AD, 2010, FACTS VIEWS VIS OBGY, V2, P1
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   Lawn JE, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000389
   Lubega AM, 2010, NEONATAL NEAR MISS S
   Mathonsi N, 2010, EFFECT MATERNAL HIV
   Mikolajczyk RT, 2011, LANCET, V377, P1855, DOI 10.1016/S0140-6736(11)60364-4
   Parry G, 2003, LANCET, V361, P1789, DOI 10.1016/S0140-6736(03)13397-1
   Pileggi C, 2010, J PEDIAT-BRAZIL, V86, P21, DOI 10.2223/JPED.1965
   Sarquis Ana Lúcia F., 2002, J. Pediatr. (Rio J.), V78, P225, DOI 10.1590/S0021-75572002000300011
   Say L, 2010, J PEDIAT-BRAZIL, V86, P1, DOI [10.2223/JPED.1978, 10.1590/S0021-75572010000100001]
   Say L, 2009, BEST PRACT RES CL OB, V23, P287, DOI 10.1016/j.bpobgyn.2009.01.007
   Shah A, 2008, B WORLD HEALTH ORGAN, V86, P126, DOI 10.2471/BLT.06.039842
   Skinner JR, 2005, ARCH DIS CHILD, V90, P528, DOI 10.1136/adc.2004.058115
   Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8
   Souza JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044129
   Souza JP, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-286
   UNDPI, 2013, SUMM HUM DEV REP 201, P1
   United Nations, 2013, MILL DEV GOALS REP 2, P68
   Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7
NR 27
TC 35
Z9 41
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
PD MAR
PY 2014
VL 121
SU 1
SI SI
BP 110
EP 118
DI 10.1111/1471-0528.12637
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AD0CU
UT WOS:000332902700013
PM 24641541
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Castellucci, RAC
   Aragon, DC
   Mussi-Pinhata, MM
AF Yamamoto, A. Y.
   Castellucci, R. A. C.
   Aragon, D. C.
   Mussi-Pinhata, M. M.
TI Early high CMV seroprevalence in pregnant women from a population with a
   high rate of congenital infection
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE CMV; cytomegalovirus; IgG antibodies; pregnant women; seroprevalence
ID CYTOMEGALOVIRUS-INFECTION; SAO-PAULO; PREVALENCE; REACTIVATION;
   ANTIBODIES; RUBELLA; BIRTH
AB Congenital cytomegalovirus (CMV) infection rates increase with maternal seroprevalence due to transmission from maternal non-primary infection. CMV seroprevalence estimates of pregnant women are needed for planning strategies against congenital CMV transmission. We aimed to determine the age-specific prevalence of serum antibodies for CMV in a representative age-stratified sample of unselected pregnant women from a Brazilian population. A total of 985 pregnant women, aged 12-46 years (median 24 years), were enrolled. Overall CMV seroprevalence was 97% (95% confidence interval 95.8-98.0), with age-specific (years) prevalence as follows: 12-19 (96.3%), 20-24 (97.7%), 25-29 (97.1%), and 30-46 (96.7%). CMV seroprevalence is almost universal (97%) and is found at similar levels in pregnant women of ages ranging from 12 to 46 years. Because high CMV seroprevalence is found even in women of a younger age in this population, this finding suggests that the majority of primary CMV infections occur early, in infancy or childhood. As a consequence, vaccines currently under development to prevent primary infection may not be a solution for the prevention of congenital CMV infection in this population.
C1 [Yamamoto, A. Y.; Castellucci, R. A. C.; Aragon, D. C.; Mussi-Pinhata, M. M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, BR-05508 Sao Paulo, Brazil.
RP Yamamoto, AY (corresponding author), FMRP USP, Dept Puericultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM yulie@fmrp.usp.br
RI Aragon, Davi C/R-6604-2016; Mussi-Pinhata, Marisa/G-6568-2012
OI Aragon, Davi C/0000-0003-1019-3654; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU Fundacao de Apoio a Pesquisa, Ensino e Assistencia do Hospital das
   Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de
   Sao Paulo (FAEPA), Brazil
FX This work was supported by the Fundacao de Apoio a Pesquisa, Ensino e
   Assistencia do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto da Universidade de Sao Paulo (FAEPA), Brazil. We are
   grateful to Claudia Siqueira Vassimon, supervisor of the Central Health
   District Castelo Branco, Ribeirao Preto, for her assistance in providing
   the prenatal serum specimens stored in the central repository.
CR Aksakal FN, 2007, JPN J INFECT DIS, V60, P157
   Almeida LNB, 2001, REV SAUDE PUBL, V35, P124, DOI 10.1590/S0034-89102001000200004
   Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438
   Borges ALV, 2007, CAD SAUDE PUBLICA, V23, P1583, DOI 10.1590/S0102-311X2007000700009
   Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655
   Dollard SC, 2011, CLIN VACCINE IMMUNOL, V18, P1895, DOI 10.1128/CVI.05228-11
   Fowler KB, 2006, J CLIN VIROL, V35, P226, DOI 10.1016/j.jcv.2005.09.016
   Gratacap-Cavallier B, 1998, EUR J EPIDEMIOL, V14, P147, DOI 10.1023/A:1007450729633
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Mehta SK, 2000, J INFECT DIS, V182, P1761, DOI 10.1086/317624
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   PANNUTI CS, 1985, REV I MED TROP, V27, P105, DOI 10.1590/S0036-46651985000200010
   Pereira Maria José Bistafa, 2004, Rev. bras. epidemiol., V7, P36, DOI 10.1590/S1415-790X2004000100005
   Seale H, 2006, CLIN VACCINE IMMUNOL, V13, P1181, DOI 10.1128/CVI.00203-06
   Souza MA, 2010, REV SOC BRAS MED TRO, V43, P359, DOI 10.1590/S0037-86822010000400004
   Staras SAS, 2006, CLIN INFECT DIS, V43, P1143, DOI 10.1086/508173
   Stowe RP, 2007, EXP GERONTOL, V42, P563, DOI 10.1016/j.exger.2007.01.005
   Suassuna J H, 1995, Rev Soc Bras Med Trop, V28, P105, DOI 10.1590/S0037-86821995000200003
   Sung H, 2010, EXPERT REV VACCINES, V9, P1303, DOI 10.1586/ERV.10.125
   Tabatabaee M, 2009, J MATERN-FETAL NEO M, V22, P517, DOI 10.1080/14767050902801678
   TOOKEY PA, 1992, ARCH DIS CHILD-FETAL, V67, P779, DOI 10.1136/adc.67.7_Spec_No.779
   Uyar Y, 2008, NEW MICROBIOL, V31, P451
   Wang D, 2011, VACCINE, V29, P9075, DOI 10.1016/j.vaccine.2011.09.056
   Yamamoto A Y, 1999, J Pediatr (Rio J), V75, P126
   Yamamoto AY, 2011, PEDIATR INFECT DIS J, V30, P1043, DOI 10.1097/INF.0b013e31822d9640
   Yamamoto AY, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.018
NR 26
TC 22
Z9 26
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD OCT
PY 2013
VL 141
IS 10
BP 2187
EP 2191
DI 10.1017/S0950268812002695
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 211EH
UT WOS:000323887200022
PM 23200458
DA 2020-12-17
ER

PT J
AU Succi, RCM
   Krauss, MR
   Harris, DR
   Machado, DM
   de Moraes-Pinto, MI
   Mussi-Pinhata, MM
   Ruz, NP
   Pierre, RB
   Kolevic, L
   Joao, E
   Foradori, I
   Hazra, R
   Siberry, GK
AF Succi, Regina C. M.
   Krauss, Margot R.
   Harris, D. Robert
   Machado, Daisy M.
   de Moraes-Pinto, Maria Isabel
   Mussi-Pinhata, Marisa M.
   Pavia Ruz, Noris
   Pierre, Russell B.
   Kolevic, Lenka
   Joao, Esau
   Foradori, Irene
   Hazra, Rohan
   Siberry, George K.
CA NISDI Pediat Study Grp 2012
TI Undervaccination of Perinatally HIV-infected and HIV-exposed Uninfected
   Children in Latin America and the Caribbean
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pediatric HIV infection; vaccination; Latin America
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PARALYTIC POLIOMYELITIS; IMMUNIZATION
   COVERAGE; VACCINE; COHORT; SAFETY; RISK; BORN
AB Background: Perinatally HIV-infected (PHIV) children may be at risk of undervaccination. Vaccination coverage rates among PHIV and HIV-exposed uninfected (HEU) children in Latin America and the Caribbean were compared.
   Methods: All PHIV and HEU children born from 2002 to 2007 who were enrolled in a multisite observational study conducted in Latin America and the Caribbean were included in this analysis. Children were classified as up to date if they had received the recommended number of doses of each vaccine at the appropriate intervals by 12 and 24 months of age. Fisher's exact test was used to analyze the data. Covariates potentially associated with a child's HIV status were considered in multivariable logistic regression modeling.
   Results: Of 1156 eligible children, 768 (66.4%) were HEU and 388 (33.6%) were PHIV. HEU children were significantly (P < 0.01) more likely to be up to date by 12 and 24 months of age for all vaccines examined. Statistically significant differences persisted when the analyses were limited to children enrolled before 12 months of age. Controlling for birth weight, sex, primary caregiver education and any use of tobacco, alcohol or illegal drugs during pregnancy did not contribute significantly to the logistic regression models.
   Conclusions: PHIV children were significantly less likely than HEU children to be up to date for their childhood vaccinations at 12 and 24 months of age, even when limited to children enrolled before 12 months of age. Strategies to increase vaccination rates in PHIV are needed.
C1 [Succi, Regina C. M.; Machado, Daisy M.; de Moraes-Pinto, Maria Isabel] Univ Fed Sao Paulo, UNIFESP, Escola Paulista Med, Sao Paulo, Brazil.
   [Krauss, Margot R.; Harris, D. Robert] Westat Corp, Rockville, MD USA.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Pavia Ruz, Noris] Hosp Infantil Mexico Dr Federico Gomez, Depto Infectol, Clin Inmunodeficiencias, Mexico City, DF, Mexico.
   [Pierre, Russell B.] Univ W Indies, Dept Child & Adolescent Hlth, Kingston, Jamaica.
   [Kolevic, Lenka] Natl Univ San Marcos Lima, Natl Inst Child Hlth, Lima, Peru.
   [Kolevic, Lenka] Natl Univ San Marcos Lima, Fac Med, Lima, Peru.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Foradori, Irene] Univ Buenos Aires, Fac Med, Buenos Aires, DF, Argentina.
   [Hazra, Rohan; Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Siberry, GK (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, 6100 Execut Blvd,Room 4B11H, Bethesda, MD 20892 USA.
EM siberryg@mail.nih.gov
RI Mussi-Pinhata, Marisa/G-6568-2012; Pinto, Jorge A/D-1743-2014; Pilotto,
   Jose Henrique/AAD-9773-2019
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Pinto, Jorge
   A/0000-0003-2987-3238; Pilotto, Jose Henrique/0000-0003-0521-8597;
   Machado, Daisy/0000-0003-1993-6442; Joao, Esau/0000-0002-2412-0627
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   HHSN267200800001C, N01-HD-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [N01HD033345, N01HD033345, N01HD033345] Funding
   Source: NIH RePORTER
FX Supported by NICHD Contract #N01-HD-3-3345 (2002 to 2007) and by NICHD
   Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001) (2007 to
   2012). The authors have no other funding or conflicts of interest to
   disclose.
CR Abzug MJ, 2012, J INFECT DIS, V206, P512, DOI 10.1093/infdis/jis386
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   Campos-Fernandez CS, 2009, EUR J PEDIATR, V168, P691
   Chitsike I, 1999, BRIT MED J, V318, P841, DOI 10.1136/bmj.318.7187.841
   Ciaranello AL, 2009, CLIN INFECT DIS, V49, P1915, DOI 10.1086/648079
   De Moraes JC, 2007, RES VACCINE COVERAGE
   Fernandez-Ibieta M, 2007, INT J STD AIDS, V18, P351, DOI 10.1258/095646207780749763
   Gamboa Cardena JR, 2001, ENF INF MICROBIOL, V31, P11
   Geretti AM, 2010, CURR OPIN INFECT DIS, V23, P32, DOI 10.1097/QCO.0b013e328334fec4
   Hazra R, 2009, INT J EPIDEMIOL, V38, P1207, DOI 10.1093/ije/dyn239
   Hesseling AC, 2009, B WORLD HEALTH ORGAN, V87, P505, DOI 10.2471/BLT.08.055657
   IONNEDELCU N, 1994, LANCET, V343, P51, DOI 10.1016/S0140-6736(94)90903-2
   Mast TC, 2006, AIDS CARE, V18, P755, DOI 10.1080/09540120500521053
   Menson EN, 2012, HIV MED, V13, P333, DOI 10.1111/j.1468-1293.2011.00982.x
   Ministry of Health Brazil, 2010, IMM DIAGN HIV INF S1
   Mofenson Lynne M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61
   Myers C, 2009, PEDIATR INFECT DIS J, V28, P996, DOI 10.1097/INF.0b013e3181a78348
   Ndirangu J, 2009, TROP MED INT HEALTH, V14, P1383, DOI 10.1111/j.1365-3156.2009.02382.x
   Schulte JM, 2000, SOUTHERN MED J, V93, P48, DOI 10.1097/00007611-200093010-00009
   Setse RW, 2006, J TROP PEDIATRICS, V52, P324, DOI 10.1093/tropej/fmk002
   Sutcliffe CG, 2010, LANCET INFECT DIS, V10, P630, DOI 10.1016/S1473-3099(10)70116-X
   Zinna SS, 2011, HIV MED, V12, P447, DOI 10.1111/j.1468-1293.2010.00895.x
NR 23
TC 5
Z9 5
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2013
VL 32
IS 8
BP 845
EP 850
DI 10.1097/INF.0b013e31828bbe68
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 301HT
UT WOS:000330524100013
PM 23860480
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Hofer, CB
   Harris, DR
   Saavedra, MC
   Haberer, JE
   Romeiro, J
   Mussi-Pinhata, MM
   Stankievich, E
   Gomes, IM
   Kreitchmann, R
   Read, JS
AF Hofer, Cristina B.
   Harris, D. Robert
   Saavedra, Mariza C.
   Haberer, Jessica E.
   Romeiro, Juliana
   Mussi-Pinhata, Marisa M.
   Stankievich, Erica
   Gomes, Ivete M.
   Kreitchmann, Regis
   Read, Jennifer S.
CA NISDI LILAC Study Team
TI Adherence to antiretroviral prophylaxis during early infancy in Latin
   America
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID SINGLE-DOSE NEVIRAPINE; TO-CHILD TRANSMISSION; HIV; PREVENTION; REGIMEN
C1 [Hofer, Cristina B.] Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Rio De Janeiro, RJ, Brazil.
   [Hofer, Cristina B.] Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, RJ, Brazil.
   [Harris, D. Robert] Westat Corp, Rockville, MD USA.
   [Saavedra, Mariza C.] Hosp Fed Servidores Estado, Rio De Janeiro, RJ, Brazil.
   [Haberer, Jessica E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Romeiro, Juliana] Univ Fed Minas Gerais, Sch Med, Grp Estudos HIV AIDS, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Stankievich, Erica] Hosp Gen Agudos JM Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina.
   [Gomes, Ivete M.] Hosp Geral Nova Iguacu, Rio De Janeiro, RJ, Brazil.
   [Kreitchmann, Regis] Irmandade de Santa Casa Misercordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Read, Jennifer S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD USA.
RP Hofer, CB (corresponding author), Rua Bruno Lobo 50, Rio De Janeiro, RJ, Brazil.
EM cbhofer@hucff.ufrj.br
RI Duarte, Geraldo/J-7906-2012; Haberer, Jessica/AAH-7976-2019;
   Mussi-Pinhata, Marisa/G-6568-2012; Melo, Anderson/L-6758-2014
OI Haberer, Jessica/0000-0001-5845-3190; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Coutinho, Conrado/0000-0003-1966-0466;
   Kreitchmann, Regis/0000-0002-1146-0497; Mofenson,
   Lynne/0000-0002-2818-9808; Melo, Anderson/0000-0002-4606-7791; Harris,
   Donald/0000-0002-8262-3716; Joao, Esau/0000-0002-2412-0627; Saavedra,
   Mariza/0000-0002-9141-4182
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001, N01-HD-3-3345, HHSN275201300003C]
   Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [HHSN267200800001G] Funding Source: Medline; PHS HHSUnited States Public
   Health Service [HHSN267200800001C] Funding Source: Medline; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033345] Funding Source: NIH RePORTER
CR Barigye H, 2010, TROP MED INT HEALTH, V15, P1163, DOI 10.1111/j.1365-3156.2010.02609.x
   Demas PA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e35
   Kuonza LR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-218
   Muller AD, 2011, AIDS BEHAV, V15, P422, DOI 10.1007/s10461-010-9825-6
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
NR 5
TC 0
Z9 0
U1 0
U2 2
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2013
VL 17
IS 4
BP 495
EP 496
DI 10.1016/j.bjid.2012.11.006
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 204AN
UT WOS:000323336800019
PM 23680065
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Gaur, AH
   Cohen, RA
   Read, JS
   Hance, LF
   Dominguez, K
   Alarcon, JO
   Menezes, J
   Peixoto, MF
   Mussi-Pinhata, MM
   Coelho, DF
   Mitchell, C
   Siberry, GK
AF Gaur, Aditya H.
   Cohen, Rachel A.
   Read, Jennifer S.
   Hance, Laura Freimanis
   Dominguez, Kenneth
   Alarcon, Jorge O.
   Menezes, Jacqueline
   Peixoto, Mario F.
   Mussi-Pinhata, Marisa M.
   Coelho, Debora F.
   Mitchell, Charles
   Siberry, George K.
TI Prechewing and Prewarming Food for HIV-Exposed Children: A Prospective
   Cohort Experience from Latin America
SO AIDS PATIENT CARE AND STDS
LA English
DT Editorial Material
ID PREMASTICATION; TRANSMISSION; INFANTS; PROMOTE; HEALTH
C1 [Gaur, Aditya H.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
   [Cohen, Rachel A.; Hance, Laura Freimanis] Westat Corp, Rockville, MD USA.
   [Read, Jennifer S.; Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, DHHS, Bethesda, MD USA.
   [Dominguez, Kenneth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Alarcon, Jorge O.] Univ San Marcos, Inst Med Trop Daniel Alcides Carrion, Seccion Epidemiol, Lima, Peru.
   [Menezes, Jacqueline] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Peixoto, Mario F.] Hosp Femina, Unidade Prevencao Transmissao Vertical, Porto Alegre, RS, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Coelho, Debora F.] Santa Casa Misericordia Porto Alegre, Ctr Pesquisa Maternoinfantil Irmandade, Porto Alegre, RS, Brazil.
   [Mitchell, Charles] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
RP Gaur, AH (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, MS 600,262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM aditya.gaur@stjude.org
RI Mussi-Pinhata, Marisa/G-6568-2012; Gaur, Aditya H/N-8057-2018
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Gaur, Aditya
   H/0000-0002-6639-5231
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   N01-HD-8-0001] Funding Source: Medline; PHS HHSUnited States Public
   Health Service [HHSN267200800001C] Funding Source: Medline; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033345] Funding Source: NIH RePORTER
CR [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P273
   Chung M, 2008, ANN INTERN MED, V149, P565, DOI 10.7326/0003-4819-149-8-200810210-00009
   Dyson L, 2010, PUBLIC HEALTH NUTR, V13, P137, DOI 10.1017/S136898000999067X
   Gaur AH, 2011, PEDIATRICS, V127, pE1206, DOI 10.1542/peds.2010-1902
   Gaur AH, 2009, PEDIATRICS, V124, P658, DOI 10.1542/peds.2008-3614
   Hafeez S, 2011, ARCH PEDIAT ADOL MED, V165, P92, DOI 10.1001/archpediatrics.2010.264
   Ivy W, 2012, JAIDS-J ACQ IMM DEF, V59, P207, DOI 10.1097/QAI.0b013e31823b4554
   Lewin S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub3
   Maritz ER, 2011, PEDIATRICS, V128, pE579, DOI 10.1542/peds.2010-3109
   Pelto GH, 2010, MATERN CHILD NUTR, V6, P4, DOI 10.1111/j.1740-8709.2009.00200.x
   Read JS, 2012, INT J EPIDEMIOL, V41, P642, DOI 10.1093/ije/dyr024
NR 11
TC 2
Z9 2
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD MAR
PY 2013
VL 27
IS 3
BP 142
EP 145
DI 10.1089/apc.2012.0459
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 105EK
UT WOS:000316048200002
PM 23477456
OA Green Published
DA 2020-12-17
ER

PT J
AU Inagaki, ADD
   Carvalheiro, CG
   Cipolotti, R
   Gurgel, RQ
   Rocha, DA
   Pinheiro, KS
   Araujo, RM
   Lima, DRR
   Winandy, JL
   Mussi-Pinhata, MM
AF de Melo Inagaki, Ana Dorcas
   Carvalheiro, Cristina Gardonyi
   Cipolotti, Rosana
   Gurgel, Ricardo Queiroz
   Rocha, Dayse Alves
   Pinheiro, Kariny Souza
   Araujo, Raquel Melo
   Resende Lima, Dorothy Ribeiro
   Winandy, Jacques Leon
   Mussi-Pinhata, Marisa Marcia
TI Birth prevalence and characteristics of congenital toxoplasmosis in
   Sergipe, North-east Brazil
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Congenital toxoplasmosis; Toxoplasma gondii; perinatal infections;
   neonatal screening; heel prick test; toxoplasmose congenitale;
   Toxoplasma gondii; infections perinatales; depistage neonatal; test de
   Guthrie; toxoplasmosis congenita; Toxoplasma gondii; infecciones
   perinatales; cribado neonatal; prueba del Talon
ID PREGNANT-WOMEN; GONDII INFECTION; CYTOMEGALOVIRUS; SYPHILIS; RUBELLA
AB Objectives To estimate, by neonatal screening, the birth prevalence of congenital toxoplasmosis among live-born infants in Sergipe state, Brazil, and to investigate the clinical features of affected infants. Methods Dried blood spot specimens obtained from 15 204 neonates were assayed for the presence of anti-T. gondii IgM antibodies. Duplicate retesting was done in infants with positive and borderline results. Confirmatory testing in peripheral blood samples consisted of testing for anti-T. gondii IgG and IgM in infants and mothers. Those with possible congenital toxoplasmosis were evaluated and followed up to a median age of 20 months. Congenital infection was confirmed in the presence of persisting anti-T. gondii IgG antibodies beyond 12 months of age. All infants with confirmed infection were treated with pyrimethamine, sulfadiazine and folinic acid for 1 year. Results Fifty-three infants had detectable IgM in dried blood spot specimens. Confirmatory testing was reactive in 39/50, of which, 38 completed follow-up. Six of 15 204 newborns were diagnosed with congenital toxoplasmosis, resulting in an estimated birth prevalence of four per 10 000 [CI 95% 1.48.0]. Four infants (67%) showed signs of congenital toxoplasmosis in their first year of life; three (75%) had retinochoroidal scars, and one had cerebral calcifications. Two infants remained asymptomatic until 20 months of age. Conclusions The birth prevalence of congenital toxoplasmosis is high in the Brazilian state of Sergipe, with most of the infants showing ocular lesions. Preventive measures are strongly warranted.
C1 [de Melo Inagaki, Ana Dorcas; Araujo, Raquel Melo] Univ Fed Sergipe, Dept Nursing, Aracaju, Brazil.
   [Carvalheiro, Cristina Gardonyi; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, Sao Paulo, Brazil.
   [Cipolotti, Rosana; Gurgel, Ricardo Queiroz] Univ Fed Sergipe, Postgrad Program Hlth Sci, Aracaju, Brazil.
   [Rocha, Dayse Alves] Univ Fed Sergipe, Lab Univ Hosp, Aracaju, Brazil.
   [Pinheiro, Kariny Souza] Cent Lab Publ Hlth Sergipe, Aracaju, Brazil.
   [Pinheiro, Kariny Souza] Ctr Hemotherapy, Serol Lab, Aracaju, Brazil.
   [Resende Lima, Dorothy Ribeiro] Nossa Senhora Lourdes Matern, Ophthalmol Serv, Aracaju, Brazil.
   [Winandy, Jacques Leon] Nossa Senhora Lourdes Matern, Ultrasonog Ctr, Aracaju, Brazil.
RP Inagaki, ADD (corresponding author), Rua Duque de Caxias,167 Edf Montparnasse,Apt 1202, BR-49015320 Aracaju, SE, Brazil.
EM anadorcas@hotmail.com
RI Gurgel, RQ/N-5105-2018; Carvalheiro, Cristina/K-8040-2012;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Gurgel, RQ/0000-0001-9651-3713; Carvalheiro,
   Cristina/0000-0003-1248-472X; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Rosana, Cipolotti/0000-0001-9070-2302
FU FAPITEC; Central Laboratory of Public Health of Sergipe; University
   Hospital of the Federal University of Sergipe; FAEPA; CAPESCAPES
FX This research was supported by FAPITEC, Central Laboratory of Public
   Health of Sergipe, University Hospital of the Federal University of
   Sergipe, FAEPA and CAPES. We thank Dr. Juan Jose Rivas and Dr. Aparecida
   Yulie Yamamoto.
CR Carvalheiro CG, 2005, EPIDEMIOL INFECT, V133, P485, DOI 10.1017/S095026880400353X
   Inagaki ADD, 2009, REV SOC BRAS MED TRO, V42, P532, DOI 10.1590/S0037-86822009000500010
   Detanico L, 2006, REV BRAS ANAL CLIN, V38, P15
   Gomez-Marin JE, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001195
   Evengard B, 2001, EPIDEMIOL INFECT, V127, P121, DOI 10.1017/S0950268801005775
   Figueiro-Filho EA, 2007, REV SOC BRAS MED TRO, V40, P181, DOI 10.1590/S0037-86822007000200007
   Gilbert RE, 2007, J MED SCREEN, V14, P8, DOI 10.1258/096914107780154440
   Gilbert RE, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000277
   GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604
   Gurgel Ricardo Queiroz, 2009, Rev. Bras. Saude Mater. Infant., V9, P167, DOI 10.1590/S1519-38292009000200006
   Jones JL, 2007, AM J TROP MED HYG, V77, P405, DOI 10.4269/ajtmh.2007.77.405
   Lago EG, 2007, PAEDIATR PERINAT EP, V21, P525, DOI 10.1111/j.1365-3016.2007.00869.x
   Lebech M, 1996, EUR J CLIN MICROBIOL, V15, P799, DOI 10.1007/BF01701522
   Lebech M, 1999, LANCET, V353, P1834, DOI 10.1016/S0140-6736(98)11281-3
   MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38
   Montoya JG, 2005, CLIN PERINATOL, V32, P705, DOI 10.1016/j.clp.2005.04.011
   Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X
   Neto EC, 2010, SCI MED, V20, P64
   Petersen E, 2007, SEMIN FETAL NEONAT M, V12, P214, DOI 10.1016/j.siny.2007.01.011
   Robert-Gangneux F, 2001, Clin Lab, V47, P135
   Rodrigues IMX, 2009, MEM I OSWALDO CRUZ, V104, P434, DOI 10.1590/S0074-02762009000300006
   Schmidt DR, 2006, ARCH DIS CHILD, V91, P661, DOI 10.1136/adc.2004.066514
   Thiebaut R, 2007, LANCET, V369, P115
   Vasconcelos-Santos DV, 2009, OPHTHALMOLOGY, V116, P2199, DOI 10.1016/j.ophtha.2009.04.042
   Villena I, 2010, EUROSURVEILLANCE, V15, P14
NR 25
TC 7
Z9 7
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2012
VL 17
IS 11
BP 1349
EP 1355
DI 10.1111/j.1365-3156.2012.03079.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 023JJ
UT WOS:000310028400006
PM 22974376
DA 2020-12-17
ER

PT J
AU Alves, MNR
   Duarte, G
   Pinhata, MMM
   De Martinis, BS
AF Alves, Marcela N. R.
   Duarte, Geraldo
   Pinhata, Marisa M. M.
   De Martinis, Bruno S.
TI Validation of a Solid Phase Extraction Procedure for Identification and
   Quantification of Cocaine and Metabolities in Meconium Using GC/MS
SO CURRENT PHARMACEUTICAL ANALYSIS
LA English
DT Review
DE Cocaine and metabolities; Crack; Gas chromatography/mass spectrometry;
   Meconium; Method validation; Solid phase extraction
ID CHROMATOGRAPHY-MASS-SPECTROMETRY; LC-MS-MS; GAS-CHROMATOGRAPHY;
   WHOLE-BLOOD; LIFE-STYLE; EXPOSURE; URINE; DRUGS; ABUSE; METHAMPHETAMINE
AB Cocaine and crack usage is a major public health concern worldwide, mainly when the target consumers are pregnant women. The purpose of this study was to develop and validate a cost-effective method for identification and quantification of cocaine, benzoylecgonine, cocaethylene, and anhydroecgonine methyl ester in meconium samples, using solid-phase extraction (SPE) and GC/MS (ion trap - full scan mode) to be employed in public hospitals in Brazil. The method was validated in the 20 - 1000 ng/g range for cocaine and cocaethylene, 40 - 1500 ng/g for benzoylecgonine and 60 - 1500 ng/g for anhydroecgonine methyl ester, using 0.5 g meconium per assay. The detector response was linear in the studied range, and the limit of detection was found to be 10 ng/g for cocaine and cocaethylene, 30 ng/g for benzoylecgonine, and 40 ng/g for anhydroecgonine methyl ester. Intra-batch coefficients of variation oscillated between 3.01% and 10.15% and inter-batch coefficients varied between 5.31% and 11.12%; accuracy was in 91.47% - 105.31% range. Recoveries were higher than 56.30%. Finally, the method was applied to meconium analysis from 20 newborns at the Hospital Clinicas da Faculdade de Medicina de Ribeirao Preto, and it identified 6 positive samples.
C1 [Alves, Marcela N. R.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14050140 Ribeirao Preto, SP, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Ginecol & Obstet, BR-14040030 Ribeirao Preto, SP, Brazil.
   [Pinhata, Marisa M. M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14040030 Ribeirao Preto, SP, Brazil.
   [De Martinis, Bruno S.] Univ Sao Paulo, Fac Filosofia Ciencias & Letras Ribeirao Preto, Dept Quim, BR-14050140 Ribeirao Preto, SP, Brazil.
RP Alves, MNR (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14050140 Ribeirao Preto, SP, Brazil.
EM marcelausp76@yahoo.com.br
RI De Martinis, Bruno/I-5388-2012; Mussi-Pinhata, Marisa/G-6568-2012;
   Duarte, Geraldo/J-7906-2012
OI De Martinis, Bruno/0000-0002-2702-5190; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; 
FU Brazilian Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES
FX This research was supported by Brazilian Coordination for the
   Improvement of Higher Education Personnel (CAPES).
CR ABUSADA GM, 1993, J ANAL TOXICOL, V17, P353, DOI 10.1093/jat/17.6.353
   Araojo R, 2008, CLIN PHARMACOL THER, V83, P520, DOI 10.1038/clpt.2008.13
   Bar-Oz B, 2003, ARCH DIS CHILD-FETAL, V88, pF98, DOI 10.1136/fn.88.2.F98
   Bearer CF, 2003, AMBUL PEDIATR, V3, P40, DOI 10.1367/1539-4409(2003)003<0040:MAABMO>2.0.CO;2
   Bielawski D, 2005, CHROMATOGRAPHIA, V62, P623, DOI 10.1365/s10337-005-0668-7
   BROWNE SP, 1992, J CHROMATOGR-BIOMED, V575, P158, DOI 10.1016/0378-4347(92)80518-U
   CARLINI E. A., 2006, 2 LEVANTAMENTO DOMIC
   CLARK GD, 1992, J ANAL TOXICOL, V16, P261, DOI 10.1093/jat/16.4.261
   Coles R, 2007, J ANAL TOXICOL, V31, P1, DOI 10.1093/jat/31.1.1
   CONE EJ, 1994, CLIN CHEM, V40, P1299
   De Martinis BS, 2007, J CHROMATOGR B, V852, P450, DOI 10.1016/j.jchromb.2007.02.017
   Duailibi L.B., 2008, PROFILE COCAINE CRAC, P24
   Gallardo E, 2008, BIOMED CHROMATOGR, V22, P795, DOI 10.1002/bmc.1009
   Gareri J, 2006, CLIN CHIM ACTA, V366, P101, DOI 10.1016/j.cca.2005.10.028
   Gray T, 2007, ANAL BIOANAL CHEM, V388, P1455, DOI 10.1007/s00216-007-1228-9
   Gray TR, 2009, THER DRUG MONIT, V31, P769, DOI 10.1097/FTD.0b013e3181bb438e
   Gray TR, 2009, ANAL BIOANAL CHEM, V393, P1977, DOI 10.1007/s00216-009-2680-5
   Hutson JR, 2009, J CHROMATOGR B, V877, P8, DOI 10.1016/j.jchromb.2008.10.056
   Kelly T, 2008, J CHROMATOGR B, V867, P194, DOI 10.1016/j.jchromb.2008.03.029
   Lester BM, 2001, PEDIATRICS, V107, P309, DOI 10.1542/peds.107.2.309
   LEWIS DE, 1994, J TOXICOL-CLIN TOXIC, V32, P697, DOI 10.3109/15563659409017976
   Loopez P, 2007, J APPL TOXICOL, V27, P464, DOI 10.1002/jat.1227
   Lopez P, 2009, J ANAL TOXICOL, V33, P351, DOI 10.1093/jat/33.7.351
   Marin SJ, 2007, J CHROMATOGR B, V858, P59, DOI 10.1016/j.jchromb.2007.08.026
   Martinez-Lopez F, 2001, PROG COLL POL SCI S, V118, P123
   Ostrea Jr EM, 1999, CURR PROBL PEDIATR, V29, P41
   Oyler J, 1996, J ANAL TOXICOL, V20, P453, DOI 10.1093/jat/20.6.453
   Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021
   Pichini S, 2003, J CHROMATOGR B, V794, P281, DOI 10.1016/S1570-0232(03)00478-1
   Roehsig M, 2010, J SEP SCI, V33, P2115, DOI 10.1002/jssc.201000118
   Xia Y, 2000, ANAL CHEM, V72, P764, DOI 10.1021/ac990201p
NR 31
TC 3
Z9 3
U1 1
U2 42
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4129
EI 1875-676X
J9 CURR PHARM ANAL
JI Curr. Pharm. Anal.
PD NOV
PY 2012
VL 8
IS 4
BP 317
EP 323
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 018KJ
UT WOS:000309658800002
DA 2020-12-17
ER

PT J
AU Read, JS
   Cohen, RA
   Hance, LF
   Machado, ES
   Mussi-Pinhata, MM
   Ceriotto, M
   Santos, B
   Succi, R
   Pilotto, JH
   Alarcon, JO
   Kreitchmann, R
AF Read, Jennifer S.
   Cohen, Rachel A.
   Hance, Laura Freimanis
   Machado, Elizabeth S.
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Santos, Breno
   Succi, Regina
   Pilotto, Jose H.
   Alarcon, Jorge O.
   Kreitchmann, Regis
CA NISDI Perinatal LILAC Study Grp
TI Missed opportunities for prevention of mother-to-child transmission of
   HIV-1 in the NISDI Perinatal and LILAC cohorts
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE HIV-1; Mother-to-child transmission; Prevention
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RISK-FACTORS; PREGNANCY
AB Objective: To evaluate cases of mother-to-child transmission of HIV-1 at multiple sites in Latin America and the Caribbean in terms of missed opportunities for prevention. Methods: Pregnant women infected with HIV-1 were eligible for inclusion if they were enrolled in either the NISDI Perinatal or LILAC protocols by October 20, 2009, and had delivered a live infant with known HIV-1 infection status after March 1, 2006. Results: Of 711 eligible mothers, 10 delivered infants infected with HIV-1. The transmission rate was 1.4% (95% CI, 0.7-2.6). Timing of transmission was in utero or intrapartum (n = 5), intrapartum (n = 2), intrapartum or early postnatal (n = 1), and unknown (n = 2). Possible missed opportunities for prevention included poor control of maternal viral load during pregnancy; late initiation of antiretrovirals during pregnancy; lack of cesarean delivery before labor and before rupture of membranes; late diagnosis of HIV-1 infection; lack of intrapartum antiretrovirals; and incomplete avoidance of breastfeeding. Conclusion: Early knowledge of HIV-1 infection status (ideally before or in early pregnancy) would aid timely initiation of antiretroviral treatment and strategies designed to prevent mother-to-child transmission. Use of antiretrovirals must be appropriately monitored in terms of adherence and drug resistance. If feasible, breastfeeding should be completely avoided. Presented in part at the XIX International AIDS Conference (Washington, DC; July 22-27, 2012); abstract WEPE163. (c) 2012 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics.
C1 [Read, Jennifer S.] NICHD, Pediat Adolescent & Maternal AIDS Branch, CRMC, NIH,DHHS, Bethesda, MD USA.
   [Cohen, Rachel A.; Hance, Laura Freimanis] WESTAT Corp, Rockville, MD 20850 USA.
   [Machado, Elizabeth S.] Univ Fed Rio de Janeiro, Infect Dis Serv, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Ceriotto, Mariana] Dr Cecilia Grierson Hosp, Infect Dis Unit, Buenos Aires, DF, Argentina.
   [Santos, Breno] Nossa Senhora da Conceicao Hosp, Infect Dis Serv, Porto Alegre, RS, Brazil.
   [Succi, Regina] Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, HIV Family Care Clin, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Lab AIDS & Mol Immunol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Alarcon, Jorge O.] UNMSM, Epidemiol Sect, DA Carrion Inst Trop Med, Lima, Peru.
   [Kreitchmann, Regis] Irmandade Santa Casa de Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
RP Read, JS (corresponding author), NVPO OASH OS DHHS, 200 Independence Ave SW,Room 739G6, Washington, DC 20201 USA.
EM jennifer.read@hhs.gov
RI Pilotto, Jose Henrique/AAD-9773-2019; Mussi-Pinhata, Marisa/G-6568-2012;
   Pinto, Jorge A/D-1743-2014
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pinto, Jorge A/0000-0003-2987-3238;
   Kreitchmann, Regis/0000-0002-1146-0497
FU National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [N01-HD-3-3345]; NICHDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [HHSN267200800001C, N01-HD-8-0001]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033345] Funding Source: NIH RePORTER
FX The present study was supported by National Institute of Child Health
   and Human Development (NICHD) Contract # N01-HD-3-3345 (2002-2007) and
   by NICHD Contract # HHSN267200800001C (NICHD Control #: N01-HD-8-0001;
   2007-2012).
CR [Anonymous], REC US ANT DRUGS PRE
   Bailey H, 2011, ANTIVIR THER, V16, P895, DOI 10.3851/IMP1849
   *CTR DIS CONTR, 1992, MMWR-MORBID MORTAL W, V41, P1
   D'Ippolito M, 2007, PEDIATR INFECT DIS J, V26, P649, DOI 10.1097/INF.0b013e3180618bd6
   Ferguson Wendy, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P182, DOI 10.1177/1545109708320685
   Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401
   Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016
   Ministry of Health Argentina, 2012, PREV MOTH TO CHILD T
   Ministry of Health Brazil, 2010, REC PREV MOTH TO CHI
   Ministry of Health Peru, 2008, 0642008MINSADGSPV01
   Peters V, 2003, PEDIATRICS, V111, P1186
   Read JS, 2011, INT J EPIDEMIOL, P1
   Rispel LC, 2009, SAMJ S AFR MED J, V99, P174
   Sturt AS, 2011, EXPERT OPIN PHARMACO, V12, P1875, DOI 10.1517/14656566.2011.584062
   Turchi MD, 2007, CAD SAUDE PUBLICA, V23, pS390, DOI 10.1590/S0102-311X2007001500007
   Whitmore SK, 2010, WOMEN HEALTH, V50, P414, DOI 10.1080/03630242.2010.506153
NR 16
TC 9
Z9 10
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD OCT
PY 2012
VL 119
IS 1
BP 70
EP 75
DI 10.1016/j.ijgo.2012.05.026
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 012OU
UT WOS:000309247200018
PM 22819316
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Nielsen-Saines, K
   Watts, H
   Veloso, VG
   Bryson, YJ
   Joao, EC
   Pilotto, JH
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, D
   Bethel, J
   Morgado, MG
   Dickover, R
   Camarca, M
   Mirochnick, M
   Siberry, G
   Grinsztejn, B
   Moreira, RI
   Bastos, FI
   Xu, JH
   Moye, J
   Mofenson, LM
AF Nielsen-Saines, Karin
   Watts, Heather
   Veloso, Valdilea G.
   Bryson, Yvonne J.
   Joao, Esau C.
   Pilotto, Jose Henrique
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy
   Bethel, James
   Morgado, Marisa G.
   Dickover, Ruth
   Camarca, Margaret
   Mirochnick, Mark
   Siberry, George
   Grinsztejn, Beatriz
   Moreira, Ronaldo I.
   Bastos, Francisco I.
   Xu, Jiahong
   Moye, Jack
   Mofenson, Lynne M.
CA NICHD HPTN 040 PACTG Protocol Team
TI Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV
   Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; MATERNAL-INFANT
   TRANSMISSION; PERINATAL TRANSMISSION; POSTEXPOSURE PROPHYLAXIS;
   ZIDOVUDINE TREATMENT; RANDOMIZED-TRIAL; VIRAL LOAD; NEVIRAPINE;
   RESISTANCE
AB BACKGROUND
   The safety and efficacy of adding antiretroviral drugs to standard zidovudine prophylaxis in infants of mothers with human immunodeficiency virus (HIV) infection who did not receive antenatal antiretroviral therapy (ART) because of late identification are unclear. We evaluated three ART regimens in such infants.
   METHODS
   Within 48 hours after their birth, we randomly assigned formula-fed infants born to women with a peripartum diagnosis of HIV type 1 (HIV-1) infection to one of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group), or zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group). The primary outcome was HIV-1 infection at 3 months in infants uninfected at birth.
   RESULTS A total of 1684 infants were enrolled in the Americas and South Africa (566 in the zidovudine-alone group, 562 in the two-drug group, and 556 in the three-drug group). The overall rate of in utero transmission of HIV-1 on the basis of Kaplan-Meier estimates was 5.7% (93 infants), with no significant differences among the groups. Intrapartum transmission occurred in 24 infants in the zidovudine-alone group (4.8%; 95% confidence interval [CI], 3.2 to 7.1), as compared with 11 infants in the two-drug group (2.2%; 95% CI, 1.2 to 3.9; P=0.046) and 12 in the three-drug group (2.4%; 95% CI, 1.4 to 4.3; P=0.046). The overall transmission rate was 8.5% (140 infants), with an increased rate in the zidovudine-alone group (P=0.03 for the comparisons with the two-and three-drug groups). On multivariate analysis, zidovudine monotherapy, a higher maternal viral load, and maternal use of illegal substances were significantly associated with transmission. The rate of neutropenia was significantly increased in the three-drug group (P < 0.001 for both comparisons with the other groups).
   CONCLUSIONS In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two-or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] and others; ClinicalTrials.gov number, NCT00099359.)
C1 [Nielsen-Saines, Karin] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Gray, Glenda; Moye, Jack; Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Bethel, James; Camarca, Margaret; Xu, Jiahong] Westat Corp, Rockville, MD USA.
   [Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisa Clin DST & AIDS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique; Morgado, Marisa G.] Fundacao Oswaldo Cruz Fiocruz, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Moreira, Ronaldo I.; Bastos, Francisco I.] Fundacao Oswaldo Cruz Fiocruz, Lab Informacoes Saude, Inst Informacao Cient & Tecnol Saude, Rio De Janeiro, Brazil.
   [Joao, Esau C.] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Gray, Glenda] Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Theron, Gerhard] Univ Stellenbosch, Cape Town, South Africa.
   [Theron, Gerhard] Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil.
   [Machado, Daisy] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Dickover, Ruth] Univ Calif Davis, Davis, CA 95616 USA.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth, Buenos Aires, DF, Argentina.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Nielsen-Saines, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, MDCC 22-442 10833 LeConte Ave, Los Angeles, CA 90095 USA.
EM knielsen@mednet.ucla.edu
RI Mofenson, Lynne/P-9631-2019; Pilotto, Jose Henrique/AAD-9773-2019;
   Veloso, Valdilea Goncalves/J-6189-2012; Mussi-Pinhata,
   Marisa/G-6568-2012; Pinto, Jorge A/D-1743-2014
OI Mofenson, Lynne/0000-0002-2818-9808; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Pinto, Jorge A/0000-0003-2987-3238; Bastos,
   Francisco/0000-0001-5970-8896; Kreitchmann, Regis/0000-0002-1146-0497;
   Joao, Esau/0000-0002-2412-0627; moye, john/0000-0001-9976-8586; Machado,
   Daisy/0000-0003-1993-6442
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001]; HIV Prevention Trials Network;
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI047986, U01 AI068632]; National Institute of
   Mental HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [AI068632]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000454, UL1TR000454, UL1TR000454,
   UL1TR000454, UL1TR000454, UL1TR000454, UL1TR000454] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI068632, UM1AI068632, U01AI068632, U01AI047986,
   U01AI068632, UM1AI068632, UM1AI068632, UM1AI068632, U01AI047986,
   U01AI068632, U01AI068632, UM1AI068632, UM1AI068632, U01AI068632,
   U01AI047986, UM1AI068632, U01AI068632, U01AI047986, U01AI068632,
   U01AI068632, U01AI068632, UM1AI068632, U01AI047986, U01AI047986,
   UM1AI068632, U01AI047986, U01AI047986, U01AI068632] Funding Source: NIH
   RePORTER
FX Supported by the NICHD (HHSN267200800001C, N01-HD-8-0001) and by a grant
   from the HIV Prevention Trials Network, which is funded by the National
   Institute of Allergy and Infectious Diseases (NIAID), to the Brazilian
   AIDS Prevention Trials International Network at the University of
   California, Los Angeles (U01 AI047986). Overall support for IMPAACT,
   which endorsed the study, was provided by grants from the NIAID (U01
   AI068632), the NICHD, and the National Institute of Mental Health
   (AI068632).
CR [Anonymous], 2010, GUID US ANT AG PED H
   [Anonymous], 2011, REC US ANT DRUGS PRE
   BrazilianMinistry of Health, 2010, REC PREV VERT TRANSM
   Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219
   Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599
   Division of AIDS (DAIDS) Regulatory Support Center, 1994, TABL GRAD SEV PED AD
   El Beitune P, 2006, EUR J OBSTET GYN R B, V128, P59, DOI 10.1016/j.ejogrb.2006.01.013
   Ellis RJ, 2003, J INFECT DIS, V188, P1820, DOI 10.1086/379894
   Eshleman SH, 2006, J INFECT DIS, V193, P479, DOI 10.1086/499967
   Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840
   Gray GE, 2005, AIDS, V19, P1289, DOI 10.1097/01.aids.0000180100.42770.a7
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Haile-Selassie HT, 2011, HIV MED, V12, P422, DOI 10.1111/j.1468-1293.2010.00902.x
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Krogstad P, 1999, CLIN INFECT DIS, V28, P1109, DOI 10.1086/514759
   Krogstad P, 2002, CLIN INFECT DIS, V34, P991, DOI 10.1086/338814
   Lambert JS, 2003, SEX TRANSM INFECT, V79, P448, DOI 10.1136/sti.79.6.448
   Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083
   Marazzi MC, 2010, AIDS, V24, P2819, DOI 10.1097/QAD.0b013e32833ff58c
   McKeegan K, 2011, AIDS PATIENT CARE ST, V25, P1, DOI 10.1089/apc.2010.0255
   Mirochnick M, 2008, JAIDS-J ACQ IMM DEF, V47, P334, DOI 10.1097/QAI.0b013e31815f3c23
   Mirochnick M, 2011, PEDIATR INFECT DIS J, V30, P769, DOI 10.1097/INF.0b013e3182242950
   Nogueira S A, 2001, Braz J Infect Dis, V5, P78
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Purohit V, 2010, J NEUROIMMUNE PHARM, V5, P507, DOI 10.1007/s11481-010-9242-7
   Simon A, 2011, JAMA-J AM MED ASSOC, V306, P70, DOI 10.1001/jama.2011.915
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Taha TE, 2004, JAMA-J AM MED ASSOC, V292, P202, DOI 10.1001/jama.292.2.202
   Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2
   Theron GB, 2011, INT J GYNECOL OBSTET, V113, P44, DOI 10.1016/j.ijgo.2010.10.011
   Veloso VG, 2010, REV SAUDE PUBL, V44, P803, DOI 10.1590/S0034-89102010005000034
   Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001
   World Health Organization (WHO), 2010, ANT THER HIV INF INF
NR 37
TC 118
Z9 123
U1 0
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 21
PY 2012
VL 366
IS 25
BP 2368
EP 2379
DI 10.1056/NEJMoa1108275
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 961GH
UT WOS:000305451700006
PM 22716975
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Alarcon, JO
   Freimanis-Hance, L
   Krauss, M
   Reyes, MF
   Cardoso, CAA
   Mussi-Pinhata, MM
   Cardoso, E
   Hazra, R
AF Alarcon, Jorge O.
   Freimanis-Hance, Laura
   Krauss, Margot
   Reyes, Mary F.
   Araujo Cardoso, Claudete Aparecida
   Mussi-Pinhata, Marisa M.
   Cardoso, Edmundo
   Hazra, Rohan
CA NISDI Pediat Study Grp 2011
TI Opportunistic and Other Infections in HIV-Infected Children in Latin
   America Compared to a Similar Cohort in the United States
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HIV-1-INFECTED CHILDREN; HERPES-ZOSTER; MORTALITY; HAART
AB Opportunistic and other infections have declined since the introduction of highly active antiretroviral therapy (HAART) in developed countries but few studies have addressed the impact of HAART in HIV-infected children from developing countries. This study examines the prevalence and incidence of opportunistic and other infections in Latin America during the HAART era. Vertically HIV-infected children enrolled in a cohort study between 2002 and 2007 were followed for the occurrence of 29 targeted infections. Cross-sectional and longitudinal analyses were performed to calculate the prevalence of infections before enrollment and the incidence rates of opportunistic and other infections after enrollment. Comparisons were made with data from a U. S. cohort (PACTG 219C). Of the 731 vertically HIV-infected children 568 (78%) had at least one opportunistic or other infection prior to enrollment. The most prevalent infections were bacterial pneumonia, oral candidiasis, varicella, tuberculosis, herpes zoster, and Pneumocystis jiroveci pneumonia. After enrollment, the overall incidence was 23.5 per 100 person-years; the most common infections (per 100 person-years) were bacterial pneumonia (7.8), varicella (3.0), dermatophyte infections (2.9), herpes simplex (2.5), and herpes zoster (1.8). All of these incidence rates were higher than those reported in PACTG 219C. The types and relative distribution of infections among HIV-infected children in Latin America in this study are similar to those seen in the United States but the incidence rates are higher. Further research is necessary to determine the reasons for these higher rates.
C1 [Alarcon, Jorge O.; Reyes, Mary F.] UNMSM, Inst Trop Med, Lima, Peru.
   [Freimanis-Hance, Laura; Krauss, Margot] Westat Corp, Rockville, MD USA.
   [Araujo Cardoso, Claudete Aparecida] Hosp Servidores Estado, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
   [Cardoso, Edmundo] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Hazra, Rohan] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Hazra, R (corresponding author), 6100 Execut Blvd,Room 4B11, Bethesda, MD 20982 USA.
EM hazrar@mail.nih.gov
RI Pilotto, Jose Henrique/AAD-9773-2019; Mussi-Pinhata, Marisa/G-6568-2012;
   Pinto, Jorge A/D-1743-2014
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pinto, Jorge A/0000-0003-2987-3238; Reyes
   Vega, Mary Felissa/0000-0003-1524-3964; Machado,
   Daisy/0000-0003-1993-6442
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   HHSN267200800001C, N01-HD-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [N01HD033345, N01HD033345, N01HD033345] Funding
   Source: NIH RePORTER
FX Supported by NICHD Contract N01-HD-3-3345 (2002-2007) and by NICHD
   Contract HHSN267200800001C (NICHD Control #: N01-HD-8-0001) (2007-2012).
CR Andino-Martinez K, 2001, REV MED POST UNAH, V6, P50
   Brady MT, 2010, JAIDS-J ACQ IMM DEF, V53, P86, DOI 10.1097/QAI.0b013e3181b9869f
   Calder D, 2009, J TROP PEDIATRICS, V55, P219, DOI 10.1093/tropej/fmp047
   Caldwell MB, 1994, MMWR RECOMM REP, V43, P1
   Candiani TMS, 2007, CAD SAUDE PUBLICA, V23, pS414, DOI 10.1590/S0102-311X2007001500009
   Centers for Disease Control and Prevention, 2010, SAS PROGR CDC GROWTH
   Chiappini E, 2007, AIDS, V21, P1607, DOI 10.1097/QAD.0b013e32823ecf5b
   Gona P, 2006, JAMA-J AM MED ASSOC, V296, P292, DOI 10.1001/jama.296.3.292
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   Guillen S, 2010, HIV MED, V11, P245, DOI 10.1111/j.1468-1293.2009.00768.x
   Hazra R, 2009, INT J EPIDEMIOL, V38, P1207, DOI 10.1093/ije/dyn239
   Levin MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P182, DOI 10.1097/QAI.0b013e31819550a4
   MartinezAguilar G, 1995, SALUD PUBLICA MEXICO, V37, P572
   Mubiana-Mbewe M, 2009, TROP MED INT HEALTH, V14, P1190, DOI 10.1111/j.1365-3156.2009.02360.x
   Nesheim SR, 2007, PEDIATRICS, V120, P100, DOI 10.1542/peds.2006-2052
   Pena A, 2007, REV CHIL INFECTOL, V24, P477, DOI [/S0716-10182007000600008, 10.4067/S0716-10182007000600008]
   Rothman K.J., 1986, MODERN EPIDEMIOLOGY
   Wood SM, 2008, PEDIATRICS, V121, pE150, DOI 10.1542/peds.2007-0564
NR 18
TC 15
Z9 16
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2012
VL 28
IS 3
BP 282
EP 288
DI 10.1089/aid.2011.0057
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 904VK
UT WOS:000301226100010
PM 21902581
OA Green Published
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Isaac, MD
   Amaral, FR
   Carvalheiro, CG
   Aragon, DC
   Manfredi, AKD
   Boppana, SB
   Britt, WJ
AF Yamamoto, Aparecida Y.
   Mussi-Pinhata, Marisa Marcia
   Isaac, Myriam de Lima
   Amaral, Fabiana R.
   Carvalheiro, Cristina G.
   Aragon, Davi C.
   da Silva Manfredi, Alessandra K.
   Boppana, Suresh B.
   Britt, William J.
TI Congenital Cytomegalovirus Infection as a Cause of Sensorineural Hearing
   Loss in a Highly Immune Population
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE cytomegalovirus; congenital infection; hearing loss; Brazilian children
ID CMV INFECTION; CHILDREN; INFANTS
AB Background: The burden of congenital cytomegalovirus (CMV)-associated sensorineural hearing loss (SNHL) in populations with CMV seroprevalence approaching 100% is unknown. The purpose of this study was to assess the rate, associated factors, and predictors of SNHL in CMV-infected infants identified by newborn screening in a highly seropositive maternal population.
   Methods: Newborns with positive saliva CMV-DNA that was confirmed by virus isolation in the first 2 weeks of life were enrolled in a prospective follow-up study to monitor hearing outcome.
   Results: Of 12,195 infants screened, 121 (1%) were infected with CMV and 12 (10%) had symptomatic infection at birth. Hearing function could be assessed in 102/121 children who underwent at least one auditory brainstem evoked response testing at a median age of 12 months. SNHL was observed in 10/102 (9.8%; 95% confidence interval: 5.1-16.7) children. Median age at the latest hearing evaluation was 47 months (12-84 months). Profound loss (>90 dB) was found in 4/5 children with bilateral SNHL while all 5 children with unilateral loss had moderate to severe deficit. The presence of symptomatic infection at birth (odds ratio, 38.1; 95% confidence interval: 1.6-916.7) was independently associated with SNHL after adjusting for intrauterine growth restriction, gestational age, gravidity, and maternal age. Among 10 infants with SNHL, 6 (60%) were born to mothers with nonprimary CMV infection.
   Conclusions: Even in populations with near universal immunity to CMV, congenital CMV infection is a significant cause of SNHL demonstrating the importance of CMV as a major cause of SNHL in children worldwide. As in other populations, SNHL is more frequently observed in symptomatic CMV infection.
C1 [Yamamoto, Aparecida Y.; Mussi-Pinhata, Marisa Marcia; Amaral, Fabiana R.; Carvalheiro, Cristina G.; Aragon, Davi C.; da Silva Manfredi, Alessandra K.] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Isaac, Myriam de Lima] Univ Sao Paulo, Dept Ophtalmol Otorrinolaringol & Head & Neck Sur, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Boppana, Suresh B.; Britt, William J.] Univ Alabama, Sch Med, Dept Pediat, Birmingham, AL USA.
   [Boppana, Suresh B.; Britt, William J.] Univ Alabama, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA.
   [Britt, William J.] Univ Alabama, Sch Med, Dept Neurobiol, Birmingham, AL USA.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Ave Bandeirantes 3900,Campus USP CEP, BR-14049900 Sao Paulo, Brazil.
EM yulie@fmrp.usp.br
RI Aragon, Davi C/R-6604-2016; Mussi-Pinhata, Marisa/G-6568-2012;
   Carvalheiro, Cristina/K-8040-2012
OI Aragon, Davi C/0000-0003-1019-3654; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Carvalheiro, Cristina/0000-0003-1248-472X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIAID AI 49537];
   Fogarty International CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R03 TW006480]; NIDCDUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD)
   [DC04162]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [02/04166-6]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF
   CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959] Funding
   Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R01HD061959] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R03TW006480, R03TW006480, R03TW006480] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI049537, R01AI089956, R01AI049537, R01AI049537, R01AI089956,
   R01AI089956, R01AI089956, R01AI049537, R01AI089956, R01AI089956,
   R01AI089956, R01AI049537, R01AI049537] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS065845, R01NS065845, R01NS065845, R01NS065845, R01NS065845]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER
   COMMUNICATION DISORDERSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [R01DC004163,
   R01DC004163, R01DC004163, R01DC004163, R01DC004163, R01DC004163,
   R01DC004163, R01DC004163] Funding Source: NIH RePORTER
FX Supported by grants from the National Institutes of Health (NIAID AI
   49537; Fogarty International Center, R03 TW006480 to WJB), (NIDCD
   DC04162 to SBB), and Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP), Brazil, Process number 02/04166-6.
CR AHLFORS K, 1984, SCAND J INFECT DIS, V16, P129, DOI 10.3109/00365548409087131
   Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X
   Bevilacqua MC, 2010, INT J PEDIATR OTORHI, V74, P510, DOI 10.1016/j.ijporl.2010.02.009
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Dahle A J, 2000, J Am Acad Audiol, V11, P283
   Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049
   Fowler KB, 2006, J CLIN VIROL, V35, P226, DOI 10.1016/j.jcv.2005.09.016
   Fowler KB, 1997, J PEDIATR-US, V130, P624, DOI 10.1016/S0022-3476(97)70248-8
   Korver AMH, 2010, JAMA-J AM MED ASSOC, V304, P1701, DOI 10.1001/jama.2010.1501
   Lazzarotto T, 1997, CLIN DIAGN LAB IMMUN, V4, P469, DOI 10.1128/CDLI.4.4.469-473.1997
   Mehl AL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e7
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.003
   SAIGAL S, 1982, AM J DIS CHILD, V136, P896, DOI 10.1001/archpedi.1982.03970460026006
   STAPELLS DR, 1991, CLIN PERINATOL, V18, P497
   WILLIAMSON WD, 1992, PEDIATRICS, V90, P862
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
NR 17
TC 86
Z9 86
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD DEC
PY 2011
VL 30
IS 12
BP 1043
EP 1046
DI 10.1097/INF.0b013e31822d9640
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 853DJ
UT WOS:000297406100009
PM 21814153
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Almeida, VD
   Negrini, BVM
   Cervi, MC
   Isaac, MD
   Mussi-Pinhata, MM
AF Almeida, Volia de Carvalho
   Negrini, Bento V. M.
   Cervi, Maria C.
   Isaac, Marcia de L.
   Mussi-Pinhata, Marisa M.
TI Pneumococcal Nasopharyngeal Carriage Among Infants Born to Human
   Immunodeficiency Virus-infected Mothers Immunized With Pneumococcal
   Polysaccharide Vaccine During Gestation
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE infant; Streptococcus pneumoniae; colonization; 23-valent polysaccharide
   pneumococcal vaccine; maternal immunization; pneumococcal carriage
ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; MATERNAL
   IMMUNIZATION; ANTIBIOTIC-RESISTANCE; COLONIZATION; CHILDREN; COMMUNITY;
   IMMUNOGENICITY; TYPE-1; IMPACT
AB Background: We have previously shown that 23-valent pneumococcal polysaccharide vaccine (PPV) is immunogenic in human immunodeficiency virus (HIV)-infected mothers and provides vaccine-induced antibodies to the infant. We compared the nasopharyngeal pneumococcal colonization (NPC) rates in <6-month-old infants born to HIV-infected mothers, according to immunization with PPV during pregnancy.
   Methods: NPC was evaluated in 45 term infants born to vaccinated women (PPV+) and in 60 infants in a control group (PPV-), at 2 months (+/- 30 days), 4 months (+/- 30 days), and 6 months (+/- 30 days) of age.
   Results: A total of 82 infants completed the study (at least 2 of 3 evaluations), 35 (77%) in the PPV+ and 47 (78.3%) in the PPV- groups, respectively. Infant gender, HIV infection status, number of adults, children, and smokers in the household, day-care attendance, occurrence of respiratory signs, and cotrimoxazole use were similar in both groups. NPC rates increased equally with age in both groups (2 months = 26.7% vs. 25.6%; 4 months = 34.5% vs. 38.6%; 6 months = 38.7% vs. 56.3%, in PPV+ and PPV-, respectively). After controlling for potential confounders, we found no association between maternal vaccination and infant pneumococcal carriage (adjusted odds ratio = 0.70; 95% confidence interval: 0.23, 2.21)
   Conclusions: Vaccination of HIV-infected mothers with PPV did not protect infants younger than 6 months of age from nasopharyngeal pneumococcal carriage.
C1 [Almeida, Volia de Carvalho; Negrini, Bento V. M.] Univ Fed Sao Carlos, Dept Med Hlth, BR-13565905 Sao Carlos, SP, Brazil.
   [Almeida, Volia de Carvalho; Negrini, Bento V. M.] Univ Fed Sao Carlos, Ctr Biol Sci, BR-13565905 Sao Carlos, SP, Brazil.
   [Cervi, Maria C.; Isaac, Marcia de L.; Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
RP Almeida, VD (corresponding author), Univ Fed Sao Carlos, Dept Med Hlth, Rod Washington Luis,Km 235,Caixa Postal 676, BR-13565905 Sao Carlos, SP, Brazil.
EM volia@ufscar.br
RI Cervi, Maria Celia/P-2567-2016; Negrini, Bento VM/J-6471-2012;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Cervi, Maria Celia/0000-0002-6563-6507; Negrini, Bento
   VM/0000-0002-9835-627X; Mussi-Pinhata, Marisa/0000-0001-8985-1570
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brasil
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [02/01294-3]
FX Support by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brasil
   (FAPESP), grant 02/01294-3 (to M.M.M.P.).
CR Almeida VD, 2009, VACCINE, V27, P3856, DOI 10.1016/j.vaccine.2009.04.018
   Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Calder D, 2009, J TROP PEDIATRICS, V55, P219, DOI 10.1093/tropej/fmp047
   Coles CL, 2001, PEDIATR INFECT DIS J, V20, P289, DOI 10.1097/00006454-200103000-00014
   Facklam R, 1991, MANUAL CLIN MICROBIO, P238
   Finkelstein JA, 2003, PEDIATRICS, V112, P862, DOI 10.1542/peds.112.4.862
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668
   Labout JAM, 2008, J PEDIATR-US, V153, P771, DOI 10.1016/j.jpeds.2008.05.061
   Leibovitz E, 1999, Int J Infect Dis, V3, P211, DOI 10.1016/S1201-9712(99)90027-9
   Lopes CRC, 2009, BRAZ J INFECT DIS, V13, P104, DOI 10.1590/S1413-86702009000200008
   Lopez-Palomo C, 2004, J MED VIROL, V72, P517, DOI 10.1002/jmv.20045
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   Mantese Orlando C., 2003, J. Pediatr. (Rio J.), V79, P537, DOI 10.1590/S0021-75572003000600013
   Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17
   Munoz FM, 2001, VACCINE, V20, P826, DOI 10.1016/S0264-410X(01)00397-8
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6
   Polack FP, 2000, PEDIATR INFECT DIS J, V19, P608, DOI 10.1097/00006454-200007000-00005
   Quiambao BP, 2007, VACCINE, V25, P4470, DOI 10.1016/j.vaccine.2007.03.021
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547
   Rusen ID, 1997, PEDIATR INFECT DIS J, V16, P656, DOI 10.1097/00006454-199707000-00007
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   SMITH T, 1993, EPIDEMIOL INFECT, V111, P27, DOI 10.1017/S0950268800056648
   Takahashi H, 2003, CLIN INFECT DIS, V37, P1534, DOI 10.1086/379511
   Woolfson A, 1997, B WORLD HEALTH ORGAN, V75, P453
   World Health Organization, 2005, WHO TECHNICAL REPORT
   Yomo A, 1997, ANN TROP PAEDIATR, V17, P239, DOI 10.1080/02724936.1997.11747894
NR 29
TC 13
Z9 14
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2011
VL 30
IS 6
BP 466
EP 470
DI 10.1097/INF.0b013e31820a1ec6
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 770OB
UT WOS:000291095600007
PM 21200361
DA 2020-12-17
ER

PT J
AU Peixoto, MF
   Pilotto, JH
   Stoszek, SK
   Kreitchmann, R
   Mussi-Pinhata, MM
   Melo, VH
   Joao, EC
   Ceriotto, M
   de Souza, RD
   Read, J
AF Peixoto, Mario Ferreira
   Pilotto, Jose Henrique
   Stoszek, Sonia Karolina
   Kreitchmann, Regis
   Mussi-Pinhata, Marisa Marcia
   Melo, Victor Hugo
   Joao, Esau Custodio
   Ceriotto, Mariana
   de Souza, Ricardo da Silva
   Read, Jennifer
TI Lopinavir/ritonavir dosing during pregnancy in Brazil and
   maternal/infant laboratory abnormalities
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE pregnancy; HIV; HIV protease inhibitors; drug toxicity
ID LOPINAVIR-RITONAVIR; PROTEASE INHIBITORS; WOMEN; PHARMACOKINETICS;
   TOXICITY; EXPOSURE; BINDING; REGIMEN; TRIAL
AB Objectives: To describe laboratory abnormalities among HIV-infected women and their infants with standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy. Methods: We evaluated data on pregnant women from NISDI cohorts (2002-2009) enrolled in Brazil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to singleton infants. Results: 164 women received LPV/r standard dosing [(798/198 or 800/200 mg/day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts >= 500 cells/mm(3). Mean plasma viral load was higher in Group 2. There were statistically significant, but not clinically meaningful, differences between groups in mean AST, ALT, cholesterol, and triglycerides. The proportion of women with Grade 3 or 4 adverse events was very low, with no statistically significant differences between groups in severe adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides. There were statistically significant, but not clinically meaningful, differences between infant groups in ALT and creatinine. The proportion of infants with Grade 3 or 4 adverse events was very low, and there were no statistically significant differences in severe adverse events related to ALT, AST, BUN, or creatinine. Conclusion: The proportions of women and infants with severe laboratory adverse events were very low. Increased LPV/r dosing during the third trimester of pregnancy appears to be safe for HIV-infected women and their infants.
C1 [Peixoto, Mario Ferreira] Hosp Femina, Unidade Prevencao Transmissao Vert, Porto Alegre, RS, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Lab AIDS & Imunol Mol, IOC Fiocruz, Rio De Janeiro, Brazil.
   [Stoszek, Sonia Karolina] Westat Corp, Rockville, MD USA.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Melo, Victor Hugo] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Joao, Esau Custodio] Hosp Servidores Estado, Rio De Janeiro, Brazil.
   [Ceriotto, Mariana] Hosp Agudos Dra Cecilia Grierson, Buenos Aires, DF, Argentina.
   [de Souza, Ricardo da Silva] Univ Caxias Sul, STD HIV Clin, Caxias Do Sul, RS, Brazil.
   [Read, Jennifer] NICHD, Pediat Adolescent & Maternal AIDS Branch, CRMC, NIH, Bethesda, MD USA.
RP Peixoto, MF (corresponding author), Serv Infectiol, Rua Mostardeiro,17-4 Andar, BR-90430000 Porto Alegre, RS, Brazil.
EM peixoto3@terra.com.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Pilotto, Jose Henrique/AAD-9773-2019
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Joao, Esau/0000-0002-2412-0627;
   Kreitchmann, Regis/0000-0002-1146-0497
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-HD-3-3345, HHSN267200800001C, N01-HD-8-0001]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [N01HD033345, N01HD033345,
   N01HD033345] Funding Source: NIH RePORTER
FX This study was supported by the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development NICHD Contract #
   N01-HD-3-3345 (2002-2007) and by NICHD Contract # HHSN267200800001C
   (NICHD Control #: N01-HD-8-0001) (2007-2012)
CR Anderson GD, 2005, CLIN PHARMACOKINET, V44, P989, DOI 10.2165/00003088-200544100-00001
   [Anonymous], 2010, REC US ANT DRUGS PRE, P1
   Aweeka FT, 2010, HIV MED, V11, P232, DOI 10.1111/j.1468-1293.2009.00767.x
   Azria E, 2009, ANTIVIR THER, V14, P423
   Barone Sylvain, 2008, THER DRUG MONIT
   Best BM, 2010, JAIDS-J ACQ IMM DEF, V54, P381, DOI 10.1097/QAI.0b013e3181d6c9ed
   Bongiovanni M, 2005, INT J ANTIMICROB AG, V26, P88, DOI 10.1016/j.ijantimicag.2005.03.003
   Cohen C, 2005, CURR MED RES OPIN, V21, P1683, DOI 10.1185/030079905X65439
   Dragsted UB, 2005, ANTIVIR THER, V10, P735
   Gulati A, 2009, DRUG METAB DISPOS, V37, P1572, DOI 10.1124/dmd.109.026708
   Lafeuillade A, 2004, HIV CLIN TRIALS, V5, P392, DOI 10.1310/Q0TG-0V50-9JML-638U
   Loebstein R, 1997, CLIN PHARMACOKINET, V33, P328, DOI 10.2165/00003088-199733050-00002
   Manavi K, 2007, AIDS, V21, P643, DOI 10.1097/QAD.0b013e328031f42e
   McArthur MA, 2009, PEDIATR INFECT DIS J, V28, P1127, DOI 10.1097/INF.0b013e3181acd17e
   *MIN SANT FRANC, 2008, POINTS FORTS REC EXT
   *MIN SAUD BRAS, 2009, REC PROF TRANSM VERT
   Mirochnick M, 2002, PEDIATR INFECT DIS J, V21, P835, DOI 10.1097/00006454-200209000-00010
   Palacios R, 2006, HIV CLIN TRIALS, V7, P319, DOI 10.1310/hct0706-319
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   READ JS, 2005, TXB PEDIAT HIV CARE, P111
   Robbins BL, 2008, ANTIMICROB AGENTS CH, V52, P3276, DOI 10.1128/AAC.00224-08
   Roustit M, 2008, BRIT J CLIN PHARMACO, V66, P179, DOI 10.1111/j.1365-2125.2008.03220.x
   Stek AM, 2006, AIDS, V20, P1931, DOI 10.1097/01.aids.0000247114.43714.90
   Szyld EG, 2006, AIDS, V20, P2345, DOI 10.1097/01.aids.0000253362.01696.9d
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
NR 25
TC 6
Z9 6
U1 0
U2 2
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2011
VL 15
IS 3
BP 253
EP 261
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 777JY
UT WOS:000291613000013
PM 21670927
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Gaur, AH
   Freimanis-Hance, L
   Dominguez, K
   Mitchell, C
   Menezes, J
   Mussi-Pinhata, MM
   Peixoto, MF
   Alarcon, J
   Coelho, DF
   Read, JS
AF Gaur, Aditya H.
   Freimanis-Hance, Laura
   Dominguez, Kenneth
   Mitchell, Charles
   Menezes, Jacqueline
   Mussi-Pinhata, Marisa M.
   Peixoto, Mario F.
   Alarcon, Jorge
   Coelho, Debora F.
   Read, Jennifer S.
TI Knowledge and Practice of Prechewing/Prewarming Food by HIV-Infected
   Women
SO PEDIATRICS
LA English
DT Article
DE HIV; prechewing; prewarming; premastication; child
ID INFANT; PREMASTICATION
AB OBJECTIVE: HIV transmission has been associated with offering a child food prechewed by an HIV-infected caregiver. We assessed awareness of prechewing and oral prewarming of food by an adult before offering it to a child among HIV-infected pregnant women and clinical investigators in 3 Latin American countries.
   METHODS: HIV-infected pregnant women at 12 sites (Eunice Kennedy Shriver National Institute of Child Health and Human Development International Site Development Initiative Perinatal Longitudinal Study in Latin American Countries, a prospective cohort trial) in Argentina, Brazil, and Peru were administered a screening survey about prechewing/prewarming of infant foods and cautioned against these feeding practices. Survey responses were analyzed, overall, and stratified according to country.
   RESULTS: Of the 401 HIV-infected pregnant women interviewed, 34% had heard about prechewing (50% from Argentina, 32% from Brazil, and 36% from Peru), 23% knew someone who prechewed food for infants, and 4% had prechewed food in the past. Seventeen percent had heard about oral prewarming of food, 13% knew someone who prewarmed food for infants, and 3% had prewarmed food for an infant in the past. Women who reported knowing someone who prechewed were more likely to also know someone who prewarmed food (P < .0001). Few site investigators anticipated that their patients would be aware of these practices.
   CONCLUSIONS: Prechewing food, a potential risk factor for HIV transmission, and orally prewarming food, which has not been associated with HIV transmission but might expose a child to blood from an HIV-infected adult, are not uncommon practices in Latin America. Both practices should be further investigated. Site investigator responses underscore that health care providers could be missing information about cultural practices that patients may not report unless specifically asked. Pediatrics 2011;127:e1206-e1211
C1 [Gaur, Aditya H.] St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
   [Freimanis-Hance, Laura] Westat Corp, Rockville, MD USA.
   [Dominguez, Kenneth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Mitchell, Charles] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
   [Menezes, Jacqueline] Hosp Servidores Estado, Policlin Santa Clara, Unidade Pesquisa Materno Infantil, Rio De Janeiro, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Peixoto, Mario F.] Hosp Femina, Dept Infect Dis, Porto Alegre, RS, Brazil.
   [Alarcon, Jorge] Univ Nacl Mayor San Marcos, Inst Med Trop Daniel Alcides Carrion, Secc Epidemiol, Lima 14, Peru.
   [Coelho, Debora F.] Irmandade Santa Casa de Misericordia, Serv Doencas Infecciosas & Parasitarias, Porto Alegre, RS, Brazil.
   [Read, Jennifer S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD 20892 USA.
RP Gaur, AH (corresponding author), St Jude Childrens Hosp, Dept Infect Dis MS 600, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM aditya.gaur@stjude.org
RI Gaur, Aditya H/N-8057-2018; Mussi-Pinhata, Marisa/G-6568-2012
OI Gaur, Aditya H/0000-0002-6639-5231; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; NICHDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [N01-HD-3-3345, HHSN267200800001C,
   N01-HD-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH RePORTER
FX Funded by the National Institutes of Health (NIH).; Principal
   investigators, co-principal investigators, study coordinators,
   coordinating center representatives, and NICHD staff include: Argentina:
   Buenos Aires: Marcelo H. Losso, Irene Foradori, Claudia Checa, Silvina
   Ivalo (Hospital General de Agudos Jose Maria Ramos Mejia); Brazil: Belo
   Horizonte: Jorge Pinto, Victor Melo, Fabiana Kakehasi (Universidade
   Federal de Minas Gerais); Caxias do Sul: Ricardo da Silva de Souza,
   Nicole Golin, S~lvia Mariani Costamilan (Universidade de Caxias do
   Sul/Servico Municipal de Infectologia); Nova Iguacu: Jose Pilotto,
   Beatriz Grinsztejn, Valdilea Veloso, Gisely Falco (Hospital Geral Nova
   de Iguacu - HIV Family Care Clinic); Porto Alegre: Ricardo da Silva de
   Souza, Breno Riegel Santos, Rita de Cassia Alves Lira (Universidade de
   Caxias do Sul/Hospital Conceicao); Ricardo da Silva de Souza, Mario
   Ferreira Peixoto, Elizabete Teles (Universidade de Caxias do
   Sul/Hospital Famina); Regis Kreitchmann, Luis Carlos Ribeiro, Fabrizio
   Motta, Debora Fernandes Coelho (Irmandade da Santa Casa de Misericordia
   de Porto Alegre); Ribeirao Preto: Marisa M. Mussi-Pinhata, Geraldo
   Duarte, Adriana A. Tiraboschi Barbaro, Conrado Milani Coutinho, Anderson
   Sanches de Melo (Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto da Universidade de Sao Paulo); Rio de Janeiro: Ricardo
   Hugo S. Oliveira, Elizabeth S. Machado, Maria C. Chermont Sapia
   (Instituto de Puericultura e Pediatria Martagao Gesteira); Esau Custodio
   Joao, Leon Claude Sidi, Ezequias Martins, Plinio Tostes Berardo
   (Hospital dos Servidores do Estado); Sao Paulo: Regina Celia de Menezes
   Succi, Prescilla Chow (Universidade Federal de Sao Paulo); Peru: Lima:
   Jorge Alarcon Villaverde (Instituto de Medicina Tropical "Daniel Alcides
   Carrion"-Seccion de Epidemiologia, UNMSM), Carlos Velasquez Vasquez
   (Instituto Nacional Materno Perinatal), Cesar Gutierrez Villafuerte
   (Instituto de Medicina Tropical "Daniel Alcides Carrion"-Seccion de
   Epidemiologia, UNMSM); Data Management and Statistical Center: Yolanda
   Bertucci, Laura Freimanis Hance, Rene Gonin, D. Robert Harris, Roslyn
   Hennessey, James Korelitz, Margot Krauss, Sharon Sothern de Sanchez,
   Sonia K. Stoszek (Westat, Rockville, MD, USA); NICHD: Rohan Hazra, Lynne
   Mofenson, Jennifer S. Read, Heather Watts, Carol Worrell (Eunice Kennedy
   Shriver National Institute of Child Health and Human Development,
   Bethesda, Maryland, USA). Supported by NICHD Contract # N01-HD-3-3345
   (2002-2007) and by NICHD Contract # HHSN267200800001C (NICHD Control #:
   N01-HD-8-0001) (2007-2012).
CR Aggett P, 2010, MATERN CHILD NUTR, V6, P2, DOI 10.1111/j.1740-8709.2009.00226.x
   Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1
   Bulkow LR, 2002, PEDIATRICS, V109, P210, DOI 10.1542/peds.109.2.210
   Gaur AH, 2009, PEDIATRICS, V124, P658, DOI 10.1542/peds.2008-3614
   HENNART P, 1980, J TROP PEDIATRICS, V26, P177, DOI 10.1093/tropej/26.5.177
   Huang M J, 1990, Zhonghua Liu Xing Bing Xue Za Zhi, V11, P129
   IMONG SM, 1995, J TROP PEDIATRICS, V41, P234, DOI 10.1093/tropej/41.4.234
   Lewis Charlotte W, 2002, Alaska Med, V44, P83
   Mbulaiteye SM, 2006, J INFECT DIS, V193, P422, DOI 10.1086/499277
   Mbulaiteye SM, 2003, J INFECT DIS, V187, P1780, DOI 10.1086/374973
   NEANDER WL, 1989, CAN J PUBLIC HEALTH, V80, P190
   Pelto GH, 2010, MATERN CHILD NUTR, V6, P4, DOI 10.1111/j.1740-8709.2009.00200.x
   RADBILL SX, 1981, CLIN PEDIATR, V20, P613, DOI 10.1177/000992288102001001
   STEINKULLER JS, 1992, J PEDIATR-US, V120, P563, DOI 10.1016/S0022-3476(05)82483-7
   TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078
   Van Esterik P, 2010, MATERN CHILD NUTR, V6, P19, DOI 10.1111/j.1740-8709.2009.00227.x
   WALBURN JN, 1988, PEDIATRICS, V82, P789
   HUMAN RELATIONS AREA
NR 18
TC 5
Z9 5
U1 0
U2 3
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2011
VL 127
IS 5
BP E1206
EP E1211
DI 10.1542/peds.2010-1902
PG 6
WC Pediatrics
SC Pediatrics
GA 757OO
UT WOS:000290097800014
PM 21482608
OA Green Published
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Motta, F
   Freimanis-Hance, L
   de Souza, R
   Szyld, E
   Succi, RCM
   Christie, CDC
   Rolon, MJ
   Ceriotto, M
   Read, JS
AF Mussi-Pinhata, Marisa M.
   Motta, Fabrizio
   Freimanis-Hance, Laura
   de Souza, Ricardo
   Szyld, Edgardo
   Succi, Regina C. M.
   Christie, Celia D. C.
   Rolon, Maria J.
   Ceriotto, Mariana
   Read, Jennifer S.
TI Lower respiratory tract infections among human immunodeficiency
   virus-exposed, uninfected infants
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-exposed; Infancy; Infections; Latin America
ID SYNCYTIAL VIRUS; IMMUNE-RESPONSES; LATIN-AMERICAN; RISK-FACTORS;
   MORBIDITY; CHILDREN; DISEASE; BRONCHIOLITIS; LYMPHOCYTES; MORTALITY
AB Objectives: To evaluate whether maternal HIV disease severity during pregnancy is associated with an increased likelihood of lower respiratory tract infections (LRTIs) in HIV-exposed, uninfected infants.
   Methods: HIV-exposed, uninfected, singleton, term infants enrolled in the NISDI Perinatal Study, with birth weight >2500 g were followed from birth until 6 months of age. LRTI diagnoses, hospitalizations, and associated factors were assessed.
   Results: Of 547 infants, 103 (18.8%) experienced 116 episodes of LRTI (incidence = 0.84 LRTIs/100 child-weeks). Most (81%) episodes were bronchiolitis. Forty-nine (9.0%) infants were hospitalized at least once with an LRTI. There were 53 hospitalizations (45.7%) for 116 LRTI episodes. None of these infants were breastfed. The odds of LRTI in infants whose mothers had CD4% <14 at enrollment were 4.4 times those of infants whose mothers had CD4% >= 29 (p = 0.003). The odds of LRTI in infants with a CD4+ count (cells/ mm(3)) <750 at hospital discharge were 16.0 times those of infants with CD4+ >= 750 (p = 0.002). Maternal CD4+ decline and infant hemoglobin at the 6-12 week visit were associated with infant LRTIs after 6-12 weeks and before 6 months of age.
   Conclusions: Acute bronchiolitis is common and frequently severe among HIV-exposed, uninfected infants aged 6 months or less. Lower maternal and infant CD4+ values were associated with a higher risk of infant LRTIs. Further understanding of the immunological mechanisms of severe LRTIs is needed. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Mussi-Pinhata, Marisa M.; Motta, Fabrizio] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Freimanis-Hance, Laura] WESTAT Corp, Rockville, MD 20850 USA.
   [de Souza, Ricardo] Univ Caxias Sul, Rio Grande Do Sul, Brazil.
   [Szyld, Edgardo] Hosp Diego Paroissien, Buenos Aires, DF, Argentina.
   [Succi, Regina C. M.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Christie, Celia D. C.] Univ W Indies, Kingston 7, Jamaica.
   [Rolon, Maria J.] Hosp Juan Fernandez, Buenos Aires, DF, Argentina.
   [Ceriotto, Mariana] Hosp Agudos Dra Cecilia Grierson, Buenos Aires, DF, Argentina.
   [Read, Jennifer S.] NICHD, Pediat Adolescent & Maternal AIDS Branch, CRMC, NIH,DHHS, Bethesda, MD USA.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Pinto, Jorge A/D-1743-2014; Mussi-Pinhata, Marisa/G-6568-2012; Pilotto,
   Jose Henrique/AAD-9773-2019
OI Pinto, Jorge A/0000-0003-2987-3238; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pilotto, Jose Henrique/0000-0003-0521-8597
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   HHSN267200800001C, N01-DK-8-0001]
FX This study was supported financially by NICHD Contract No. N01-HD-3-3345
   and No. HHSN267200800001C (NICHD Control No. N01-DK-8-0001).
CR Albernaz EP, 2003, REV SAUDE PUBL, V37, P485, DOI 10.1590/S0034-89102003000400014
   [Anonymous], 2006, Arch. argent. pediatr., V104, P159
   Bout L, 2002, INTENS CARE MED, V28, P616, DOI 10.1007/s00134-002-1256-z
   Cardoso MRA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-19
   Cashat-Cruz Miguel, 2005, Semin Pediatr Infect Dis, V16, P84, DOI 10.1053/j.spid.2005.12.005
   *CDCP, 1992, MMWR-MORBID MORTAL W, V41
   Centers for Disease Control and Prevention, 2010, SAS PROGR CDC GROWTH
   Chougnet C, 2000, J INFECT DIS, V181, P1590, DOI 10.1086/315458
   Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871
   DAINIAK N, 1988, BRIT J HAEMATOL, V69, P299, DOI 10.1111/j.1365-2141.1988.tb02366.x
   Escuder MML, 1999, REV SAUDE PUBL, V33, P349, DOI 10.1590/S0034-89101999000400005
   Fiore S, 2006, J REPROD IMMUNOL, V70, P143, DOI 10.1016/j.jri.2005.12.001
   Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057
   GESNER M, 1994, PEDIATRICS, V93, P624
   Jeena PM, 2003, SAMJ S AFR MED J, V93, P291
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Kuhn L, 2002, CLIN INFECT DIS, V34, P267, DOI 10.1086/338153
   Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3
   Law BJ, 2002, RESP MED, V96, pS1, DOI 10.1053/rmed.2002.1294
   Melendi GA, 2007, PEDIATRICS, V120, pE410, DOI 10.1542/peds.2006-3283
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   *NAT I ALL INF DIS, 2004, TABL GRAD SEV AD PED
   Nielsen SD, 2001, BLOOD, V98, P398, DOI 10.1182/blood.V98.2.398
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8
   Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997
   Shapiro RL, 2007, J INFECT DIS, V196, P562, DOI 10.1086/519847
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Van Rie A, 2006, CLIN VACCINE IMMUNOL, V13, P246, DOI 10.1128/CVI.13.2.246-252.2006
   Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5
NR 30
TC 26
Z9 26
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2010
VL 14
SU 3
BP E176
EP E182
DI 10.1016/j.ijid.2010.01.006
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 660LA
UT WOS:000282643000035
PM 20452798
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Procianoy, RS
   Silveira, RC
   Mussi-Pinhata, MM
   Rugolo, LMSS
   Leone, CR
   Lopes, JMD
   de Almeida, MFB
AF Procianoy, Renato S.
   Silveira, Rita C.
   Mussi-Pinhata, Marisa M.
   Souza Rugolo, Ligia Maria S.
   Leone, Clea R.
   de Andrade Lopes, Jose Maria
   de Almeida, Maria Fernanda B.
CA Brazilian Network Neonatal Res
TI Sepsis and Neutropenia in Very Low Birth Weight Infants Delivered of
   Mothers with Preeclampsia
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID NEONATAL RESEARCH NETWORK; COLONY-STIMULATING FACTOR; MATERNAL
   HYPERTENSION; NOSOCOMIAL INFECTION; NATIONAL-INSTITUTE; PRETERM
   DELIVERY; ONSET SEPSIS; CHILD-HEALTH; RISK; PREGNANCIES
AB Objective To study the association between maternal preeclampsia and neonatal sepsis in very low birth weight newborns.
   Study design We studied all infants with birth weights between 500 g and 1500 g who were admitted to 6 neonatal intensive care units of the Brazilian Network on Neonatal Research for 2 years. Exclusion criteria were major malformations, death in the delivery room, and maternal chronic hypertension. Absolute neutrophil count was performed in the first 72 hours of life.
   Results A total of 911 very low birth weight infants (preeclampsia, 308; non-preeclampsia, 603) were included. The preeclampsia group had significantly higher gestational age, more cesarean deliveries, antenatal steroid, central catheters, total parenteral nutrition, and neutropenia, and less rupture of membranes >18 hours and mechanical ventilation. Both groups had similar incidences of early sepsis (4.6% and 4.2% in preeclampsia and non-preeclampsia groups, respectively) and late sepsis (24% and 22.1% in preeclampsia and non-preeclampsia groups, respectively). Vaginal delivery and neutropenia were associated with multiple logistic regressions with early sepsis, and mechanical ventilation, central catheter, and total parenteral nutrition were associated with late sepsis. Death was associated with neutropenia in very preterm infants.
   Conclusions Preeclampsia did not increase neonatal sepsis in very low birth weight infants, and death was associated with neutropenia in very preterm infants. (J Pediatr 2010; 157: 434-8).
C1 [Procianoy, Renato S.; Silveira, Rita C.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Hosp Clin, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Souza Rugolo, Ligia Maria S.] Univ Estadual Paulista, Hosp Clin, Fac Med Botucatu, Botucatu, SP, Brazil.
   [Leone, Clea R.] Univ Sao Paulo, Hosp Clin Sao Paulo, Sao Paulo, Brazil.
   [de Andrade Lopes, Jose Maria] Fundacao Osvaldo Cruz, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [de Almeida, Maria Fernanda B.] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
RP Procianoy, RS (corresponding author), Rua Tobias Silva 99 Conj 302, BR-90570020 Porto Alegre, RS, Brazil.
EM renatosp@terra.com.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Leone, Clea/ABA-6374-2020; Procianoy,
   Renato/I-5133-2014; Rugolo, Ligia Maria/G-1628-2013; de Souza Machado,
   Adelmir/F-7822-2012; Bentlin, Maria Regina/H-6282-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Procianoy,
   Renato/0000-0001-8297-4164; Rugolo, Ligia Maria/0000-0002-1550-0740;
   Bentlin, Maria Regina/0000-0001-7310-0895
CR Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X
   [Anonymous], 2000, AM J OBSTET GYNECOL, V183, P51
   Aslan H, 2004, GYNECOL OBSTET INVES, V58, P96, DOI 10.1159/000078679
   Basso O, 2006, JAMA-J AM MED ASSOC, V296, P1357, DOI 10.1001/jama.296.11.1357
   Bhaumik S, 2000, Indian Pediatr, V37, P775
   CADNAPAPHORNCHAI M, 1992, J PEDIATR-US, V121, P956, DOI 10.1016/S0022-3476(05)80351-8
   CHRISTENSEN RD, 1980, J PEDIATR-US, V96, P316, DOI 10.1016/S0022-3476(80)80837-7
   DORON MW, 1994, J PEDIATR-US, V125, P452, DOI 10.1016/S0022-3476(05)83294-9
   FRIEDMAN SA, 1995, AM J OBSTET GYNECOL, V172, P1785, DOI 10.1016/0002-9378(95)91412-9
   Funke A, 2000, PEDIATRICS, V106, P45, DOI 10.1542/peds.106.1.45
   Kocherlakota P, 1998, PEDIATRICS, V102, P1107, DOI 10.1542/peds.102.5.1107
   KOENIG JM, 1989, NEW ENGL J MED, V321, P557, DOI 10.1056/NEJM198908313210901
   LAGAMMA EF, 1995, J PEDIATR-US, V126, P457, DOI 10.1016/S0022-3476(95)70469-8
   MAKHLOUF RA, 1995, J PEDIATR-US, V126, P454, DOI 10.1016/S0022-3476(95)70468-X
   MANROE BL, 1977, J PEDIATR-US, V91, P632, DOI 10.1016/S0022-3476(77)80522-2
   MANROE BL, 1979, J PEDIATR-US, V95, P89, DOI 10.1016/S0022-3476(79)80096-7
   MOUZINHO A, 1994, PEDIATRICS, V94, P76
   MOUZINHO A, 1992, PEDIATRICS, V90, P430
   Ngoc NTN, 2006, B WORLD HEALTH ORGAN, V84, P699
   Palta M, 2008, J PERINATOL, V28, P604, DOI 10.1038/jp.2008.65
   Paul DA, 1999, AM J PERINAT, V16, P365, DOI 10.1055/s-2007-993886
   SOMAN M, 1985, AM J EPIDEMIOL, V121, P712, DOI 10.1093/aje/121.5.712
   Stoll BJ, 2005, PEDIATR INFECT DIS J, V24, P635, DOI 10.1097/01.inf.0000168749.82105.64
   Stoll BJ, 2003, SEMIN PERINATOL, V27, P293, DOI 10.1016/S0146-0005(03)00046-6
   Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285
   Stoll BJ, 1996, J PEDIATR-US, V129, P72, DOI 10.1016/S0022-3476(96)70192-0
   Zook KJ, 2009, J PERINATOL, V29, P8, DOI 10.1038/jp.2008.104
   Zuppa AA, 2002, EUR J OBSTET GYN R B, V102, P131, DOI 10.1016/S0301-2115(01)00601-7
   PNEUMONIA FLOW DIAGR
NR 29
TC 17
Z9 17
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
J9 J PEDIATR-US
JI J. Pediatr.
PD SEP
PY 2010
VL 157
IS 3
BP 434
EP U118
DI 10.1016/j.jpeds.2010.02.066
PG 6
WC Pediatrics
SC Pediatrics
GA 641HT
UT WOS:000281116100020
PM 20400101
DA 2020-12-17
ER

PT J
AU Rego, MAC
   Martinez, FE
   Elias, J
   Mussi-Pinhata, MM
AF Rego, Maria Aparecida C.
   Martinez, Francisco Eulogio
   Elias, Jorge, Jr.
   Mussi-Pinhata, Marisa Marcia
TI Diagnostic value of interleukin-6 and C-reactive protein on early onset
   bacterial infection in preterm neonates with respiratory distress
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE C-reactive protein; cytokine; early onset neonatal sepsis;
   interleukin-6; neonatal respiratory distress syndrome; neonatal sepsis;
   preterm infant
ID TUMOR-NECROSIS-FACTOR; IMMEDIATE POSTNATAL-PERIOD; FACTOR-ALPHA; ILLNESS
   SEVERITY; NEWBORN-INFANTS; PLASMA-LEVELS; SEPSIS; PROCALCITONIN;
   MARKERS; RECEPTORS
AB Aims: To evaluate the C-reactive protein (CRP) and interleukin-6 (IL-6) as diagnostic tools for early onset infection in preterm infants with early respiratory distress (RD).
   Methods: CRP and IL-6 were quantified at identification of RD and 24 h after in 186 newborns. Effects of maternal hypertension, mode of delivery, Apgar score, birth weight, gestational age, mechanical ventilation, being small for gestational age (SGA), and the presence of infection were analyzed.
   Results: Forty-four infants were classified as infected, 42 as possibly infected, and 100 as uninfected. Serum levels of IL-6 (0 h), CRP (0 h), and CRP (24 h), but not IL-6 (24 h) were significantly higher in infected infants compared to the remaining groups. The best test for identification of infection was the combination of IL-6 (0 h) 36 pg/dL and/or CRP (24 h) 0.6 mg/dL, which yielded 93% sensitivity and 37% specificity. The presence of infection and vaginal delivery independently increased IL-6 (0 h), CRP (0 h) and CRP (24 h) levels. Being SGA also increased the CRP (24 h) levels. IL-6 (24 h) was independently increased by mechanical ventilation.
   Conclusions: The combination of IL-6 (0 h) and/or CRP (24 h) is helpful for excluding early onset infection in preterm infants with RD but the poor specificity limits its potential benefit as a diagnostic tool.
C1 [Rego, Maria Aparecida C.; Martinez, Francisco Eulogio; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Elias, Jorge, Jr.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Radiol, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Martinez, Francisco E/H-1194-2014;
   Junior, Jorge Elias/A-6683-2008
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Martinez, Francisco
   E/0000-0002-6269-9182; Junior, Jorge Elias/0000-0002-1158-1045
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   BrazilCAPES
FX We are grateful to the nursing and medical staff of the NICU of Hospital
   das Clinicas de Ribeirao Preto, University of Sao Paulo (HCFMRP-USP) for
   their collaboration in the process of recruiting patients for the study,
   and to Davi C. Aragon for his assistance with the multiple linear
   regression statistical analysis. This study was partially funded by
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazil.
CR Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X
   Attar Mohammad Ali, 2002, Semin Neonatol, V7, P353, DOI 10.1053/siny.2002.0129
   BAKER CJ, 1988, ANN NY ACAD SCI, V549, P193, DOI 10.1111/j.1749-6632.1988.tb23972.x
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   BATAILLE R, 1992, ARTHRITIS RHEUM-US, V35, P982, DOI 10.1002/art.1780350824
   Benitz WE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.4.e41
   Berner R, 1998, PEDIATR RES, V44, P469, DOI 10.1203/00006450-199810000-00002
   BUCK C, 1994, PEDIATRICS, V93, P54
   Chiesa C, 2003, CLIN CHEM, V49, P60, DOI 10.1373/49.1.60
   Chiesa C, 2001, CLIN CHEM, V47, P1016
   De Jongh RF, 1999, AM J PERINAT, V16, P121, DOI 10.1055/s-2007-993845
   Doellner H, 1998, J PEDIATR-US, V132, P295, DOI 10.1016/S0022-3476(98)70448-2
   Dollner H, 2001, J CLIN EPIDEMIOL, V54, P1251, DOI 10.1016/S0895-4356(01)00400-0
   Dollner H, 2001, BIOL NEONATE, V80, P41, DOI 10.1159/000047118
   Franz AR, 1999, PEDIATR INFECT DIS J, V18, P666, DOI 10.1097/00006454-199908000-00003
   Franz AR, 2001, ACTA PAEDIATR, V90, P1025, DOI 10.1080/080352501316978110
   GERDES JS, 1987, PEDIATR INFECT DIS J, V6, P443, DOI 10.1097/00006454-198705000-00005
   GRACIA SR, 2003, AN PEDIATR, V59, P246
   HANEY PJ, 1984, AM J ROENTGENOL, V143, P23, DOI 10.2214/ajr.143.1.23
   Janota J, 2000, Ceska Gynekol, V65 Suppl 1, P29
   Jokic M, 2000, BRIT J OBSTET GYNAEC, V107, P420, DOI 10.1111/j.1471-0528.2000.tb13241.x
   Joram N, 2006, ARCH DIS CHILD-FETAL, V91, pF65, DOI 10.1136/adc.2005.074245
   Kallman J, 1999, ACTA PAEDIATR, V88, P880, DOI 10.1080/08035259950168829
   Martin H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e61
   Mathai Elizabeth, 2004, Indian Pediatr, V41, P895
   MATHERS NJ, 1987, EUR J PEDIATR, V146, P147, DOI 10.1007/BF02343221
   Mehr S, 2000, PEDIATR INFECT DIS J, V19, P879, DOI 10.1097/00006454-200009000-00014
   Messer J, 1996, J PEDIATR-US, V129, P574, DOI 10.1016/S0022-3476(96)70123-3
   Panero A, 1997, PEDIATR INFECT DIS J, V16, P370, DOI 10.1097/00006454-199704000-00007
   PHILIP AGS, 1980, PEDIATRICS, V65, P1036
   Resch B, 2003, ACTA PAEDIATR, V92, P243, DOI 10.1111/j.1651-2227.2003.tb00534.x
   Richardosn DK, 2001, J PEDIATR-US, V138, P92, DOI 10.1067/mpd.2001.109608
   RODWELL RL, 1988, J PEDIATR-US, V112, P761, DOI 10.1016/S0022-3476(88)80699-1
   Romagnoli C, 2001, EUR J PEDIATR, V160, P345, DOI 10.1007/PL00008445
   Silveira RC, 1999, ACTA PAEDIATR, V88, P647, DOI 10.1080/08035259950169314
   Stoll BJ, 2005, PEDIATR INFECT DIS J, V24, P635, DOI 10.1097/01.inf.0000168749.82105.64
   SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615
   WAGLE S, 1994, J PAEDIATR CHILD H, V30, P40, DOI 10.1111/j.1440-1754.1994.tb00564.x
   ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523
NR 39
TC 10
Z9 10
U1 0
U2 6
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD SEP
PY 2010
VL 38
IS 5
BP 527
EP 533
DI 10.1515/JPM.2010.071
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 646TT
UT WOS:000281566600012
PM 20443669
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Boppana, SB
   Novak, Z
   Wagatsuma, VM
   Oliveira, PD
   Duarte, G
   Britt, WJ
AF Yamamoto, Aparecida Yulie
   Mussi-Pinhata, Marisa Marcia
   Boppana, Suresh B.
   Novak, Zdenek
   Wagatsuma, Virginia M.
   Oliveira, Patricia de Frizzo
   Duarte, Geraldo
   Britt, William J.
TI Human cytomegalovirus reinfection is associated with intrauterine
   transmission in a highly cytomegalovirus-immune maternal population
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE congenital cytomegalovirus infection; cytomegalovirus reinfection;
   maternal reinfection with cytomegalovirus
ID ANTIVIRAL ANTIBODY-RESPONSES; NEWBORN-INFANTS; RELATIVE IMPORTANCE;
   INFECTION; MOTHERS; STRAIN; WOMEN; BORN; CMV; PREVENTION
AB OBJECTIVE: To determine contribution of reinfection with new strains of cytomegalovirus in cytomegalovirus seromimmune women to incidence of congenital cytomegalovirus infection.
   STUDY DESIGN: In 7848 women studied prospectively for congenital cytomegalovirus infection from a population with near universal cytomegalovirus seroimmunity, sera from 40 mothers of congenitally infected infants and 109 mothers of uninfected newborns were analyzed for strain-specific anticytomegalovirus antibodies.
   RESULTS: All women were cytomegalovirus seroimmune at first prenatal visit. Reactivity for 2 cytomegalovirus strains was found in 14 of 40 study mothers and in 17 of 109 control mothers at first prenatal visit (P=.009). Seven of 40 (17.5%) study women and 5 of 109 (4.6%) controls (P=.002) acquired antibodies reactive with new cytomegalovirus strains during pregnancy. Evidence of infection with more than 1 strain of cytomegalovirus before or during current pregnancy occurred in 21 of 40 study mothers and 22 of 109 controls (P<.0001).
   CONCLUSION: Maternal reinfection by new strains of cytomegalovirus is a major source of congenital infection in this population.
C1 [Yamamoto, Aparecida Yulie; Mussi-Pinhata, Marisa Marcia; Wagatsuma, Virginia M.; Oliveira, Patricia de Frizzo] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Gynecol & Obstet, Sao Paulo, Brazil.
   [Boppana, Suresh B.; Novak, Zdenek; Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA.
   [Boppana, Suresh B.; Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA.
   [Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Neurobiol, Birmingham, AL 35294 USA.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
RI Duarte, Geraldo/J-7906-2012; Wagatsuma, Virginia/F-1643-2013;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Wagatsuma, Virginia/0000-0003-3801-3280; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIAID AI 49537, R03
   TW006480, NIDCD DC04162]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP), BrazilFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [02/04166-6]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959] Funding
   Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R01HD061959] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R03TW006480, R03TW006480, R03TW006480] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI049537, R01AI049537, R01AI049537, R01AI049537, R01AI049537,
   R01AI049537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD)
   [R01DC004163, R01DC004163, R01DC004163, R01DC004163, R01DC004163,
   R01DC004163, R01DC004163, R01DC004163] Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institutes of Health
   (NIAID AI 49537; Fogarty International Center, R03 TW006480, to W. J.
   B., and NIDCD DC04162 to S. B. B.) and Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Brazil, process no. 02/04166-6.
CR ADLER SP, 1995, J INFECT DIS, V171, P26, DOI 10.1093/infdis/171.1.26
   Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969
   Ahlfors K, 2001, PEDIATRICS, V107, P1227, DOI 10.1542/peds.107.5.1227
   AHLFORS K, 1984, SCAND J INFECT DIS, V16, P129, DOI 10.3109/00365548409087131
   Bale JF, 1996, J PEDIATR-US, V128, P347, DOI 10.1016/S0022-3476(96)70279-2
   Bodeus M, 2001, EUR J CLIN MICROBIOL, V20, P248, DOI 10.1007/s100960100484
   BOPPANA SB, 1995, J INFECT DIS, V171, P1115, DOI 10.1093/infdis/171.5.1115
   Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   Bradley AJ, 2008, J MED VIROL, V80, P1615, DOI 10.1002/jmv.21241
   BRITT W, 2007, HUMAN HERPESVIURSES, V1
   BRITT WJ, 1990, J INFECT DIS, V161, P214, DOI 10.1093/infdis/161.2.214
   BRITT WJ, 1990, 8 INT C VIR BERL GER
   Burkhardt C, 2009, J GEN VIROL, V90, P1951, DOI 10.1099/vir.0.010967-0
   CHANDLER SH, 1987, J INFECT DIS, V155, P655, DOI 10.1093/infdis/155.4.655
   Chinnawirotpisan P, 2008, ARCH VIROL, V153, P2225, DOI 10.1007/s00705-008-0249-9
   CHOU SW, 1986, NEW ENGL J MED, V314, P1418, DOI 10.1056/NEJM198605293142205
   Dahle A J, 2000, J Am Acad Audiol, V11, P283
   Daiminger A, 1999, J CLIN VIROL, V13, P161, DOI 10.1016/S1386-6532(99)00028-1
   Dal Monte P, 2001, J HUMAN VIROL, V4, P26
   Dar L, 2008, PEDIATR INFECT DIS J, V27, P841, DOI 10.1097/INF.0b013e3181723d55
   Erice A, 2003, CLIN INFECT DIS, V37, P567, DOI 10.1086/375843
   Fowler KB, 2006, J CLIN VIROL, V35, P226, DOI 10.1016/j.jcv.2005.09.016
   Fowler KB, 2003, JAMA-J AM MED ASSOC, V289, P1008, DOI 10.1001/jama.289.8.1008
   GALLOWAY DA, 1990, MOL BIOL MED, V7, P59
   Giroglou T, 2001, VACCINE, V19, P1783, DOI 10.1016/S0264-410X(00)00370-4
   GRUNDY JE, 1987, TRANSPLANT P, V19, P2126
   HARRIS S, 1984, EAR HEARING, V5, P352, DOI 10.1097/00003446-198411000-00006
   HENDRY RM, 1988, J INFECT DIS, V157, P640, DOI 10.1093/infdis/157.4.640
   HICKS T, 1993, J PEDIATR-US, V123, P779, DOI 10.1016/S0022-3476(05)80859-5
   Ishibashi K, 2007, CLIN INFECT DIS, V45, P60, DOI 10.1086/518571
   KNIESS N, 1991, J VIROL, V65, P138, DOI 10.1128/JVI.65.1.138-146.1991
   Lazzarotto T, 1997, CLIN DIAGN LAB IMMUN, V4, P469, DOI 10.1128/CDLI.4.4.469-473.1997
   MEYER H, 1992, J GEN VIROL, V73, P2375, DOI 10.1099/0022-1317-73-9-2375
   MUELENAER PM, 1991, J INFECT DIS, V164, P15, DOI 10.1093/infdis/164.1.15
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   Novak Z, 2009, CLIN VACCINE IMMUNOL, V16, P288, DOI 10.1128/CVI.00281-08
   Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749
   Pengsaa K, 2008, PEDIATR INFECT DIS J, V27, P461, DOI 10.1097/INF.0b013e3181646d45
   Pignatelli S, 2003, J GEN VIROL, V84, P647, DOI 10.1099/vir.0.18704-0
   Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.003
   Ross SA, 2005, J INFECT DIS, V192, P1727, DOI 10.1086/497150
   SCHOPFER K, 1978, ARCH DIS CHILD, V53, P536, DOI 10.1136/adc.53.7.536
   Shimamura M, 2006, J VIROL, V80, P4591, DOI 10.1128/JVI.80.9.4591-4600.2006
   STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601
   STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904
   STAGNO S, 1983, SEMIN PERINATOL, V7, P31
   STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203
   STAGNO S, 1982, Clinical Obstetrics and Gynecology, V25, P563, DOI 10.1097/00003081-198209000-00014
   STAGNO S, 2006, INFECT DIS FETUS NEW
   Stanton R, 2005, J MED VIROL, V75, P42, DOI 10.1002/jmv.20235
   URBAN M, 1992, J VIROL, V66, P1303, DOI 10.1128/JVI.66.3.1303-1311.1992
   UTZ U, 1992, J IMMUNOL, V149, P214
   VANDERSCHAAR HM, IMMUNOBIOLOGY
   WAGNER B, 1992, J VIROL, V66, P5290, DOI 10.1128/JVI.66.9.5290-5297.1992
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
NR 60
TC 130
Z9 130
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2010
VL 202
IS 3
AR 297.e1
DI 10.1016/j.ajog.2009.11.018
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 568IV
UT WOS:000275516900032
PM 20060091
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
   Brito, R
   Duarte, G
   Boppana, S
   Britt, WJ
AF Mussi-Pinhata, M. M.
   Yamamoto, A. Y.
   Brito, R.
   Duarte, G.
   Boppana, S.
   Britt, W. J.
TI MATERNAL CORRELATES OF CONGENITAL CMV INFECTION IN A POPULATION WITH
   HIGH VSEROPREVALENCE RATE: A CASE-CONTROL STUDY
SO ACTA PAEDIATRICA
LA English
DT Meeting Abstract
C1 [Mussi-Pinhata, M. M.; Yamamoto, A. Y.; Brito, R.] Univ Sao Paulo, Dept Pediat, BR-14049 Ribeirao Preto, Brazil.
   [Duarte, G.] Univ Sao Paulo, Dept Obstet & Gynecol, BR-14049 Ribeirao Preto, Brazil.
   [Boppana, S.; Britt, W. J.] Univ Alabama, Dept Pediat, Birmingham, AL USA.
RI Duarte, Geraldo/J-7906-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD OCT
PY 2009
VL 98
BP 273
EP 273
PG 1
WC Pediatrics
SC Pediatrics
GA 495AR
UT WOS:000269862100701
DA 2020-12-17
ER

PT J
AU Hazra, R
   Stoszek, SK
   Hance, LF
   Pinto, J
   Marques, H
   Peixoto, M
   Alarcon, J
   Mussi-Pinhata, M
   Serchuck, L
AF Hazra, Rohan
   Stoszek, Sonia K.
   Hance, Laura Freimanis
   Pinto, Jorge
   Marques, Heloisa
   Peixoto, Mario
   Alarcon, Jorge
   Mussi-Pinhata, Marisa
   Serchuck, Leslie
CA NISDI Pediat Study Grp 2008
TI Cohort Profile: NICHD International Site Development Initiative (NISDI):
   a prospective, observational study of HIV-exposed and HIV-infected
   children at clinical sites in Latin American and Caribbean countries
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID INFANT TRANSMISSION; ZIDOVUDINE; WOMEN
C1 [Hazra, Rohan; Serchuck, Leslie] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA.
   [Stoszek, Sonia K.; Hance, Laura Freimanis] Westat Corp, Rockville, MD USA.
   [Pinto, Jorge] Univ Fed Minas Gerais, Dept Pediat, Div Immunol, Belo Horizonte, MG, Brazil.
   [Peixoto, Mario] Hosp Femina, Grp Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Nacl Mayor San Marcos, Inst Med Trop Daniel Alcides Carrion, Lima 14, Peru.
   [Mussi-Pinhata, Marisa] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RP Hazra, R (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, 6100 Execut Blvd,Room 4B11, Bethesda, MD 20892 USA.
EM hazrar@mail.nih.gov
RI Calvet, GA/G-6959-2013; Mussi-Pinhata, Marisa/G-6568-2012; Pinto, Jorge
   A/D-1743-2014; Pilotto, Jose Henrique/AAD-9773-2019
OI Calvet, GA/0000-0002-3545-5238; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pinto, Jorge A/0000-0003-2987-3238; Pilotto,
   Jose Henrique/0000-0003-0521-8597; Machado, Daisy/0000-0003-1993-6442;
   Cervi, Maria Celia/0000-0002-6563-6507; Joao, Esau/0000-0002-2412-0627;
   Mofenson, Lynne/0000-0002-2818-9808; moye, john/0000-0001-9976-8586
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [#N01-HD-3-3345]
   Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [#N01-DK-8-0001] Funding Source: Medline; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [N01HD033345, N01HD033345, N01HD033345]
   Funding Source: NIH RePORTER
CR CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   *PER HIV GUID WORK, 2007, PUBL HLTH SERV TASK, P59
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   Spector SA, 2006, AIDS, V20, P1777, DOI 10.1097/01.aids.0000242825.97495.a7
   Sullivan JL, 2001, NEW ENGL J MED, V345, P1568, DOI 10.1056/NEJM200111223452111
NR 8
TC 26
Z9 26
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD OCT
PY 2009
VL 38
IS 5
BP 1207
EP 1214
DI 10.1093/ije/dyn239
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 510PH
UT WOS:000271101800009
PM 19036797
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Monteiro, JP
   Freimanis-Hance, L
   Faria, LB
   Mussi-Pinhata, MM
   Korelitz, J
   Vannucchi, H
   Queiroz, W
   Succi, RCM
   Hazra, R
AF Monteiro, Jacqueline P.
   Freimanis-Hance, Laura
   Faria, Lidiane B.
   Mussi-Pinhata, Marisa M.
   Korelitz, James
   Vannucchi, Helio
   Queiroz, Wladimir
   Succi, Regina C. M.
   Hazra, Rohan
TI Both human immunodeficiency virus-infected and human immunodeficiency
   virus-exposed, uninfected children living in Brazil, Argentina, and
   Mexico have similar rates of low concentrations of retinol,
   beta-carotene, and vitamin E
SO NUTRITION RESEARCH
LA English
DT Article
DE beta-carotene; Children; HIV; Retinol; Vitamin E
ID ACUTE-PHASE RESPONSE; ALPHA-TOCOPHEROL; A-DEFICIENCY; NUTRITIONAL
   ASSESSMENT; MICRONUTRIENT LEVELS; SERUM; SUPPLEMENTATION; AMERICAN;
   MARKERS; ANEMIA
AB Our objective was to describe the prevalence of low concentrations of retinol, beta-carotene, and vitamin E in a group of human immunodeficiency virus (HIV)-infected Latin American children and a comparison group of HIV-exposed, uninfected children. Our hypothesis was that the rates of low concentrations of these micronutrients would be higher in the HIV-infected group than those in the HIV-exposed, uninfected group. This was a cross-sectional substudy of a larger cohort study at clinical pediatric HIV centers in Latin America. Serum levels of micronutrients were measured in the first stored sample obtained after each child's first birthday by high-performance liquid chromatography. Low concentrations of retinol, beta-carotene, and vitamin E were defined as serum levels below 0.70, 0.35, and 18.0 mu mol/L, respectively. The Population for this analysis was 336 children (124 HIV-infected, 212 HIV-exposed, uninfected) aged I year or older to younger than 4 years. Rates of low concentrations were 74% for retinol, 27% for beta-carotene, and 89% for vitamin E. These rates were not affected by HIV status. Among the HIV-infected children, those treated with anti retrovirals were less likely to have retinol deficiency, but no other HIV-related factors correlated with micronutrient low serum levels. Low concentrations of retinol, beta-carotene, and vitamin E are very common in children exposed to HIV living in Brazil, Argentina, and Mexico, regardless of HIV-infection status. Published by Elsevier Inc.
C1 [Hazra, Rohan] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD 20892 USA.
   [Monteiro, Jacqueline P.; Faria, Lidiane B.; Mussi-Pinhata, Marisa M.; Vannucchi, Helio] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil.
   [Freimanis-Hance, Laura; Korelitz, James] WESTAT Corp, Rockville, MD 20850 USA.
   [Queiroz, Wladimir] Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Succi, Regina C. M.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Hazra, R (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD 20892 USA.
EM hazrar@mail.nih.gov
RI Monteiro, Jacqueline/F-6987-2012; Mussi-Pinhata, Marisa/G-6568-2012;
   Vannucchi, Helio/B-8060-2013
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Vannucchi,
   Helio/0000-0003-4161-3228
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   N01-DK-8-0001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH RePORTER
FX Source of Financial Support: NICHD Contracts #N01-HD-3-3345 and
   #N01-DK-8-0001.
CR Allard JP, 1998, AM J CLIN NUTR, V67, P143
   Allen LH, 2005, AM J CLIN NUTR, V81, p1206S
   Allen LH, 2000, AM J CLIN NUTR, V71, P1485
   ARNAUD J, 1991, J CHROMATOGR-BIOMED, V572, P103, DOI 10.1016/0378-4347(91)80476-S
   Austin J, 2006, EUR J CLIN NUTR, V60, P1266, DOI 10.1038/sj.ejcn.1602447
   Azzi A, 2004, ANN NY ACAD SCI, V1031, P86, DOI 10.1196/annals.1331.009
   Baeten JM, 2007, INT J STD AIDS, V18, P202, DOI 10.1258/095646207780132541
   Baeten JM, 2002, JAIDS, V31, P243, DOI 10.1097/00126334-200210010-00016
   Calleja JMG, 2002, AIDS, V16, pS3, DOI 10.1097/00002030-200212003-00002
   *CDCP, 2008, MMWR MORB MORTAL RR, V12, P1
   Cohen J, 2006, SCIENCE, V313, P468, DOI 10.1126/science.313.5786.468
   COMSTOCK GW, 1993, CLIN CHEM, V39, P1075
   CunninghamRundles S, 1996, J NUTR, V126, pS2674
   Eley BS, 2002, ANN TROP PAEDIATR, V22, P19, DOI 10.1179/027249302125000111
   ESCOBAL N, 2001, ARCH PEDIATR-URUG, V72, P312
   Ferraz Ivan S., 2005, J. Pediatr. (Rio J.), V81, P169, DOI [10.2223/JPED.1324, 10.1590/S0021-75572005000300014]
   Figueiredo J F, 2001, Rev Soc Bras Med Trop, V34, P429
   Ford ES, 1999, AM J EPIDEMIOL, V150, P290, DOI 10.1093/oxfordjournals.aje.a010001
   FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141
   Hazra R, 2009, INT J EPIDEMIOL, V38, P1207, DOI 10.1093/ije/dyn239
   Henderson RA, 1997, J AM DIET ASSOC, V97, P1377, DOI 10.1016/S0002-8223(97)00333-7
   HSING AW, 1989, CLIN CHEM, V35, P2145
   *INT VIT A CONS GR, 1989, GUID DEV SIMPL DIET
   Intorre F, 2008, EUR J CLIN NUTR, V62, P1215, DOI 10.1038/sj.ejcn.1602844
   Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE1092, DOI 10.1152/ajpendo.1999.276.6.E1092
   Jones CY, 2006, JAIDS-J ACQ IMM DEF, V43, P475, DOI 10.1097/01.qai.0000243096.27029.fe
   Kim YN, 2006, J AM DIET ASSOC, V106, P385, DOI 10.1016/j.jada.2005.12.010
   Mastroiacovo P, 1996, INT J VITAM NUTR RES, V66, P141
   Monteiro JP, 2000, NUTRITION, V16, P339, DOI 10.1016/S0899-9007(00)00227-6
   Omene JA, 1996, J NATL MED ASSOC, V88, P789
   Papathakis PC, 2007, AM J CLIN NUTR, V85, P182
   PERIQUET BA, 1995, AIDS, V9, P887, DOI 10.1097/00002030-199508000-00009
   POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689
   Pollitt E, 2000, J NUTR, V130, p350S, DOI 10.1093/jn/130.2.350S
   Ramalho Rejane Andréa, 2006, Rev. Assoc. Med. Bras., V52, P170, DOI 10.1590/S0104-42302006000300018
   Read JS, 1999, PEDIATR INFECT DIS J, V18, P134, DOI 10.1097/00006454-199902000-00010
   *REG COMPL CTR, 2004, DIV AIDS TABL GRAD S
   Ribaya-Mercado JD, 2007, AM J CLIN NUTR, V85, P1041
   Ribaya-Mercado JD, 2008, BIOSCIENCE REP, V28, P97, DOI 10.1042/BSR20070045
   Russell RM, 2000, AM J CLIN NUTR, V71, P878
   SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149
   Skurnick JH, 1996, J ACQ IMMUN DEF SYND, V12, P75, DOI 10.1097/00042560-199605010-00011
   THURNHAM DI, 1991, T ROY SOC TROP MED H, V85, P194, DOI 10.1016/0035-9203(91)90017-S
   Valencia ME, 1999, J NUTR SCI VITAMINOL, V45, P747, DOI 10.3177/jnsv.45.747
   Vieira ACF, 2007, J PEDIAT-BRAZIL, V83, P370, DOI [10.1590/S0021-75572007000500014, 10.2223/JPED.1680]
   WHO, IND ASS VIT A DEF TH
   YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051
   YOUNG DS, 1987, ANN INTERN MED, V106, P114, DOI 10.7326/0003-4819-106-1-114
NR 48
TC 12
Z9 13
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD OCT
PY 2009
VL 29
IS 10
BP 716
EP 722
DI 10.1016/j.nutres.2009.10.001
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 528GW
UT WOS:000272432000005
PM 19917451
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
   Brito, RMM
   Isaac, MD
   Oliveira, PFDE
   Boppana, S
   Britt, WJ
AF Mussi-Pinhata, Marisa M.
   Yamamoto, Aparecida Y.
   Brito, Rosangela M. Moura
   Isaac, Myriam de Lima
   de Carvalho e Oliveira, Patricia F.
   Boppana, Suresh
   Britt, William J.
TI Birth Prevalence and Natural History of Congenital Cytomegalovirus
   Infection in a Highly Seroimmune Population
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INFANTS BORN; NEWBORN-INFANTS; RISK-FACTORS; DIAGNOSIS; EPIDEMIOLOGY;
   BLOOD; TRANSMISSION; PREGNANCY; AVIDITY; MOTHERS
AB Background. The natural history of congenital cytomegalovirus (CMV) infection is scarcely known in populations with high maternal CMV seroprevalence. This study evaluated the birth prevalence, clinical findings at birth, and hearing outcome in CMV-infected children from such a population.
   Methods. Consecutively born infants were screened for the presence of CMV in urine and/or saliva specimens during the first 2 weeks after birth. Neonatal clinical findings were recorded, and CMV-infected children were tested to document hearing function during follow-up. A subset of mothers of CMV-infected infants were prenatally tested for the presence of anti-CMV immunoglobulin G antibodies.
   Results. Congenital CMV infection was confirmed in 87 (1.08%; 95% confidence interval [CI], 0.86%-1.33%) of 8047 infants. Seven infants (8.1%; 95% CI, 3.3%-15.9%) had at least 1 clinical finding suggestive of CMV infection, and 4 (4.6%; 95% CI, 1.3%-11.3%) had 13 findings of systemic disease. Sensorineural hearing loss was found in 5 (8.6%; 95% CI, 2.9%-19.0%) of 58 children tested at a median age of 21 months. Bilateral profound hearing loss was observed in 2 children, and the hearing threshold was 160 decibels in all 5 children with hearing loss, including 2 children born to mothers with probable nonprimary CMV infection.
   Conclusions. The results of this large newborn screening study in a population with high CMV seroimmunity provide additional evidence that congenital CMV disease occurs in populations with high seroprevalence rates, with a similar incidence of CMV-related hearing loss to that reported in the offspring of women from populations in developed countries with lower rates of seroimmunity to CMV.
C1 [Mussi-Pinhata, Marisa M.; Yamamoto, Aparecida Y.; Brito, Rosangela M. Moura; de Carvalho e Oliveira, Patricia F.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
   [Isaac, Myriam de Lima] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Ophtalmol Otolaryngol Head & Neck Surg, Sao Paulo, Brazil.
   [Boppana, Suresh; Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA.
   [Boppana, Suresh; Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL USA.
   [Britt, William J.] Univ Alabama Birmingham, Sch Med, Dept Neurobiol, Birmingham, AL USA.
RP Mussi-Pinhata, MM (corresponding author), FMRP USP, Dept Puericultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/04166-6]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Allergy and Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI49537]; Fogarty
   International CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R03 TW006480]; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD061959, R01HD061959, R01HD061959,
   R01HD061959, R01HD061959, R01HD061959, R01HD061959, R01HD061959,
   R01HD061959] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD061959] Funding Source: NIH RePORTER;
   FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R03TW006480, R03TW006480, R03TW006480]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI089956, R01AI049537,
   R01AI049537, R01AI049537, R01AI089956, R01AI089956, R01AI089956,
   R01AI049537, R01AI049537, R01AI089956, R01AI089956, R01AI049537,
   R01AI089956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS065845,
   R01NS065845, R01NS065845, R01NS065845, R01NS065845] Funding Source: NIH
   RePORTER
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (02/04166-6),
   Brazil; the National Institutes of Health, National Institute of Allergy
   and Infectious Disease (AI49537 to W.J.B.); and the Fogarty
   International Center (R03 TW006480 to WJB).
CR Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969
   Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X
   Barbi M, 2006, PEDIATR INFECT DIS J, V25, P156, DOI 10.1097/01.inf.0000199261.98769.29
   Barbi M, 2003, PEDIATR INFECT DIS J, V22, P39, DOI 10.1097/00006454-200301000-00012
   BERGE P, 1990, PEDIATR INFECT DIS J, V9, P170, DOI 10.1097/00006454-199003000-00005
   Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   Dahle A J, 2000, J Am Acad Audiol, V11, P283
   Dar L, 2008, PEDIATR INFECT DIS J, V27, P841, DOI 10.1097/INF.0b013e3181723d55
   Eggers M, 2000, J MED VIROL, V60, P324, DOI 10.1002/(SICI)1096-9071(200003)60:3&lt;324::AID-JMV11&gt;3.0.CO;2-D
   Fisher S, 2000, J VIROL, V74, P6808, DOI 10.1128/JVI.74.15.6808-6820.2000
   FOWLER KB, 1993, J INFECT DIS, V168, P552, DOI 10.1093/infdis/168.3.552
   Gaytant MA, 2002, OBSTET GYNECOL SURV, V57, P245, DOI 10.1097/00006254-200204000-00024
   Gaytant MA, 2003, EUR J PEDIATR, V162, P248, DOI 10.1007/s00431-002-1115-3
   Halwachs-Baumann G, 2000, SCAND J INFECT DIS, V32, P137, DOI 10.1080/003655400750045222
   ISTAS AS, 1995, CLIN INFECT DIS, V20, P665, DOI 10.1093/clinids/20.3.665
   JEWETT DL, 1971, BRAIN, V94, P681, DOI 10.1093/brain/94.4.681
   Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535
   Kylat RI, 2006, EUR J PEDIATR, V165, P773, DOI 10.1007/s00431-006-0172-6
   LARKE RPB, 1980, J INFECT DIS, V142, P647, DOI 10.1093/infdis/142.5.647
   Larsson S, 1998, TRANSFUSION, V38, P271, DOI 10.1046/j.1537-2995.1998.38398222871.x
   Lazzarotto T, 2003, PEDIATRICS, V112, pE153, DOI 10.1542/peds.112.2.e153
   Lazzarotto T, 1997, CLIN DIAGN LAB IMMUN, V4, P469, DOI 10.1128/CDLI.4.4.469-473.1997
   Miura Clarissa Schreiner, 2006, J. Pediatr. (Rio J.), V82, P46, DOI [10.2223/JPED.1436, 10.1590/S0021-75572006000100010]
   MONTGOMERY JR, 1980, SOUTHERN MED J, V73, P590, DOI 10.1097/00007611-198005000-00012
   Murph JR, 1998, AM J EPIDEMIOL, V147, P940, DOI 10.1093/oxfordjournals.aje.a009384
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   Neto EC, 2004, EMERG INFECT DIS, V10, P1069, DOI 10.3201/eid1006.030830
   Noyola DE, 2003, PEDIATR INFECT DIS J, V22, P89, DOI 10.1097/00006454-200301000-00022
   Noyola DE, 2001, J PEDIATR-US, V138, P325, DOI 10.1067/mpd.2001.112061
   PANNUTI CS, 1985, REV I MED TROP, V27, P105, DOI 10.1590/S0036-46651985000200010
   Rahav G, 2007, EMERG INFECT DIS, V13, P1791, DOI 10.3201/eid1311.061289
   Rahbar AR, 2004, TRANSFUSION, V44, P1059, DOI 10.1111/j.1537-2995.2004.03292.x
   SOHN Y M, 1992, Journal of Korean Medical Science, V7, P47
   STAGNO S, 1982, J PEDIATR-US, V101, P897, DOI 10.1016/S0022-3476(82)80006-1
   STAPELLS DR, 1991, CLIN PERINATOL, V18, P497
   Tsai CH, 1996, ACTA PAEDIATR, V85, P1241, DOI 10.1111/j.1651-2227.1996.tb18237.x
   USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   WARREN WP, 1992, J CLIN MICROBIOL, V30, P786, DOI 10.1128/JCM.30.4.786-789.1992
   Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
   Yamamoto-Tabata T, 2004, J VIROL, V78, P2831, DOI 10.1128/JVI.78.6.2831-2840.2004
   Yinon Y, 2006, BJOG-INT J OBSTET GY, V113, P295, DOI 10.1111/j.1471-0528.2006.00854.x
NR 47
TC 160
Z9 165
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2009
VL 49
IS 4
BP 522
EP 528
DI 10.1086/600882
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 472UI
UT WOS:000268157300005
PM 19583520
OA Bronze, Green Accepted
DA 2020-12-17
ER

PT J
AU de Oliveira, PR
   Yamamoto, AY
   de Souza, CBS
   de Araujo, NM
   Gomes, SD
   Heck, AR
   Figueiredo, JFD
   Mussi-Pinhata, MM
AF de Oliveira, Patricia Ribeiro
   Yamamoto, Aparecida Yulie
   Sandoval de Souza, Cleonice Barbosa
   de Araujo, Natalia Motta
   de Andrade Gomes, Selma
   Heck, Analia Ribeiro
   de Castro Figueiredo, Jose Fernando
   Mussi-Pinhata, Marisa Marcia
TI Hepatitis B viral markers in banked human milk before and after Holder
   pasteurization
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis B virus; Human milk donor; Human milk bank; Lactating women
ID POLYMERASE-CHAIN-REACTION; VIRUS; TRANSMISSION; INFANTS; LIFE; PRETERM;
   VACCINE; MOTHERS; HBV; DNA
AB Background: Blood screening for hepatitis B virus (HBV) is not universally performed for donor selection in human milk banks.
   Objectives: To evaluate the frequency of detection of HBV surface antigen (HBsAg) and HBV-DNA in colostrum of HBV-infected nursing mothers before and after Holder pasteurization.
   Study design: Forty-two concentrated breast milk samples were obtained within two postnatal weeks from 24 HBsAg-positive women (4 HBeAg-positive and 20 HBeAg-negative, anti-HBe-positive) were tested for the presence of HBsAg and HBV-DNA before and after Holder pasteurization (30 min at 62.5 degrees C).
   Results: Before pasteurization, HBsAg and HBV-DNA were found in 14/24 (58%), and 20/24 (75%) first milk samples, respectively, obtained by 4 days after delivery. At least one marker was detected in 20/24 (83%) milk samples. Both markers were identified in milk of HBeAg-positive mothers, and most mothers with anti-HBe in blood had at least one HBV marker. Once detected, viral markers were frequently found in milk samples subsequently obtained from the same woman. Holder pasteurization did not affect the probability of detecting HBsAg (8/18, 44%), HBV-DNA (12/18, 67%). or at least one of them (15118, 83%).
   Conclusions: Although the biological implications of these findings remain to be determined, considering that HBV is highly contagious and most recipients of banked human milk are preterm infants, these findings should be taken into account when donors are enlisted for human milk banks without serological screening. (C) 2009 Elsevier B.V. All rights reserved.
C1 [de Oliveira, Patricia Ribeiro; Yamamoto, Aparecida Yulie; Sandoval de Souza, Cleonice Barbosa; Mussi-Pinhata, Marisa Marcia] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [de Araujo, Natalia Motta; de Andrade Gomes, Selma] Inst Oswaldo Cruz, Mol Virol Lab, BR-20001 Rio De Janeiro, Brazil.
   [Heck, Analia Ribeiro] Univ Sao Paulo, Fac Med Ribeirao Preto, Human Milk Bank, Univ Hosp, BR-14025090 Sao Paulo, Brazil.
   [de Castro Figueiredo, Jose Fernando] Univ Sao Paulo, Dept Internal Med, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM propat@ig.com.br; yulie@fmrp.usp.br; cleonice@fmrp.usp.br;
   nmaraujo@ioc.fiocruz.br; selma@ioc.flocruz.br; analia_heck@uol.com.br;
   jfcfigue@fmrp.usp.br; mmmpinha@fmrp.usp.br
RI Araujo, Natalia M/B-6596-2013; gomes, selma A/D-2762-2015;
   Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Gomes,
   Selma/0000-0003-0233-3370
FU CNPq, BrazilNational Council for Scientific and Technological
   Development (CNPq)
FX This work was partially supported by CNPq, Brazil. Funding: No authors
   have any competing interests to declare. Ethical approval: This study
   was approved by the Research Ethics Committee of the Hospital (Process #
   9032/2001). Written informed consent was obtained from all subjects.
CR BALMER SE, 1995, J HOSP INFECT, V31, P155, DOI 10.1016/0195-6701(95)90173-6
   BEASLEY RP, 1975, LANCET, V2, P1089
   BEASLEY RP, 1975, LANCET, V2, P740
   BOXALL EH, 1975, LANCET, V2, P979
   da Motta MSF, 2002, VACCINE, V20, P1557, DOI 10.1016/S0264-410X(01)00493-5
   Gomes SA, 1996, ACTA VIROL, V40, P133
   Hamprecht K, 1998, J VIROL METHODS, V70, P167, DOI 10.1016/S0166-0934(97)00179-1
   Hilfenhaus J, 1997, TRANSFUSION, V37, P935, DOI 10.1046/j.1537-2995.1997.37997454021.x
   Huang YH, 2006, J VIRAL HEPATITIS, V13, P336, DOI 10.1111/j.1365-2893.2005.00688.x
   Jones Frances, 2003, J Hum Lact, V19, P313, DOI 10.1177/0890334403255857
   LEE AKY, 1978, J INFECT DIS, V138, P668, DOI 10.1093/infdis/138.5.668
   LIN HH, 1993, J PEDIATR GASTR NUTR, V17, P207, DOI 10.1097/00005176-199308000-00014
   Lin J Y, 1986, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, V19, P81
   LINNEMANN CC, 1974, LANCET, V2, P155
   MITSUDA T, 1989, LANCET, V2, P886
   NIEL C, 1994, J MED VIROL, V44, P180, DOI 10.1002/jmv.1890440212
   NOWAK T, 1993, DEV BIOL STAND, V81, P169
   Pan Calvin Q, 2005, Int J Med Sci, V2, P36
   POOVORAWAN Y, 1992, PEDIATR INFECT DIS J, V11, P816, DOI 10.1097/00006454-199210000-00002
   Prince A M, 2001, ILAR J, V42, P85
   ROGNUM TO, 1992, PEDIATR RES, V32, P145, DOI 10.1203/00006450-199208000-00003
   Schultz U, 2004, ADV VIRUS RES, V63, P1, DOI 10.1016/S0065-3527(04)63001-6
   Seidel BM, 2000, EUR J PEDIATR, V159, P789, DOI 10.1007/s004310000546
   Tully D B, 2001, J Hum Lact, V17, P152, DOI 10.1177/089033440101700212
   Tully M R, 2001, J Hum Lact, V17, P51, DOI 10.1177/089033440101700110
   Yang Dexian, 1999, Hunan Yike Daxue Xuebao, V24, P44
   YANG X, 1994, ZHONGHUA FU CHAN KE, V29, P635
NR 27
TC 16
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2009
VL 45
IS 4
BP 281
EP 284
DI 10.1016/j.jcv.2009.04.003
PG 4
WC Virology
SC Virology
GA 480AN
UT WOS:000268703900004
PM 19473876
DA 2020-12-17
ER

PT J
AU Almeida, VD
   Mussi-Pinhata, MM
   De Souza, CBS
   Kubo, CA
   Martinez, EZ
   Carneiro-Sampaio, MM
   Duarte, G
AF Almeida, Volia De Carvalho
   Mussi-Pinhata, Marisa Marcia
   Sandoval De Souza, Cleonice Barbosa
   Kubo, Christina Arslanian
   Martinez, Edson Zangiacomi
   Carneiro-Sampaio, Magda Maria
   Duarte, Geraldo
TI Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in
   HIV-infected pregnant women and kinetics of passively acquired
   antibodies in young infants
SO VACCINE
LA English
DT Article
DE Pneumococcal polysaccharide vaccine; HIV-infected pregnant woman;
   Passively acquired pneumococcal antibodies
ID MATERNAL IMMUNIZATION; STREPTOCOCCUS-PNEUMONIAE; PLACENTAL-TRANSFER; 22F
   POLYSACCHARIDE; CONJUGATE VACCINE; VIRAL LOAD; SERUM IGG; DISEASE;
   ADULTS; TRANSMISSION
AB Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 613, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Almeida, Volia De Carvalho] Univ Fed Sao Carlos, Biol & Hlth Sci Ctr, Dept Med, BR-13565905 Sao Carlos, SP, Brazil.
   [Mussi-Pinhata, Marisa Marcia; Sandoval De Souza, Cleonice Barbosa] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Kubo, Christina Arslanian] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil.
   [Martinez, Edson Zangiacomi] Univ Sao Paulo, Dept Social Med, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Carneiro-Sampaio, Magda Maria] Univ Sao Paulo, Dept Pediat, Fac Med, BR-05403900 Sao Paulo, Brazil.
   [Duarte, Geraldo] Univ Sao Paulo, Dept Gynecol & Obstet, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Almeida, VD (corresponding author), Univ Fed Sao Carlos, Ctr Ciencias Biol & Saude, Dept Med, Rod Washington Luis Km 235,Caixa Postal 676, BR-13565905 Sao Carlos, SP, Brazil.
EM volia@ufscar.br; mmmpinha@fmrp.usp.br; cleonice@fmrp.usp.br;
   arslani@usp.br; edson@fmrp.usp.br; magda.carneiro@icr.usp.br;
   gduarte@fmrp.usp.br
RI Duarte, Geraldo/J-7906-2012; Sampaio, Magda/AAU-6748-2020; Martinez,
   Edson Zangiacomi/A-3638-2008; Mussi-Pinhata, Marisa/G-6568-2012
OI Sampaio, Magda/0000-0002-1924-4043; Martinez, Edson
   Zangiacomi/0000-0002-0949-3222; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
FU Fundacao de Amparo A Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [02/01294-3]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), BrazilNational Council for Scientific and
   Technological Development (CNPq) [302759/2002]
FX We are grateful to the staff of the HCFMRP-USP AMIGO (HIV-pregnant
   women), and AMIB (HIV-exposed infants) clinics for their help in
   providing the study participants with care and follow-up. Sources of
   Financial Support: Fundacao de Amparo A Pesquisa do Estado de Sao Paulo
   (FAPESP), Brazil (Grant # 02/01294-3 to MMMP), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil (scholarship #
   302759/2002- to VCA). Conflicts of interest: No authors have any
   conflict of interest to disclose.
CR Ahmed F, 1996, J INFECT DIS, V173, P83, DOI 10.1093/infdis/173.1.83
   Amendola A, 2002, VACCINE, V20, P3720, DOI 10.1016/S0264-410X(02)00357-2
   Baril L, 2004, CLIN EXP IMMUNOL, V135, P474, DOI 10.1111/j.1365-2249.2003.02357.x
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191
   Brown H, 2006, APPL MIXED MODELS ME
   CASTEN U, 1993, GEOPHYS PROSPECT, V41, P1, DOI 10.1111/j.1365-2478.1993.tb00562.x
   Concepcion NF, 2001, CLIN DIAGN LAB IMMUN, V8, P266, DOI 10.1128/CDLI.8.2.266-272.2001
   de Moraes-Pinto MI, 1999, J REPROD IMMUNOL, V42, P167, DOI 10.1016/S0165-0378(98)00083-7
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077, DOI 10.1093/infdis/173.5.1077
   FARLEY JJ, 1994, J PEDIATR-US, V124, P853, DOI 10.1016/S0022-3476(05)83170-1
   Farquhar C, 2005, JAIDS-J ACQ IMM DEF, V40, P494, DOI 10.1097/01.qai.0000168179.68781.95
   Feikin DR, 2004, CLIN DIAGN LAB IMMUN, V11, P137, DOI 10.1128/CDLI.11.1.137-141.2004
   French N, 2004, J INFECT DIS, V190, P707, DOI 10.1086/421911
   French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1
   FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540
   Go ES, 1996, J ALLERGY CLIN IMMUN, V98, P205, DOI 10.1016/S0091-6749(96)70244-0
   Goetz MB, 2002, AIDS, V16, P1421, DOI 10.1097/00002030-200207050-00015
   Inostroza J, 2005, CLIN DIAGN LAB IMMUN, V12, P722, DOI 10.1128/CDLI.12.6.722-726.2005
   Janoff EN, 1997, J INFECT DIS, V175, P975, DOI 10.1086/514004
   Joao EC, 2003, AIDS, V17, P1853, DOI [10.1097/01.aids.0000076326.42412.7a, 10.1097/00002030-200308150-00016]
   Keller M, 2000, PEDIATR INFECT DIS J, V19, P613, DOI 10.1097/00006454-200007000-00006
   Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793
   KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008
   Lehmann D, 2003, VACCINE, V21, P3446, DOI 10.1016/S0264-410X(03)00348-7
   Lehmann D, 2002, VACCINE, V20, P1837, DOI 10.1016/S0264-410X(02)00040-3
   Lesprit P, 2007, AIDS, V21, P2425, DOI 10.1097/QAD.0b013e3282887e91
   Littell R. C., 2006, SAS MIXED MODELS
   Mantese Orlando C., 2003, J. Pediatr. (Rio J.), V79, P537, DOI 10.1590/S0021-75572003000600013
   Margolis P, 1999, PEDIATR INFECT DIS J, V18, pS23
   Matida LH, 2005, AIDS, V19, pS37, DOI 10.1097/01.aids.0000191489.59112.13
   Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003
   Munoz FM, 2001, VACCINE, V20, P826, DOI 10.1016/S0264-410X(01)00397-8
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Mussi-Pinhata MM, 2001, INT J STD AIDS, V12, P197, DOI 10.1258/0956462011916901
   Oddy Wendy H, 2002, Breastfeed Rev, V10, P5
   ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6
   Overturf G D, 2000, Pediatrics, V106, P367, DOI 10.1542/peds.106.2.367
   Penaranda M, 2007, CLIN INFECT DIS, V45, pE82, DOI 10.1086/520977
   Quataert S, 2001, IMMUNOL INVEST, V30, P191, DOI 10.1081/IMM-100105064
   Quiambao BP, 2007, VACCINE, V25, P4470, DOI 10.1016/j.vaccine.2007.03.021
   Quiambao BP, 2003, VACCINE, V21, P3451, DOI 10.1016/S0264-410X(03)00349-9
   Rodriguez-Barradas MC, 2008, CLIN INFECT DIS, V46, P1093, DOI 10.1086/529201
   Rodriguez-Barradas MC, 2003, CLIN INFECT DIS, V37, P438, DOI 10.1086/375841
   RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Simonsen V, 2005, BRAZ J MED BIOL RES, V38, P251, DOI 10.1590/S0100-879X2005000200014
   Vidarsson G, 1998, INFECT IMMUN, V66, P2866, DOI 10.1128/IAI.66.6.2866-2870.1998
   Yoon JK, 2001, J KOREAN MED SCI, V16, P9, DOI 10.3346/jkms.2001.16.1.9
NR 50
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 12
PY 2009
VL 27
IS 29
BP 3856
EP 3861
DI 10.1016/j.vaccine.2009.04.018
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 465KA
UT WOS:000267581300008
PM 19443091
DA 2020-12-17
ER

PT J
AU Inagaki, ADD
   de Oliveira, LAR
   de Oliveira, MFB
   Santos, RCS
   Araujo, RM
   Alves, JAB
   Pinheiro, KS
   Gurgel, RQ
   Mussi-Pinhata, MM
AF de Melo Inagaki, Ana Dorcas
   Resende de Oliveira, Livia Albuquerque
   Batista de Oliveira, Maria Fabiana
   Silvestre Santos, Ricardo Cley
   Araujo, Raquel Melo
   Barreto Alves, Jose Antonio
   Pinheiro, Kariny Souza
   Gurgel, Ricardo Queiroz
   Mussi-Pinhata, Marisa Marcia
TI Seroprevalence of antibodies for toxoplasmosis, rubella,
   cytomegalovirus, syphilis and HIV among pregnant women in Sergipe
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE Seroprevalence; Congenital infection; Pregnant women; Prenatal; Sergipe
ID INFECTION; PREVALENCE; VIRUS
AB The seroprevalence of antibodies for HIV, syphilis, toxoplasmosis, cytomegalovirosis and rubella and its association with age and origin was investigated among pregnant women in Sergipe, northeastern Brazil. A total of 9,550 pregnant women (2,112 from the state capital and 7,438 from other municipalities) were enrolled in the study and consecutively tested during their first antenatal care visit in 2007. The following serum prevalences were found: syphilis (0.9%; 95% CI 0.7%-1.6%), HIV (0.14%; 95% CI 0.08%-0.2%), toxoplasmosis (IgG 69.3%; 95% CI 68.3%-70.2%; IgM 0.4%, 95% CI 0.3%-0.6%), cytomegalovirosis (IgG 76.6%, 95% CI 75.7%-77.5%; IgM 0.2%, 95% CI 0.09%-0.3%) and rubella ( IgG 71.6%, 95% CI 70.7%-72.6%; IgM 0.1%, 95% CI 0.04%-0.2%). Toxoplasmosis seropositivity increased with age. The prevalences of IgG antibodies for toxoplasmosis, cytomegalovirus and rubella were higher in Aracaju (state capital) than in other municipalities in the State of Sergipe. The results showed that a large proportion of the pregnant women, particularly in municipalities other than the state capital, were susceptible to toxoplasmosis, rubella and cytomegalovirus, with a risk for their infants.
C1 [de Melo Inagaki, Ana Dorcas] Univ Sao Paulo, Fac Med Ribeirao Preto, Curso Posgrad Saude Crianca & Adolescente, Ribeirao Preto, SP, Brazil.
   [Resende de Oliveira, Livia Albuquerque; Batista de Oliveira, Maria Fabiana; Silvestre Santos, Ricardo Cley; Araujo, Raquel Melo] Univ Fed Sergipe, Acad Curso Enfermagem, Aracaju, SE, Brazil.
   [Barreto Alves, Jose Antonio] Univ Fed Sergipe, Curso Posgrad Ciencias Sande, Aracaju, SE, Brazil.
   [Pinheiro, Kariny Souza] Lab Cent Sergipe LACEN, Programa Protecao Gestante, Aracaju, SE, Brazil.
RP Inagaki, ADD (corresponding author), Rua Duque Caxias 167-1202, BR-49015320 Aracaju, SE, Brazil.
EM anadorcas@usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Gurgel, RQ/N-5105-2018
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Gurgel,
   RQ/0000-0001-9651-3713
CR Cantos G A, 2000, Rev Assoc Med Bras (1992), V46, P335, DOI 10.1590/S0104-42302000000400033
   de Lemos LMD, 2005, REV BRAS GINECOL OBS, V27, P32, DOI 10.1590/S0100-72032005000100007
   DUARTE G, 1999, 48 C BRAS GIN OBST G, P175
   DUARTE G, 1994, REV BRASILEIRA GINEC, V16, P153
   Porto AMF, 2008, REV ASSOC MED BRAS, V54, P242, DOI 10.1590/S0104-42302008000300018
   Figueiro EA, 2005, REV BRAS GINECOL OBS, V27, P442, DOI 10.1590/S0100-72032005000800002
   Figueiro-Filho EA, 2007, REV SOC BRAS MED TRO, V40, P181, DOI 10.1590/S0037-86822007000200007
   Fowler KB, 2006, PEDIATRICS, V118, pE286, DOI 10.1542/peds.2005-1142
   Gaytant MA, 2002, OBSTET GYNECOL SURV, V57, P245, DOI 10.1097/00006254-200204000-00024
   Gras L, 2004, EPIDEMIOL INFECT, V132, P541, DOI 10.1017/S0950268803001948
   INAGAKI ADM, 1998, THESIS UNIFESP SAO P
   MACHADO CM, 1991, REV I MED TROP, V33, P159, DOI 10.1590/S0036-46651991000200012
   Meek B, 2001, DIAGN MICR INFEC DIS, V41, P131, DOI 10.1016/S0732-8893(01)00291-7
   *MIN SAUD BRAS, PROGR NAC IM
   *MIN SAUD BRAS, COORD NAC DST AIDS
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Olbrich NJ, 2004, REV SOC BRAS MED TRO, V37, P28, DOI [10.1590/S0037-86822004000100008, DOI 10.1590/S0037-86822004000100008]
   PANNUTI CS, 1985, REV I MED TROP, V27, P105, DOI 10.1590/S0036-46651985000200010
   Reiche E M, 2000, Rev Soc Bras Med Trop, V33, P519, DOI 10.1590/S0037-86822000000600002
   Reis MM, 2006, REV BRAS GINECOL OBS, V28, P158, DOI 10.1590/S0100-72032006000300004
   Rey Luis C., 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P171, DOI 10.1590/S0036-46651999000300007
   Santos Jairo Vvo Dos, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P343
   Segundo GRS, 2004, MEM I OSWALDO CRUZ, V99, P13, DOI 10.1590/S0074-02762004000100002
   Spalding Sílvia Maria, 2003, Rev. Soc. Bras. Med. Trop., V36, P483, DOI 10.1590/S0037-86822003000400009
   Varella Ivana S., 2003, J. Pediatr. (Rio J.), V79, P69, DOI 10.1590/S0021-75572003000100012
NR 25
TC 24
Z9 26
U1 0
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2009
VL 42
IS 5
BP 532
EP 536
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 529BJ
UT WOS:000272490400010
PM 19967235
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Cruz, MLS
   Harris, DR
   Read, JS
   Mussi-Pinhata, MM
   Succi, RCM
AF Cruz, Maria Leticia S.
   Harris, D. Robert
   Read, Jennifer S.
   Mussi-Pinhata, Marisa M.
   Succi, Regina C. M.
CA Natl Inst Child Hlth & Human Dev
TI Association of body mass index of HIV-1-infected pregnant women and
   infant birth weight, body mass index, length, and head circumference:
   the National Institute of Child Health and Human Development
   International Site Development Initiative Perinatal Study
SO NUTRITION RESEARCH
LA English
DT Article; Proceedings Paper
CT 43rd Annual Meeting of the Infectious-Diseases-Society-of-America
CY OCT 06-09, 2005
CL San Francisco, CA
SP Infect Dis Soc Amer
DE maternal BMI; low birth weight; preterm; HIV-exposed infants;
   HIV-infected pregnant women
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED WOMEN; NUTRITIONAL-STATUS;
   PRETERM BIRTH; PREDICTORS; MORTALITY; OUTCOMES; RISK; BORN; DETERMINANTS
AB This study assessed the relationship between the body mass index (BMI) of HIV-1-infected women and their infants' perinatal outcomes. The study population was composed of women enrolled in the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study, with data allowing calculation of their BMI adjusted for length of gestation (adjBMI), who delivered singleton infants. Outcome variables included infant growth parameters at birth (weight, BMI, length, and head circumference) and gestational age. Among the 697 women from Argentina, the Bahamas, Brazil, and Mexico who were included in the analysis, adjBMI was classified as underweight for 109 (15.6%), as normal for 418 (60.0%), as overweight for 88 (12.6%), and as obese for 82 (11.8%). Median infant birth weight, BMI, length, and head circumference differed significantly according to maternal adjBMI (P <= .0002). Mothers who were underweight gave birth to infants with lower weight, lower BMI, shorter length, and smaller head circumference, whereas infants born to mothers who were of normal weight, overweight, and obese were of similar characteristics. (c) 2007 Elsevier Inc. All rights reserved.
C1 Hosp Servidores Estado, Serv Doencas Infecciosas & Parasitarias, BR-20221903 Rio De Janeiro, Brazil.
   Westat Corp, Rockville, MD 20850 USA.
   NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Div Pediat Infect Dis, BR-04049003 Sao Paulo, Brazil.
RP Cruz, MLS (corresponding author), Hosp Servidores Estado, Serv Doencas Infecciosas & Parasitarias, 4 Andar,Anexo 4, BR-20221903 Rio De Janeiro, Brazil.
EM mleticia@diphse.com.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Cruz, Maria Leticia/Y-5632-2019
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033345] Funding Source: NIH RePORTER; NICHD NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01 HD033345]
   Funding Source: Medline
CR Barros FC, 2005, LANCET, V365, P847, DOI 10.1016/S0140-6736(05)71042-4
   Brasil. Ministerio da Saude, 2005, PLAN ESTR PROGR NAC
   Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x
   Castetbon K, 1999, J TROP PEDIATRICS, V45, P152, DOI 10.1093/tropej/45.3.152
   *CDCP, 2002, MMWR-MORBID MORTAL W, V1251, P589
   Chauveau P, 2000, SEMIN DIALYSIS, V13, P241, DOI 10.1046/j.1525-139x.2000.00066.x
   Dreyfuss ML, 2001, AM J CLIN NUTR, V74, P814
   Ellis J, 2002, AM J OBSTET GYNECOL, V186, P903, DOI 10.1067/mob.2002.123407
   FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141
   Friis H, 2004, BRIT J NUTR, V92, P833, DOI 10.1079/BJN20041275
   Hviid A, 2007, AM J EPIDEMIOL, V165, P756, DOI 10.1093/aje/kwk064
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
   Lambert JS, 2000, AIDS, V14, P1389, DOI 10.1097/00002030-200007070-00012
   Leroy V, 1998, AIDS, V12, P643, DOI 10.1097/00002030-199806000-00014
   Malvy D, 2001, J AM COLL NUTR, V20, P609, DOI 10.1080/07315724.2001.10719065
   McDermott AY, 2005, CLIN INFECT DIS, V41, P1662, DOI 10.1086/498022
   Molls RR, 2005, J NUTR, V135, P2644
   Mwanyumba F, 2001, J Obstet Gynaecol, V21, P27, DOI 10.1080/01443610020022078
   Nucci LB, 2001, REV SAUDE PUBL, V35, P502, DOI 10.1590/S0034-89102001000600002
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   READ JS, 1994, AM J EPIDEMIOL, V140, P721, DOI 10.1093/oxfordjournals.aje.a117320
   *SAS I INC, 1999, SAS STAT SOFTW VERS
   Shirima CP, 2005, NUTRITION, V21, P32, DOI 10.1016/j.nut.2004.09.006
   Szyld EG, 2006, AIDS, V20, P2345, DOI 10.1097/01.aids.0000253362.01696.9d
   Thompson JN, 2007, NEONATAL NETW, V26, P235, DOI 10.1891/0730-0832.26.4.235
   Thorne C, 2004, AIDS, V18, P2337, DOI 10.1097/00002030-200411190-00019
   Wei RL, 2004, PEDIATR INFECT DIS J, V23, P530, DOI 10.1097/01.inf.0000129691.42964.eb
   WHO, 1995, B WHO S, V73, P98
NR 29
TC 6
Z9 6
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD NOV
PY 2007
VL 27
IS 11
BP 685
EP 691
DI 10.1016/j.nutres.2007.09.005
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 236BC
UT WOS:000251277000004
PM 19081829
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Aparecida, M
   Rego, MAC
   Freimanis, L
   Kakehasi, FM
   Machado, DM
   Cardoso, EM
   Read, JS
AF Mussi-Pinhata, Marisa M.
   Aparecida, Maria
   Rego, Maria Aparecida C.
   Freimanis, Laura
   Kakehasi, Fabiana M.
   Machado, Daisy Maria
   Cardoso, Edmundo M.
   Read, Jennifer S.
CA NISDI Perinatal Protocol Study Grp
TI Maternal antiretrovirals and hepatic enzyme, Hematologic abnormalities
   among human immunodeficiency virus type 1-uninfected infants - The NISDI
   perinatal study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE infant; pregnancy; transaminases; hematopoiesis; antiretrovirals; Latin
   America; Caribbean
ID AMNIOTIC-FLUID ACCUMULATION; PREGNANT-WOMEN; FETAL TRANSFER; ZIDOVUDINE;
   HEMATOPOIESIS; INHIBITORS
AB Objectives: To assess hepatic enzyme (HE) and hematologic abnormalities among human immunodeficiency virus-1-uninfected infants according to maternal antiretroviral regimen during pregnancy.
   Study Design: In a prospective cohort, HE and hematologic values of human immunodeficiency virus-1-uninfected, term infants with hospital discharge (HD) within 6 days after birth were evaluated. Maternal antiretroviral regimens were categorized as: 1 or 2 nucleoside reverse transcription inhibitors (NRTIs), highly active antiretroviral therapy (HAART)/protease inhibitor (PI), or HAART/non-NRTI.
   Results: Among 503 infants, 63% and 24% had HE and hemoglobin abnormalities, respectively, at HD. Most or all HE and hemoglobin abnormalities (96-100%) were grade 1 or 2. At HD, infants with maternal HAART/PI or HAART/non-NRTI were more likely to have elevated HE [adjusted odds ratio (AOR): 1.9, 2.4, respectively] compared with infants whose mothers received 1 or 2 NRTIs. Infants with maternal HAART/PI were less likely to have abnormal hemoglobin values at HD (AOR, 0.5) when compared with those whose mothers received 1 or 2 NRTIs. Persistently abnormal hemoglobin and HE values decreased with time, such that <10% of infants had abnormalities at 6 months of age.
   Conclusions: Maternal receipt of HAART regimens was associated with an increased risk of HE abnormalities, and maternal HAART/PI was associated with a lower risk of abnormal hemoglobin values, at HD. Abnormalities of HE and hemoglobin were generally mild and transient.
C1 WESTAT Corp, Rockville, MD 20850 USA.
   Univ Sao Paulo, Dept Pediat, Sao Paulo, Brazil.
   Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
   Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil.
   Na Sa Conceicao Hosp, Porto Alegre, RS, Brazil.
   NICHD, NIH, Dept Pediat Adolescent & Mat, AIDS Branch, Bethesda, MD USA.
RP Mussi-Pinhata, MM (corresponding author), FMRP USP, Dept Puericultura & Pediat, Avenida Bandeirantes 3900, BR-14049900 Ribeirao Preto, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
CR ALLEN K, 1998, FETAL NEONATAL PHYSL, P1530
   Beiner ME, 2003, AM J PERINAT, V20, P49, DOI 10.1055/s-2003-37948
   Bunders M, 2005, AIDS, V19, P1071, DOI 10.1097/01.aids.0000174454.63250.22
   Cano JMB, 2004, MED SCI MONITOR, V10, pCR179
   Carr R, 2000, ARCH DIS CHILD-FETAL, V83, pF160, DOI 10.1136/fn.83.2.F160
   *CDCP, 1992, MMWR-MORBID MORTAL W, V41
   Chappuy H, 2004, ANTIMICROB AGENTS CH, V48, P4332, DOI 10.1128/AAC.48.11.4332-4336.2004
   Chappuy H, 2004, AM J OBSTET GYNECOL, V191, P558, DOI 10.1016/j.ajog.2004.01.034
   Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
   DAINIAK N, 1988, BRIT J HAEMATOL, V69, P299, DOI 10.1111/j.1365-2141.1988.tb02366.x
   Division of AIDS National Institute of Allergy and Infectious Diseases, 2004, DIVISION AIDS TABLE
   Giaquinto C, 2004, AIDS, V18, P2009
   Le Chenadec J, 2003, AIDS, V17, P2053, DOI 10.1097/00002030-200309260-00006
   Lippi G, 2006, CLIN CHEM LAB MED, V44, P311, DOI 10.1515/CCLM.2006.054
   Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002
   Minkoff H, 2001, AM J OBSTET GYNECOL, V184, P1221, DOI 10.1067/mob.2001.113871
   Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380
   NICHOLSON J, 2004, NELSON TXB PEDIAT, V2396, P2398
   Olivero OA, 1999, AIDS, V13, P919, DOI 10.1097/00002030-199905280-00007
   Pacifici GM, 2005, EARLY HUM DEV, V81, P647, DOI 10.1016/j.earlhumdev.2005.02.002
   *PUBL HLTH SERV TA, 1996, REC US ANT DRUGS PRE
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   Shah MM, 1996, AIDS, V10, P1239, DOI 10.1097/00002030-199609000-00010
   Spengler U, 2002, J HEPATOL, V36, P283, DOI 10.1016/S0168-8278(01)00311-7
   Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012
   STOCKMAN JA, 1978, CLIN HAEMATOL, V7, P3
   Taha TE, 2002, AIDS, V16, P851, DOI 10.1097/00002030-200204120-00004
NR 27
TC 14
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2007
VL 26
IS 11
BP 1032
EP 1037
DI 10.1097/INF.0b013e31812f56ed
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 229QE
UT WOS:000250818300010
PM 17984811
DA 2020-12-17
ER

PT J
AU Weinberg, A
   Louzao, R
   Mussi-Pinhata, MM
   Cruz, MLS
   Pinto, JA
   Huff, MF
   de Castro, AC
   Sucupira, MC
   Denny, TN
AF Weinberg, Adriana
   Louzao, Raul
   Mussi-Pinhata, Marisa M.
   Cruz, Maria L. S.
   Pinto, Jorge A.
   Huff, Maria F.
   de Castro, Andrea C.
   Sucupira, Maria C.
   Denny, Thomas N.
TI Quality assurance program for peripheral blood mononuclear cell
   Cryopreservation
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; CLINICAL-TRIALS; MULTICENTER; VIABILITY; DISEASE
AB Seven Brazilian sites participating in the Pediatric AIDS Clinical Trials Group international cryopreservation quality assurance pilot program cryopreserved and shipped peripheral blood mononuclear cells (PBMC) to a central U.S. laboratory for analysis. Cell viability and recovery significantly increased over time. A wet-laboratory training session conducted at the central laboratory significantly improved the quality of the cryopreserved PBMC.
C1 Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA.
   Duke Univ, Raleigh, NC USA.
   Univ Sao Paulo, Sao Paulo, Brazil.
   Hosp Servidor Estadual, Rio De Janeiro, Brazil.
   Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   Hosp Conceicao, Porto Alegre, RS, Brazil.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Weinberg, A (corresponding author), 4200 E,9th Ave,Campus Box C227, Denver, CO 80262 USA.
EM Adriana.Weinberg@uchsc.edu
RI Araripe Sucupira, Maria Cecilia/K-1931-2012; Cruz, Maria
   Leticia/Y-5632-2019; Mussi-Pinhata, Marisa/G-6568-2012; Pinto, Jorge
   A/D-1743-2014
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pinto, Jorge A/0000-0003-2987-3238; Denny,
   Thomas/0000-0002-7364-8276
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033162, N01HD033162, N01HD033162, N01HD033162,
   N01HD033162, N01HD033162, N01HD033162, N01HD033162, N01HD033162,
   N01HD033345, N01HD033162, N01HD033162, N01HD033162, N01HD033162,
   N01HD033162, N01HD033162, N01HD033162, N01HD033162, N01HD033162,
   N01HD033162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01AI095356, N01AI95356,
   N01AI095356, N01AI095356, N01AI095356] Funding Source: NIH RePORTER;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI95356, N01-AI-95356] Funding Source:
   Medline; NICHD NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01 HD033162, N01-HD-33345, N01HD33345, N01-HD-33162] Funding Source:
   Medline
CR Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Dyer WB, 2007, CLIN VACCINE IMMUNOL, V14, P52, DOI 10.1128/CVI.00214-06
   GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019
   Kleeberger CA, 1999, CLIN DIAGN LAB IMMUN, V6, P14, DOI 10.1128/CDLI.6.1.14-19.1999
   Reimann KA, 2000, CLIN DIAGN LAB IMMUN, V7, P352, DOI 10.1128/CDLI.7.3.352-359.2000
   Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003
   Sleasman JW, 1997, CLIN DIAGN LAB IMMUN, V4, P653, DOI 10.1128/CDLI.4.6.653-658.1997
   Weinberg A, 2006, J INFECT DIS, V193, P488, DOI 10.1086/499826
   Weinberg A, 2000, CLIN DIAGN LAB IMMUN, V7, P714, DOI 10.1128/CDLI.7.4.714-716.2000
NR 9
TC 12
Z9 12
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD SEP
PY 2007
VL 14
IS 9
BP 1242
EP 1244
DI 10.1128/CVI.00187-07
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 210XH
UT WOS:000249488400027
PM 17652524
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Wagatsuma, VMD
   Marin, LJ
   Duarte, G
   Figueiredo, LTM
AF Yamamoto, Aparecida Yulie
   Mussi-Pinhata, Marisa Marcia
   de Deus Wagatsuma, Virginia Mara
   Marin, Lauro Juliano
   Duarte, Geraldo
   Moraes Figueiredo, Luis Tadeu
TI Human cytomegalovirus glycoprotein B genotypes in Brazilian mothers and
   their congenitally infected infants
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE CMV; gB genotypes; infants; mothers; congenital infection
ID RENAL-TRANSPLANT RECIPIENTS; STRAINS; IMMUNOCOMPETENT; POLYMORPHISMS;
   TRANSMISSION; POPULATION; BLOOD; CELL
AB A case-control study design was used in order to compare the distribution of human cytomegalovirus (HCMV) glycoprotein B (gB) genotypes in 48 mothers of 49 congenitally infected infants with that observed in 144 mothers of 146 uninfected infants to study genetic variation of HCMV strains and maternal-fetal transmission. Congenital infection with HCMV was characterized by DNA detection and virus isolation from two urine or saliva samples collected prior to the third week of life. Genotyping of HCMV was carried out by a polymerase chain reaction-restriction fragment length polymorphism analysis of the variable region of the gB gene, testing for four genotypes. Genotype frequency was similar among the 28 non-transmitting mothers who were shedding virus (gB1: 25%; gB2: 28.6%; gB3: 42.8%; gB4: 0%), the 37 transmitting mothers (gB1: 21.6%; gB2: 46%; gB3: 27%; gB4: 0%), and the 49 infected infants (gB1: 39%; gB2: 37%; gB3: 24%; gB4: 0%). The same genotype was detected at different body sites (urine, saliva, and blood) of each infected newborn and in the respective mother (breast milk, urine, and saliva). Co-infection with multiple genotypes was observed in the immediate postpartum period in two mothers of infected infants (5.4%) and one non-transmitting mother (3.6%). The gB genotype was not correlated with intrauterine HCMV transmission. The genotype distribution found reflects the overall frequency of wild strains circulating in this geographic region. A single genotype is responsible for congenital HCMV infection. Co-infection with more than one strain, as characterized by gB genotype, was infrequent in women who were presumably immunocompetent.
C1 Univ Sao Paulo, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Dept Obstet & Gynecol, BR-14049900 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Ribeirao Preto Preto Sch Med, Virus Res Unit, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Dept Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM ayamamoto@hcrp.fmrp.usp.br
RI Duarte, Geraldo/J-7906-2012; Mussi-Pinhata, Marisa/G-6568-2012;
   Figueiredo, Luiz T/E-3702-2012; Wagatsuma, Virginia/F-1643-2013
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Wagatsuma,
   Virginia/0000-0003-3801-3280
CR Aquino VH, 2000, J MED VIROL, V61, P138, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;138::AID-JMV22&gt;3.0.CO;2-#
   Arav-Boger R, 2002, J INFECT DIS, V186, P1057, DOI 10.1086/344238
   Arav-Boger R, 2006, J INFECT DIS, V194, P464, DOI 10.1086/505427
   Arista S, 2003, ARCH VIROL, V148, P547, DOI 10.1007/s00705-002-0941-0
   Baldanti F, 1998, ARCH VIROL, V143, P1701, DOI 10.1007/s007050050410
   Bale JF, 2000, J INFECT DIS, V182, P933, DOI 10.1086/315770
   Barbi M, 2001, J CLIN VIROL, V21, P75, DOI 10.1016/S1386-6532(00)00188-8
   Carraro E, 2003, J MED VIROL, V70, P240, DOI 10.1002/jmv.10383
   CHANDLER SH, 1987, J INFECT DIS, V155, P655, DOI 10.1093/infdis/155.4.655
   CHOU SW, 1991, J INFECT DIS, V163, P1229, DOI 10.1093/infdis/163.6.1229
   Lukacsi A, 2001, J MED VIROL, V65, P537, DOI 10.1002/jmv.2070
   Meyer-Konig U, 1998, J MED VIROL, V55, P75, DOI 10.1002/(SICI)1096-9071(199805)55:1<75::AID-JMV12>3.0.CO;2-Z
   Meyer-Konig U, 1998, LANCET, V352, P1280, DOI 10.1016/S0140-6736(05)70487-6
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   NAVARRO D, 1993, VIROLOGY, V197, P143, DOI 10.1006/viro.1993.1575
   Picone O, 2005, J CLIN MICROBIOL, V43, P25, DOI 10.1128/JCM.43.1.25-29.2005
   Picone O, 2004, PRENATAL DIAG, V24, P1001, DOI 10.1002/pd.942
   Pignatelli S, 2003, J CLIN VIROL, V28, P38, DOI 10.1016/S1386-6532(02)00236-6
   STAGNO S, 1983, SEMIN PERINATOL, V7, P31
   STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203
   STAGNO S, 1982, NEW ENGL J MED, V326, P663
   Tanaka K, 2005, J MED VIROL, V76, P356, DOI 10.1002/jmv.20366
   Trincado DE, 2000, J MED VIROL, V61, P481, DOI 10.1002/1096-9071(200008)61:4&lt;481::AID-JMV11&gt;3.0.CO;2-H
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
NR 25
TC 23
Z9 23
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2007
VL 79
IS 8
BP 1164
EP 1168
DI 10.1002/jmv.20903
PG 5
WC Virology
SC Virology
GA 184LF
UT WOS:000247642200017
PM 17597488
DA 2020-12-17
ER

PT J
AU D'Ippolito, M
   Read, JS
   Korelitz, J
   Joao, EC
   Mussi-Pinhata, M
   Rocha, N
AF D'Ippolito, Marcos
   Read, Jennifer S.
   Korelitz, James
   Joao, Esau Custodio
   Mussi-Pinhata, Marisa
   Rocha, Neiva
CA NISDI Perinatal Study Grp
TI Missed opportunities for prevention of mother-to-child transmission of
   human immunodeficiency virus type 1 in Latin America and the Caribbean:
   The NISDI Perinatal Study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HIV-1; mother-to-child transmission; prevention
ID INTRAPARTUM TRANSMISSION; HIV TRANSMISSION
AB Cases of mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) in a prospective cohort study in Latin America and the Caribbean were analyzed. Eight of 820 eligible infants became infected [transmission rate, 0.98% (95% CI = 0.45-1.96%)]. Five cases (62%) represented missed opportunities for prevention of MTCT of HIV-1, suggesting the need for ongoing training and education of clinicians regarding prevention of MTCT of HIV-1.
C1 NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA.
   Hosp Servidores Estado, Rio De Janeiro, Brazil.
   Westat Corp, Rockville, MD USA.
   Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   Ambulatorio Municipal DST AIDS, Caxias Do Sul, Brazil.
RP Read, JS (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Execut Bldg,Room 4B11F,6100 Execut Blvd MSC 7510, Bethesda, MD 20892 USA.
EM jennifer_read@nih.gov
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Joao,
   Esau/0000-0002-2412-0627
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345]
   Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF
   CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [N01HD033345, N01HD033345, N01HD033345] Funding Source: NIH
   RePORTER
CR BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718
   *BUEN AIR, 2004, REC PREV TRANSM VERT
   *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1
   Joao EC, 2003, AIDS, V17, P1853, DOI [10.1097/01.aids.0000076326.42412.7a, 10.1097/00002030-200308150-00016]
   Kourtis AP, 2001, JAMA-J AM MED ASSOC, V285, P709, DOI 10.1001/jama.285.6.709
   Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016
   *MIN SAUD SECR VIG, 2004, REC PROF TRANSM VERT
   Mussi-Pinhata MM, 2003, INT J STD AIDS, V14, P818, DOI 10.1258/095646203322556156
   Read JS, 2007, OBSTET GYNECOL, V109, P1358, DOI 10.1097/01.AOG.0000265211.76196.ac
   READ JS, 2005, TXB PEDIAT HIV CARE, P111
NR 10
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUL
PY 2007
VL 26
IS 7
BP 649
EP 653
DI 10.1097/INF.0b013e3180618bd6
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 185FS
UT WOS:000247697400021
PM 17596813
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Freimanis, L
   Yamamoto, AY
   Korelitz, J
   Pinto, JA
   Cruz, MLS
   Losso, MH
   Read, JS
AF Mussi-Pinhata, Marisa M.
   Freimanis, Laura
   Yamamoto, Aparecida Y.
   Korelitz, James
   Pinto, Jorge A.
   Cruz, Maria L. S.
   Losso, Marcelo H.
   Read, Jennifer S.
CA Natl Inst Child Hlth Human Dev Int
TI Infectious disease morbidity among young HIV-1 exposed but uninfected
   infants in Latin American and Caribbean countries: The National
   Institute of Child Health and Human Development International Site
   Development Initiative Perinatal Study
SO PEDIATRICS
LA English
DT Article
DE HIV-1; infancy; infections; Latin America; Caribbean
ID SYNCYTIAL VIRUS-INFECTION; COTRIMOXAZOLE PROPHYLAXIS; BORN;
   HOSPITALIZATION; BRONCHIOLITIS; MORTALITY; MOTHERS; RATES; LIFE
AB OBJECTIVE. The goal was to describe the frequency, characteristics, and correlates of infectious disease morbidity during the first 6 months of life among HIV-1 exposed but uninfected infants.
   METHODS. The study population consisted of infants enrolled in the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study who were HIV-1 uninfected and had follow- up data through the 6- month study visit. Definitive and presumed infections were recorded at study visits ( birth, 6 - 12 weeks, and 6 months).
   RESULTS. Of 462 HIV-1-uninfected infants with 11 644 child- weeks of observation, 283 experienced >= 1 infection. These 283 infants experienced 522 infections ( 1.8 infections per infant). The overall incidence rate of infections was 4.5 cases per 100 child- weeks of observation. Overall, the most common infections were skin or mucous membrane infections ( 1.9 cases per 100 child- weeks) and respiratory tract infections ( 1.7 cases per 100 child- weeks). Thirty-six percent of infants had > 1 respiratory tract infection ( 1.8 cases per 100 child- weeks). Incidence rates of upper and lower respiratory tract infections were similar ( 0.89 cases per 100 child- weeks and 0.9 cases per 100 child- weeks, respectively). Cutaneous and/ or oral candidiasis occurred in 48 neonates ( 10.3%) and 92 older infants ( 19.3%). Early neonatal sepsis was diagnosed in 12 infants ( 26.0 cases per 1000 infants). Overall, 81 of 462 ( 17.5%) infants were hospitalized with an infection. Infants with lower respiratory tract infections were hospitalized frequently ( 40.7%). The occurrence of >= 1 neonatal infection was associated with more- advanced maternal HIV-1 disease, tobacco use during pregnancy, infant anemia, and crowding. Lower maternal CD4(+) cell counts, receipt of intrapartum antibiotic treatment, and country of residence were associated with postneonatal infections.
   CONCLUSIONS. Close monitoring of HIV-1-exposed infants, especially those who are anemic at birth or whose mothers have more- advanced HIV-1 disease or who smoked during pregnancy, remains important.
C1 Univ Sao Paulo, FMPR, Dept Pucricultura & Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   Westat Corp, Rockville, MD USA.
   Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   Hosp Servidores Estado, Rio De Janeiro, Brazil.
   Hosp Gen Agudos, Buenos Aires, DF, Argentina.
   NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, Bethesda, MD 20892 USA.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, FMPR, Dept Pucricultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Pinto, Jorge A/D-1743-2014; Mussi-Pinhata, Marisa/G-6568-2012; Cruz,
   Maria Leticia/Y-5632-2019
OI Pinto, Jorge A/0000-0003-2987-3238; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; 
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01HD033345,
   N01HD033345, N01HD033345] Funding Source: NIH RePORTER; NICHD NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345]
   Funding Source: Medline
CR Albernaz EP, 2003, REV SAUDE PUBL, V37, P485, DOI 10.1590/S0034-89102003000400014
   Bakaki P, 2001, J ACQ IMMUN DEF SYND, V28, P35, DOI 10.1097/00042560-200109010-00006
   Barnhart HX, 1996, PEDIATRICS, V97, P710
   Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   Carbonell-Estrany X, 2001, PEDIATR INFECT DIS J, V20, P874, DOI 10.1097/00006454-200109000-00010
   Castro Melania X, 2003, Braz J Infect Dis, V7, P387, DOI 10.1590/S1413-86702003000600006
   *CDCP, 1992, MMWR-MORBID MORTAL W, V41
   Centers for Disease Control and Prevention, 2010, SAS PROGR CDC GROWTH
   Coutsoudis A, 2005, SAMJ S AFR MED J, V95, P339
   DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0
   DiFranza JR, 2004, PEDIATRICS, V113, P1007
   Escuder MML, 1999, REV SAUDE PUBL, V33, P349, DOI 10.1590/S0034-89101999000400005
   FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492
   FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141
   Gauthier TW, 2005, ALCOHOL CLIN EXP RES, V29, P1035, DOI 10.1097/01.ALC.0000167956.28160.5E
   Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057
   GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4
   Hankin C, 2004, AIDS CARE, V16, P293, DOI 10.1080/09540120410001665303
   Kattan M, 2001, PEDIATR PULM, V31, P267, DOI 10.1002/ppul.1038
   KLEIN JO, 2001, INFECT DIS FETUS NEW, P943
   Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029
   Levy A, 2005, EUR J EPIDEMIOL, V20, P277, DOI 10.1007/s10654-004-6515-6
   LEWIS DB, 2001, INFECT DIS FETUS NEW, P25
   LIDINJANSSON G, 1994, PEDIATRICS, V94, P815
   Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7
   Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003
   MORAESPINTO MI, 1998, ARCH DIS CHILD-FETAL, V79, P202
   Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17
   NELSON WE, 1987, NELSON TXB PEDIAT, P1535
   Oddy Wendy H, 2002, Breastfeed Rev, V10, P5
   Panitch HB, 2001, CURR OPIN PEDIATR, V13, P256, DOI 10.1097/00008480-200106000-00008
   Paul ME, 2005, PEDIATR INFECT DIS J, V24, P46, DOI 10.1097/01.inf.0000148879.83854.7e
   READ J, 2005, 12 C RETR OPP INF FE
   *REG COMPL CTR DIV, TABL GRAD SEV AD PED
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   Sinha A, 2003, PEDIATR INFECT DIS J, V22, P244, DOI 10.1097/00006454-200303000-00008
   Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56
   TAHA TE, 2000, PEDIATRICS, V106
   Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5
NR 40
TC 65
Z9 66
U1 0
U2 10
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2007
VL 119
IS 3
BP E694
EP E704
DI 10.1542/peds.2006-1856
PG 11
WC Pediatrics
SC Pediatrics
GA 141LK
UT WOS:000244579800067
PM 17296782
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Marin, LJ
   Brito, RM
   Carvalho Oliveira, PF
   Coelho, TB
AF Yamamoto, Aparecida Yulie
   Mussi-Pinhata, Marisa Marcia
   Marin, Lauro Juliano
   Brito, Rosangela Moura
   Carvalho Oliveira, Patricia Frizzo
   Coelho, Thalita Bonadio
TI Is saliva as reliable as urine for detection of cytomegalovirus DNA for
   neonatal screening of congenital CMV infection?
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE cytomegalovirus; congenital infection; neonatal screening; saliva; PCR
ID POLYMERASE-CHAIN-REACTION; VIRUS; BLOOD
AB Background: There are no studies on the detection of cytomegalovirus (CMV) DNA by molecular methods in the saliva of newborn infants in large scale screening programs.
   Objectives: To evaluate the usefulness of saliva as a sample for the neonatal screening of congenital CMV infection as compared to urine when processed by a PCR.
   Study Design: Saliva and urine samples were obtained during the first week of life. Both samples were attempted to be obtained from the first 2816 neonates. Subsequently, only saliva was obtained from other 1623 infants. Urine and saliva were processed by DNA-PCR. Confirmation of positive results was done by PCR and virus isolation by 3 weeks after birth.
   Results: A urine sample was not obtainable from 893/2816 (31.7%) infants. Both saliva and urine samples were obtained from the remaining 1923 infants. Of these, 28 (1.45%) were CMV-infected. There was 99.7% agreement between the results with both samples. CMV excretion was similar when PCR was applied to urine (1.3%) or to saliva (1.2%) samples. Among the subsequent 1623 infants for whom only a saliva sample was planned for screening, 16 (0.98%) were CMV-infected.
   Conclusions: Saliva samples are as useful as urine for the identification of CMV-DNA in large use for screening programs. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Campus USP,Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM ayamamoto@hcrp.fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Abrams, William R/A-5782-2008
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
CR BALCAREK KB, 1993, J INFECT DIS, V167, P1433, DOI 10.1093/infdis/167.6.1433
   Barbi M, 1996, CLIN DIAGN VIROL, V6, P27, DOI 10.1016/0928-0197(96)00228-0
   Demmler GJ, 2005, J PEDIATR-US, V146, P162, DOI 10.1016/j.jpeds.2004.11.020
   DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177
   Fowler KB, 1999, J PEDIATR-US, V135, P60, DOI 10.1016/S0022-3476(99)70328-8
   Halwachs-Baumann G, 2002, J CLIN VIROL, V25, pS81
   Kabir S, 2004, HELICOBACTER, V9, P115, DOI 10.1111/j.1083-4389.2004.00207.x
   KHAN G, 1991, J CLIN PATHOL, V44, P360, DOI 10.1136/jcp.44.5.360
   Mahony J, 1998, J CLIN MICROBIOL, V36, P3122, DOI 10.1128/JCM.36.11.3122-3126.1998
   Nogueira E, 2000, ACTA HAEMATOL-BASEL, V103, P73, DOI 10.1159/000041023
   Schwaiger M, 2003, J CLIN VIROL, V27, P136, DOI 10.1016/S1386-6532(02)00168-3
   Tsai CH, 1996, ACTA PAEDIATR, V85, P1241, DOI 10.1111/j.1651-2227.1996.tb18237.x
   WARREN WP, 1992, J CLIN MICROBIOL, V30, P786, DOI 10.1128/JCM.30.4.786-789.1992
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
NR 14
TC 84
Z9 89
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
IS 3
BP 228
EP 230
DI 10.1016/j.jcv.2006.03.011
PG 3
WC Virology
SC Virology
GA 060AE
UT WOS:000238772600011
PM 16750653
DA 2020-12-17
ER

PT J
AU Carvalheiro, CG
   Mussi-Pinhata, MM
   Yamamoto, AY
   De Souza, CBS
   Maciel, LMZ
AF Carvalheiro, CG
   Mussi-Pinhata, MM
   Yamamoto, AY
   De Souza, CBS
   Maciel, LMZ
TI Incidence of congenital toxoplasmosis estimated by neonatal screening:
   relevance of diagnostic confirmation in asymptomatic newborn infants
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID PREGNANT-WOMEN; FILTER-PAPER; MULTICENTER EVALUATION; GONDII INFECTION;
   IMMUNOGLOBULIN-M; PREVENTION; BLOOD; ANTIBODIES; CHILDREN; CHAIN
AB Congenital toxoplasmosis is rarely identified by routine clinical examination. The aim of this study was to estimate the incidence of the disease in the region of Ribeirao Preto, south-eastern Brazil. A definitive diagnosis was made on the basis of the persistence of anti-Toxoplasma IgG antibodies beyond I year of age. Blood samples obtained from 15 162 neonates and adsorbed onto filter paper were tested for anti-Toxoplasma IgM antibodies. Fifteen samples gave positive results. A definitive diagnosis was confirmed in five of the 13 infants (38.5%) who completed follow-up. These five infants presented with serum IgM and/or IgA antibodies, and clinical abnormalities. Disease incidence was estimated to be 3.3/10000 (95% CI 1.0-7.7), indicating the need for preventive measures. Neonatal screening is feasible, but screening tests with a better performance are required; positive screening results must be carefully confirmed.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Maciel, Lea MZ/O-6539-2015;
   Carvalheiro, Cristina/K-8040-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Carvalheiro,
   Cristina/0000-0003-1248-472X
CR Ajzenberg D, 2002, J INFECT DIS, V186, P684, DOI 10.1086/342663
   Ambroise-Thomas P, 2001, B ACAD NAT MED PARIS, V185, P665, DOI 10.1016/S0001-4079(19)34515-7
   BERGER R, 1992, SCAND J INFECT DIS, P46
   DUARTE G, 1999, REV BRAS GINECOL OBS, V21, P175
   Eaton RB, 1996, J CLIN MICROBIOL, V34, P3147, DOI 10.1128/JCM.34.12.3147-3150.1996
   Evengard B, 2001, EPIDEMIOL INFECT, V127, P121, DOI 10.1017/S0950268801005775
   Fletcher RH, 1996, CLIN EPIDEMIOLOGY ES
   FRENKEL JK, 1974, B NEW YORK ACAD MED, V50, P228
   Gilbert RE, 2000, BRIT J OPHTHALMOL, V84, P224, DOI 10.1136/bjo.84.2.224
   GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604
   Jenum PA, 1998, J CLIN MICROBIOL, V36, P2900, DOI 10.1128/JCM.36.10.2900-2906.1998
   KOPPE JG, 1986, LANCET, V1, P254
   Lebech M, 1996, EUR J CLIN MICROBIOL, V15, P799, DOI 10.1007/BF01701522
   Lebech M, 1999, LANCET, V353, P1834, DOI 10.1016/S0140-6736(98)11281-3
   Logar J, 2002, SCAND J INFECT DIS, V34, P201, DOI 10.1080/00365540110080386
   MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38
   Mets MB, 1996, AM J OPHTHALMOL, V122, P309, DOI 10.1016/S0002-9394(14)72057-4
   Mozzatto Liége, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P147, DOI 10.1590/S0036-46652003000300006
   Naessens A, 1999, J PEDIATR-US, V135, P714, DOI 10.1016/S0022-3476(99)70090-9
   Neto EC, 2000, INT J EPIDEMIOL, V29, P941, DOI 10.1093/ije/29.5.941
   Paul M, 2000, PEDIATR INFECT DIS J, V19, P30, DOI 10.1097/00006454-200001000-00007
   Petersen E, 2001, INT J PARASITOL, V31, P115, DOI 10.1016/S0020-7519(00)00140-5
   Pinon JM, 2001, J CLIN MICROBIOL, V39, P2267, DOI 10.1128/JCM.39.6.2267-2271.2001
   Reiche E M, 2000, Rev Soc Bras Med Trop, V33, P519, DOI 10.1590/S0037-86822000000600002
   Remington J.S., 2001, INFECT DIS FETUS NEW, P205
   Rey Luis C., 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P171, DOI 10.1590/S0036-46651999000300007
   Spalding Sílvia Maria, 2003, Rev. Soc. Bras. Med. Trop., V36, P483, DOI 10.1590/S0037-86822003000400009
   Szenasi Z, 1997, INT J EPIDEMIOL, V26, P428, DOI 10.1093/ije/26.2.428
   THOUMSIN H, 1992, SCAND J INFECT DIS S, V84, P84
   Varella Ivana S., 2003, J. Pediatr. (Rio J.), V79, P69, DOI 10.1590/S0021-75572003000100012
   Wallon M, 1999, EUR J PEDIATR, V158, P645, DOI 10.1007/s004310051168
   WILSON CB, 1980, PEDIATRICS, V66, P767
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
NR 33
TC 22
Z9 23
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUN
PY 2005
VL 133
IS 3
BP 485
EP 491
DI 10.1017/S095026880400353X
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 939NF
UT WOS:000230079000012
PM 15962555
OA Green Published
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
   Rego, MAD
   Pinto, PCG
   Da Motta, MSF
   Calixto, C
AF Mussi-Pinhata, MM
   Yamamoto, AY
   Rego, MAD
   Pinto, PCG
   Da Motta, MSF
   Calixto, C
TI Perinatal or early-postnatal cytomegalovirus infection in preterm
   infants under 34 weeks gestation born to CMV-seropositive mothers within
   a high-seroprevalence population
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID NONFILTERED-IRRADIATED BLOOD; LOW-BIRTH-WEIGHT; NEWBORN-INFANTS; VIRUS
   INFECTION; TRANSMISSION; TRANSFUSION; PREMATURE; PREVENTION; DIFFERENCE;
   ANTIBODIES
AB In a prospective study, we evaluated the frequency, correlates, and clinical significance of perinatal or early-postnatal cytomegalovirus (CMV) infection in <34-week-gestation infants (n = 95) born to CMV-seropositive mothers. None had congenital CMV infection. Overall, 21 (22.1%; 95% CI = 14.2-31.8) infants were found to be infected; 10 excreted CMV at <60 days, and 11 had later excretion. Blood transfusion, birth weight, and vaginal delivery were not associated factors. Receiving natural breast milk within the first 30 days (OR = 4.5, P=.02) or for >30 days (OR = 7.9, P<.01) was associated with infection. Only one (4.8%) of the infected infants was symptomatic. For <34-week-gestation infants, frequency of perinatal and early-postnatal CMV infection is high. Early or prolonged exposure to breast milk is an associated factor. However, most infections are asymptomatic, indicating that CMV infection in preterm infants within such a population is a serious problem infrequently.
C1 Univ Sao Paulo, Sch Med, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, FMRP, Dept Puericultura & Pediat, Avenida Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
CR ADLER SP, 1983, PEDIATR INFECT DIS J, V2, P114, DOI 10.1097/00006454-198303000-00009
   Almeida LNB, 2001, REV SAUDE PUBL, V35, P124, DOI 10.1590/S0034-89102001000200004
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   BALLARD RA, 1979, AM J DIS CHILD, V133, P482, DOI 10.1001/archpedi.1979.02130050026005
   BOPPANA SB, 1995, J INFECT DIS, V171, P1115, DOI 10.1093/infdis/171.5.1115
   DECATES CR, 1994, J INFECTION, V28, P25, DOI 10.1016/S0163-4453(94)94037-1
   Fergusson D, 2002, TRANSFUSION, V42, P159, DOI 10.1046/j.1537-2995.2002.00022.x
   GALEA G, 1992, VOX SANG, V62, P200, DOI 10.1111/j.1423-0410.1992.tb01199.x
   GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1
   GONCZOL E, 1986, J VIROL METHODS, V14, P37, DOI 10.1016/0166-0934(86)90005-4
   Hamprecht K, 2001, LANCET, V357, P513, DOI 10.1016/S0140-6736(00)04043-5
   Luban NLC, 2000, TRANSFUSION, V40, P387, DOI 10.1046/j.1537-2995.2000.40030387.x
   Maschmann J, 2001, CLIN INFECT DIS, V33, P1998, DOI 10.1086/324345
   Mosca F, 2001, LANCET, V357, P1800, DOI 10.1016/S0140-6736(00)04914-X
   Mussi-Pinhata MM, 2003, J MED VIROL, V69, P232, DOI 10.1002/jmv.10271
   Ohto H, 1999, TRANSFUSION, V39, P201, DOI 10.1046/j.1537-2995.1999.39299154736.x
   PARYANI SG, 1985, J PEDIATR-US, V107, P451, DOI 10.1016/S0022-3476(85)80533-3
   PREIKSAITIS JK, 1988, TRANSFUSION, V28, P205, DOI 10.1046/j.1537-2995.1988.28388219143.x
   Sharland M, 2002, ARCH DIS CHILD-FETAL, V86, P140
   SMITH D, 1983, TRANSFUSION, V23, P420
   STAGNO S, 1985, J CLIN MICROBIOL, V21, P930, DOI 10.1128/JCM.21.6.930-935.1985
   STEINMANN J, 1994, J CLIN LAB ANAL, V8, P191, DOI 10.1002/jcla.1860080403
   Vochem M, 1998, PEDIATR INFECT DIS J, V17, P53, DOI 10.1097/00006454-199801000-00012
   Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0
   Yasuda A, 2003, PEDIATRICS, V111, P1333, DOI 10.1542/peds.111.6.1333
   YEAGER AS, 1981, J PEDIATR-US, V98, P281, DOI 10.1016/S0022-3476(81)80662-2
   YEAGER AS, 1974, AM J DIS CHILD, V128, P478, DOI 10.1001/archpedi.1974.02110290048008
   YEAGER AS, 1983, J PEDIATR-US, V102, P918, DOI 10.1016/S0022-3476(83)80025-0
NR 28
TC 36
Z9 36
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD NOV
PY 2004
VL 145
IS 5
BP 685
EP 688
DI 10.1016/j.jpeds.2004.07.025
PG 4
WC Pediatrics
SC Pediatrics
GA 870VM
UT WOS:000225086800028
PM 15520780
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Marin, LJ
   Wagatsuma, VM
   Brito, RMM
   Duarte, G
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Marin, LJ
   Wagatsuma, VM
   Brito, RMM
   Duarte, G
TI Human cytomegalovirus (HCMV) genotypes and vertical transmission in
   Brazilian mother-infant pairs
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the Pediatric-Academic-Societies
CY MAY   04, 2004
CL San Francisco, CA
SP Pediatr Acad Soc
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RI Duarte, Geraldo/J-7906-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2004
VL 55
IS 4
SU S
MA 1808
BP 318A
EP 318A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 808TJ
UT WOS:000220591101874
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Carvalheiro, CG
   Yamamoto, AY
   Maciel, LZ
AF Mussi-Pinhata, MM
   Carvalheiro, CG
   Yamamoto, AY
   Maciel, LZ
TI Neonatal screening for congenital toxoplasmosis: Relevance of diagnosis
   confirmation in asymptomatic newborn infants
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the Pediatric-Academic-Societies
CY MAY   04, 2004
CL San Francisco, CA
SP Pediatr Acad Soc
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RI Carvalheiro, Cristina/K-8040-2012; Maciel, Lea MZ/O-6539-2015
OI Carvalheiro, Cristina/0000-0003-1248-472X; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2004
VL 55
IS 4
SU S
MA 2259
BP 397A
EP 397A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 808TJ
UT WOS:000220591102325
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Nobre, RA
   Martinez, FE
   Jorge, SM
   Ferlin, MLS
   Goncalves, AL
AF Mussi-Pinhata, MM
   Nobre, RA
   Martinez, FE
   Jorge, SM
   Ferlin, MLS
   Goncalves, AL
TI Early-onset bacterial infection in Brazilian neonates with respiratory
   distress: A hospital-based study
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID LATEX AGGLUTINATION; NEWBORN-INFANT; SEPSIS; DIAGNOSIS; DISEASE;
   STREPTOCOCCUS; SEPTICEMIA; MENINGITIS; WOMEN; RISK
AB We investigated infants with respiratory distress within 4 days of birth whose mothers had not received antibiotic prophylaxis to evaluate the frequency and etiology of bacterial infection and associated risk factors. The study was conducted on 261 infants suffering respiratory distress admitted to a Brazilian neonatal intensive care unit, 94 per cent of whom were born prematurely. Gestational and delivery history; bacteriological cultures of blood, cerebrospinal fluid, tracheal aspirates and urine; complete and differential blood counts; a urinary group B streptococcal latex antigen test; and a chest radiograph were analysed. Indications of infection were found in 38.7 per cent and confirmed in 11.9 per cent of the neonates. Gram-positive (70.9 per cent) and Gram-negative bacteria (29.1 per cent) were found in 31 cases of confirmed early bacteremia. Group B Streptococcus was the predominant causative agent (19.4 per cent) in infants exhibiting confirmed infection. Culture-proven infection was more frequent among infants delivered vaginally (adjusted OR = 2.53,p = 0.05) or born to mothers with signs of intra-amniotic infection (adjusted OR = 2.83, p = 0.04). Preventive measures against early bacterial infection in preterm infants from this population are strongly warranted.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Sao Paulo, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, FMRP, Dept Puericultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Martinez, Francisco E/H-1194-2014
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Martinez, Francisco
   E/0000-0002-6269-9182
CR Baker CJ, 1997, CLIN PERINATOL, V24, P59
   BAKER CJ, 1988, ANN NY ACAD SCI, V549, P193, DOI 10.1111/j.1749-6632.1988.tb23972.x
   BAKER CJ, 1983, J PEDIATR-US, V102, P393, DOI 10.1016/S0022-3476(83)80657-X
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   BENCHETRIT LC, 1982, J CLIN MICROBIOL, V15, P787, DOI 10.1128/JCM.15.5.787-790.1982
   BOYLE RJ, 1978, PEDIATRICS, V62, P744
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   de Araujo MCK, 1999, EARLY HUM DEV, V56, P1
   DORAND RD, 1979, SOUTHERN MED J, V72, P1262, DOI 10.1097/00007611-197910000-00014
   Eichenwald EC, 1997, INFECT DIS CLIN N AM, V11, P223, DOI 10.1016/S0891-5520(05)70350-0
   GOMEZ R, 1995, CLIN PERINATOL, V22, P281
   HALL SL, 1991, PEDIATR INFECT DIS J, V10, P57, DOI 10.1097/00006454-199101000-00012
   Joseph TA, 1998, ARCH PEDIAT ADOL MED, V152, P35
   KINNEY JS, 1993, PEDIATR INFECT DIS J, V12, P739, DOI 10.1097/00006454-199309000-00007
   KOUTOUBY A, 1995, J TROP PEDIATRICS, V41, P177, DOI 10.1093/tropej/41.3.177
   MORENO MT, 1994, PEDIATR INFECT DIS J, V13, P516, DOI 10.1097/00006454-199406000-00010
   ROBILLARD PY, 1993, ACTA PAEDIATR, V82, P687, DOI 10.1111/j.1651-2227.1993.tb18041.x
   RODWELL RL, 1988, J PEDIATR-US, V112, P761, DOI 10.1016/S0022-3476(88)80699-1
   SANCHEZ PJ, 1990, J PEDIATR-US, V116, P601, DOI 10.1016/S0022-3476(05)81613-0
   Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497
   SPIGELBLATT L, 1985, PEDIATR INFECT DIS J, V4, P56, DOI 10.1097/00006454-198501000-00014
   STGEME JW, 1984, J PEDIATR-US, V104, P608, DOI 10.1016/S0022-3476(84)80562-4
   STOLL BJ, 1995, LANCET, V345, P1236, DOI 10.1016/S0140-6736(95)92017-X
   Stoll BJ, 1996, J PEDIATR-US, V129, P72, DOI 10.1016/S0022-3476(96)70192-0
   TESSIN I, 1990, ACTA PAEDIATR SCAND, V79, P1023, DOI 10.1111/j.1651-2227.1990.tb11378.x
   WEISMAN LE, 1992, J PEDIATR-US, V121, P428
   Zaleznik DF, 2000, CLIN INFECT DIS, V30, P276, DOI 10.1086/313665
NR 27
TC 6
Z9 8
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
EI 1465-3664
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD FEB
PY 2004
VL 50
IS 1
BP 6
EP 11
DI 10.1093/tropej/50.1.6
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 773AG
UT WOS:000188875100003
PM 14984162
OA Bronze
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Kato, CM
   Duarte, G
   Paschoini, MC
   Bettiol, H
   Quintana, SM
AF Mussi-Pinhata, MM
   Kato, CM
   Duarte, G
   Paschoini, MC
   Bettiol, H
   Quintana, SM
TI Factors associated with vertical HIV transmission during two different
   time periods: the impact of zidovudine use on clinical practice at a
   Brazilian reference centre
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE vertical disease transmission; HIV; zidovudine; risk factors; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; CHILD
   TRANSMISSION; INFECTED WOMEN; RISK-FACTORS; COHORT; TYPE-1; PREGNANCY;
   REDUCTION; TRENDS
AB Vertical HIV transmission rates and associated factors among mother-infant pairs cared for at a Brazilian reference centre from 1988 to 1993 (period 1), and from 1996 to 1999 (period 2) were evaluated. A total of 150 and 239 infants born to HIV+ mothers were enrolled at birth during these periods. No zidovudine prophylaxis was available in period 1. In period 2, 92.4% of the infants were exposed to zidovudine (54% started at delivery or in the post-natal period). During period 1, 25 of 129 infants were found to be infected (19.4%; 95% confidence interval [CI] = 13-27) vs 20 of 232 (8.6%; 95% CI = 5-13) during period 2 (P<0.01). After controlling for co-variables, this decline was due to zidovudine prophylaxis, either with complete (odds ratio [OR] = 0.24; 95% CI = 0.08-0.70) or incomplete (OR=0.37; 95% CI=0.17-0.81) regimens. Premature rupture of membranes (OR = 3.2) and rhesus-negative blood type of the infant (OR = 2.6) facilitated transmission. Although confirming the protective effect of zidovudine prophylaxis, alternative approaches aimed at pregnant women identified late are needed for this population.
C1 Univ Sao Paulo, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Dept Obstet & Gynaecol, Fac Med, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Dept Pediat, Av Bandeirantes 3900,Campus USP, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Bettiol, Heloisa/B-4190-2013; Quintana, Silvana Maria/D-6953-2015;
   Mussi-Pinhata, Marisa/G-6568-2012; Duarte, Geraldo/J-7906-2012
OI Bettiol, Heloisa/0000-0001-8744-4373; Quintana, Silvana
   Maria/0000-0002-9311-786X; Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
CR BROCKLEHURST P, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003510
   Bulterys M, 1997, J ACQ IMMUN DEF SYND, V15, P76, DOI 10.1097/00042560-199705010-00012
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1
   Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P225
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207
   DUARTE G, 1993, 9 INT C AIDS BERL GE
   DURAN A, 2000, 13 INT AIDS C DURB S
   Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840
   Harris NS, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e60
   KENJ G, 1999, 2 C GLOB STRAT PREV
   KREITCHMANN R, 2000, 13 INT AIDS C DURB S
   Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501
   Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531
   MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188
   *MIN SAUD BRAS, 1994, REV DEF NAC CAS AIDS, V1, P11
   *MIN SAUD BRAS PRO, 1999, B EP AIDS ANO 13, V1
   Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601
   Mussi-Pinhata M M, 1994, J Pediatr (Rio J), V70, P338
   Nduati R, 2000, ADV EXP MED BIOL, V478, P201
   Neves FRAL, 1999, REV SAUDE PUBL, V33, P624, DOI 10.1590/S0034-89101999000600015
   Newell ML, 1996, AIDS, V10, P1675
   Nogueira S A, 2001, Braz J Infect Dis, V5, P78
   PINTO J, 1998, 12 WORLD AIDS C GEN
   RUBINI NPM, 1996, 11 INT C AIDS VANC C
   SARACENI V, 2000, 13 INT AIDS C DURB S
   *SECR EST SAUD SAO, 2000, B EPIDEMIOLOGICO 17, V1
   Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013
   Thorne C, 2000, EARLY HUM DEV, V58, P1, DOI 10.1016/S0378-3782(00)00049-9
   Van Dyke RB, 1999, J INFECT DIS, V179, P319, DOI 10.1086/314580
   Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001
NR 31
TC 13
Z9 15
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD DEC
PY 2003
VL 14
IS 12
BP 818
EP 825
DI 10.1258/095646203322556156
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 751BE
UT WOS:000187032300008
PM 14678590
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Rego, MA
   Pinto, PC
   Motta, MS
   Calixto, C
   Oliveira, PR
   Junior, WS
   Rodrigues, LT
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Rego, MA
   Pinto, PC
   Motta, MS
   Calixto, C
   Oliveira, PR
   Junior, WS
   Rodrigues, LT
TI Perinatal cytomegalovirus (CMV) infection in preterm infants despite
   high levels of neutralizing antibodies
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the Pediatric-Academic-Society
CY MAY 03-06, 2003
CL SEATTLE, WASHINGTON
SP Pediat Acad Soc, Amer Pediat Soc, Soc Pediat Res, Ambulatory Pediat Assoc, Tulane Univ Hlth Sci Ctr, Ctr Continuing Educ
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2003
VL 53
IS 4
SU S
MA 1779
BP 312A
EP 312A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 661PA
UT WOS:000181897901778
DA 2020-12-17
ER

PT J
AU Martinez, FE
   Mussi-Pinhata, MM
   Marba, S
   Neto, AA
   Procianoy, R
   Miura, E
   Lopes, JMA
   Bomfim, O
   Guinsburg, R
   Almeida, MFB
   Ferlin, MLS
   Miyoshi, M
   Leone, CR
   Sadeck, LSR
   Vaz, FAC
   Fiori, RM
   Garcia, TT
   Trindade, CEP
   Betlin, MR
AF Martinez, FE
   Mussi-Pinhata, MM
   Marba, S
   Neto, AA
   Procianoy, R
   Miura, E
   Lopes, JMA
   Bomfim, O
   Guinsburg, R
   Almeida, MFB
   Ferlin, MLS
   Miyoshi, M
   Leone, CR
   Sadeck, LSR
   Vaz, FAC
   Fiori, RM
   Garcia, TT
   Trindade, CEP
   Betlin, MR
TI Antenatal corticosteroid therapy and its repercussions at preterm
   neonates from the Brazilian Neonatal Network
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
CT Annual Meeting of the Pediatric-Academic-Society
CY MAY 03-06, 2003
CL SEATTLE, WASHINGTON
SP Pediat Acad Soc, Amer Pediat Soc, Soc Pediat Res, Ambulatory Pediat Assoc, Tulane Univ Hlth Sci Ctr, Ctr Continuing Educ
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   Univ Estadual Campinas, Campinas, SP, Brazil.
   UFRS, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   Fiocruz MS, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin Sao Paulo, BR-05508 Sao Paulo, Brazil.
   PUCRS, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   Univ Estadual Paulista Julio Mesquita Filho, Fac Med Botucatu, Botucatu, SP, Brazil.
RI Leone, Clea/ABA-6374-2020; Martinez, Francisco E/H-1194-2014; Guinsburg,
   Ruth/F-1984-2013
OI Martinez, Francisco E/0000-0002-6269-9182; Guinsburg,
   Ruth/0000-0003-1967-9861
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2003
VL 53
IS 4
SU S
MA 2553
BP 452A
EP 452A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 661PA
UT WOS:000181897902551
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Pinto, PCG
   Yamamoto, AY
   Berencsi, K
   de Souza, CBS
   Andrea, M
   Duarte, G
   Jorge, SM
AF Mussi-Pinhata, MM
   Pinto, PCG
   Yamamoto, AY
   Berencsi, K
   de Souza, CBS
   Andrea, M
   Duarte, G
   Jorge, SM
TI Placental transfer of naturally acquired, maternal cytomegalovirus
   antibodies in term and preterm neonates
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE maternally-acquired immunity; neutralizing antibodies; IgG antibodies
ID FULL-TERM; PREMATURE-INFANTS; NEWBORN-INFANTS; VIRUS INFECTIONS;
   GESTATIONAL-AGE; IGG SUBCLASSES; IMMUNOGLOBULIN; TRANSMISSION;
   DIAGNOSIS; RECEPTORS
AB Maternal antibodies may protect the fetus and neonate against severe forms of CMV-caused disease, therefore this study investigated the efficiency-of the placental transfer of naturally acquired, maternal total anti-cytomegalovirus (CMV) IgG and neutralizing antibodies at different gestational ages. The study was conducted on 182 healthy CMV-seropositive Brazilian mothers and their 196 infants who were not infected congenitally with CMV, as determined by CMV detection in urine. The study groups were composed of 44 infants aged 28-30 weeks; 51 infants aged 31-33 weeks; 62 infants aged 3436 weeks, and 39 infants of gestational age greater than or equal to37 weeks. Quantitative detection of total CMV IgG was carried out using EIA and virus neutralizing titers were determined by a microneutralization assay in sera from mothers and infants. CMV IgG levels and neutralizing titers of the infants correlated with maternal levels (r = 0.873 and r = 0.841, respectively). The efficiency of placental transfer of these antibodies was enhanced significantly as gestation progressed until 3436 weeks, when values similar to those of fullterm infants (90-100%) were found. Transfer ratios were significantly higher for neutralizing compared to total CMV IgG antibodies at gestational age 31-33 weeks (100% vs. 84%, respectively) and at gestational age 28-30 weeks (75% vs. 60%, respectively). We conclude that placental transfer of naturally acquired maternal CMV neutralizing and total CMV IgG antibodies are similarly efficient above 34 weeks of gestational age. At less than 34 weeks of gestational age, transfer of neutralizing antibodies may be favored and these antibodies reach the neonatal serum of 99% of these premature infants.
C1 Univ Sao Paulo, Dept Pediat, Sch Med Ribeirao Preto, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Obstet & Gynecol, Sch Med Ribeirao Preto, Sao Paulo, Brazil.
   Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
RP Mussi-Pinhata, MM (corresponding author), FMRP USP, Dept Puericultura & Pediat, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
RI Mussi-Pinhata, Marisa/G-6568-2012; Duarte, Geraldo/J-7906-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
CR ALFORD CA, 1990, REV INFECT DIS S, V12, P743
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   BALLARD RA, 1979, AM J DIS CHILD, V133, P482, DOI 10.1001/archpedi.1979.02130050026005
   BATAGLIA F, 1967, J PEDIATR, V71, P159
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   Chatterjee A, 2001, J INFECT DIS, V183, P1547, DOI 10.1086/320714
   CHRISTENSEN KK, 1984, EUR J PEDIATR, V142, P86, DOI 10.1007/BF00445584
   Costa-Carvalho BT, 1999, CLIN DIAGN LAB IMMUN, V6, P50
   CostaCarvalho BT, 1996, BRAZ J MED BIOL RES, V29, P201
   EINHORN MS, 1987, J PEDIATR-US, V111, P783, DOI 10.1016/S0022-3476(87)80268-8
   GILLJAM G, 1989, J VIROL METHODS, V25, P139, DOI 10.1016/0166-0934(89)90028-1
   Goncalves G, 1999, EPIDEMIOL INFECT, V122, P273, DOI 10.1017/S0950268899002046
   GONCZOL E, 1986, J VIROL METHODS, V14, P37, DOI 10.1016/0166-0934(86)90005-4
   GOTLIEBSTEMATSKY T, 1983, ISRAEL J MED SCI, V19, P984
   Gupta CK, 1996, BIOLOGICALS, V24, P117, DOI 10.1006/biol.1996.0015
   KAMEDA T, 1991, PLACENTA, V12, P15, DOI 10.1016/0143-4004(91)90506-B
   Linder N, 1999, INFECTION, V27, P203, DOI 10.1007/BF02561529
   Linder N, 1997, PEDIATR INFECT DIS J, V16, P245, DOI 10.1097/00006454-199702000-00015
   Linder N, 1998, VACCINE, V16, P236, DOI 10.1016/S0264-410X(97)00180-1
   Ozbek S, 1999, ACTA PAEDIATR, V88, P1254, DOI 10.1080/080352599750030383
   REYNOLDS DW, 1978, J INFECT DIS, V137, P564, DOI 10.1093/infdis/137.5.564
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   Simister NE, 1997, J REPROD IMMUNOL, V37, P1, DOI 10.1016/S0165-0378(97)00068-5
   SNEDECOR GW, 1989, STAT METHODS, P138
   SNYDMAN DR, 1995, PEDIATR INFECT DIS J, V14, P34, DOI 10.1097/00006454-199501000-00007
   STAGNO S, 1985, J CLIN MICROBIOL, V21, P930, DOI 10.1128/JCM.21.6.930-935.1985
   STEINMANN J, 1994, J CLIN LAB ANAL, V8, P191, DOI 10.1002/jcla.1860080403
   TOIVANEN P, 1968, IMMUNOLOGY, V15, P395
   Vochem M, 1998, PEDIATR INFECT DIS J, V17, P53, DOI 10.1097/00006454-199801000-00012
   WEBER B, 1993, J MED VIROL, V40, P28, DOI 10.1002/jmv.1890400107
   Wesumperuma HL, 1999, ANN TROP MED PARASIT, V93, P169, DOI 10.1080/00034989958654
   Yamamoto A Y, 1999, J Pediatr (Rio J), V75, P126
   Yamamoto A Y, 1998, Rev Soc Bras Med Trop, V31, P19, DOI 10.1590/S0037-86821998000100003
   Yamamoto A Y, 1999, J Pediatr (Rio J), V75, P23
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   YEAGER AS, 1981, J PEDIATR-US, V98, P281, DOI 10.1016/S0022-3476(81)80662-2
   YEAGER AS, 1983, J PEDIATR-US, V102, P918, DOI 10.1016/S0022-3476(83)80025-0
NR 38
TC 25
Z9 27
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 2003
VL 69
IS 2
BP 232
EP 239
DI 10.1002/jmv.10271
PG 8
WC Virology
SC Virology
GA 631VU
UT WOS:000180188300011
PM 12683413
DA 2020-12-17
ER

PT J
AU Martinez, FE
   Sieber, VM
   Jorge, SM
   Ferlin, MLS
   Mussi-Pinhata, MM
AF Martinez, FE
   Sieber, VM
   Jorge, SM
   Ferlin, MLS
   Mussi-Pinhata, MM
TI Effect of supplementation of preterm formula with long chain
   polyunsaturated fatty acids on mineral balance in preterm infants
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE long chain polyunsaturated fatty acids; preterm nutrition; preterm
   formula; mineral balance; calcium; phosphorus; magnesium; zinc; copper
ID BIRTH-WEIGHT INFANTS; HUMAN-MILK; PREMATURE-INFANTS; TRACE-ELEMENTS;
   YOUNG INFANT; CALCIUM; GROWTH; LIPIDS; FETUS; ABSORPTION
AB Background: Incorporation of long chain polyunsaturated fatty acids (LCP) into formulas may interfere with mineral metabolism. We investigate mineral balance in preterm infants who were fed a formula with LCP.
   Methods: Infants were randomized in a double-blind manner, 20 infants in each group, to receive a formula with LCP (F+LCP) or without LCP (F) for 30 days. Plasma levels (at the beginning and after 30 days) and nutritional balance (after 1 week) for Ca, P, Mg, Zn, and Cu were obtained for all infants.
   Results: Groups were similar regarding birth weight, gestational age, weight, and corrected age at study start. During the 30-day study period, the groups had comparable milk intake and reached similar and satisfactory weight gains and longitudinal growth. Within each group, there was no change in plasma mineral concentrations over the course of the study, and there were no differences at each time point between groups. All values were within the normal range for age. No differences in mineral balance were detected between the F and F+LCP groups, with both groups demonstrating comparable intake, net retention, and fecal losses of each mineral.
   Conclusions: Adding a content of LCP blend similar to that of human milk to a preterm formula caused no disturbance in Ca, P, Mg, Zn, or Cu nutritional balance.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil.
   Milupa GmbH & Co KG, Dept Sci, Friedrichsdorf, Germany.
RP Martinez, FE (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM femartin@fmrp.usp.br
RI Martinez, Francisco E/H-1194-2014; Mussi-Pinhata, Marisa/G-6568-2012
OI Martinez, Francisco E/0000-0002-6269-9182; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
CR ATKINSON SA, 1983, J PEDIATR-US, V102, P99, DOI 10.1016/S0022-3476(83)80302-3
   CARLSON SE, 1992, LIPIDS, V27, P901, DOI 10.1007/BF02535870
   CRAWFORD MA, 1989, J INTERN MED, V225, P159, DOI 10.1111/j.1365-2796.1989.tb01450.x
   CRAWFORD MA, 1993, AM J CLIN NUTR, V57, P703
   FOMON SJ, 1993, NUTR NORMAL INFANTS, P261
   GERTNER JM, 1990, PEDIATR CLIN N AM, V37, P1441
   HERNELL O, 1991, ACTA PAEDIATR SCAND, V80, P887
   HOLT LE, 1935, J PEDIATR-US, V6, P427
   KASHYAP S, 1990, AM J CLIN NUTR, V52, P254
   KOLETZKO B, 1991, Z ERNAHRUNGSWISS, V30, P289, DOI 10.1007/BF01651958
   KOLETZKO B, 1992, EUR J CLIN NUTR, V46, pS51
   KOLETZKO B, 1990, BIOL NEONATE, V57, P172, DOI 10.1159/000243188
   KOLETZKO B, 1995, J PEDIATR GASTR NUTR, V21, P200, DOI 10.1097/00005176-199508000-00012
   KOLETZKO B, 1995, INT J VITAM NUTR RES, V65, P101
   KOLETZKO B, 1992, J PEDIAT S, V120, P62
   KOO WWK, 1991, J AM COLL NUTR, V10, P474
   Kruger MC, 1997, PROG LIPID RES, V36, P131, DOI 10.1016/S0163-7827(97)00007-6
   LUBCHENCO LO, 1963, PEDIATRICS, V32, P793
   MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8
   MARTINEZ M, 1991, WORLD REV NUTR DIET, V66, P87
   MARTINEZ M, 1988, J NEUROSCI RES, V20, P484, DOI 10.1002/jnr.490200412
   MAUER AM, 1985, PEDIATRICS, V75, P976
   MUGGLI R, 1989, HEALTH EFFECTS OF FISH AND FISH OILS, P201
   O'Connor DL, 2001, PEDIATRICS, V108, P359, DOI 10.1542/peds.108.2.359
   ODUTUGA AA, 1982, COMP BIOCHEM PHYS A, V71, P383, DOI 10.1016/0300-9629(82)90422-4
   RAIOL MRS, 1993, J PEDIATR, V123, P985
   Schanler RJ, 1999, PEDIATRICS, V103, P1150, DOI 10.1542/peds.103.6.1150
   SHAW JCL, 1980, AM J DIS CHILD, V134, P74
   SHAW JCL, 1979, AM J DIS CHILD, V133, P1260, DOI 10.1001/archpedi.1979.02130120052011
   TANTIBHEDHYANGKUL P, 1978, PEDIATRICS, V61, P537
   WILLIAMS ML, 1970, AM J CLIN NUTR, V23, P1322
   ZIEGLER EE, 1976, GROWTH, V40, P329
NR 32
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD OCT
PY 2002
VL 35
IS 4
BP 503
EP 507
DI 10.1097/00005176-200210000-00008
PG 5
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 605EY
UT WOS:000178665500008
PM 12394374
DA 2020-12-17
ER

PT J
AU da Motta, MSF
   Mussi-Pinhata, MM
   Jorge, SM
   Yoshida, CFT
   de Souza, CBS
AF da Motta, MSF
   Mussi-Pinhata, MM
   Jorge, SM
   Yoshida, CFT
   de Souza, CBS
TI Immunogenicity of hepatitis B vaccine in preterm and full term infants
   vaccinated within the first weeks of life
SO VACCINE
LA English
DT Article
DE hepatitis B vaccine; immunogenicity; preterm neonate; full term neonate
ID PERINATAL ACQUISITION; RECOMBINANT; SAFETY; VIRUS; BORN; IMMUNIZATION;
   PREVENTION; AGE
AB The immunogenicity of a Hepatitis B vaccine was evaluated in 110 neonates (57 full term and 53 preterm) born to Hepatitis B Surface antigen (HBsAg) negative mothers. Three 10 mug doses of recombinant Hepatitis B vaccine were administered: the first dose within the first week of life; the second between 1 and 2 months; and the third at 5-7 months of age. Anti-HBs antibody titres were measured 3 months after the third dose. The seroconversion rate in preterm infants (77%; 95% Cl = 64.7-87.1) was significantly lower than in full term infants (98%; 95% Cl = 91.6-99.9) while the mean anti-HBs titres among those infants that did seroconvert was lower in preterm (186.6 mIU ml(-1)) than in full term infants (537.5 mIU ml(-1)). More full term than preterm infants showed titres greater than 100 mIU ml(-1) (71.9 and 41.5%, respectively). We conclude that the administration of a recombinant Hepatitis B vaccine shortly after birth is less immunogenic in preterm infants weighing < 1800 g at birth than in full term infants. Currently accepted recommendations for post exposure perinatal prophylaxis may be inadequate to protect preterm infants. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, Ribeirao Preto, SP, Brazil.
   Fiocruz MS, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
RP da Motta, MSF (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, Av dos Bandeirantes 3900, Ribeirao Preto, SP, Brazil.
EM marciasfmotta@hotmail.com; mmmpinha@fmrp.usp.br; smjorge@fmrp.usp.br;
   cyoshida@gene.dbbm.fiocrux.br
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
CR *AM AC PED, 2000, 2000 RED BOOK REP CO, P289
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   BEASLEY RP, 1983, LANCET, V2, P1099
   BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185
   Belloni C, 1998, ACTA PAEDIATR, V87, P336, DOI 10.1080/08035259850157426
   Belson A, 1996, J PEDIATR GASTR NUTR, V23, P252, DOI 10.1097/00005176-199610000-00008
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   CHAWAREEWONG S, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P39
   CHENG KF, 1994, VACCINE, V12, P899, DOI 10.1016/0264-410X(94)90032-9
   CHIRICO G, 1993, PEDIATRICS, V92, P717
   DELCANHO R, 1993, PEDIATR INFECT DIS J, V12, P407, DOI 10.1097/00006454-199305000-00012
   Faldella G, 1998, VACCINE, V16, P1646, DOI 10.1016/S0264-410X(98)00060-7
   GHENDON Y, 1987, J VIROL METHODS, V17, P69, DOI 10.1016/0166-0934(87)90070-X
   Goldfarb J, 1996, PEDIATR INFECT DIS J, V15, P764, DOI 10.1097/00006454-199609000-00004
   GOLDFARB J, 1994, PEDIATR INFECT DIS J, V13, P18, DOI 10.1097/00006454-199401000-00005
   Golebiowska M, 1999, EUR J PEDIATR, V158, P293, DOI 10.1007/s004310051075
   GREENBERG DP, 1993, PEDIATR INFECT DIS J, V12, P438, DOI 10.1097/00006454-199305000-00037
   Huang FY, 1997, ARCH DIS CHILD-FETAL, V77, pF135, DOI 10.1136/fn.77.2.F135
   Jilg W, 1998, VACCINE, V16, pS65, DOI 10.1016/S0264-410X(98)00300-4
   Kesler K, 1998, PEDIATR INFECT DIS J, V17, P116, DOI 10.1097/00006454-199802000-00007
   LAU YL, 1992, J PEDIATR-US, V121, P962, DOI 10.1016/S0022-3476(05)80352-X
   Lee CY, 1997, J PEDIATR-US, V130, P981, DOI 10.1016/S0022-3476(97)70287-7
   Losonsky GA, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e14
   Mahoney F.J., 1999, VACCINES, P158
   MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599
   Patel DM, 1997, J PEDIATR-US, V131, P641, DOI 10.1016/S0022-3476(97)70078-7
   POOVORAWAN Y, 1992, PEDIATR INFECT DIS J, V11, P816, DOI 10.1097/00006454-199210000-00002
   POOVORAWAN Y, 1990, VACCINE, V8, pS56, DOI 10.1016/0264-410X(90)90237-G
   Poovorawan Y, 1997, ARCH DIS CHILD-FETAL, V77, pF47, DOI 10.1136/fn.77.1.F47
   SHAPIRO CN, 1993, PEDIATR INFECT DIS J, V12, P433, DOI 10.1097/00006454-199305000-00036
   Shokri F, 1997, MED MICROBIOL IMMUN, V185, P231, DOI 10.1007/s004300050035
   Wilson CB, 1999, SEMIN PEDIAT INFECT, V10, P83
   World Health Organization, 1992, WHO LAB MAN EX HUM S, p[3, 41, 87]
   XU ZY, 1985, PEDIATRICS, V76, P713
   Yerushalmi B, 1997, PEDIATR INFECT DIS J, V16, P587, DOI 10.1097/00006454-199706000-00009
NR 35
TC 28
Z9 32
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 22
PY 2002
VL 20
IS 11-12
BP 1557
EP 1562
AR PII S0264-410X(01)00493-5
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 536DR
UT WOS:000174685900011
PM 11858862
DA 2020-12-17
ER

PT J
AU Cruz, AAV
   Mussi-Pinhata, MM
   Akaishi, PMS
   Cattebeke, L
   da Silva, JT
   Elia, J
AF Cruz, AAV
   Mussi-Pinhata, MM
   Akaishi, PMS
   Cattebeke, L
   da Silva, JT
   Elia, J
TI Neonatal orbital abscess
SO OPHTHALMOLOGY
LA English
DT Article
ID ACUTE SINUSITIS; COMPLICATIONS; ETHMOIDITIS; CHILDREN
AB Purpose: To describe two cases of orbital abscess in neonates and to review the literature of orbital cellulitis in neonates.
   Design: Two interventional case reports.
   Methods: Photographs, orbital computed tomography scans, and full pediatric examination were obtained in two cases of orbital abscess in neonates.
   Results: Acute ethmoiditis with orbital abscess formation was found in both infants. In one of them, Staphylococcus aureus was identified as the source of infection.
   Conclusions: The clinical findings of our cases concur with the literature (eight cases) indicating that orbital abscess caused by Staphylococcal ethmoiditis is the most common form of orbital cellulitis in neonates. (C) 2001 by the American Academy of Ophthalmology.
C1 USP, Fac Med Ribeirao Preto, Dept Oftalmol, Sch Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Dept Paediat, Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Dept Radiol, Ribeirao Preto, SP, Brazil.
RP Cruz, AAV (corresponding author), USP, Fac Med Ribeirao Preto, Dept Oftalmol, Sch Med Ribeirao Preto, Hosp Clin Campus,Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
RI Junior, Jorge Elias/A-6683-2008; Mussi-Pinhata, Marisa/G-6568-2012
OI Junior, Jorge Elias/0000-0002-1158-1045; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
CR BURNARD E D, 1959, Br J Ophthalmol, V43, P9, DOI 10.1136/bjo.43.1.9
   Carr R, 2000, BRIT J HAEMATOL, V110, P18, DOI 10.1046/j.1365-2141.2000.01992.x
   CHANDLER JR, 1970, LARYNGOSCOPE, V80, P1414, DOI 10.1288/00005537-197009000-00007
   CLARY RA, 1992, ANN OTO RHINOL LARYN, V101, P598, DOI 10.1177/000348949210100710
   CLAYMAN GL, 1991, LARYNGOSCOPE, V101, P234
   ELLENBOGEN E, 1975, AM J OPHTHALMOL, V80, P1024, DOI 10.1016/0002-9394(75)90332-3
   FEARON B, 1979, LARYNGOSCOPE, V89, P947
   GORMLEY PD, 1994, J PEDIATR OPHTHALMOL, V31, P59
   GOUYON JB, 1990, ANN PEDIATR-PARIS, V37, P21
   HORNBLASS A, 1984, SURV OPHTHALMOL, V29, P169, DOI 10.1016/0039-6257(84)90202-9
   Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P47
   JOSEPHSON A, 1991, AM J MED, V91, pS131, DOI 10.1016/0002-9343(91)90358-5
   KRAUS M, 1992, INT J PEDIATR OTORHI, V24, P217, DOI 10.1016/0165-5876(92)90019-L
   KROHEL GB, 1982, OPHTHALMOLOGY, V89, P492
   MARUSZCZAK D, 1979, ACTA OPHTHALMOL, V57, P643
   Moloney J R, 1987, J Laryngol Otol Suppl, V12, P1
   Paradisi F, 2001, MED CLIN N AM, V85, P1, DOI 10.1016/S0025-7125(05)70302-3
   Reddy SC, 1999, INT J PEDIATR OTORHI, V49, P81, DOI 10.1016/S0165-5876(99)00042-7
   RICE DH, 1995, SINUSES, V1, P15
   SAUNDERS MW, 1993, J LARYNGOL OTOL, V107, P1043, DOI 10.1017/S0022215100125228
   SWIFT AC, 1990, J LARYNGOL OTOL, V104, P213, DOI 10.1017/S0022215100112319
   WAGENMANN M, 1992, J ALLERGY CLIN IMMUN, V90, P552, DOI 10.1016/0091-6749(92)90184-4
   WEISS A, 1983, OPHTHALMOLOGY, V90, P195
   Wilson CB, 1999, SEMIN PEDIAT INFECT, V10, P83
   Zabala Charramendieta E, 1997, An Esp Pediatr, V46, P79
NR 25
TC 21
Z9 21
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2001
VL 108
IS 12
BP 2316
EP 2320
DI 10.1016/S0161-6420(01)00859-4
PG 5
WC Ophthalmology
SC Ophthalmology
GA 496VM
UT WOS:000172417800050
PM 11733278
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
   Figueiredo, LTM
   Jorge, SM
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
   Figueiredo, LTM
   Jorge, SM
TI Usefulness of blood and urine samples collected on filter paper in
   detecting cytomegalovirus by the polymerase chain reaction technique
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE congenital cytomegalovirus infection; neonatal diagnosis; multiplex PCR;
   nested PCR; DNA amplification; dried spot blood; dried spot urine
ID INFECTION; DNA
AB A rapid test for the diagnosis of congenital CMV infection is still needed. This study evaluated the usefulness of dried blood and urine samples collected on filter paper for detecting cytomegalovirus (CMV) by the polymerase chain reaction (PCR) assay compared with the use of liquid urine. Samples were obtained from 332 infants aged 1-7 days. Liquid urine samples were collected into bags, cultured in human fibroblasts, and processed using a multiplex PCR technique. Dried urine samples were obtained by placing a piece of filter paper in contact with the infant's genitals. The heels of neonates were punctured and capillary blood was blotted onto filter paper and dried. Dried blood and urine specimens were analyzed by multiplex PCR and nested-PCR assays. A diagnosis of congenital CMV infection was established by isolating the virus, and by detecting viral DNA in the liquid urine. Of the 332 liquid urine samples collected from 332 neonates. seven (2.1%) were positive for CMV and 325 were negative. by both cell culture and PCR assay. In dried samples, CMV DNA was detectable only with a nested PCR assay. Compared with known CMV infection status, 5/7 (71.4%) neonates were positive for congenital CMV infection using dried blood samples. All 325 uninfected neonates were negative. In the dried urine samples. 4/4 CMV-infected infants gave positive tests, and all 262 uninfected infants were negative. Although further improvements in sample collection and/or processing are still needed, PCR testing on dried urine or blood collected on filter paper is a promising approach in the diagnosis of neonatal CMV infection. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Puericultura & Pediat, BR-14049900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Unidade Pesquisa Virol, BR-14049900 Ribeirao Preto, Brazil.
RP Yamamoto, AY (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Puericultura & Pediat, BR-14049900 Ribeirao Preto, Brazil.
RI Figueiredo, Luiz T/E-3702-2012; Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
CR Aquino VH, 2001, BRAZ J MED BIOL RES, V34, P93, DOI 10.1590/S0100-879X2001000100011
   Barbi M, 1996, PEDIATR INFECT DIS J, V15, P898, DOI 10.1097/00006454-199610000-00013
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   CHOU SW, 1991, J INFECT DIS, V163, P1229, DOI 10.1093/infdis/163.6.1229
   CHOU SW, 1992, J INFECT DIS, V166, P604, DOI 10.1093/infdis/166.3.604
   DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177
   Ehrnst A, 1996, SCAND J INFECT DIS, P64
   HAWKES RA, 1979, VIRAL RICKETTSIAL CH, P3
   Ivarsson SA, 1997, PEDIATRICS, V99, P800, DOI 10.1542/peds.99.6.800
   Johansson PJH, 1997, SCAND J INFECT DIS, V29, P465, DOI 10.3109/00365549709011855
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   NOGUEIRA E, 1997, THESIS FACULDADE CIE
   PANNUTI CS, 1985, REV I MED TROP, V27, P105, DOI 10.1590/S0036-46651985000200010
   PORTERJORDAN K, 1990, J MED VIROL, V30, P85, DOI 10.1002/jmv.1890300202
   SHIBATA M, 1994, J VIROL METHODS, V46, P279, DOI 10.1016/0166-0934(94)90111-2
   STAGNO S, 1983, SEMIN PERINATOL, V7, P31
   Yamamoto A Y, 1998, Rev Soc Bras Med Trop, V31, P19, DOI 10.1590/S0037-86821998000100003
   Yamamoto A Y, 1999, J Pediatr (Rio J), V75, P23
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
NR 19
TC 60
Z9 65
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD SEP
PY 2001
VL 97
IS 1-2
BP 159
EP 164
DI 10.1016/S0166-0934(01)00347-0
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 467AG
UT WOS:000170677900015
PM 11483226
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Cervi, MC
   Isaac, ML
AF Mussi-Pinhata, MM
   Cervi, MC
   Isaac, ML
TI Predicting perinatal HIV infection in young Brazilian infants: how
   accurate are signs, symptoms and immunological abnormalities?
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE human immunodeficiency virus; perinatal HIV infection; paediatric AIDS;
   diagnosis; infants
ID IMMUNODEFICIENCY-VIRUS-INFECTION; POLYMERASE CHAIN-REACTION; DISEASE
   PROGRESSION; CHILDREN; DIAGNOSIS; PATTERNS; DIARRHEA; COHORT; LIFE
AB Early identification of infants perinatally infected with HIV (HIV+) requires costly laboratory tests which are not widely available in countries with limited resources. We evaluated the utility of detection of non-specific HIV-related signs and symptoms and immunological abnormalities in the diagnosis of perinatal HIV infection in Brazilian infants younger than 10 months of age and followed from birth. A total of 27 HIV+ and 43 uninfected infants were studied. All infants exhibited one or more non-specific HIV-related findings at least once. HIV+ infants were more frequently symptomatic than HIV- infants only when older than 3 months. Combinations of clinical and immunological findings resulted in high sensitivity (85-100%) and low specificity (25-65%) rates for the diagnosis of HIV infection. Conversely, low CD4+ cell counts and hyperimmunoglobulinaemia showed low sensitivity (52%) and high specificity (100%) rates. In conclusion, the detection of similar findings in HIV- and HIV+ infants underscores the need of early confirmatory laboratory testing.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, Campus, BR-14049900 Ribeirao Preto, SP, Brazil.
EM mmmpinha@fmrp.usp.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Cervi, Maria Celia/P-2567-2016
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Cervi, Maria
   Celia/0000-0002-6563-6507
CR BARBOSA MT, 1996, AIDS B EPIDEMIOLOGIC, V4, P2
   Barnhart HX, 1996, PEDIATRICS, V97, P710
   BORKOWSKY W, 1992, J INFECT DIS, V166, P616, DOI 10.1093/infdis/166.3.616
   *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1
   Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S
   Cesar JA, 1997, REV SAUDE PUBL, V31, P53, DOI 10.1590/S0034-89101997000100008
   CHANTRY CJ, 1995, PEDIATR INFECT DIS J, V14, P382, DOI 10.1097/00006454-199505000-00009
   COLEBUNDERS RI, 1987, AIDS, V1, P151
   DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5
   Diaz C, 1998, J ACQ IMMUN DEF SYND, V18, P221, DOI 10.1097/00042560-199807010-00004
   DUARTE G, 1991, J BRAS GINEC OBSTET, V1, P169
   GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783
   GALLI L, 1995, AIDS, V9, P455, DOI 10.1097/00002030-199509050-00007
   Jean SS, 1997, PEDIATR INFECT DIS J, V16, P600, DOI 10.1097/00006454-199706000-00011
   LIDINJANSSON G, 1994, PEDIATRICS, V94, P815
   MARQUES HH, 1998, 12 WORLD AIDS C GEN, P47
   Meyer MP, 1997, S AFR MED J, V87, P158
   *MIN HLTH, 1998, 12 WORLD AIDS C AIDS, P11
   Morris CR, 1996, PEDIATR INFECT DIS J, V15, P321, DOI 10.1097/00006454-199604000-00008
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   MUSSIPINHATA MM, 1989, J TROP PEDIATRICS, V35, P147, DOI 10.1093/tropej/35.4.147
   Owens DK, 1996, JAMA-J AM MED ASSOC, V275, P1342, DOI 10.1001/jama.275.17.1342
   Paul MO, 1997, CLIN DIAGN LAB IMMUN, V4, P75, DOI 10.1128/CDLI.4.1.75-78.1997
   PECKHAM CS, 1991, LANCET, V337, P253
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   QUINN TC, 1994, PEDIAT AIDS CHALLENG, P31
   SCHORLING JB, 1990, AM J EPIDEMIOL, V132, P144, DOI 10.1093/oxfordjournals.aje.a115626
   Tetali S, 1998, AIDS RES HUM RETROV, V14, P571, DOI 10.1089/aid.1998.14.571
   *UNAIDS WHO, 1998, HIV AIDS GLOB SIT RE, P6
   VICTORA CG, 1992, B WORLD HEALTH ORGAN, V70, P467
   WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018
NR 32
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD MAR
PY 2001
VL 12
IS 3
BP 197
EP 203
DI 10.1258/0956462011916901
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 412DZ
UT WOS:000167540300010
PM 11231874
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Cristina, P
   Pinto, G
   Figueiredo, LTM
   Jorge, SM
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Cristina, P
   Pinto, G
   Figueiredo, LTM
   Jorge, SM
TI Congenital cytomegalovirus infection in preterm and full-term newborn
   infants from a population with a high seroprevalence rate
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE cytomegalovirus; congenital infection; preterm newborn infants;
   full-term newborn infants; cytomegalovirus seroprevalence rate
ID BORN
AB Background. Cytomegalovirus (CMV) is the most frequent cause of congenital infections in humans. Prematurity occurs in as many as 34% of infants with symptomatic congenital CMV infection.
   Objective. To determine the clinical presentation and frequency of congenital CMV infection among preterm infants and full-term infants from a population with a high seroprevalence rate.
   Design/methods. A total of 289 preterm infants (median gestational age, 34 weeks; median birth weight, 1757 g) and 163 term infants (median gestational age, 39 weeks; median birth weight, 3150 g) sequentially born were included in the study. Serum IgG antibodies to CMV were measured in all mothers. One urine sample was collected within the first 7 days of age from all newborns. Virus isolation in urine samples was performed by tissue culture, and viral DNA was detected by a multiplex PCR. CMV infection was diagnosed in infants with virus excretion detected by both methods on at least two occasions within the first 3 weeks of life.
   Results. Maternal CMV seropositivity rate was 95.7%. Congenital CMV infection was detected in 6 of 289 (2.1%) (95% confidence interval, 0.84 to 4.68) preterm infants and in 3 of 163 term infants (1.8%) (95% confidence interval, 0.48 to 5.74) (P > 0.05). Four of 6 preterm infants with congenital CMV infection were symptomatic, but none of the term infants was symptomatic (P = 0.16).
   Conclusion. The frequency of congenital CMV infection in preterm newborn infants from mothers with a high seropositive rate was similar to that found in term infants. No significant difference was found between the proportion of symptomatic infants among preterm and term infants. Our finding of symptomatic congenital CMV infection underscores the need of further evaluation of correlates of congenital symptomatic infection in highly immune populations.
C1 Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Puericulture & Pediat, BR-14049900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Unit, BR-14049900 Ribeirao Preto, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Campus USP, BR-14049900 Ribeirao Preto, Brazil.
RI Mussi-Pinhata, Marisa/G-6568-2012; Figueiredo, Luiz T/E-3702-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
CR Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969
   BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9
   BARROS FC, 1992, PEDIATRICS, V90, P238
   BATAGLIA F, 1967, J PEDIATR, V71, P159
   Bettiol H, 2000, PAEDIATR PERINAT EP, V14, P30, DOI 10.1046/j.1365-3016.2000.00222.x
   Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   CHANDLER SH, 1987, J INFECT DIS, V155, P655, DOI 10.1093/infdis/155.4.655
   FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003
   ISTAS AS, 1995, CLIN INFECT DIS, V20, P665, DOI 10.1093/clinids/20.3.665
   PANHANI S, 1994, SCAND J INFECT DIS, V26, P375, DOI 10.3109/00365549409008607
   PANNUTI CS, 1985, REV I MED TROP, V27, P105, DOI 10.1590/S0036-46651985000200010
   PERLMAN JM, 1992, ANN NEUROL, V31, P64, DOI 10.1002/ana.410310112
   SETEINMANN J, 1994, J CLIN LAB ANAL, V20, P191
   STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601
   STAGNO S, 1982, J PEDIATR-US, V101, P897, DOI 10.1016/S0022-3476(82)80006-1
   STAGNO S, 1983, SEMIN PERINATOL, V7, P31
   STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203
   Yamamoto A Y, 1998, Rev Soc Bras Med Trop, V31, P19, DOI 10.1590/S0037-86821998000100003
   Yamamoto A Y, 1999, J Pediatr (Rio J), V75, P23
NR 21
TC 49
Z9 55
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2001
VL 20
IS 2
BP 188
EP 192
DI 10.1097/00006454-200102000-00014
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 402UL
UT WOS:000167006500012
PM 11224840
DA 2020-12-17
ER

PT J
AU Pinto, PCG
   Mussi-Pinhata, MM
   Yamamoto, AY
   Jorge, SM
AF Pinto, PCG
   Mussi-Pinhata, MM
   Yamamoto, AY
   Jorge, SM
TI Placental transfer of naturally-acquired maternal anti-cytomegalovirus
   (CMV) antibodies
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2000
VL 47
IS 4
SU S
MA 1977
BP 335A
EP 335A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 298TM
UT WOS:000086155301975
DA 2020-12-17
ER

PT J
AU Motta, MSF
   Mussi-Pinhata, MM
   Jorge, SM
   Yoshida, CFT
AF Motta, MSF
   Mussi-Pinhata, MM
   Jorge, SM
   Yoshida, CFT
TI Early hepatitis B vaccination of preterm infants under 1800 g at birth
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   FIOCRUZ, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2000
VL 47
IS 4
SU S
MA 2032
BP 344A
EP 344A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 298TM
UT WOS:000086155302031
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
TI Utility of PCR detection of cytomegalovirus (CMV) DNA in dried blood or
   urine on filter paper for diagnosis of congenital CMV infection
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
RI Figueiredo, Luiz T/E-3702-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2000
VL 47
IS 4
SU S
MA 2060
BP 349A
EP 349A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 298TM
UT WOS:000086155302059
DA 2020-12-17
ER

PT J
AU Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
   Jorge, SM
   Figueiredo, LTM
AF Yamamoto, AY
   Mussi-Pinhata, MM
   Pinto, PCG
   Jorge, SM
   Figueiredo, LTM
TI Congenital cytomegalovirus infection among preterm infants
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Virol Unit, Sao Paulo, Brazil.
RI Figueiredo, Luiz T/E-3702-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 2000
VL 47
IS 4
SU S
MA 2061
BP 349A
EP 349A
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA 298TM
UT WOS:000086155302060
DA 2020-12-17
ER

PT J
AU Martinez, FE
   dos Santos, MM
   Sieber, VM
   Camelo, JS
   Ferlin, MLS
   Goncalves, AL
   Pinhata, MMM
   Jorge, SM
AF Martinez, FE
   dos Santos, MM
   Sieber, VM
   Camelo, JS
   Ferlin, MLS
   Goncalves, AL
   Pinhata, MMM
   Jorge, SM
TI Growth and nitrogen balance in preterm infants fed formula with long
   chain polyunsaturated fatty acids
SO NUTRITION RESEARCH
LA English
DT Article
DE growth; nutrition; human milk; formula; LCP; preterm infants
ID PLASMA AMINO-ACID; HUMAN-MILK
AB A decrease in nitrogen retention and growth rate has been observed in some formulas supplemented with LCP. In the present study we report on the growth and nitrogen balance of preterm infants fed formula supplemented with or without a blend of LCP containing both omega-3 and omega-6 fatty acids. A prospective study was conducted on 58 VLBW-infants with a mean +/- SEM weight of 1245+/-21g. The infants were divided into 3 groups. If the mother had milk, the infant received human milk fortified (18 infants). If the mother had no milk, the infant received one of two identical formulas except for the fat component in a double-blind manner (20 infants each group). Infants were followed up for 30 days on their diets. Initial and final anthropometric parameters, BUN, total protein, and albumin were normal and similar in the three groups. Both, protein intake and protein excretion through urine and feces, were similar for the three groups. Mean percent protein absorption was 71%. Plasma amino acid levels were similar at the beginning of the study and after 30 days were similar for the infants fed the two formulas. The infants that received fortified human milk presented significantly higher proline levels and significantly lower lysine, aspartic acid, threonine, glutamic acid, and methionine levels compared to the infants fed the two formulas. We conclude that the addition of LCP to preterm infant formula did not affect protein absorption or plasma amino acid profile. The formulas did not mimic fully the amino acid profile of preterm infants fed enriched human milk. (C) 1999 Elsevier Science Inc.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, Brazil.
   Milupa GmbH & Co KG, Dept Sci, Friedrichsdorf, Germany.
RP Martinez, FE (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, Brazil.
EM femartin@fmrp.usp.br
RI Martinez, Francisco E/H-1194-2014; Camelo, Jose/AAL-4716-2020; Camelo,
   Jose S/G-3169-2012; Mussi-Pinhata, Marisa/G-6568-2012
OI Martinez, Francisco E/0000-0002-6269-9182; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570
CR BRACCO U, 1992, NESTLE NUTR WORKS SE, V28, P147
   CAMELO JS, 1995, THESIS U SAO PAULO R
   CRAWFORD M A, 1981, Progress in Lipid Research, V20, P31, DOI 10.1016/0163-7827(81)90011-4
   GUERRINI P, 1994, ACTA PAEDIATR, V83, P37, DOI 10.1111/j.1651-2227.1994.tb13358.x
   HEINE WE, 1994, NESTLE NUTR WORKSHOP, V43, P121
   KOLETZKO B, 1995, J PEDIATR GASTR NUTR, V21, P200, DOI 10.1097/00005176-199508000-00012
   MORO G, 1989, ACTA PAEDIATR SCAND, V78, P18, DOI 10.1111/j.1651-2227.1989.tb10880.x
   MORO G, 1992, RECENT ADV INFANT FE, P160
   ODLEY JR, 1977, ARCH DIS CHILD, V52, P287
   RAYOL MRS, 1993, J PEDIATR-US, V123, P985, DOI 10.1016/S0022-3476(05)80399-3
   RIGO J, 1994, ACTA PAEDIATR, V83, P127, DOI 10.1111/j.1651-2227.1994.tb13033.x
   RIGO J, 1994, ACTA PAEDIATR, V83, P100, DOI 10.1111/j.1651-2227.1994.tb13370.x
   RIGO J, 1992, RECENT ADV INFANT FE, P164
   SAWATZKI G, 1995, NUEVAS PERSPECTIVAS, P61
   UAUY R, 1989, SEMIN PERINATOL, V13, P118
   VANASSELT WA, 1992, RECENT ADV INFANT FR, P156
NR 16
TC 2
Z9 2
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD OCT
PY 1999
VL 19
IS 10
BP 1497
EP 1505
DI 10.1016/S0271-5317(99)00106-2
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 241AQ
UT WOS:000082859600006
DA 2020-12-17
ER

PT J
AU Mussi-Pinhata, MM
   Yamamoto, AY
   Figueiredo, LTM
   Cervi, MC
   Duarte, G
AF Mussi-Pinhata, MM
   Yamamoto, AY
   Figueiredo, LTM
   Cervi, MC
   Duarte, G
TI Congenital and perinatal cytomegalovirus infection in infants born to
   mothers infected with human immunodeficiency virus
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID CHAIN-REACTION; DISEASE; WOMEN
AB Objectives: To determine the rates of congenital and perinatal cytomegalovirus (CMV) infection among infants born to mothers infected with HIV compared with infants born to mothers not infected with HIV from a CMV-immune, low-income population.
   Study design: A total of 325 newborns from CMV-seropositive mothers were enrolled and evaluated for congenital CMV infection (150 infants from HIV+ mothers and 175 infants from HIV- mothers. A total of 101 infants from HIV+ mothers and 33 infants from HIV- mothers were evaluated for perinatal CMV infection. The virus was isolated from urine by culture in human fibroblasts and was detected by polymerase chain reaction at birth and at 15 days and 12 weeks of age.
   Results: Only 13 of 150 HIV+ mothers (8.7%) had an AIDS-defining condition, and none had a late-stage HIV infection. Congenital CMV infection was detected in 4 of 150 (2.7%) infants from HIV+ mothers and in 5 of 175 (2.9%) infants from HIV- mothers (p = 1.00). Perinatal CMV infection was diagnosed in 8 of 101 (7.9%) infants from HIV+ mothers and in 13 of 33 (39.4%) infants from HIV- mothers (p < 0.00001). Most infants (93.3%) from HIV- mothers and only 5.9% of infants from HIV+ mothers were breastfed.
   Conclusions: CMV coinfection in mothers without advanced HIV disease from a CMV-immune population does not enhance the likelihood of congenital CMV infection. Perinatal CMV transmission from HIV-infected mothers may be decreased by avoiding breastfeeding. Further studies on mothers with late-stage HIV infection are needed.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Virol Unit, BR-14049900 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Obstet & Gynecol, BR-14049900 Sao Paulo, Brazil.
RP Mussi-Pinhata, MM (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, Av Bandeirantes 3900,Campus USP, BR-14049900 Sao Paulo, Brazil.
RI Mussi-Pinhata, Marisa/G-6568-2012; Duarte, Geraldo/J-7906-2012; Cervi,
   Maria Celia/P-2567-2016; Figueiredo, Luiz T/E-3702-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; Cervi, Maria
   Celia/0000-0002-6563-6507; 
CR ALFORD CA, 1990, REV INFECT DIS, V12, pS745
   Alford CA, 1981, HUMAN HERPESVIRUSES, P159
   [Anonymous], 1994, MMWR Recomm Rep, V43, P1
   BLITH CR, 1983, J AM STAT ASSOC, V78, P108
   Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, P1
   CHANDLER SH, 1985, J INFECT DIS, V152, P597, DOI 10.1093/infdis/152.3.597
   Clarke LM, 1996, J INFECT DIS, V173, P77, DOI 10.1093/infdis/173.1.77
   COOPER ER, 1992, PEDIATR AIDS HIV INF, V3, P302
   DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177
   DUARTE G, 1991, J BRAS GINEC OBSTET, V1, P169
   FORBES BA, 1989, CLIN MICROBIOL REV, V2, P204, DOI 10.1128/CMR.2.2.204-216.1989
   FRENKEL LD, 1990, REV INFECT DIS, V12, pS820
   FRIES BC, 1994, J INFECT DIS, V169, P769, DOI 10.1093/infdis/169.4.769
   GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223
   GRAY GE, 1996, 11 INT C AIDS INT AI
   MASUR H, 1992, AM J MED, V92, pS1, DOI 10.1016/0002-9343(92)90328-9
   MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   MUSTAFA MM, 1994, PEDIATR INFECT DIS J, V13, P249, DOI 10.1097/00006454-199404000-00001
   REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101
   REYNOLDS DW, 1979, DIAGNOSTIC PROCEDURE, P339
   SAENZ M, 1993, 33 INT C ANT AG CHEM
   SCHWEBKE K, 1995, J PEDIATR-US, V126, P293, DOI 10.1016/S0022-3476(95)70563-5
   SCOTT GB, 1985, JAMA-J AM MED ASSOC, V253, P363, DOI 10.1001/jama.253.3.363
   SORBELLO AF, 1988, J CLIN MICROBIOL, V26, P1111, DOI 10.1128/JCM.26.6.1111-1114.1988
   STAGNO S, 1980, NEW ENGL J MED, V302, P1073, DOI 10.1056/NEJM198005083021908
   STAGNO S, 1983, SEMIN PERINATOL, V7, P31
   STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203
   STAGNO S, 1982, Clinical Obstetrics and Gynecology, V25, P563, DOI 10.1097/00003081-198209000-00014
   STERN H, 1986, BRIT MED J, V292, P718, DOI 10.1136/bmj.292.6522.718
   STEWART JA, 1995, CLIN INFECT DIS, V21, pS114, DOI 10.1093/clinids/21.Supplement_1.S114
   *WHO, 1991, WKLY EPIDEMIOL REC, V66, P353
NR 32
TC 40
Z9 45
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD FEB
PY 1998
VL 132
IS 2
BP 285
EP 290
DI 10.1016/S0022-3476(98)70446-9
PG 6
WC Pediatrics
SC Pediatrics
GA ZA254
UT WOS:000072344800021
PM 9506642
DA 2020-12-17
ER

PT J
AU Tess, BH
   Granato, C
   Parry, JV
   Santos, VA
   Lago, TG
   Newell, ML
   Dunn, DT
   Rodrigues, LC
   MussiPinhata, MM
   Cervi, MC
   Duarte, G
   Nishimoto, TMI
   Porto, AGM
   Succi, RC
   Kenjy, G
   Marques, HHS
   Zugaib, M
   daSilva, MTN
   Amaral, E
   Amarante, JMB
   Tsukumo, MKK
   Garcia, SAL
AF Tess, BH
   Granato, C
   Parry, JV
   Santos, VA
   Lago, TG
   Newell, ML
   Dunn, DT
   Rodrigues, LC
   MussiPinhata, MM
   Cervi, MC
   Duarte, G
   Nishimoto, TMI
   Porto, AGM
   Succi, RC
   Kenjy, G
   Marques, HHS
   Zugaib, M
   daSilva, MTN
   Amaral, E
   Amarante, JMB
   Tsukumo, MKK
   Garcia, SAL
TI Salivary testing for human immunodeficiency virus type 1 infection in
   children born to infected mothers in Sao Paulo, Brazil
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE human immunodeficiency virus type 1 antibodies; oral fluid; children;
   Latin America; IgG antibody-capture enzyme-linked immunosorbent assay
   (GACELISA) sensitivity; specificity
ID HIV SURVEILLANCE; ANTIBODIES; SERUM
AB Objective. To validate a method for salivary testing for HIV infection in children older than 12 months.
   Methods. Oral fluid samples were collected via sponge foam swabs from children born to HIV-positive mothers and were tested for antibodies to HIV-1 and HIV-2 with an IgG antibody capture enzyme-linked immunosorbent assay and a modified Western blot for confirmation. In each child serum antibody status was the standard used to validate the salivary antibody test.
   Results. We obtained 331 oral fluid samples from children born to HIV-positive mothers. The specificity and sensitivity of salivary testing compared with results on sera were both 100% (297 of 297 (95% confidence interval 98.8 to 100%) and 34 of 34 (95% confidence interval 89.7 to 100%), respectively). Compliance in the study population increased from 91% to 97% when mothers were offered the opportunity to provide oral fluid from their children instead of blood specimens.
   Conclusion. Salivary testing provides an accurate and acceptable noninvasive method for assessing the HIV infection status of children born to infected mothers by using IgG antibody capture enzyme-linked immunosorbent assay alone with a strategy of duplicate retesting of reactive specimens.
C1 PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,LONDON,ENGLAND.
   INST CHILD HLTH,LONDON,ENGLAND.
   INST SAUDE SECRETARIA SAUDE ESTADO SAO PAULO,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,HOSP CLIN,BR-05508 SAO PAULO,BRAZIL.
RP Tess, BH (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.
RI Cervi, Maria Celia/P-2567-2016; Duarte, Geraldo/J-7906-2012; Zugaib,
   Marcelo/A-5724-2013; Newell, Marie-Louise/AAE-8222-2019; Mussi-Pinhata,
   Marisa M/G-6568-2012
OI Cervi, Maria Celia/0000-0002-6563-6507; Zugaib,
   Marcelo/0000-0003-1155-2671; Newell, Marie-Louise/0000-0002-1074-7699;
   TESS, BEATRIZ HELENA/0000-0002-9921-9234; Dunn,
   David/0000-0003-1836-4446; Mussi-Pinhata, Marisa M/0000-0001-8985-1570;
   Rodrigues, Laura Cunha/0000-0001-9008-660X
CR ARCHIBALD DW, 1986, J CLIN MICROBIOL, V24, P873, DOI 10.1128/JCM.24.5.873-875.1986
   ARCHIBALD DW, 1990, AIDS, V4, P417, DOI 10.1097/00002030-199005000-00006
   ARMITAGE P, 1988, STATISTICAL METHODS, P115
   BEHETS FM, 1991, J ACQ IMMUN DEF SYND, V4, P183
   COATES R, 1991, CAN J PUBLIC HEALTH, V82, P397
   CONNELL JA, 1993, J MED VIROL, V41, P159, DOI 10.1002/jmv.1890410212
   COVELL R, 1993, J INFECTION, V26, P27, DOI 10.1016/0163-4453(93)96712-Y
   FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5
   JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006
   MAJOR CJ, 1991, J INFECT DIS, V163, P699, DOI 10.1093/infdis/163.4.699
   Mortimer P P, 1994, Clin Diagn Virol, V2, P231, DOI 10.1016/0928-0197(94)90048-5
   PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1
   TAMASHIRO H, 1994, B WORLD HEALTH ORGAN, V72, P135
NR 13
TC 8
Z9 10
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD SEP
PY 1996
VL 15
IS 9
BP 787
EP 790
DI 10.1097/00006454-199609000-00010
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA VG538
UT WOS:A1996VG53800009
PM 8878222
DA 2020-12-17
ER

PT J
AU Leal, LM
   MussiPinhata, MM
   Goncalves, AL
AF Leal, LM
   MussiPinhata, MM
   Goncalves, AL
TI Follow up of asymptomatic newborns of mothers with positive tests for
   syphilis.
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,DEPT PEDIAT,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD APR
PY 1996
VL 39
IS 4
BP 1767
EP 1767
PN 2
PG 1
WC Pediatrics
SC Pediatrics
GA UD238
UT WOS:A1996UD23801767
DA 2020-12-17
ER

PT J
AU MUSSIPINHATA, MM
   GONCALVES, AL
   FOSS, NT
AF MUSSIPINHATA, MM
   GONCALVES, AL
   FOSS, NT
TI BCG VACCINATION OF FULL-TERM INFANTS WITH CHRONIC INTRAUTERINE
   MALNUTRITION - INFLUENCE OF IMMUNIZATION AGE ON DEVELOPMENT OF
   POSTVACCINATION, DELAYED TUBERCULIN HYPERSENSITIVITY
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID LOW-BIRTH-WEIGHT; GROWTH-RETARDATION; FETAL GROWTH; GESTATIONAL-AGE;
   IMMUNITY; MORBIDITY; CHILDREN
AB To determine the effect of intrauterine growth retardation (IUGR) on the response to BCG vaccination, we evaluated the specific delayed tuberculin hypersensitivity of 57 full-term infants with symmetric IUGR (SGA or small for gestational age) and 52 full-term infants with normal intrauterine growth (AGA or appropriate for gestational age). The infants were evaluated using post-vaccination skin tests to tuberculin purified protein derivative (PPD) and tuberculin lymphocyte transformation tests. Using a positive response to the skin test as an indicator of delayed hypersensitivity, we found that the rate of response to BCG in the SGA and AGA groups was similar. A total of 65% of infants with IUGR responded to BCG vaccination. The response rate among SGA infants who were vaccinated at 5 days of age, about 26 days of age (weight greater-than-or-equal-to 2500 g), 3 months of age, and 6 months of age was 68%, 47%, 69%, and 88%, respectively. The overall response rate for infants with no IUGR was 71%; the rate of response to BCG vaccination among this group was 52% (those vaccinated at 5 days of age), 90% (3 months of age), and 80% (6 months of age). Our data suggest that the immunogenicity of BCG vaccine is similar in term infants who have normal or abnormal intrauterine growth and the presence of IUGR should not be a reason for delaying BCG vaccination.
C1 UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,DEPT INTERNAL MED,BR-14100 RIBEIRAO PRE,SP,BRAZIL.
RP MUSSIPINHATA, MM (corresponding author), UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,DEPT PUERICULTURE & PEDIAT,AV BANDEIRANTES 3900,BR-14049 RIBEIRAO PRE,SP,BRAZIL.
RI Mussi-Pinhata, Marisa/G-6568-2012; FOSS, NORMA/I-6002-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570; 
CR BHASKARAM C, 1977, ACTA PAEDIATR SCAND, V66, P617, DOI 10.1111/j.1651-2227.1977.tb07957.x
   CHANDRA RK, 1975, AM J DIS CHILD, V129, P450, DOI 10.1001/archpedi.1975.02120410038013
   DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   FERGUSON AC, 1978, J PEDIATR-US, V93, P52, DOI 10.1016/S0022-3476(78)80599-X
   FILHO VW, 1990, B WORLD HEALTH ORGAN, V68, P69
   GHOSH S, 1971, INDIAN J MED RES, V59, P122
   KELLER MA, 1987, PEDIATR RES, V22, P277, DOI 10.1203/00006450-198709000-00008
   LOCKWOOD CJ, 1986, CLIN PERINATOL, V13, P3
   MANERIKAR SS, 1976, CLIN EXP IMMUNOL, V26, P173
   MILLER HC, 1971, PEDIATRICS, V48, P511
   MILSTIEN JB, 1990, B WORLD HEALTH ORGAN, V68, P93
   MOTA FSB, 1982, REV BRAS MED, V39, P333
   NARAIN R, 1978, INDIAN J MED RES, V68, P403
   Narmada R, 1976, Indian Pediatr, V13, P263
   PABST HF, 1987, CLIN EXP IMMUNOL, V68, P209
   PITTARD WB, 1984, CLIN IMMUNOL IMMUNOP, V30, P178, DOI 10.1016/0090-1229(84)90052-7
   RAJAJEE S, 1985, J TROP PEDIATRICS, V31, P85, DOI 10.1093/tropej/31.2.85
   SAHA K, 1983, J TROP PEDIATRICS, V29, P278, DOI 10.1093/tropej/29.5.278
   SARNO EN, 1988, BRAZ J MED BIOL RES, V21, P461
   SHERRIS JD, 1987, POPULATION REPORTS, V5, pL14
   STARFIELD B, 1982, J PEDIATR-US, V101, P978, DOI 10.1016/S0022-3476(82)80025-5
   TANNER JM, 1970, ARCH DIS CHILD, V45, P566, DOI 10.1136/adc.45.242.566
   VILLAR J, 1982, AM J OBSTET GYNECOL, V143, P793, DOI 10.1016/0002-9378(82)90012-6
   VILLAR J, 1986, B WORLD HEALTH ORGAN, V64, P847
   1980, WHO TECHNICAL REPORT, V652, P10
   1981, WEEKLY EPIDEMIOLOGIC, V56, P393
NR 27
TC 14
Z9 14
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1993
VL 71
IS 1
BP 41
EP 48
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KR352
UT WOS:A1993KR35200005
PM 8440036
DA 2020-12-17
ER

PT J
AU MUSSIPINHATA, MM
   GONCALVES, AL
AF MUSSIPINHATA, MM
   GONCALVES, AL
TI SERUM IMMUNOGLOBULIN LEVELS AND INCIDENCE OF INFECTION DURING THE 1ST
   YEAR OF LIFE IN FULL-TERM AND PRETERM INFANTS
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
RP MUSSIPINHATA, MM (corresponding author), UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,DEPT PUERICULTURE & PEDIAT,AV BANDEIRANTES 3900,BR-14048 RIBEIRAO PRETO,SP,BRAZIL.
RI Mussi-Pinhata, Marisa/G-6568-2012
OI Mussi-Pinhata, Marisa/0000-0001-8985-1570
CR ADAMKIN D, 1978, J PEDIATR-US, V93, P604, DOI 10.1016/S0022-3476(78)80895-6
   ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5
   AMER J, 1963, PEDIATRICS, V32, P4
   BALLOW M, 1986, PEDIATR RES, V20, P899, DOI 10.1203/00006450-198609000-00019
   BRYAN MH, 1973, PEDIATRICS, V52, P169
   Cates K L, 1983, Curr Probl Pediatr, V13, P1
   COATES AL, 1977, J PEDIATR-US, V90, P611, DOI 10.1016/S0022-3476(77)80382-X
   CONWAY SP, 1985, ARCH DIS CHILD, V60, P208, DOI 10.1136/adc.60.3.208
   DOUGLAS JWB, 1953, BMJ-BRIT MED J, V1, P748, DOI 10.1136/bmj.1.4813.748
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   EIFE RF, 1974, CELL IMMUNOL, V14, P435, DOI 10.1016/0008-8749(74)90194-4
   ETCHES PC, 1979, ARCH DIS CHILD, V54, P218, DOI 10.1136/adc.54.3.218
   FULGINITI VA, 1966, J PEDIATR-US, V68, P723, DOI 10.1016/S0022-3476(66)80444-4
   Haridas N, 1983, Indian Pediatr, V20, P757
   HAWORTH JC, 1965, ARCH DIS CHILD, V40, P243, DOI 10.1136/adc.40.211.243
   HUBERT M, 1972, SOCIAL STATISTICS
   KOHLER PF, 1966, NATURE, V210, P1070, DOI 10.1038/2101070a0
   Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
   MILLER ME, 1973, IMMUNOLOGIC DISORDER, P127
   PAPADATOS C, 1969, BIOL NEONATORUM, V14, P365
   SASIDHARAN P, 1988, CLIN PEDIATR, V27, P271, DOI 10.1177/000992288802700601
   SAVILAHTI E, 1987, ACTA PAEDIATR SCAND, V76, P1, DOI 10.1111/j.1651-2227.1987.tb10404.x
   SAVILAHTI E, 1983, PEDIATRICS, V72, P312
   STIEHM ER, 1966, PEDIATRICS, V37, P715
   TONOOKA T, 1979, PEDIATR RES, V13, P148, DOI 10.1203/00006450-197903000-00002
NR 25
TC 14
Z9 14
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD AUG
PY 1989
VL 35
IS 4
BP 147
EP 153
DI 10.1093/tropej/35.4.147
PG 7
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA AY233
UT WOS:A1989AY23300002
PM 2810457
DA 2020-12-17
ER

EF